

The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents.

TO CANAL STREET, THE CANAL STREET, FOR LONG

Citation of specific commercial equipment, material, or trade names in this report does not constitute an official endorsement or approval of the use of such commercial products.

Copies of this report are available at the Defense Documentation Center, Alexandria, Virginia 22314.

Destroy this report when it is no longer needed. Do not return it to the originator.

ちなったのであったのがあったのないないないないないないないないないないないできょうないのできょうとうないのできょうないないないないないないないないないない

いなどにない、いたいに、小川日本のなどと

In conducting the research described in this report, the investigators adhered to the 'Guide for Laboratory Animal Facilities and Care,' as promulgated by the Committee on the Guide for Laboratory Animal Facilities and Care of the Institute of Laboratory Animal Resources, National Academy of Sciences - National Resources, Council.

£7.6.55.51	នៃ		
tils.	While Section	ot	
00G	Beff Scelion		
Read of the	E3 ·		
JUSTIcidati	io <i>x.</i>		
BY DiSTRIZUI	HOR/AVAILABILITY CO	DES	
	1		
A			

Item 24, (U) Dogs and sheep will be utilized as models. Experimental dorsal longitudinal sinus clots will be produced. $I_{-}^{131}_{-}$ tagged fibringen will then be injected and renal brain scans taken and compared to control scans and correlated with clots present at autopsy.

Page 73, Item 23. (U) This study was initiated in 1968 rt the written request of the military consultant in dermatology to the Surgeon General because tropical acne was the most common cause of evacuation for skin disease from Vietnam.

> Item 24. (U) To develop new techniques to determine the composition and structure of minute quantities of lipids. Apply the evolved techniques to study surface skin lipids of normal men, uninvolved skin of acne patients, comedones and pustules of acne patients. Then study the influence of new medicaments on acne patients.

Page 191, Item 23. (U) This study attempts to determine why nuclear casualties become nauscated and vomit and to develop treatment and prevention of these symptoms.

> Item 24. (U) Physiological and biochemical manifestations in laboratory animals will be systematically correlated with the observed clinical course following irradiation. Results of these studies will be evaluated for clues to the development of improved and new methods for diagnosis and treatment of acute and chronic radiation injury. Of particular interest are potential applications of dietary, chemical, and antibiotic therapy of radiation casualties and of radiation-treated patients. In addition, the program to provide pre-clinical evaluation of radiopharmaceuticals for diagnostic and therapeutic use in Army hospitals will be continued.

as and to make the here we have a second state of the second state and second state and

A NUMBER

Letterman Army Institute of Research

Annual Progress Report, FY 1972 RCS SGRD-288(R1)

30 June 1972

ERRATA

Cover: LAIR Report No. 11

alle allowed by a start a little and

A CONSIGNATION OF THE PARTY OF

area in a state whether and and and the state

Page 8, Item 23. (U) Laboratory support of studies on cutaneous fungal infections, periodontal disease, wound healing, burns. and allergic responses in soldiers.

> Item 24. (U) Leukocytes will be isolated from whole blood by agglutination of erythrocytes with dextran. The leukocytes will be separated on buffered, isotonic density gradients made with a high polymer of sucrose. Each cell type will be disrupted by shear or sonication, and the soluble and membrane-bound fractions will be injected into rabbits for the production of antibody.

Page 11, Item 23. (U) In severely wounded soldiers death may occur from shock despite alleged adequate whole blood replacement. Some evidence suggest oxygen is still not being delivered adequately in tissues. This study was initiated to demonstrate whether adequate oxygen is being delivered by the blood to tissues. Presently, no clinical laboratory technique is available, particularly for field use.

> Item 24. (U) Adequate baseline studies will be performed using sheep blood to ascertain reproducibility and sensitivity of the technique. Effects of pH, PCO₂, hematocrit and other variables will be determined. The dissociation curve of sheep blood will be followed prior to, during, and following recovery from experimentally induced shock and the results correlated with the physiologic status of the model as determined by independent means.

and the second of the second second of the second of the second second

- Page 20, Item 23. (U) To develop an animal model using mice for producing chronic ileitis and colitis since diarrheal diseases, especially in tropical areas, rank second in cause of man days lost in soldiers.
- Page 23, Item 23. (U) To develop an animal model to study the role of bloodbrain-barrier in irreversible shock due to hemorrhagic shock as occurs in combat. Factors of sludged blood and thromboses are introduced.

UNCLASSIFIED Security Classification			. 250
DOCUMENT C	ONTROL DATA - R &	L D	
(Security classification of litle, body of abstract and inde	xing annotation must be e	ntered when the overall report is cl	asellied;
Letterman Army Institute of Research	1	LASSIF	CATION
Presidio of San Francisco, California	94129	2b. GROUP	
. REPORT TITLE		N/A	
Letterman Army Institute of Research	n Annual Progre	ess Report, FY 1972	
4. DESCRIPTIVE NOTES (Type of report and inclusive dater)			
Annual Progress Report, FY 1972, 1 AUTHORIS) (First name, middle initial, last name)	July 1971 - 30	June 1972	
· · · · · · · · · · · · · · · · · · ·			
30 June 1972	74. TOTAL NO. OF	PAGES 75. NO. OF REFS	
. CONTRACT OR GRANT NO.	MA. ORIGINATOR'S	REPORT NUMBER(S)	
N/A A. PROJECT NO.	LAIR Repo	ort No. 11	
۶.	35. OTHER REPOR this report)	T NO(S) (Any other numbers that m	ay be assigned
<i>d.</i>	RCS SGRI	D-288(R1)	
Reproduced from	12. SPONSORING M U.S. Arm Develor	Medical Research a Dent Command	and
	Washingto	n, D.C. 20314	
efforts of Fiscal Year 1972, at Letterm units are devoted to basic and applied importance; the effects of hemorrhagic ment of techniques for the early manag- injuries; to identify diseases of the or special importance to the field soldier problems; advising, guiding, supporti Letterman General Hospital.	k unit summari han Army Institu research in ski c shock on the h gement of comp al and maxillof and to obtain b ing, and encour	es of the investigativ ute of Research. Th n diseases of militar neart and brain; the lex maxillofacial woo acial tissues which a asin information on t aging clinical resear	re ese work y develop- inds and ire of these ich at
i I A.			

251UNCLASSIFIED

M. M. Marine

Sector Sector

All beita han san kan sa bana kana an Kana sa

を行ったかいたのとこ

110

-	KEY WORDS	LIN	IKA	LIN	IK B	LIN	IK C
		ROLE	WT	ROLE	WT	ROLE	WT
**				1		1	
Hemorrhagic shock		1	1		1		
Blood		1				1	
Brain			I	1			
škin]	1	{		
kin diseases			1				
fungal infection			}				
Friction blisters			1		1		
Human volunteers				ļ			
Maxillofacial injuries	1		1			1	
Clinical Investigation	8	1				ł	
Experimental animals	- R	1					
	•						
						1	
		1	1			1	
]	 		1	l
			[1	
							1
						1	
					2		
				1			
			1	1			
			1	ł			
				ł		I	
				1			
				1	- 1		
			1		1		
			1	l			
						1	
				1	1		
						1	
					1	1	
	a .		ł	I			
	il l				1		

Ì

\$U.S. GOVERNMENT PRINTING OFFICE: 1972-792 444/166

AD_____

¥

HEADQUAR TERS LETTERMAN ARMY INSTITUTE OF RESEARCH Presidio of San Francisco, California 94129

ANNUAL PROGRESS REPORT, FY 1972

1 July 1971 - 30 June 1972

RCS SGRD-288(R1)

iC

FOREWORD

This report summarizes the investigative effort of Fiscal Year 1972 at the Letterman Army Institute of Research. Seven of our 23 investigators with doctoral degrees concluded their service at the laboratory this fiscal year so their work is presented in more detail. New, significant knowledge was gained concerning man's immunological response to cutaneous fungal infections, the effect of prolonged water exposure on man's skin, true oxyhemoglobin dissociation curves in hemorrhagic shock, mandibular bone grafting using cadaver cortical bone and autologous marrow, and identification of the most acceptable oral suture material presently available.

Those clinical investigations at Letterman General Hospital involving collaborative studies or major financial, personnel, laboratory, or animal resources support from LAIR are included.

William a akene

WILLIAM A. AKERS Colonel, Medical Corps Commanding

And West and the second second

TABLE OF CONTENTS

Work Unit	Page
INDEPENDENT LABORATORY IN-HOUSE RESEA	<u>RCH</u>
Summary	2
380 Studies on Cerebral Pathophysiology in Early Hemorrhagic Shock	3
382 Characterization and Kinetic Studies of Discrete Classes of Granulocytes	8
386 Development of a Rapid Clinical Procedure for Assessing Blood-Oxygen Affinity Curves	11
387 Pathogenesis of Coliform Induced Colitis in Mice	20
388 Detection of (Superior Sagittal Sinus) Throm- bosis (In Dogs) Using Radionuclide Labelled Fibrogen	23
389 The Relationship of Polymorphonuclear Neutrophil (PMN) Chemotactic Activity to Inflammatory Periodontal Diseases in Military Personnel	26
391 Some Effects of Hypertonic Medium on Cultured Mammalian Cells	32
DERMATOLOGY RESEARCH DIVISION	
Summary	34
155 More Effective Topical Repellents Against Malaria Bearing Mosquitoes	35
156 Investigation on the Pathogenesis, Prevention and Management of Tropical Acne	41

Work Unit	Page
159 Studies on Blistering Produced by Mechanical, Thermal and Chemical Agente: Einetics of Blister Fluid Proteins	49
160 Clinical Evaluation of Alpha-Cyanoacrylates and Trearment of Friction Blisters	52
161 Biosynthesis of Proteins and Lipids in Human Skin with Particular Emphasis on Prickly Heat	59
162 Studies on the Effects of Heat and Humidity Upon the Skin with Particular Emphasis on Prickly Heat and Consequent Disabling Dermatoses	62
Normal and Abnormal Variations in Eccrine. Sweat Delivery and Distribution	.71
163 Composition of Lipids	. 73
167 Evaluation of Promising Antifungal Agents in Soldiers in a Combat Zone	76
168 The Effects of Prolonged Water Exposure on Human Skin	84
Bacterial Sampling Technique	92
001 Delayed Type Skin Reaction and Lymphocyte . Transformation in Cutaneous Diseases	9 4
004 Biochemical Mechanisms of Pathogenesis in Fungal Skin Infections	108
005 Development of Methods for Diagnosing and Combatting Susceptibility to Fungal Infections	109
006 Experimental Fungus Infections in the Skin of Man: A Therapeutic Model	117

GENERAL AND AND

Martin States and States and States

WARD THE LEAST

÷.

ï

١.

CALL CONTRACTOR OF CONTRACT

Work Unit	Page
009 Yeast Flora of Interdigital Areas of the Foot	118
MAXILLOFACIAL SCIENCES DIVISION	
Summary	124
135 Oral Disease in Military Populations	125
137 Oral Fluorescent Bacteria in Military Populations	126
141 Control of Bacteremia Associated with Tooth Extraction	130
143 Endodontics in Military Dentistry	133
144 Prevention of Post-Extraction Alveolitis	138
146 Effect of Electric Stimulation on Bone Repair	142
147 Bone Repair	146
060 Early Management of Oral & Maxillofacial Wounds	150
061 Early Restoration of Oral Integrity	151
062 Incidence of Oral and Maxillofacial Injuries	156
063 Early Restoration of Mandibular Continuity	159
064 Mandibular Bone Grafts	164
066 Tissue Reaction to Sutures	172
067 Repair of Salivary Gland [®] Ducts	178
068 Oral and Maxillofacial Wound Infection	181
069 Actinic Blocking Agents for Protection of Lip Mucosa	185

÷¢

17. N. S. S. S. S.

1 m m m

5

v

Work Unit	Page
CLINICAL RESEARCH SUPPORT DIVISION	
Summary	190
091 Clinical Management of Patients Undergoing Radiation Therapy	191
092 In-vitro Interactions of Digitoxin-I-125 and its Metabolites with Cholestyramine and Tetra- ethylenepentamine	195
CLINICAL RESEARCH SERVICE LETTERMAN GENERAL HOSPITAL	
004 Clinical Investigations - LGH and LAIR	204
Study of the Effect of Availability of a Computer Program to Suggest the Digoxin Dosage and Attendant Toxicity/Efficacy	205
Sensory Characteristics of Autistic Children	213
Lecithin/Spingomyelin Ratio in Amniotic Fluid and its Clinical Application	215
In-vitro Study of the Prausnitz-Kustner Reaction	218
Antibiotic Therapy of Acute Otitis Media in Infants and Young Children. Infections Caused by Hemophilus Influenzae	221
The Study of Adriamycin NSC-123127 for Disseminated Malignancy	223
Techniques of Vitreous Surgery	226
Evaluation of the Renin Angiotensin I System in Labor	. 229

nyesse postani

STANK STANK

à

Work Unit	Page
Documentation of Hand Function: A Comparative Analysis of Direct Electrostatic Systems with	
Standard Clinical Procedures	242
LAIR PUBLICATIONS - FY 72	245
LAIR PRESENTATIONS - FY 72	247
DISTRIBUTION	249
DD FORM 1473	250

\$

and the same

• • • •

and a first stranger a sufficiency and sense as a particular and

•

Ł

4

`\$

vii

IN-HOUSE LABORATORY INDEPENDENT RESEARCH

Program Element 6.11.01.A

Project Number 3A061101A91C

Task Area Number 00

Charles To The Anna South 2

a the set with the set of the set

E Charles Constant and Co

INDEPENDENT LABORATORY IN-HOUSE RESEARCH

The Independent Laboratory In-House Research Program consists of research the Commander considers worthwhile toward solution of military medical problems that are not funded in other programs. Seven separate investigations are being conducted in this area.

Preliminary findings of research in hemorrhagic shock reveal light and fluorescent microscopy have demonstrated endothelial distortions in the cerebral capillaries and protein dye leaks in the blood-brain barrier of sheep in hypovolemic shock. These lesions appear to be an early and potentially reversible factor in shock. Preliminary findings indicate that simple protective therapy may be possible to prevent lesions and the development of irreversible shock.

A simple, rapid method for determining blood-oxygen affinity has been developed which requires small quantities of blood and uses equipment available in most medical facilities. This technique has great potential for evaluating acutely injured patients in combat medical facilities.

A laboratory animal model has been developed to study superior sagittal sinus thrombosis. Studies are in progress to develop methods for diagnosing this condition. This would be of great use in treating patients with acute head injuries.

Ways to separate and obtain pure samples of the five types of white blood cells are being developed. Findings indicate that this method is more accurate than current techniques.

An investigation is underway to determine if coliform induced colitis in mice is comparable to human chronic idiopathic ileitis and colitis and a suitable laboratory animal model is being perfected.

Studies to determine if neutrophil chemotactic variations in the normal individual influence susceptibility to inflammatory diseases could lead to a method for screening and identifying individuals susceptible to other inflammatory diseases.

In-vitro laboratory studies are being conducted on mammalian cell function. This work is directed toward identifying factors which could influence wound healing in patients.

States and the last

2

	AND TECHNOLOGY	WORK UNIT S	UMARY	DA	OB 68	09:	72 ()7 O		DD-D	UNTROL SYMBO (LE(AR)u36
71 07 01	a sine of summary D.Change	B SUMMARY SCYV ^B	N. WORK SECURITY"	P. NEON	IA		NL	R'N	A SPECIFIC C	ATA - ACC £35 AO	A UDAK UNS
NO./CODES:*	PROGRAM ELENENT	PROJECT	NUMBER	TASK A	REA NU	NEER			WORK UNIT	NUMBER	
PRIMARY	61101A	3A061101	A91C	1	00	_	,	3	80		والمحصوما والمقاب المارود الرع
					<u>× × · · · · · · · · · · · · · · · · · ·</u>	· ·	\$ 5.00	: <u> </u>			
				1			*:***				· · ·
TITLE (Procedo with	Somethy Classificonian Code	,•									
(U) Studies	on Cerebral Path	orhysiology i	n Early Hem	orrhag	ic Sho	ck (05)				
003300 - C				1			<u></u>				
					A 1				C. Lu ha		
0712			NI.		A				C. In-no	use	
- CUNTRACT/GRANT				10. RES		STIMAT		PESSI	HAL MAN YRS	L PUN	06 (7n these as th
DATENEFFECTIVE	' NA	EXPIRATION.		1	~	3	1		2	1	-
NUMBER.®				FISCAL		<u> </u>	<u> </u>		<u> </u>		7
, type .		4 ANDUST:		YEAR	Country of	•	ľ		_	1	•
KIND OF AVARD:		f. CUM. AMT			7	3			3		8
AESPONSIOLE DOD	GREANIZATION			SO. PER	FORMING	ORCANI	ATION				
ME:0 Letter	man Army Institu	ite of Research		HALE:*	Lei	tterm	an ['] Arr	nv ľ	stitute o	f Rese	arch
Presidi	io of San Francisc	co, CA 94129				nicel ⁴	Decor	wh C	unnart N	ivicia-	
DOREM:*		,		ADDRES	41 ⁰ D	uivat . sidio	ncscal	CII 3	ncieco C	A GA1	29
				1	L LC	JIUIU	UI Jäl	r T. Týl	nuscu, C	n 771	u /
				PMHCI	AL INVES		A (Pumlah		I U.S. Anndrait	jne likulias	•
	WAL			-	* Rec	nchu	ac M	M۸	IMC		
ANG Akore	W.A. COL MC			TELE	DIL PHONE:	415:4	561.41	74			
TARTIS	5.561.5181			-	L SECURI	TY ACCO		. 7 -7 068:			
	-301-3101		······			TIANTA					
											D
	. BACK all Samuelly Classif	tentan Cada)		1							
(U) Hemor	rhagic shock: (11)	sheen: (11) o	erebrai blood	flow:	(In b	lood-	brain-l	arrie	27		
TECHNICAL ABUT	TIVE .* 24 APPERATE	PROGRESS / Dunish		dentified to		Proceedin 4			turity Classific	elles Cad	
25. (U) 71 1 3 5 7 7	07 – 72 06 Stud Fechniques for ob Fechnique for seq copy are now bei acuolation and ca protein bound dye These microscopic mportant cerebra	dies on cerebr serving piat (o uential cerebr ng used. Ligh apillary endot es about capil c changes are a l lesion in her nt somewhat i	al pathophys cerebral cortic ral biopsy, lig it microscopy helial distorti laries (leak of all potentially norrhagic sho improved EE	iology cal) an ht and y show ions. 1 blood y revers ock. G and i	in ear d retir electr s eden Fluore l brain sible a blood late th	ly her hal mir ron m na of scence barri nd su brain at sin	morrh icrosc icrosc the ce e micr ier). E pport barrie	agic : cula opy : rebra osco lecti our cur er in	shock we ture were and fluor al cortex, py shows conmicros postulate a series o tive there	re con devise escence neuro leaks icopy d early f expe	tinued. ed. e micro- nal of is pending and riments
i P)	NaHCO ₃ treatment with pathologic ve A manuscript is be	erification and eing prepared	l support the	hozra			• •			••	possiole.

180

DD, 1498

and the second secon

1

the states

· · · ····

and the state of the

Studies on Cerebral Pathophysiology in Early Hemorrhagic Shock

Michael M. Bronshvag, MAJ, MC

PROBLEM:

Studies of hemorrhagic shock and especially of cerebral abnormalities in shocked organisms are directed towards answering basic questions:

1) Is there a structural lesion or physiologic derangement of the brain in the shocked but viable organism, as opposed to an analogous lesion observable only in the moribund organism?

2) Is such a lesion the cause of loss of protective (autoregulatory and homeostatic) mechanisms, contributing to impaired viability?

3) Is such a lesion the marker for borderline "irreversibility"? Is such irreversibility due only to impaired homeostasis or also to cerebral damage per se?

4) Can supportive treatment protect the brain and enhance viability while shock and its causes are being corrected?

We defined shock as hypotension plus systemic dysfunction caused by a disease or injury, and studied shock caused by atraumatic, acute blood loss ("hemorrhagic shock") in the adult, unanesthetized sheep. By doing this, we hoped to avoid possible artifacts induced by general anesthesia, coexisting tissue necrosis or infection, or chronic hypotensive state and secondary metabolic changes. We used sheep because they are docile and can be examined unsedated during blood loss.

Both our previous experimental experience and the clinical writings of others describe in hemorrhagic hypotension with shock, the sudden appearance on the EEG of continuous high voltage 1-3 ps delta waves, and we have also noted associated cortical suppression. This striking change, called the "slow wave point" by us, occurring in an awake and viable sheep, suggested that an early, primary cerebral lesion exists. We, therefore, used EEG changes as an important parameter in our studies.

As described below, we monitored EEG, blood-brain barrier and sequential histopathology, and believe we have described an early cerebral lesion of theoretical interest and perhaps clinical importance.

We have also begun investigation of simple pharmacologic agents, specifically trying to find one which would prevent or modify the early cerebral lesion in hemorrhagic shock and hopefully also improve viability of the organism.

APPROACH:

Unanesthetized adult sheep were bled from a femoral artery catheter to the slow wave point at the rate of 10-20 cc per minute. Average blood loss was 800-1000 cc or approximately 40 cc/kg of body weight. EEG was recorded bilaterally from frontal and occipital areas. Integrity of the vascular endothelium with regard to albumin ("bloodbrain barrier") was measured by serial technitium99 -albumin brain scanning, and also by gross and fluorescent microscopic examination of cerebral tissue after the injection of Evan's blue (T1826) - an albumin-bound dye that fluoresces red in blue-free light. Tissues were taken for light and electron microscopic examination. In some animals 10 cc of isotonic NaHOO, was injected slowly into one carotid to see if it protected the ipsilateral cerebral hemisphere.

RESULTS AND DISCUSSION:

1. EEG - As previously discussed, the EEG changes (slowing to 1-3 cps high voltage activity) were of relatively sudden onset, and did not correlate very well with BP or amount of blood loss, although they were a sign of severe blood loss (mean 23.4 cc/kg to allow wave point). They probably represent the onset of some hemodynamic or metabolic event. Since in compensated hemorrhagic hypotension, systemic vasoconstriction is associated with cerebral vasodilation to maintain cerebral blood flow (cerebral autoregulation), so the slow wave point may represent that time at which cerebral autoregulatory mechanisms fail. An additional or alternative hypothesis is that the slow wave point represents that point at which a perverse metabolic process (ammonia or lactate buildup, endothelial edema or necrosis) causes cellular dysfunction. A metabolic process of this type might be singularly susceptible to simple pharmacologic treatment.

2. Vascular Permeability to Albumin - "Blood Brain Barrier" - As shown by technitium⁹⁹ pertechnitate scanning (9 of 11 experiments), technitium⁹⁹ - albumin couples (4 of 5 experiments), and Evans blue dye technique (gross inspection 9 of 10: fluorescence microscopy 3 of 4), a vascular leak occurs in the capillary endothelium to albumin-sized molecules. This type of lesion generates considerable theoretical and practical interest for it is not typical of anoticischemic cerebral lesions, but is seen in CO narcosis and hypertensive encephalopathy and strongly suggests²that a metabolic or vasospastic phenomenon in addition to simple oligenic hypoxia is present. 3. Results of NaHCO, Treatment - In hopes of reversing a postulated metabolic cerebral of metabolic cerebral endothelial lesion, several sheep had 10 cc of isotonic NaHCO, injected into the right carotid artery. Results were equivocal. ³(In no animal was unequivocal EEG improvement noted: in 4 of 10 brain scan protection against vascular leak was noted; and in 3 of 3 sheep, decreased Evans blue staining was noted.)

4. Neuropathology - Although a formal neuropathological description (which will be the basis of a manuscript is pending) the following changes have been noted in shocked but viable animals.

A. Light microscope - 1) Edema, extra-cellular and about blood vessels and neurons, similar to that seen in cases of vascular vasogenic protein leak (breakdown in blood brain barrier). 2) Anoxic neuronal changes - nuclear and cytoplasmic vacuolations, chromatolysis, increased cytoplasmic eosinophilia. 3) Endothelial changes ring hemorrhages and vascular distortion. These light microscopic changes are more compatible with an anoxic-metab-lic plus vascular (vasogenic lesion than with pure anoxic change.

B. Electron microscopic changes - pending

C. Fluorescence microscopy - Evan's blue, when activated, fluoresces red. Fluorescence microscopy has shown in several animals perivascular fluorescence compatible with vascular protein leak (breakdown of blood-brain barrier.)

DISCUSSION:

or and the second se

6

The neuropathology and pathophysiology of hemorrhagic shock in sheep has been examined. Evidence for a metabolic and/or vascular lesion exists in contrast to the pure anoxic-ischemic type lesion described in the literature. Vascular and metabolic lesions perhaps can be modified by simple pharmacologic treatment.

PLANS:

1. With the aid of a consulting neuropathologist, we will quantify and describe the light microscopic, electron microscopic and fluorescence micropic changes.

2. Test a series of simple pharmacologic compounds to see if they can protect the cerebral microvasculature (blocd-brain barrier) from pathologic change and hopefully improve organism viability.

3. Using depth electrode technique, further examine EEG changes in hemorrhagic shock, looking for useful clinical parameters.

4. Using the Kowa fundus camera, examine vascular permeability to fluorescein of the retina (blood-retina barrier).

のないないとない

*

シードになっていた。

このでなどといいたたいという

the state with the state of the

4

5. Using the Xencu¹³³ desoburation technique and the Doppler flowmeter, to measure and correlate cerebral blocd flow with the above changes.

	AND TECHNOLOGY	WORK UNIT S	UNNARY	DA	OC 6791	12.0	72 07 01	5ART	DU-DI	CONTROL SYNDO K&E(AR)636
DATE PREV SUMAY	4 KIND OF SUMMARY	s. summary setv ^a U	4 NORK SECURITY	P. REGR	ACING [®] BR	NI	N INSTA'N	AN SPECIFI	C DATA-	A WORK UNIT
NO./CODES:*	PROGRAM ELEMENT	PROJECT	NUMBER	TASK A		Γ		WORK UN	IT NUMBER	1
PRIVARY	61101A	<u>3A061101</u>	<u>IA91C</u>	0	0	-	382			
CONTRIBUTING				 	·	4			· · · · · ·	
CONTRIBUTING	teastin Cleanilitation Code	•				<u> </u>				
U) Characte	rization and Kin	etic Studies o	f Discrete Cla	isses of	f Granuloc	yte	S			
SCIENTIFIC AND TEN 03500 - Clir	CHHOLOGICAL AREAS*	02300 - Bio	chemistry							
START DATE		14. ESTIMATED CON	LETION DATE	TIL FUN	DING AGENCY	_		16. PERFOI	MANCE MET	HOP
70 03				D	4			C. In-ł	iouse	
CONTRACT/GRANT				18. AES		TE	-		AS & FUR	106 (In thousands
DATES/EFFECTIVE:	NA	EXPIRATION			PRECEDING		-			1
1936CR."		4 AMOUNT.		FISCAL	72 CURRENT		1			1
		. Citta A14*		1	73	ļ				0
RESPONSIBLE DOU	DRGANIZATION		·	30. PER	FORMING ORGAN	II GAT	ION	- <u>T</u>		
			····	-						
Lette	rman Army Insti	tute of Resea	rch		Lei	tter	man Arr	ny Insti	tute of	Kesearch
essie Presid	tio of San Franci	sco, CA 9412	59	ADDRES	s:* Bio Dec)Che	emistry I	aporat	SCO CA	94129
					rre	:21Q)	10 01 280	1 fanci	<i>, </i>	74147
				PRINCIP	AL INVESTIGAT	'OR ()	ruminh SEAM I	I Ų.S. Acadec	nic (nativilar	Ŋ
PONSIBLE INDIVID	JAL	•		NANE:	• Ch	ene	y, B.A	M.A.		
Aken	s, W.A., COL MC			TELE	PHONE: 41	5-5	61-2483			
APHONE: 415-5	561-5181				L SECURITY AC	COUN	Y NUMBER:			
4949445 ¥82				NANE		JH3				
				MAMP	1					DA
NEVBORDS (Procede	BACH with Somering Classic	laukonaiaaia.	(II) homotol	0.01/						
neveorios (Pricidi (<u>U) leukocyt</u> technical objec 25. (U) 71 (tive." in sector (U)	leukopoiesis; Phoeness (Furnish) rential marro	(U) hematolo Interioral perspector (w cell counts	ogy milliod h have l	been made	on	about 2	o subje	cts. Mai	rrow cores
(U) leukocy1 (U) leukocy1 Technical object 25. (U) 71 0 were were data	e isolatich: (U) rive, a Approach, an 07 - 72 06 Diffe e embedded in pla made on triplica has been obtained	leukopoiesis; Prential marro astic and 3µ s te from each d for definiti	(U) hematole antivious perspective (w cell counts ections were sample. Agree	ogy Amilliod by have l selecti sement	been made vely staine t was exce	on d.	about 2 Counts of t in good	0 subjection 0 f 10,00 1 section	cts. Mar 00 20 ns, but 1	rrow cores (100 cells not enougl
(U) leukocy1 (U) leukocy1 Technical object 25. (U) 71 0 were were data	te isolation; (U) rive, a approach, and rive, a approach, a approach, and rive, a approach, a ap	leukopoiesis: Procestis (Formion astic and 3μ s te from each d for definitin	(U) hematole antividual paragraphe (w cell counts ections were sample. Agree ve evaluation.	ogy Amilliod by have l selecti sement	peen made vely staine t was exce	on d.	about 2 Counts of t in good	o subjection of 10,00 section	itterium cont cts. Mar 00 20 ns, but 1	rrow cores ,000 cells not enougl
NEVERGEORIA (Process (U) leukocy1 Technical object 25. (U) 71 0 were were data	tive." 14 approach, 18 77 - 72 06 Diffe e embedded in pl made on triplica has been obtaine	leukopoiesis: Prential marro astic and 3µ s te from each d for definitin	(U) hematole w cell counts ections were sample. Agree ve evaluation.	ogy dmilliod by have l selecti eement	been made vely staine t was excel	on ed. llen	about 2 Counts of t in good	0 subject of 10,00 I section	itestion contracts. Man 00 20 ns, but 1	rrow cores ,000 cells not enougl
NEVERADO (Processo (U) leukocy1 TECHNICAL OBJEC 25. (U) 71 0 were were data	te isolation: (U) Tive, a approach, and tive, a approach, a approach, and tive, a approach, a a	leukopoiesis: Prential marro astic and 3µ s te from each d for definitin	(U) hematole intribut products (w cell counts ections were sample. Agre ve evaluation.	ogy Animed b selecti sement	been made vely staine t was excel	on ed. llen	about 2 Counts of t in good	0 subject of 10,00 I section	cts. Mar cts. Mar 00 — 20 ns, but 1	rrow cores ,(100 cells not enougl
NEVERDE (D) leukocyt (U) leukocyt Technical objec 25. (U) 71 0 were were data	le isolatic n: (U) rive. [*] at Approach, an 07 - 72 06 Diffe e embedded in pla made on triplica has been obtaine	leukopoiesis; Prosets (formion astic and 3µ s te from each d for definitir	(U) hematole introduct programs (w cell counts sections were sample. Agree ve evaluation.	ogy Amilliod b selecti sement	been made vely staine t was exce	on d. llen	about 2 Counts of t in good	0 subjection of 10,00 i section		rrow cores ,000 cells not enougl
NEVERDE (Processon (U) leukocyt Technical objec 25. (U) 71 0 were were data	te isolation; (U) rive, * 24 Approven, 24 rive, * 24 Approven, 24 07 - 72 06 Diffe e embedded in pl made on triplica has been obtaine	leukopoiesis: Prosetta (Formion astic and 3µ s te from each d for definitin	(U) hematole w cell counts ections were sample. Agre ve evaluation.	ogy Aminina h have l selecti sement	been made vely staine t was exce	on ed. llen	about 2 Counts of t in good	o subject of 10,00 I section		rrow cares ,000 cells not enougl
(U) leukocyl (U) leukocyl technical objec 25. (U) 71 0 were were data	te isolation: (U) 11/12.* 24 APPROACH, 25 11/12.* 24 APPROACH, 25 27 - 72 06 Diffe e embedded in pl made on triplica has been obtaine	leukopoiesis; Prosestis (Formion of astic and 3µ s te from each d for definition	(U) hematole w cell counts ections were sample. Agre ve evaluation.	ogy Amilliod b selecti sement	been made vely staine t was exce	e on ed. llen	about 2 Counts t in good	o subject of 10,00 I section	ts. Mar 00 - 20 ns, but 1	rrow cores ,000 cells not enoug
(U) leukocyi (U) leukocyi technical objec 25. (U) 71 0 were were data	te isolation; (U) (U) (U) (U) (U) (U) (U) (U) (U) (U) (U)	leukopoiesis: Prosettial marro astic and 3µ s te from each d for definitir	(U) hematole introduction personation (w cell counts ections were sample. Agree ve evaluation.	ogy fmilliod h selecti sement	been made vely staine t was exce	on ed. llen	about 2 Counts of t in good	o subject of 10,00 I section	cts. Mar 00 — 20 ns, but 1	rrow cares ,000 cells not enoug
(U) leukocyi (U) leukocyi technical objec 25. (U) 71 (were were data	te isolation: (U) Tive, ' 14 APPROACH, 21 Tive, ' 14 APPROACH, 21 Ti	leukopoiesis: Prosetta (rumie) astic and 3µ s te from each d for definitin	(U) hematole introduct personance w cell counts sections were sample. Agre ve evaluation.	ogy fmillied h selecti ement	been made vely staine t was exce	on d. llen	about 2 Counts of t in good	0 subjector of 10,00 1 section	ts. Mar 00 20 ns, but 1	now cores ,000 cells not enoug
(U) leukocyi (U) leukocyi technical objec 25. (U) 71 (were were data	le isolation; (U) Tive, * 24 Approvace, 24 Tive, * 24 Approvace, 24 07 - 72 06 Diffe e embedded in pl made on triplica has been obtaine	leukopoiesis; Prosets (Furnite of astic and 3µ s te from each d for definition	(U) hematole introduct programs (w cell counts sections were sample. Agre ve evaluation.	ogy fmilliod h selecti sement	been made vely staine t was exce	on ed. llen	about 2 Counts of t in good	O subject of 10,00 I section	cts. Mai 00 20 ns, but 1	not enoug
(U) leukocy1 (U) leukocy1 technical objec 25. (U) 71 (were were data	le isolation; (U) Tive, " at Approach, and Tive," at Approach, and true," at Approach, and true, " at Approach, and true," at Approach, and true, " at Approach, and true," at Approach, and true, " at Approach, and true," at Approach, and true," at Approach, and true, " at Approach, and true," at Approach, and true," at Approach, at Approach, and true, at Approach, at	leukopoiesis: Prosetta (Furnich of astic and 3µ s te from each d for definition	(U) hematole introduct programs (w cell counts sections were sample. Agre ve evaluation.	ogy have I selecti sement	been made vely staine t was exce	on ed. llen	about 2 Counts of t in good	o subject of 10,00 I section	ttento con cts. Mar 00 20 ns, but 1	not enoug
(U) leukocy1 (U) leukocy1 technical objec 25. (U) 71 (were were data	te isolation; (U) tive, 'a approach, and tive, 'a ap	leukopoiesis; Prential marro astic and 3µ s te from each d for definiti	(U) hematole introduction percentation w cell counts ections were sample. Agree ve evaluation.	ogy Amililied b selecti sement	been made vely staine t was exce	on ed. llen	about 2 Counts of t in good	o subjec of 10,00 I section	tteellen con	nov cores (100 cells) not enoug
(U) leukocy1 (U) leukocy1 technical objec 25. (U) 71 (were data	le isolation; (U) Tive, ⁹ 24 Appendace, 24 Tive, ⁹ 24 Tive, ⁹ 24 Appendace, 24 Tive, ⁹ 2	leukopoiesis: Prential marro astic and 3µ s te from each d for definitin	(U) hematole individual personants we cell counts sections were sample. Agree ve evaluation.	ogy fmillied h selecti ement	been made vely staine t was exce	on ed. llen	about 2 Counts of t in good	0 subjec of 10,00 1 section	cts. Mar 00 20 ns, but 1	nov cores (000 cells not enoug
NEVERAL OBJECT	le isolation: (U) Tive, " 14 APPROACH, 21 Tive," 24 APPROACH, 24 Tive," 24 APPROACH, 24 Tive," 24	leukopoiesis; Prosets (rumie) astic and 3µ s te from each d for definition	(U) hematole introduct perspective (w cell counts vections were sample. Agre ve evaluation.	ogy fmillied b selecti ement	been made vely staine t was exce	on ed. llen	about 2 Counts of t in good	0 subjector of 10,00 I section	ts. Mar 00 20 ns, but 1	not enoug
(U) leukocyi (U) leukocyi Technical objec 25. (U) 71 (were were data	le isolation: (U) Tive, " a apenoach, an 07 - 72 06 Diffe e embedded in planate on triplica has been obtaine	leukopoiesis: Prosets (formion of astic and 3µ s te from each d for definition	(U) hematole introduct perspective (w cell counts sections were sample. Agre ve evaluation.	ogy fmillied b selecti sement	been made vely staine t was exce	on ed. llen	about 2 Counts of t in good	0 subjec of 10,00 1 section	cts. Mai 00 20 ns, but 1	not enoug
NEVEORDS (Proceed (U) leukocy1 TECHNICAL OBJEC 25. (U) 71 (were were data	te isolation; (U) rive, 'a approach, and rive, 'a approach, and prove, 'a approach, and true, 'a a	leukopoiesis; Prosets (formited) astic and 3µ s te from each d for definition	(U) hematole introduct perspective (w cell counts sections were sample. Agre ve evaluation.	ogy have I selecti ement	been made vely staine t was exce	on ed. lien	about 2 Counts of t in good	0 subjector of 10,00 1 section	ttenter con	not enoug
(U) leukocyt (U) leukocyt Technical objec 25. (U) 71 (were were data	te isolation; (U) tive, 'a approach, and tive, 'a ap	leukopoiesis; Prential marro astic and 3µ s te from each d for definiti	(U) hematole w cell counts ections were sample. Agre ve evaluation.	ogy Amililied b selecti sement	been made vely staine t was exce	on ed. llen	about 2 Counts of t in good	o subjec of 10,00 I section	tteetten contraction cts. Mar 00 20 ns, but 1	not enoug
(U) leukocy1 TECHNICAL OBJEC 25. (U) 71 (were were data	tive," 14 APPROACH, 14 Tive," 14 APPROACH, 18 07 - 72 06 Diffe e embedded in pl made on triplica has been obtaine	leukopoiesis: Prosetta (rumion o astic and 3µ s te from each d for definitin	(U) hematole individual personante w cell counts sections were sample. Agre ve evaluation.	ogy fmillied h selecti ement	peen made vely staine t was exce	on ed. llen	about 2 Counts of t in good	0 subjec of 10,00 I section	tteetten contraction contracti	now cores (000 cells not enough
NEVEORDS (Process (U) leukocy1 TECHNICAL OBJEC 25. (U) 71 (were were data	le isolatic n; (U) Tive, ⁹ 24 APPROACH, 28 107 - 72 06 Diffe e embedded in pl made on triplica has been obtaine	leukopoiesis; Prosetta (rumion o astic and 3µ s te from each d for definitio	(U) hematole introduct perspective (w cell counts vections were sample. Agre ve evaluation.	ogy fmillied h selecti ement	been made vely staine t was exce	on ed. llen	about 2 Counts of t in good	0 subjector for the section	ts. Mar 00 20 ns, but 1	rrow cores ,000 cells not enoug
NEVERBORDS (Protect (U) leukocy1 TECHNICAL OBJEC 25. (U) 71 (were were data	te isolation: (U) Tive, " a approach, and tive," a approach, and prove of the option of the optio	leukopoiesis: PROGRESS (Furmited i rential marro astic and 3µ s te from each d for definition	(U) hematole introduct perspective (w cell counts sections were sample. Agre ve evaluation.	ogy fmillied h selecti sement	been made vely staine t was exce	on ed. llen	about 2 Counts of t in good	0 subjector of 10,00 1 section	ts. Mar 00 20 ns, but 1	not enoug

Section 1

And advertising the second

A. Samer

ちょうやい うち いちえいち ちちい

9

v_anger

š.,

3

\$

2

ويووسها والمجالية والمحافظ والما المكافع عاكم

Sec. .*

Characterization and Kinetic Studies of Discrete Classes of Granulocytes

Barbara Cheney, M.A., Medical Zoologist

PROBLEM:

An accurate enumeration of the cells of the bone marrow is essential to effectively study granulocyte kinetics. The granulocyte develops, proliferates, matures, and is stored in the marrow until it is needed. Rate of development and cell numbers in the different states will vary being dependent on body needs, e.g. normal state, infection, and hematological disorders.

Cell counts made from bone marrow aspirates are not satisfactory as many cells are damaged in the preparation, and, therefore, unidentifiable. It is necessary to obtain a marrow "core" and prepare this so that the cells are intact and countable in situ. Once normal values are established, changes in marrow cell count in abnormal states can be interpreted. Marrow section data will be correlated with other available techniques (1, 2, 3).

APPROACH:

The marrow samples have been obtained at the University of Washington Hospital and prepared in the laboratory of the Division of Hematology. Cell counting has been done at LAIR. Marrow cores are fixed in glutaraldehyde, decalcified in FDTA, and embedded in methyl-methacrylate. Sections, 3 micra thick, are cut and stained with eosine-y and azure II after reaction with Naoce-Kl. The granulocytes are tallied in the following groups: blasts, promyelocytes, and myelocytes (proliferative compartment); metamyelocyte and bands (maturational compartment); segmented cells (storage compartment). Eosinophilic granulocytes are totalled separately from neutrophilic granulocytes. Normoblasts, megakaryocytes, lymphocytes and plasma cells are also counted. There is an "unknown" category for cells that cannot be identified for whatever reason.

RESULTS AND DISCUSSION:

The preparation of these slides and the cell differentiation is a lengthy, time-consuming process. Approximately twenty subjects have been counted to date in triplicate. Agreement between good sections has been excellent and I believe that this method of enumeration will be satisfactory.

-146.2007-De

While the marrow preparation was being developed, samples were obtained from patients hospitalized for blood dyscrasias. It is only now that specimens are underway from normal subjects.

FUTURE PLANS:

Marrow cell counts from "normals" are in progress. More data has to be added from patients. Granulocyte survival and turnover studies are underway at the University of Washington.

REFERENCES :

- Harper, Laurence A., Megakaryocyte Quantitation. J. Clin. Investigation, 47:452-457, 1968.
- Harper, Laurence A., Kinetics of Thrombopoiesis.
 <u>J. Clin. Investigation</u>, 47:458-464, 1968.
- 3. Harper, Laurence A., Thrombokinetics in Man. J. Clin. Investigation, 48:963-974, 1969.

RESEARCH	AND TECHNOLOG	Y WORK UNIT S	UMMARY	DA C	сч ассение ЭС 6813	1. DATE OF 1	C11	ABPORT DD-D	CONTROL SYNS R&E(AR)030
BATE PREVEUMAY	6. KIND OF SUMMARY	S. SUMMARY SCTT	. TOAK SECURITY	P AUER	ADING" RO	DIER'N META'N	SA SPECIFH	C DATA -	0. L.VEL 07 5
71 07 01	D. Change	U	บ	N	IA	NL	10 yes		A. WORK YH
. #0./COBES:*	PHOORAM ELEMENT	PROJECT	NUMBER	-		•	WORK UN	IT NUMBE	harman an the state of the stat
PRALARY	61101A	3A06110	1A91C		00		386		
	62110A	3A06211	0A826		00		217	,,	
Affinity Curr Affinity Curr b scientific and te 003500 - Clin	res (05) CHMOLOGICAL AREAS [®] Dical Medicine	"(U) Develop	ment of a Ra	pid Cli	inical Pro	cedure for	Assessing	Blood-	Oxygen
START DATE		14. ESTINATED COM	PLATION DATE	15 PUNE	HAS AGENCY		IL. PERPOA	MARCE ME	00
70 09		CONT		DA	i		C. In	-house	
CONTRACT/URANT				-	OURCES ESTIN	ATE & PROPE	SHOWAL MAN Y	RS L FU	NDL (In these the
DATES/EFFECTIVE:	NA	EXPIRATION:			******				
NUMBER."				FISCAL	72		1		13
1772:		4 ANOUNT:		YEAR	CUMMENT				
KIND OF AWARD:		f. CUM. AMT.		<u></u>	73	<u>I</u>	.75		12
. RESPONSIBLE DOD (DRGANIZATION	L		38. PERI	foinn 6 or 6/	untation			
AMEI* Lette Donese:* Presid	rman Army Inst lie of San Franc	itute of Resea isco, CA 9412	rch 29	NAME:" ADORES PRINCIP	Lettern Clinical Presidio	nan Army Research o of San Fr	Institute o Support E cancisco, C	of Resea Division CA 941	arch 29
	AL			-	• Mavilla	ID Phr	\	•••••••••••••••••••••••••••••••••••••••	•
	WA. COLMO	•		TELEP		.561.4714	7.		
IANE: Aleri		•		-	L SECURITY A	COUNT NUMBER	•		
NAME: AKCT	561.5181			4					
NAME: ARET	61-5181	ودر مشواط المددون الأراك سارت		ANOCIA	TE INVESTIGA	TORS			
NAME: AKER TELEPHONE: 415.4	51-5181				TE INVESTIGA	7 086			

(U) Blood-oxygen affinity curve; (U) oxyhemoglobin dissociation; (U) blood-gas transport

. TECHNIGAL OBJECTIVE,® 24. APPROACH, 28. PROARESS (Panilah & Kindeol parapartie Idealities) by number. Freedow cast of and primiting Constituenting Constituents

25. (U) 71 07 - 72 06 Data accumulated during the past year indicates that the technique can be successfully applied as a rapid clinical procedure for determining blood-oxygen affinity. Baseline studies of healthy volunteer subjects produced normal values for standard measures of the shape and position of the oxyhemoglobin dissociation curve ($P_{50} \triangle P_{50/\Delta} \log pH$, and the "n" value for Hill plot slope). The test requires only 0.20 of blood and can be completed in 5 or 10 minutes, making it ideal for routine applications. In addition, the required instrumentation is commonly available in most hospitals or clinics and relatively unskilled technical personnal can become facile with the technique after a few trials. This latter advantage results in part from the fact that volumetric accuracy is not necessary and also that the required information is translated to an electrical signal, thus permitting a permanent record of the test that can be retrieved and checked as required. Application of the technique to several clinical problems has been initiated and although the results do not at yet warrant definitive conclusions, several interesting observations have been obtained. For instance, volunteers receiving the antimalarial drug primaguine displayed a significant (both statistically and physiologically) decrease in blood-oxygen affinity commencing on about the fourth day after start of the drug, a shift which was correlated with a decrease in functional hemoglobin. All subjects displayed a predictable negative relation between functional hemoglubin and P50 whether on or off the drug. Several in vitro trials have suggested that epinephrine may alter oxygen affinity. Additional tests of this effect are planned. Working arrangements with LGH's Intensive Care Unit have been formulated to permit analysis of oxygen affinity with patients undergoing treatment in this facility.

D. # 1498

Maria Salar Side and State Secure were w

ちょういろんべいとしていたちとういうとうと

Development of a Rapid Clinical Procedure for Assessing Blood-Oxygen Affinity Curves

J. Ryan Neville, Ph.D., Research Physiologist

PROBLEM:

Interest in oxygen transport has recently been stimulated by the discovery that the position of the oxyhemoglobin dissociation curve is significantly altered by changes in the intracellular concentration of a number of metabolic intermediates, particularly 2, 3-diphosphoglycerate (DPG) and adenosine triphosphate (ATP) (1). These relatively small chemical entities, whose traditional role has been involved with the storage and release of chemical energy for cellular metabolic processes, have been shown to combine with the protein chain associated with a deoxygenated here group and to affect the allosteric properties of the entire 4-chain hemoglobin molecule. As a consequence of this alteration, there is a change in the ease with which oxygen molecules react with the remaining heme sites and this manifests itself by a shift of the oxyhemoglobin dissociation curve. With increasing concentrations of high energy organic phosphates the curve shifts to the right (decreased affinity) and an opposite shift (increased affinity) occurs when these molecules are absent or present in lower than normal concentrizations. For example, in a number of anemic conditions, one finds a decreased oxygen affinity associated with an increase in erythrocyte DPG (2). The increased oxygen affinity of stored blood, first noted some twenty years ago, is now known to be associated with decreases in erythrocyte DPG. Several recent reports have noted a dramatic improvement in the condition of infants with respiratory distress when transfused with fresh adult blood (3,4). The physiologic basis for this improvement relates to the enhanced capacity of fresh adult blood to deliver oxygen to tissues by virtue of its low oxygen affinity compared with fetal henoglobin.

Thus, the interest of the medical community in oxygen transport phenomena is well justified, not only because such knowledge sharpens the precision and scientific basis of known diagnostic and treatment procedures but also, perhaps more importantly, because it offers potential insight into morbid processes that are not well understood.

A comprehensive evaluation of the functional status of the oxygen transport system requires a knowledge of the shape and position of the oxyhemoglobin dissociation curve or blood-oxygen affinity. Consequently, the degree to which interest in this area can be translated into practical clinical routine is most likely to be

conditioned by the ease with which an individual's blood-oxygen affinity can be measured. Unfortunately, the classic experimental approach to this problem is not, for various reasons, suitable for the usual clinical setting. In view of this, as well as the potential importance of such information to effective medical care, this effort has been devoted to perfecting and evaluating a method that will permit routine measurement of blood-oxygen affinity.

APPROACH:

大学のないないないないない

The general approach has been described previously (See LAIR Report No. 8, Annual Progress Report FY 1971, 30 June 1971.), and recent work has incorporated this approach without any essential m'dification. Briefly, when a sample of blood to be tested is nixe with a buffered solution containing a small quantity of glucose, oxygen and yeast cells, the yeast will consume oxygen at a constant rate, the value of which depends primarily upon the number of yeast cells and the temperature. By injecting this mixture into the chamber of an electrochemical blood-gas apparatus, this oxygen consumption is determined by following the time course of the change in partial pressure of dissolved oxygen, most conveniently accomplished with the use of a strip-chart recorder. The resulting record of oxygen tension versus time has two clearly distinguished features: 1) an initial linear portion where the blood remains saturated and only dissolved oxygen is consumed by the yeast; 2) a sigmoid portion that first becomes evident when the partial pressure is reduced to the point where combined oxygen begins to dissociate from the hemoglobin. During this latter phase, both combined and dissolved oxygen are removed by the respiration of the yeast until the solution is completely depleted of oxygen. Since the oxygen consumption during this last phase remains constant and equal to the oxygen consumption during the initial linear phase, it is possible to compute the existing per cent saturation of the blood at any point along the sigmoid portion of the tension-time trace. Actually, tedious computations are unnecessary and the record can be graphically analyzed by merely equating the time axis of the sigmoid portion of the trace into proportional units of per cent saturation. In other words, if the combined oxygen requires 5 minutes for its removal by yeast the hemoglobin in the blood sample would be 80 per cent saturated at one minute, 60 per cent saturated at two minutes, and similarly for any other time interval on the sigmoid trace. The trace height, of course, is directly proportional to the oxygen partial pressure. Thus, all the information necessary for determining the oxygen affinity of the blood sample under the conditions of the test (temperature and pH) is available from inspection of this single, continuous record.

RESULTS AND DISCUSSION:

A baseline study of 10 hematologically normal volunteer subjects has indicated that the technique yields reproducible oxygen affinity data that confirms published standards. For instance, the Bohr shift was found to coincide extremely well with the accepted ratio of .48 for d log $P_{0.0}/d$ pH. Fig. 1 graphically displays representative data, each point being the mean of 5 separate determinations.

In Fig. 2, plot of the data from a typical tension-time curve according to the Hill equation gives the expected regression line with slope equal (in the case shown) to 2.6. The plot is actually slightly curvilinear, again as expected, because of the theoretical deficiency of the Hill concept, which is based on a one-heme model of the hemoglobin molecule. This particular treatment of oxygen affinity data remains common despite such an erroneous theoretical basis because of its convenience and the fact that the straight line equation is followed reasonably accurately in the physiologic range.

The individual P_{50} values (oxygen pressure at 50 per cent saturation corrected to pH 7.4) found for the group studied ranged from about 24 to 28 mm Hg, daily average group values usually being about 26.5 mm Hg. This average coincides very well with standard values of 26 to 27 mm Hg cited in the literature. Repeated daily observations of individual P_{50} values remained reasonably fixed within a range of ± 1.0 mm Hg, the differences between subjects apparently being real and probably related to differences in hemoglobin concentration levels (See below.). Observations have been completed on 10 normal volunteer subjects who received 15 mg of primaquine daily for two weeks. Oxygen affinity of each subject was measured three days and immediately prior to administration of the antimalarial drug, as well as at the 4th, 7th, 11th, and 14th day after start of the drug regimen. Results are shown in Fig. 3. These values represent both a statistically and physiologically significant shift of the oxyhemoglobin dissociation curve to the right (lowered oxygen affinity) and are teleologically consistent with the concept of a compensatory mechanism aimed at maintaining tissue oxygenation in the face of diminished oxygen combining capacity. This latter value declined from a mean group value near 20.0 vol. per cent prior to the drug to 16.0 vol per cent at the termination of the study. Fig. 4 shows the good negative relationship found in these subjects between P80 and functional hemoglobin. Such a relationship appeared to be valid whether or not the subjects were on primaquine. There was no indication of a relationship between either methemoglobinemia or diaphorase activity and P80. Methemoglobin has been reported to shift the curve leftward (5) in a fashion similar to that produced by carbon

the full procession and a state of the state of the

monoxide. In this previous study, the concentrations of methemoglobin (produced by nitrite and ferri-cyanide) were excessive- up to 70 per cent of total pigment- and not comparable to the relatively small methemoglobin levels observed in this study- usually less than five per cent. Any tendency to shuft leftward in our study would presumably have been counterbalanced by the opposite shift in the curve caused by low hemoglobin levels.

The importance to tissue oxygenation of the shift in oxygen affinity observed in this study can be appreciated by referring to Fig. 5. The upper curve (solid line) shows the average condition of the group oxygen affinity before the drug was administered. Going from a normal arterial PO, of about 100 nm Hg to a normal mixed venous PO, of about 40 mm Hg would result in the delivery of 4.8 cc of oxygen for each 100 cc of cardiac output. After the primaquine-related shift in oxygen affinity and the decreased carrying capacity of the blood had become established, the situation was that shown in the lower solid curve. Noteworthy is the fact that despite the decreased oxygen capacity, oxygen delivery to the tissues is unimpaired, the blood giving up 4.8 cc of oxygen with each 100 cc of cardiac output. Had the oxygen affinity remained fixed in its pre-drug position (dashed line), the observed decrement in the oxygen carrying capacity of blood would have resulted in a 27 per cent decrease in oxygen delivery to tissues, the blood in this instance delivering only 3.5 cc of oxygen per 100 cc output. Thus, a potential tissue hypoxia was avoided by the efficient expedient of altering the oxygen affinity rather than resorting to the less desirable means of increasing cardiac output.

Preliminary observations have indicated that adrenalin may alter the oxygen affinity of blood. Attempts to substantiate such an effect in the near future have been encouraged by several recently published findings indicating the possible presence of adrenergic receptors in the erythrocyte membrane. Adrenalin was found to block a propranolol-induced release of DPG absorbed on the red cell membrane (8) and also to cause a measureable change in the erythrocyte deformability (9). Both of these reported effects support a concept that endows red blood cells with an active role in the control of the microcirculation. The clinical implications of such a concept could become extremely important.

SUMMARY AND FUTURE PLANS:

シャンシュート

20年代中国的大学中国大学校的大学校的大学校的大学校,中国大学校的大学校和大学校和大学校的大学校的大学校的大学校、大学校的大学校的大学校的大学校的大学校、大学校和大学

Information now available suggests that the yeast technique for measuring oxygen affinity can be used profitably in a clinical setting. The method is easy to perform, requires a negligible (0.2 cc) sample of blood, and produces rapid results of acceptable accuracy. In addition to follow-up experiments aimed at measuring

the effect of adrenalin on the oxygen affinity, future plans call for a survey of oxygen affinity in patients admitted to the Intensive Care Unit at Letterman General Hospital. Also planned is a study to determine whether or not oxygen affinity may play a role during experimentally induced hemorrhagic shock in rats.

A series of the series of the series of

a conferration of the state of a second state a state of the second a the second second

REFERENCES:

颖

1. Benesch, R., R. E. Benesch, and Y. Enoki. The interaction of hemoglobin and its subunits with 2, 3-Diphosphoglycerate. <u>Proc.</u> <u>Nat. Acad. Sci.</u> (USA) 61, 1102-1106 (1968).

2. Bromberg, P. A. Cellular cyanosis and the Shifting Sigmoid: The Blood Oxygen Dissociation Curve. <u>Am. Jour. Med. Sci.</u> 260: 1-10, (1970).

3. Delivoria - Papadopoulos, Maria, Nevenka P. Roncevic, and Frank A. Oski. Postnatal Changes in Oxygen Transport of Term, Premature and Sick Infants: The role of Red Cell 2, 3-Diphosphoglycerate and Adult Hemoglobin. <u>Pediat. Res.</u> 5, 235-245 (1971).

4. Miller, Leonard D., Frank A. Oski, Joseph F. Diaco, Harvey J. Sugarman, A. J. Gottlieb, Douglas Davidson and Maria Delivoria - Papdopoulos. The Affinity of Hemoglobin for Oxygen. Its Control and in vivo Significance. Surgery 68, 187-195 (1970).

5. Darling, Robert C. and F. J. W. Roughton. The Effect of Methemoglobin on the Equilibrium Between Oxygen and Hemoglobin. <u>Am.</u> J. <u>Physiol.</u> 137, 56-68 (1942).

6. Oski, Frank A., Leonard D. Miller, Maria Delivoria-Papadopoulos, Joel H. Manchester, and James C. Shelburne. Oxygen Affinity in Red Cells: Changes Induced in vivo by Propranolol. <u>Science</u> 175: 1372-3 (1972).

7. Allen, James E. and Howard Rasmussen. Human Red Blood Cells: Prostaglandin E_2 , Epinephrine, and Iso-proterenol Alter Deformability. Science 174: 512-514, (1971).





OXYGEN DELIVERY & OXYGEN AFFINITY

WH FER THIS

NYYY

NO. 88.

19

1

845EX.2X9270

Figure 5

Sec. 3 8 19 19 19 19 19 19 19 19

CORNE

A BAYE PREV SUMPRY A. HIND 72 03 16 D. C 10. NO./CODEB.* PROOF 10. NO./CODEB.* PROOF 10. NO./CODEB.* PROOF 10. PRIMARY 61 b. CONTRIBUTING E. c. CONTRIBUTING E. c. CONTRIBUTING E. c. CONTRIBUTING E. 11. TITLE (Proceds with social P (U) Pathogenesis O 12. SCIENTIFIC AND TECHNOLOG 003500 - Clinical P 13. START BATE 72 03 17. CONTRACT/GRANT A DATES/EFFECTIVE: N NUMBER.* c. TYPE. a. KIND OF AWARD. 19. RESPONSIBLE COD ORGANIE NAME:* Letterman ADDAESS.* PRESIDIO OF ARESPONSIBLE INDIVIDUAL NAME: AKERS, W.A TELEPHONE: 41. S-S61-5 51. GENERAL USE	A., COL MC Stange Change RAM ELEMENT 101A 3 Classification Code, ⁵ Of Coliform Ind GICAL AREAS ⁵ Medicine; 0101 14. E 14.	U PROJECT N 3A061101A Juced Coliti 100 - Micro 100 - Micro 73 01 EXPIRATION: A AMOUNT: 7. CUM. AMT. e of Resear 0, CA 94125	U U U U S in Mice obiology E TION DATE	(05) 15. PUNC DA 10. RESC PISCAL VEAR 30. PERF NAME: ⁰ ADDRESC	АСИНС ^Ф НА НА ПЛЕА НОМВІ ОО ОО ОО ОО ОО ОО ОО ОО ОО О		Army	HAL MAN VA 1 Institute s Divisio	
ID. NO./CODES: ⁰ PRODI ID. NO./CODES: ⁰ PRODI ID. CONTRIBUTING C. CONTRIBUTING C. CONTRIBUTING II. TITLE (Proceed with socurity ((U) Pathogenesis of II. SCIENTIFIC AND TECHNOLOG 003500 - Clinical I II. START DATE 72 03 IT. CONTRACT/GRANT A DATES/EPFECTIVE: N IN NUMBER. ⁰ C. TYPE. A. KIND OF AWARD. ID. RESPONSIBLE INDIVIDUAL NAME: AKETS, W.A TELEPHONE. 415-561-5 SI. GENERAL USE	Army Instituto f San Francisco	PROJECT N 3A0611014 Juced Coliti 100 - Micro 37000 3700 37000 37000 37000 3	UMBER A91C s in Mice obiology etion date	(05) 15. PUNC DA 10. RESC PISCAL VEAR 30. PERF NAME: ⁰ ADDRESC	о		Army	WORK UNI 387 18. PERFORM C. In-F Institute s Divisio	
A PRIMARY 61 CONTRIBUTING CONTRIBUTING CONTRIBUTING (U) Pathogenesis o 10. Stant date 72 03 17. CONTRACT/GRANT DATES/EFFECTIVE: N NUUBER.* CTVPE. KIND OF AWARD. 19 RESPONSIBLE DOD ORGANIZ NAME:* Lettersman ADDRESS.* Presidio of RESPONSIBLE INDIVIDUAL NAME: AKERS, W.A TELEPHONE. 415-561-5 51. GENERAL USE	101A 3 Classification Code/* 6 of Coliform Ind 101 GIGAL ANEAS* 101 Medicine; 0101 14 IA 14 <td< td=""><td>3A061101A luced Coliti 100 - Micro 37/INATED COMPC 73 01 EXPIRATION: 4 AMOUNT: 4. CUM. AMT. 5. CLM. AMT. 9. CA 94125</td><td>s in Mice obiology attion patte</td><td>(05) IL PUNC DA II. RESC PISCAL VEAR MAME:[©] ADDRESC</td><td>00 DIMG AGENCY OUNCES ESTIN 72 СОЛИЕНУ 73 ТОЛЬНИС ОЛС Let 6.• Anii Pres</td><td>ANIZATION terman mal Re</td><td>Army</td><td>10. PERFORM C. In-fr Institute s Divisio</td><td>nance we nouse s b ru e of Re n , CA 9</td></td<>	3A061101A luced Coliti 100 - Micro 37/INATED COMPC 73 01 EXPIRATION: 4 AMOUNT: 4. CUM. AMT. 5. CLM. AMT. 9. CA 94125	s in Mice obiology attion patte	(05) IL PUNC DA II. RESC PISCAL VEAR MAME: [©] ADDRESC	00 DIMG AGENCY OUNCES ESTIN 72 СОЛИЕНУ 73 ТОЛЬНИС ОЛС Let 6.• Anii Pres	ANIZATION terman mal Re	Army	10. PERFORM C. In-fr Institute s Divisio	nance we nouse s b ru e of Re n , CA 9
E. CONTRIBUTING II. TIVLE (Pricode aim socurity ((U) Pathogenesis o IZ. BCIENTIFIC AND TECHNOLOG 003500 - Clinical P IJ. START DATE 72 03 IT. CONTRACT/GRANT & DATES/EFFECTIVE: N & NUMBER.* C. TVPE. & KIND OF AWARD. ID. RESPONSIBLE DOD ORGANIE NAME:* Lettersman ADDRESS:* Presidio of RESPONSIBLE INDIVIDUAL NAME: Akers, W.A TELEPHONE. 415-561-5 SI. GENERAL USE	CIANNINGATION COLL MC SIGNAL AREAS ⁶ Medicine; 0101 (4. 6) (4. 6) IA TATION Army Instituto f San Francisco A., COL MC 5181	luced Coliti 100 – Micro stimated compu- 73 01 expiration: 4 Amount: 7, cum. Amt. e of Resear 5, CA 94125	s in Mice obiology errow parte	(05) IL PUNC DA IO. RESC PISCAL VEAR 20. PERF NAME: ⁰ ADORESC	DIMG AGENCY OUNCES ESTI PRECEDINE 72 CUNNENY 73 FORMING ORD Let s.• Ani Pres		Army	10. PERFORM C. In-H Inal Man VR .1 1 1 Institute s Divisio	tance we nouse is is pu e of Ro n, CA 9
(U) Pathogenesis ((U) Pathogenesis (12. BCIENTIFIC AND TECHNOLOG 003500 - Clinical ! 13. START DATE 72 03 17. CONTRACT/GRANT & DATES/EPFECTIVE: N & NUMBER. ⁶ C. TYPE. C. KIND OF AWARD. 18. RESPONSIBLE COD ORGANIE MAME: ADDRESS: ⁸ Presidio of RESPONSIBLE INDIVIDUAL NAME: AKERS, W.A TELEPHONE. 415-561-5 31. GENERAL USE	A., COL MC	luced Coliti 100 – Micro 31/00 – Micro 73 01 EXPIRATION: A AMOUNT: 6. CUM. AMT. e of Resear 0, CA 94125	s in Mice obiology Etion DATE	(05) IS PUNC DA IN RESC PISCAL VEAR 20. PERF NAME: ⁰ ADDRESS	OURCES ESTI OURCES ESTI PRECEDING 72 CURRENT 73 FORMING ORG Let 6.• Ani Pres	ANIZATIO Terman mal Re	Army	IL. PERFORM C. In-H INAL MAN VR .1 1 Institute s Divisio	e of Ron , CA 9
12. BCIENTIFIC AND TECHNOLOG 003500 - Clinical I 13. START DATE 72.03 17. CONTRACT/GRANT & DATES/EFFECTIVE: N IN NUMBER. ⁶ C. TYPE. 4. KIND OF AWARD. 19. RESPONSIBLE DOD ORGANIE MAME: ⁹ Letterman ADDRESS: ⁹ Presidio of RESPONSIBLE INDIVIDUAL NAME: AKERS, W.A TELEPHONE. 415-561-5 21. GENERAL USE	GICAL AREAS ⁴ Medicine; 0101 (4. 6) IA IA IA IA IA IA IA IA IA IA IA IA IA	100 - Micro 3711NATED COMPL 73 01 EXPIRATION: 6 ANOUNT: 7. CUM. AMT. 9. CLM. AMT. 9. CA 94125	obiology ETION DATE	15. PUNE DA 16. RESC PISCAL VEAR 20. PERF NAME: ⁰ ADDRESC	OUNCES ESTI OUNCES ESTI PRECEDINE 72 CUNNENT 73 FORMING ORG Let 6.• Anii Prece	ANIZATION terman mal Re	Army	10. PERFORM C. In-F INAL MAN VA .1 1 Institute s Divisio	e of Ren , CA 9
13. START DATE 72 03 17. CONTRACT/GRANT A DATES/EFFECTIVE: N h NUMBER.* C TYPE. 4. KIND OF AWARD. 19 RESPONSIBLE DOD ORGANIZ MAME:* Lettersman ADDRESS:* Presidio Of RESPONSIBLE INDIVIDUAL NAME: Akers, W.A TELEPHONE. 415-561-5 \$1. GENERAL USE	A., COL MC	AMOUNT: CCUM. AMT. CCUM. AMT. CCUM. AMT. CCUM. AMT.	ch	IL PUNC DA 16. RESC PISCAL VEAR 20. PERI NAME: ⁰ ADDRESC	онисте езти очисте езти ридствина 72 сонити 73 голына опа Let 6.• Ani Pres	ANIZATION terman mal Re	Army	C. In-F	tance we nouse s ru e of Re n, CA 9
12 US 17. CONTRACT/GRANT A DATES/EFFECTIVE: N A NUMBER. ⁴ C TYPE. A KIND OF AVARD. 19 RESPONSIBLE ECOD ORGANIE NAME: ⁹ ADDRESS: ⁹ Presidio of RESPONSIBLE INDIVIDUAL NAME: AKERS, W.A TELEPHONE. 415-561-5 31. GENERAL USE	A., COL MC	A MOUNT: A MOUNT: A CUM. AMT. e of Resear b, CA 94129	 ch	DA 10. RESC PISCAL VEAR 30. PERI NAME: ⁰ ADORES	очасть сати риссебна 72 счинену 73 голынсово Let 6.• Ani Pres	ANIZATION terman mai Re	Army	C. In-h	e of Ren , CA 9
a dates/effective: N b number.° c type. a kind of avard. 19 Aesponsible dod organiz name:° Letteriman address:° Presidio of responsible individual name: Akers, W.A telephone. 415-561-5 11. gemeral use	Army Institute Army Institute f San Francisco	EXPIRATION: A AMOUNT: (. CUM. AMT. e of Resear b, CA 94129	 ch)	20. PERF	T2 CURRENT 72 73 FORMING ORG Let 6.• Anii Pres	ANIZATION terman mal Re	Army	.1 1 Institute s Divisio	e of Ron , CA 9
d number.* c type. d. Kind of avard. 19 Responsible dod organiiz hame:* Address:* Responsible individual name: Ame: Akers, W.A telephone. 415-561-5 51. general use	Army Institute f San Francisco A., COL MC 5181	4 AMOUNT: 7. CUM. AMT. 7. CUM. AMT. 9. CM 94125 9. CA 94125	 ch	20. PERI NAME: [©]	73 FORMING ORG Let a.• Ani Pres	ANIZATIO	Army	1 Institute s Divisio	e of Ron n, CA 9
L KIND OF AWARD. 19 RESPONSIBLE COD ORGANIE HANE: ADDRESS: RESPONSIBLE INDIVIDUAL NAME: NAME: AKERS, W.A TELEPHONE: 415-561-5 51. GENERAL USE	Army Institute f San Francisco A., COL MC 5181	e of Resear	ch)	20. PERI HAME: ⁰ ADDRES	73 FORMING ORG Let a.o Ani Pres	ANIZATION terman mal Re	Army sources	1 Institute s Divisio	e of Ron n , CA 9
ID RESPONSIBLE DOD ORGANIZ WANE:* ADDRESS:* Presidio of RESPONSIBLE INDIVIDUAL NAME: AKERS, W.A TELEPHONE. 415-561-5 \$1. GENERAL USE	Army Institute f San Francisco A., COL MC 5181	e of Resear o, CA 94129	_1 ch)	20. PERI HAME: ⁰ ADDRES	Let Ani Pres	terman mal Re	Army source:	Institute s Divisio	e of Ro n , CA 9
SE REVEORDS (Procede BACK -	18 Jourily Classification	Code)		NAME:					
(U) Experimental	animal; (U) m	odel; (U) n	nice; (U) co	olitis in	mice; (U) baci	erial co	olitis; (U	J) path
25. (U) 72 03 - 7 indicates t of reduced colonic co were enco during the	72 06 Analyses that the culture d food intake. ontent noted 7 o ountered. Bacte e course of the s	of the clini e utilized wa Gross lesion days post e erial popula study.	ical and gro as of low vin ns were sub xposure. N tions of col	oss findi rulence otle and lo signif lonic co	ings and . The ar consiste ficant mi ontents is	study o iimals v d of an icrosco ndicate	of selec went th increa pic find d no tr	ted cases rough a sed mois lings of s end tow	s micre transie sture o a chroi ard ho

CONSTRUCTION OF STREET

SIN CONTRACTOR

set Distance berg

•••••• :...

ž

, , ; ;

1

• • • •

•

¥

Ť

Pathogenesis of Coliform Induced Colitis in Mice

Robert M. Kovatch, MAJ, VC

PROBLEM:

This study was designed to document the sequential development of the lesions in the digestive tract of mice exposed to a coliform bacterium tentatively identified as a lysine decarboxylase-negative <u>Enterobacter hafnia</u>. The agent was obtained from the National Institutes of Health and was originally isolated from a mouse during an outbreak at Fort Detrick, Frederick, Maryland. The objective of the study was to document the morphologic changes in exposed mice and to compare the lesions to those of chronic idiopathic ileitis and colitis of man. It was hoped this small laboratory animal system might be developed to study the complex mechanisms active in the inducement of chronic idiopathic ileitis and colitis of man.

APPROACH:

The study will be divided into two phases (1) cesarean-derived, barrier maintained mice will be exposed to 2 levels $(10^7 \text{ and } 10^5)$ of a washed saline suspension of <u>E</u>. <u>hafnia</u> by gavage and by intrarectal instillation. From these four groups of animals, 2 animals will be killed at weekly intervals for 5 consecutive weeks. Gross and microscopic alterations will be evaluated to determine the most favorable parameters for reproducing the disease. (2) Utilizing information derived from phase I of the study, additional barrier maintained mice will be exposed to the appropriate number of bacteria and by the better of the routes of exposure determined in phase I of the study. Animals will be killed at 1, 3, 6 and 9 days and 2, 3, 4, 6, 12 and 18 weeks post exposure. The gross and microscopic evaluation of the developing lesion and their residua will be documented. The lesions will be compared to those reported for chronic idiopathic ileitis and colitis of man.

RESULTS AND DISCUSSION:

Sixty mice were divided into 5 groups (4 exposed and 1 control group) and exposed to 0.1 cc of a washed saline suspension of a coliform culture determined to contain 1.32×10^7 and 3.5×10^8 cells/cc. These suspensions were given by gavage and intrarectally. Control mice were given 0.1 cc of saline by both routes. Two animals from each group were killed at weekly intervals and autopsies were done. From one animal of each group fecal samples were taken from the colon for bacteriological determination. Tissues were selected and

ACCOUNTS AND AND ADDRESS.

and a start of the second start and the second start and a second start and a second start and a second start a

fixed in 10% neutrol buffered formalin for microscopic examination. Analyses of the clinical and gross findings and study of selected cases microscopically indicates that the culture utilized was of low virulence. The animals went through a transient period of reduced food intake. Gross lesions were subtle and consisted of an increased moisture of the colonic content noted 7 days post exposure. No significant microscopic findings of a chronic nature were encountered. Bacterial populations of colonic contents indicated no trend toward homogenicity during the course of the study.

FUTURE PLANS:

1

During FY 1973/phase I of the study will be repeated utilizing another isolate currently being analyzed at the National Institutes of Health. Preliminary studies there indicate they now have an isolate of high virulence. Should phase I of the study show promise utilizing the new isolate, phase II of the planned study will be done.

RESEARCH AND TECHNOLOGY WORK UNIT SUMMARY					CV ACCESSION®	2 DATE OF SUI 72 07 0	DATE OF SUMARY REPORT CONTROL 72 07 01 DD-DRAE(AF		E(AR)636	
72 03 20	D.Change	U SUMMANY SCTY	U TONK SECUNTY	P REGR	NA NA	NL	CONTRACTOR	ACCESS	LEVEL OF S	
NO./CODES:*	PROGRAM ELEMENT	PROJECT		TASK /	REA NUMBER	WORK UNIT NUMBER				
-	61101A	3A061101/	191C)0	3	88			
CONTRIBUTING				<u> </u>						
TITLE (Proced and Radionuclide SCIENTIFIC AND TE	Labelled Fibrian CHADELES AREAS	(U) Detection gen	n of (Superio	or Sagit	tal Sinus) 7	Thrombosi	is (In Dog	s) Using	<u>}</u>	
START DATE	nical Medicine	IA ESTIMATED COMP	LETION DA E		DING AGENCY		IS. PERFORM		00	
72 03	CONT			DA		1	C. In-house			
CONTRACT/GRANT	ACT/GRANT			18. RESOURCES ESTIMATE		E & PROFESS	SSIGNAL MAR YRS & FUNDS (In these		K (In thousand	
NATES/EFFECTIVE: NA		EXPIRATION:		PARCELINA						
NUMBER " TYPE:		4 AMOUNT:		YEAR	CURRENT		•1		4	
KIND OF AWARD:		f. CUM. AMT.			73				7	
RESPONSIBLE DOD	ORGANIZATION			30. PER	FORMENG OR SI'NI	EATION			1	
IESPONSIBLE INDIVIDUAL NAME: Akers, W.A., COL MC TELEPHONE,415-561-5181					Presidio of San Francisco, CA 94129 PRINCIPAL INVESTIGATOR (Pumilen MAN II U.S. Acceduate Intelligence NAME:* Bronshvag, M., MAJ MC TELEPHONE: 415-561-4714 SOCIAL SECURITY ACCOUNT NUMBER: ASSOCIATE INVESTIGATORS					
. GENERAL USE				NAME:	TE INVESTIGATO	R8				
				-					DA	
. KEYBORDS (Proced	BACH with Somethy Classifi	Callen Code)	1				aluaian			
25. (U) 72 0 has b (appi	3 – 72 06 A mer een devised. Part oximately 50%); ma camera scanni	thod of induci íal tagging of i however, we ng has been ao	ng occlusior fibrinogen w are attempti chieved.	inside ith Te ng to c	99 M-perteo Dotain 95%	he dorsal l chnitate ha tagging. S	longitudin as been ac some satis	al sinus complis factory	s of dogs shed Pho	
Gami										
Gami										
Gami										

NON MARCEN

Similar and the ne

and the second second

and the second se

to have and and
Detection of (Superior Sagittal Sinus) Thrombosis (In Dogs) Using Radionuclide Labelled Fibringen

Michael M. Bronshvag, MAJ, MC

PROBLEM:

Detecting vascular occlusive disease is most gratifying before it has caused infarction or embolization. Superior sagittal sinus (and other dural venous) occlusion is a good example of this, for it produces minimal clinical symptomatology (headache, raised intracranial pressure) or none, before extension of the clot into cerebral veins causes cerebral infarction. Demonstrating such clots presently depends upon angiography. Angiography carries inconvenience and risk. Intravascular clots are known to accumulate fibrinogen as fresh fibrin as they propagate or maintain their size. Propagating leg venous thrombi can be detected using Il25 and Il31 labelled fibrinogen and a point-imaging detector. However, virtual imaging (analogous to organ scanning) cannot be accomplished in humans using these radionuclides because of their high emission of alpha and beta particles relative to gamma emissions cause damage to tissues.

These isotopes can be used in animals to attempt clot imaging. If these techniques are successful, I^{123} can be substituted for human use since it is essentially a pure gamma emitter (but is quite expensive and therefore unsuitable for routine experimental use). Also Tc^{99M} may be used in humans and animals being a pure gamma emitter, having a 6 - 6 1/2 hours half-life, and being inexpensive; however, attempts to label it with fibrinogen have not been uniformly successful. Therefore, we plan experiments with I^{125} Il31 and Tc^{99M} in dogs to devise a technique for clot detection by virtual imaging suitable for human use (I^{123} or Tc^{99M}).

APPROACH:

A. Operation: Adult dogs are anesthetized and a midline incision made in the head down to the skull with a Bovie coagulating scalpel. A hole is drilled through the skull in the midline in the superior sagittal sinus and a 2.5 - 5.0 cm length of 190 PE polyethylene tubing inserted. The drill hole is closed in the bone wax and the scalp wound sewn.

B. Preparation of Radionuclides: Iodine tagged fibrinogen is prepared by the method of alkaline incubation (ICI vol. 42, pg. 346, 1963). Technitium tagged fibrinogen is prepared by Clyde Cole, CPT,

ne na her eiter eine die bezehren de die nacht eine nacht die bestehren die ster die bestehrt. Aus die ster ste

and the second second second as a second second

all and a state which we all the second

25

MSC, Radiopharmacist, LAIR, by a modification of the TC-Albumin method of zirconium electrolysis (J. Nuc. Ned. vol. 13, pg. 180, 1972).

C. Scanning: Radion Blide-tagged fibringen is injected into control and experimental animals (before and after tube placement); AP and vertex brain scanning is done by conventional techniques using the Pho Gamma III camera. A positive scan will show a virtual image of the experimentally induced clot.

D. Autopsy: All dogs are sacrificed subsequently and examined for success of tube placement, presence of clot, and also presence of cerebral infarction or surgical complications.

DESULTS AND DISCUSSION:

1. The technique for tube placement is successful without complications 50% of the time. More posterior placement of the tube should result in a higher success rate.

2. Tagging attempts with Tc^{99M} have resulted in a mixture of 50% tagged technitium and 50% clottable technitium-fibrinogen complex. Hopefully, empiric adjustment of the zirconium electrolytic procedure will result in higher tagged per cent.

3. In one animal to date injected with the To-Fibrinogen complex after successful tube placement, satisfactory clot imaging was obtained.

FUTURE PLANS:

1. Refinement of above techniques is planned. I believe a satisfactory new clinical tool will emerge.

2. Other workers have studied disappearance rates of fibrinogen as an indicator of intravascular thrombosis. LTC Logan (Hematologist and Chief, Clinical Research Support Division, LAIR), is studying this technique and we plan to collaborate with him to correlate scan and fibrinogen disappearance studies.

part and y seeks 1 seeks account <	RESEARCH	AND TECHNOLOGY	WORK UNIT S	UMMARY) ASEN	CV ACCESSION®	3. DATE OF W)1	REPORT (DD-DI	CONTROL STRUCT
web/Cooks* A. New O International Control of the Processing of	BATE PAEV SUURY	A BLOW	S SUMMARY SCTY	A. VORK SECURITY	7 REGRI		HIPH INSTATA	AL SPECIFIC	DATA-	. LEVEL OF SU
Instrument Figure 1 Additionage Instrument Instrument Instrument Construment Construment Construment Construment Construment		A. NEW	0					LOS YES		
Contractivity Other intervention Other intervention Other intervention Contractivity Inflammatory Periodontal Diseases in Military Personnel Inflammatory Periodontal Diseases in Military Personnel Extensive and intervention of the state of t	NO./CODES -	61101A	34061101	AQIC			├ ────	189		
Contransives Contransives <td< td=""><td>CONTRIBUTING</td><td></td><td>57001101</td><td></td><td><u> </u></td><td></td><td></td><td></td><td></td><td></td></td<>	CONTRIBUTING		57001101		<u> </u>					
thrse remove construction of logs The Relationship of Polymorphonuclear Neutrophil (PMN) Chemotactic Activity to Inflammatory Periodontal Diseases in Military Personnel Sector (2000) 003500 - Clinical Medicine The transfer construction operation operat	CONTRIBUTING				<u>+</u>			••••	, :	
Activity to Inflammatory Periodontal Diseases in Military Personnel Externing and recommedation Externing and recommedation DA It Function sectory President control It Function sectory Control of the control of	TITLE (Proceds with	Socurity Classification Code	U) The Rel	ationship of P	olymo	orphonucle	ar Neutro	phil (PMN	I) Chen	iolaclic
003500 - Clinical Medicine It Etitizates Counter the variable of the control of a counter the variable of the control of the	Activity to I	nflammatory Peri	idontal Dise	ases in Militar	ry Pers	sonnel		-		
72 07 73 07 DA C. In-house * Contract/reaser ************************************	003500 - Cli	nical Medicine	A RETINATED CON		Tes eval			Lia. Prasta		NO.0
1/2017 1/30177 1/30177 1/30177 <td>74 07</td> <td></td> <td>73.07</td> <td></td> <td>DA</td> <td>1</td> <td>1</td> <td>C In-h</td> <td>ouse</td> <td></td>	74 07		73.07		DA	1	1	C In-h	ouse	
Outside Prective: NA explantion: Intervention:	CONTRACT/GRANT		1301					10		
ausses 1 7 1 7 intervent intervent 1 1 1 1 intervent intervent 1 1 1 1 1 intervent intervent intervent 1	DATES/EFFECTIVE:	NA	EXPIRATION:			PRECEDING				
TYPE. 4 AMOUNT: 73 1 AMOUNT: F. CUM. ANT. 73 1 AMOUNT: F. COMOUNT: F. COMOUNT: F. COMOUNT: AMOUNT: F. COMOUNT: F. COMOUNT: F. COMOUNT: AMOUNT: A F. COMOUNT: F. COMOUNT: F. COMOUNT: <td></td> <td></td> <td></td> <td></td> <td>FISCAL</td> <td>72</td> <td></td> <td>1</td> <td></td> <td>7</td>					FISCAL	72		1		7
Letterman Armay Institute of Research Presidio of San Francisco, CA 94129 Amet. ³ Letterman Armay Institute of Research Maxillofacial Sciences Division Amet. ³ Letterman Armay Institute of Research Maxillofacial Sciences Division Image. ³ Letterman Armay Institute of Research Maxillofacial Sciences Division Amet. ³ Letterman Armay Institute of Research Maxillofacial Sciences Division Image. ³ Letterman Armay Institute of Research Maxillofacial Sciences Division Amet. ³ Letterman Armay Institute of Research Maxillofacial Sciences Division Image. ³ Letterman Armay Institute of Research Maxillofacial Sciences Division Image. Akers, W.A., COL MC Image. ³ Tempel, T.R., MAJ DC Image. 415-561-5181 Image. ⁴ Image. ⁴ Image. Alsociant investment action in a second in the sec	TYPE.		& ANOUNT:		YEAR	CURNERV				
Aust. ² Letterman Army Institute of Research Presidio of San Francisco, CA 94129 Subontible 5 INDIVIDUAL Mast. ² Letterman Army Institute of Research Maxillofacial Sciences Division Maxillofacial Science			f. CUM. AMT.			73	1	l	1	4
 Letterman Army Institute of Research Presidio of San Francisco, CA 94129 Strontball (1997) Bank Francisco, CA 94129 Strontball (1997) Bank (1997) B	RESPONSIBLE DOD				SO. PER	COMING OR CAN	TATION			
 association in the laboratory using a Boyden chamber. The WBC chemotactic activity of cells from patients with severe inflammatory periodontal disease will be compared with the chemotactic activity of cells from healthy controls. 25. (U) None. New Study. 	Presidio Presidio	nan Army Institu o of San Francisc	te of Researc o, CA 94129	h	**************************************	Letterman Maxillofaci Fresidio of	Army Ins ial Science San Fran	stitute of l es Division cisco, CA	Kesearc 1 94129	n S
velocitie 415-561-5181 velocity secial Steumity account number: name: Hutchinson, R.A., LTC DC name: Lilly, G.E., COL DC D/ t reveals (neurophonuclear neutrophil; (U) periodontal disease; (U) periodontitis; (U) chemotaxis; D/ (11) polymorphonuclear neutrophil; (U) white blood cell; (U) bacteria; (U) inflammation secial Stevents; exception to the second second cell; (U) bacteria; (U) inflammation * recondcar second cell; (U) Determine the variability of the PMN chemotactic response in military personnel. (2) Determine relationship between PMN chemotactic response and inflammatory periodontal disease; (3) Determine relationship between PMN chemotactic response in other specific infection diseases in pediatric patients. 24. (U) White blood cell (WBC) migration (chemotaxis) will be measured in the laboratory using a Boyden chamber. The WBC chemotactic activity of cells from patients with severe inflammatory periodontal disease will be compared with the chemotactic activity of cells from healthy controls. 25. (U) None. New Study.	esponsible individi name: Akers.	W.A., COL MC			NAME.	• Tempel, 7 mone: 415-5	Г. <mark>R., МАЈ</mark> 61-4042	DC		
 Adversals use Adversals Adversals		-561-5181			10CIA	L SECURITY ACC	OVNT NUMBER:			
 Hutchinson, R.A., LTC DC NAME: Hutchinson, R.A., LTC DC NAME: Lilly, G.E., COL DC D/ U) periodontal disease; (U) periodontitis; (U) chemotaxis; (I) polymorphonuclear neutrophil: (U) white blood cell: (U) bacteria; (U) inflammation A Technical Sourcever, it substates (Pendat individual perspense idmittled by number. Periods that of each of B pendity Classification Cent.) 23. (U) (1) Determine the variability of the PMN chemotactic response in military personnel. (2) Determine relationship between PMN chemotactic response and inflammatory periodontal disease. (3) Determine relationship between PMN chemotactic response in other specific infection diseases in pediatric patients. 24. (U) White blood cell (WBC) migration (chemotaxis) will be measured in the laboratory using a Boyden chamber. The WBC chemotactic activity of cells from patients with severe inflammatory perio- dontal disease will be compared with the chemotactic activity of cells from healthy controls. 25. (U) None. New Study. 	. GENERAL USE				A100CIA		AS			
 1 HANE: Lilly, G.E., COL DC D7 2.1. Lilly, G.E., Col D7 2.1. Lilly, G.E., C					HANE:	Hutchins	son, R.A. ,	LTC DC		
 (1) polymorphonuclear neutrophil: (1) white blood cell: (1) bacteria: (1) inflammation (1) polymorphonuclear neutrophil: (1) white blood cell: (1) bacteria: (1) inflammation (2) Determine the variability of the PMN chemotactic response in military personnel. (2) Determine relationship between PMN chemotactic response and inflammatory periodontal disease. (3) Determine relationship between PMN chemotactic response in other specific infectiou diseases in pediatric patients. 24. (1) White blood cell (WBC) migration (chemotaxis) will be measured in the laboratory using a Boyden chamber. The WBC chemotactic activity of cells from patients with severe inflammatory periodontal disease will be compared with the chemotactic activity of cells from healthy controls. 25. (1) None. New Study. 					-	Lilly, G.	<u>E., COL D</u>	<u>)C</u>		DA
 23. (U) (1) Determine the variability of the PMN chemotactic response in military personnel. (2) Determine relationship between PMN chemotactic response and inflammatory periodontal disease. (3) Determine relationship between PMN chemotactic response in other specific infectiou diseases in pediatric patients. 24. (U) White blood cell (WBC) migration (chemotaxis) will be measured in the laboratory using a Boyden chamber. The WBC chemotactic activity of cells from patients with severe inflammatory periodontal disease will be compared with the chemotactic activity of cells from healthy controls. 25. (U) None. New Study. 	<u>(II) palyma</u>	phonuclear neut	rophil: (U) p	eriodontal dis white blood co	sease; ll: (U	(U) period) bacteria:	ontitis; (U) chemo mmation	taxis;	
25. (U) None. New Study.	23. (U) (1) (2) dis dis 24. (U) Wh ch do	Determine the va Determine relative ease. (3) Determine eases in pediatric ite blood cell (Wi amber. The WBC intal disease will b	riability of t onship betwo nine relations patients. BC) migration chemotaction re compared	he PMN chem en PMN chen ship between n (chemotaxis e activity of co with the chem	otacti notact PMN c) will ells fro notacti	c response ic response hemotactio be measure om patients ic activity of	in military and infla c response d in the la with seve of cells fro	y personn mmatory in other : aboratory re inflam om health	el. periodo specific using a matory y contro	ontal infectiou Boyden perio- ols.
	25. (U) No	ne. New Study.								

•

SERVICE STREET

Sector Sector

Stree of a

ź

<u>acianes</u>

anderen hear of the source of the source of the second more supported to the source of the source of the source

8 F

artikation and the subsection of the state of the subsection of t

Ł

The Relationship of Polymorphonuclear Neutrophil (PMN) Chemotactic Activity to Inflammatory Periodontal Diseases in Military Personnel

Major Thomas R. Tempel, DC

PROBLEM:

The primary objective of this study is to evaluate polymorphonuclear neutrophil (PMN) chemotactic response as a possible laboratory means of detecting the degree of inflammatory periodontal disease in a soldier. Our hypothesis is that variations occur in the chemotactic response of polymorphonuclear leukocytes in individuals, who are otherwise "normal"; and such differences account for variations in individual susceptibility, resistance, and response to infectious inflammatory diseases. The chemotactic response can be measured in the laboratory and variations in PMN chemotaxis can be correlated with the severity of inflammatory periodontal disease.

Present evidence favors the concept that oral bacteria are the most important etiologic agent in periodontal disease. The bacteria colonize as dental plaque adjacent to the gum tissue. PMNs are found in the normal gingival sulcus as well as the periodontal disease lesion adjacent to the dental plaque and are thought to play an important role in the patient's resistance to periodontal disease. Patients with reduced numbers of PMNs or PMN chemotaxis defects (neutropenia, agranulocytosis, and Chediak-Higashi disease) are known to be prone to severe destructive periodontal disease. Recent studies have established that PMN chemotaxis defects occur in some individuals. Such individuals have altered inflammatory responses and are predisposed to infections. This abnormality has been recognized in specific diseases involving children and adults.

In view of recent findings concerning chemotaxis, this defect may conceivably be a factor in the etiology and course of other inflammatory diseases. Current laboratory procedures and findings offer a method for evaluating PMN chemotaxis which could prove of value in dedetermining etiology, course, and patient susceptibility to inflammatory diseases, and provide methods for monitoring and diagnosing such diseases.

In 1962 Boyden developed an <u>in-vitro</u> method of studying cell migration which is sensitive, reproducible, and yields quantitative data relative to PMN chemotactic response to a variety of chemotactic factors.

Studies during the past 10 years have clearly established the following:

1. PMNs respond to a chemotactic substance by unidirectional migration toward the greatest concentration of the attractant substance (chemotaxis).

2. Most bacteria elaborate a product that is directly chemotactic for PMNs. It is not known if fungi or mycoplasma elaborate a similar chemotactic product.

3. Antigen-antibody complexes (IgG and IgN) generate a chemotactic factor by activating complement. This factor has a molecular weight of 15,000 and is derived from C5 with the active fragment C5a.

4. PMNs from patients with Chediak-Higashi disease and diabetes have been shown to be defective in their ability to respond to chemotactic stimuli.

5. Recent evidence suggests that patients with inflammatory periodontal disease or stomatitis may show variations in PMN chemotactic response when compared to controls.

APPROACH:

Our hypothesis will be tested by correlating the periodontal disease index with the PMN chemotaxis index. The experimental methods and controls are outlined below.

Thirty patients with varying degrees of periodontal disease will serve as subjects in this study. Thirty additional individuals without periodontal disease will serve as healthy controls.

All subjects will be involved in the following experimental procedure : ž

1. Periodontal Disease Index:

a. Recording of personal data: age, rank, social security number, sex, and a brief medical and dental history.

b. Clinical dental examinations will be given and the degree of periodontal disease measured using the Ramjford periodontal disease index. A sample of dental plaque will be removed with a scaler and frozen in a preweighed plastic tube.

2. PMN Chemotaxis Index:

a. Ten (10) ml of blood will be drawn from the antecubital vein into a heparinized tube. Ten (10) additional ml of blood will be used to prepare fresh serum.

b. The heparinized blood will be sedimented in a 2 percent methyl cellulose solution. The plasma is separated and PMNs diluted in Hanks or Gey's solution. Cells are washed twice and concentration adjusted to 2.2 x 10^6 cells per ml by centrifugation, cell counts, and dilution. The final suspension of PMNs will be placed in the upper part of the Boyden chamber after the chemotactic substance is placed in the lower part.

c. The serum will be removed from the clotted blood and frozen if not used immediately.

d. Chemotactic stimuli:

(1) Bacterial chemotactic factor will be prepared from strains of human oral bacteria and purified by Biogel P-2 molecular sieve and Dowex I ion exchange column chromatography.

(2) Endotoxin from an oral gram negative microcrganism will be used to activate fresh serum complement and the 15,000 MW C5a chemotactic factor purified on a G-2000 molecular sieve column.

(3) Two lambda of the dental plaque sample will be used to activate 1.0 ml of the patients' fresh serum. Serum inactivated at 56 degrees C for 30 minutes will be a negative control.

29

e. Millipore filters will be numbered and placed in the Boyden chamber.

Ĭ

f. The chemotactic stimuli or control will be placed in Gey's or Hanks solution in the lower part of the Boyden chamber; the PMN suspension in the same medium will be placed in the upper part.

g. The following experimental protocol will be followed for each subject. The number of PMNs in the upper part of the chamber remains constant and the PMN response to varying chemotactic stimuli will be evaluated in the following manner. Each chamber will be run in duplicate.

Chamber	Num	ber Ch	emotactic	subs	stance	PMNs	
1 &	2	Bacterial	СТХ	50	lambda	2.2 x	10 ⁶
3 &	4	UP	89	200	88	10	
5 &	6	. "	86	400	11	81	
7 &	8	C5a Comple derived C	ement (C) TX	50	81	17	
<u>ه</u> 9	10	ts	87	200	84	Ħ	
11 &	12	ŧ*	87	400	87	71	
13 æ	14	heat inac plus dent	tivated C al plaque	200		81	
15 &	16	heat inact plus denta	tivated C al plaque	200	"	96	
17 &	18	patient so plus denta	erum al plaque	200	**	n	
19 &	20	Hanks med: •control	ium	200	n		
21 &	22	saline com	ntrol	200	۳		

30

ł

h. The chambers are incubated for three hours at 37 degrees C, \cdot 5 percent CO₂ in high humidity.

i. Filters are washed, stained with hemaroxylin, cleared and mounted on microscopic slides with a cover glass.

j. Cells will be counted on the bottom of the filter discs using 450X magnification and a grid. Ten random fields will be counted and averaged. The average number of PMNs per high power field is the chemotactic activity. The chemotactic activity minus the background cell migration is the chemotaxis index. Reading of slides is done in a single blind manner on coded slides. When the chemotaxis values are established, the values are decoded.

k. The chemotaxis index for each subject will be correlated with the periodontal disease index using statistical methods. RESULTS AND DISCUSSION:

None. New study.

Late PAC UNDERVISE Late PAC	RESEARCH	AND TECHNOLOG	Y WORK UNIT S	UMMARY	I. AGEN	CY ACCESSI	ON® 2	DATE OF SUI	MARY®	REPORT O	CONTROL STR
A. New U U NA NL Entransmitter construction A work in a. no./CODEs* PROGRAM ELGUENT PROJECT NUMBER TABLE AND ALL AUGUST WORK ON THUMBER b. no./CODEs* PROGRAM ELGUENT PROJECT NUMBER TABLE AND ALL AUGUST WORK ON THUMBER b. no./CODEs* PROJECT NUMBER CONT OO 391 c. CONTRADUTE AND TECNOLOGICAL AND AND TECHNOLOGICAL AND TECHNOLOGICAL AND	ANTE POLY SUPPRY	TA SIND OF SUBMARY	TE SUMMARY SCTY	. WORK SECURITY	DA DA	OC 692	9	/	Tab SORCIFIC	DATA	LEVEL OF
B. HOLOGODES ¹ PROGRAM ELCENTY PROJECT NUMBER TASK AREA NUMBER WORK OWNT NUMBER A MARAY G1101A 3A061101A91C 00 391 CONTRUMING 1 <td< th=""><th></th><th>A. New</th><th>U</th><th>U</th><th>N</th><th>IA</th><th></th><th>NL</th><th>CONTRACTOR</th><th>ACC 815</th><th>A WORK U</th></td<>		A. New	U	U	N	IA		NL	CONTRACTOR	ACC 815	A WORK U
• Ammany 61101A 3A061101A91C 00 391 • Communities • Communities • Communities 391 • Communities • Communities • Communities 00 391 • Title (procedul and record)* U) Some Effects of Hypertonic Medium on Cultured Mammalian Cells (05) • Formation of the State of the	J. NO./CODES ^{.®}	PROGRAM ELEMENT	PROJECT	NUMBER	TASK	AREA NUMB			WORK UNI	T NUMBER	1
Contransurial Contran	L PRIMARY	61101A	<u>3A0611</u>	<u>01A91C</u>		00	<u></u>		<u>391</u>		
contrasting in the intervention of the interventintervention of the intervention of the intervention	. CONTRIBUTING		4							•	
1 The process of a second classification of control of the second classification of the second classi	. CONTRIBUTING		<u> </u>		<u> </u>		<u> </u>				
U) Some Effects of Hypertonic Medium on Cultured Mammalian Cells (US) is creating any requised control Antal Output of the second and any required mammalian Cells (US) is creating any required control Antal Total Control Control Antal Control Contr	TITLE (Procedo error.	Security Classification Com			••	~					
Lecterina and reconcession of the deficient of the second	U) Some Elle	cts of Hypertoni	c Medium on	Cultured Man	<u>nmalıa</u>	in Cells	(05)				
A draw bare IL ESTIMATED COMPLETION DATE IL PORTEGUAL IL PROFEMICIAL ENTITIES OF THE TOP DATE 71 04 CONT DA C. In-house 72 CONTACTION DA C. In-house A STEADERT CETIVE: NA EXPERIMENT ON PREFERENCE SETIMATE A PROFESSIONAL MAY YEL FUND OF CONTACTION A NUMBER.* A MOUNT: IN REPORT CETIVE: A MOUNT: IN REPORT CETIVE: A MOUNT: A KIND OF APARD: f. CUM. AMT. PREFERENCE TO A MOUNT: IN REPORT CONTACTION IN TO A START A REPORT OF APARD: f. CUM. AMT. PREFERENCE S. S 3 A REPORT OF APARD: f. CUM. AMT. PREFERENCE TO A START IN TO A START A REPORT OF APARD: f. CUM. AMT. PREFERENCE TO A START TO A START TO A START IN TO A START	003500 - Clin	lical Medicine		· ·							
71 Od DA C. In-house *. Conversion Conversion of Advance Description of Ad	STAAT BATE		14. ESTIMATED COMP	LETION DATE	IS FUN	DING AGENC	v		H. PERFOR	IANCE MET	MOD
Procent Pact / GRAM T In RESOURCES ESTIMATE In RESOURCES ESTIMATEIn RESOURCES ESTIMATE In RESOURCES ESTI	71 04		U	JNI	DA	<u> </u>			C. In-	house	
A DATEAPERENTICAL EXPENSION Classification (Action of cell growth) Responsible (action of the found to stimulate cell growth and division which would be applicable to closure of wounds. Responsible center of the found to stimulate cell growth and division which would be applicable to closure of wounds. 24. (U) Cell culture experiments using biochemical, light microscopy and electron micrographic technique. 25. (U) None. New study.	7. CONTRACT/GRANT				16 RES	OURCES EST	IMATE	& PROFESS			106 (In these an
A MUNDERN ¹ C TYPE: 4 ANOUNT: AND OF AWARD: f. CUM. AMT. KIND OF AWARD: f. CUM. AMT. REPORTING CODE ORGANIZATION Responsible C DDD DRGANIZATION Responsible C DDD DRGANIZATION Responsible C DDD DRGANIZATION Responsible C DDD DRGANIZATION RAWE Letterman Army Institute of Research Responsible C BDD DRGANIZATION RAWE Letterman Army Institute of Research Responsible C BDD DRGANIZATION RAWE Letterman Army Institute of Research Responsible C BDD DRGANIZATION RAWE Letterman Army Institute of Research RAWE Letterman Army Institute of Research RAWE Letterman Army Institute of Research RAWE RAWE:	A DATEL/EFFECTIVE:	NA	EXPIRATION			PARCEOINE		[1	
c. TYPE: 4 ANOUNT: 73 .5 3 a. KIND OF AVARD: f. CUM. AMT. 73 .5 3 WE REFORMEDED DOD DRGAMIZATION PREFORMENCE DOD DRGAMIZATION Image: 7 73 .5 3 WARE* Letterman Army Institute of Research apport Division Active ORGANIZATION Image: Classify Construction Organization Image: Classify Construction Organization Image: Classify Construction Organization MARE* Letterman Army Institute of Research apport Division Active Organization Image: Classify Construction Organization Image: Classify Class	h number:"				FISCAL	72			125		1
a KIND OF ANARD: 1.3 .3 a KIND OF ANARD: 1.3 .3 b. RESPONSIBLE DOD DRGAMIZATION 1.4 1.4 ANARE* Letterman Army Institute of Research ABOMESS-PRESIDIO OF San Francisco, CA 94129 Index* Letterman Army Institute of Research Clinical Research Support Division Clinical Research Support Division ABOMESS-PRESIDIO OF San Francisco, CA 94129 Index* Letterman Army Institute of Research ABOMESS-PRESIDIO OF San Francisco, CA 94129 Index* Presidio of San Francisco, CA 94129 MARE: Akers, W.A., COL MC TELEPHONE: 415-561-3006 VELEPHONE: 415-561-5181 Social SECURITY ACCOUNT NUMBER IN. GENERAL USE MARE: Dettor, C.M., LTC MSC VELEPHONE: 415-561-3006 Social SECURITY ACCOUNT NUMBER IN. GENERAL USE MARE: MARE: IN. GENERAL USE MARE: MARE: IS TECHNICAL GREETIVE.* SA APPROACH. Standard Greet of Market Presenter Instal Area with Security Classification Code.) IS TECHNICAL GREETIVE.* Standard Greet of Market Presenter Instal Area with Security Classification Code.) In and Classification Code.) IS TECHNICAL GRECTIVE.* </td <td>G TYPE:</td> <td></td> <td>& ANGUNT:</td> <td></td> <td>YEAR</td> <td>CURRENT</td> <td></td> <td></td> <td>÷</td> <td>T</td> <td>3</td>	G TYPE:		& ANGUNT:		YEAR	CURRENT			÷	T	3
 RESPONSIBLE DOD DRGANIZATION RESPONSIBLE DOD DRGANIZATION RAME * Letterman Army Institute of Research ADDRESS * Presidio of San Francisco, CA 94129 RESPONSIBLE INDUVIDUAL NAME: Letterman Army Institute of Research Clinical Research Support Division ADDRESS * Presidio of San Francisco, CA 94129 RESPONSIBLE INDUVIDUAL NAME: Dettor, C.M., LTC MSC TELEPHONE: 415-561-5181 RESPONSIBLE INDUVIDUAL NAME: 415-561-5181 RESPONSIBLE ALL USE Cell growth; cell division; stimulation of cell growth It Stemeral use classes effected on mammalian cells by hypertonic treatment in order to determi ie if a reasonable means can be found to stimulate cell growth and division which would be applicable to closure of wounds. (U) Cell culture experiments using biochemical, light microscopy and electron micrographic technique. 25. (U) None. New study. 	. KIND OF AWARD:		S. CUM. AMT.	,	I	15			5		5
 Lettermian Army Institute of Research ABDARESS * Presidio of San Francisco, CA 94129 MAME.* Letterman Army Institute of Research Clinical Research Support Division, CORESS * Presidio of San Francisco, CA 94129 MERSPONSIBLE HIDDIVIDUAL MAME.* Dettor, C.M., LTC MSC TELEPHONE: 415-561-5181 TELEPHONE: 415-561-5181 TECHNICAL OUE CIVE.* 18 APPROACH. 33 PROGRESS (Period Individual Research Control Research Res	. RESPONSIOLE DOD	DRGANIZATION	1		20. PER	FORMING OR	GANIZA	TION			
Letternian Anny institute of Research anoness-Presidio of San Francisco, CA 94129 Messonause individual mane: Akers, W.A., COL MC Telephone: 415-561-3006 Social security account number Asbociate investigation to effected and invision; stimulation of cell growth Is Technical objective." 24 APPROACH, 25 Prostitution individual programs individual programs individual and in order to determine if a reasonable means can be found to stimulate cell growth and division which would be applicable to closure of wounds. 24. (U) Cell culture experiments using biochemical, light microscopy and electron micrographic technique. 25. (U) None. New study.	ANE* 1 attorn	Army Institu	the of Researc	h		Lette	man	Aemy I	estitute o	f Resea	arch
ABBORESS-Presidio of San Francisco, CA 94129 MESPONSIBLE INDIVIDUAL NAME: Akers, W.A., COL MC TELEPAONE: 415-561-5181 D. GEMERAL USE D. G	Lettern	Jan Aimy maria	at of Acoustics			Clinic	nina. Nat Ri	search S	unnort D	ivision	11.0.1
Responsible E INDIVIDUAL MARE: Akers, W.A., COL MC TELEPHONE: 415-561-5181 TI. SENERAL USE TELEPHONE: 415-561-3006 SOCIAL SECURITY ACCOUNT NUMBER ASSOCIATE INVESTIGATORS NAME: MARE: MARE: MARE: 1. SENERAL USE TELEPHONE: Constitution of cell growth Cell growth; cell division; stimulation of cell growth TE REVENICAL GRIECTIVE." 24 APPROACH. 25 PROGRESS (Pumile) Individual paragraphs idmilling by hypertonic treatment in order to determi in e if a reasonable means can be found to stimulate cell growth and division which would be applicable to closure of wounds. 24. (U) Cell culture experiments using biochemical, light microscopy and electron micrographic technique. 25. (U) None. New study.	ABORESS + Presidio) of San Francisc	o, CA 94129		ADDRES	•• Presid	lio ol	San Fra	ncisco, C	A 9412	29
MANE: Akers, W.A., COL MC TELEPAONE: 415-561-5181 TELEPAONE: 415-561-3006 TELEPAONE: 415-561-					PRINCI		GATOR	Furnish SEAN	il li S. Atademi	e tastitulias	-4
NAME: Akers, W.A., COL MC YELEFADDRE: 415-561-5181 ST. SERERAL USE SOCIAL SECURITY ACCOUNT NUMBER ANDE: ANDE: SCALE SECURITY ACCOUNT NUMBER ANDE: NAME: NAME: NAME: NAME: NAME: SCALE SECURITY ACCOUNT NUMBER NAME: NAME: NAME: SCALE SECURITY Classifier Code) Cell growth; cell division; stimulation of cell growth ST. SECURITY Classifier Code) Cell growth; cell division; stimulation of cell growth ST. TECHNICAL OBJECTIVE.* 24 APPROACH. 25 PROGRESS (Pumile) Instribution Code) Protocod Inst of each with Security Classification Code.) 23. (U) Quantitate changes effected on mammalian cells by hypertonic treatment in order to determi ie if a reasonable means can be found to stimulate cell growth and division which would be applicable to closure of wounds. 24. (U) Cell culture experiments using biochemical, light microscopy and electron micrographic technique. 25. (U) None. New study.		4)41	•		NAME	. Detto	or, C.	M., LTC	MŚĆ	6 group	<i>v</i>
 TELEFADORE: 415-561-5181 STREERAL USE STREERAL USE	Manz. Alare				TELE		15.5	<1-3006			
III. EXPRONE 41.3-301-3101 All. SERERAL USE Associate investion constants Associate investion constants NAME: NAME: NAME: III. EXPRONE (Proceds Each of the sensitive closel/fication code) NAME: Cell growth; cell division; stimulation of cell growth NAME: III. EXPRONE OBJECTIVE.* 14 APPROACH. 25 PROGRESS (Provide Instituted by number. Proceed test of each of security closel/fication code.) 23. (U) Quantitate changes effected on mammalian cells by hypertonic treatment in order to determine if a reasonable means can be found to stimulate cell growth and division which would be applicable to closure of wounds. 24. (U) Cell culture experiments using biochemical, light microscopy and electron micrographic technique. 25. (U) None. New study.	Alt	H.A., COL MC			SOCIA	-	ACCOU				
 RAME: MAME: MAME: MAME: MAME: RELYBOADS (Precede 2aCH with Senseth) Clearthteation Code) Cell growth; cell division; stimulation of cell growth TECHNICAL OBJECTIVE.* 34 APPROACH. 35 PROGRESS (Pumish Individual prographic Identified by number. Precede test with Security Clearthteather Code.) 23. (U) Quantitate changes effected on mammalian cells by hypertonic treatment in order to determine if a reasonable means can be found to stimulate cell growth and division which would be applicable to closure of wounds. 24. (U) Cell culture experiments using biochemical, light microscopy and electron micrographic technique. 25. (U) None. New study. 	TELEPAURE: 41	3-301-3101	······		-						
 NAME: Cell growth; cell division; stimulation of cell growth 11. TECHNICAL OBJECTIVE.* 34 APPROACH. 33. PROGRESS (Pumish individual paragraphs idmillifed by number. Protects test of with Security Classification code.) 23. (U) Quantitate changes effected on mammalian cells by hypertonic treatment in order to determine if a reasonable means can be found to stimulate cell growth and division which would be applicable to closure of wounds. 24. (U) Cell culture experiments using biochemical, light microscopy and electron micrographic technique. 25. (U) None. New study. 					HAME		¥# • • • • •	1			
 21. EEVership (Private Each of A Society Closefficient code) Cell growth; cell division; stimulation of cell growth 23. (U) Quantitate changes effected on mammalian cells by hypertonic treatment in order to determine if a reasonable means can be found to stimulate cell growth and division which would be applicable to closure of wounds. 24. (U) Cell culture experiments using biochemical, light microscopy and electron micrographic technique. 25. (U) None. New study. 					MAME						
 Cell growth; cell division; stimulation of cell growth at TECHNICAL GROUCTIVE." 24 APPROACH. 25 PROGRESS (Funith Intriduct programs Idmittled by number. Protoco test of with socially classification code.) 23. (U) Quantitate changes effected on mammalian cells by hypertonic treatment in order to determine if a reasonable means can be found to stimulate cell growth and division which would be applicable to closure of wounds. 24. (U) Cell culture experiments using biochemical, light microscopy and electron micrographic technique. 25. (U) None. New study. 	IL KEYBONDS (Procedo	BACH with Semility Clevell	fication Code)		4						
 23. (U) Quantitate changes effected on mammalian cells by hypertonic treatment in order to determine if a reasonable means can be found to stimulate cell growth and division which would be applicable to closure of wounds. 24. (U) Cell culture experiments using biochemical, light microscopy and electron micrographic technique. 25. (U) None. New study. 	Cell growth;	, cell division; st	imulation of c	cell growth	<u></u> ,	،					
 23. (U) Quantitate changes effected on mammalian cells by hyperionic treatment in order to determine in a reasonable means can be found to stimulate cell growth and division which would be applicable to closure of wounds. 24. (U) Cell culture experiments using biochemical, light microscopy and electron micrographic technique. 25. (U) None. New study. 	83. TECHNICAL DEJECT	TIVE," 24 APPROACH, 21	. PROGRESS (Pumish I	ndividual paragraphe id	Juntilied by	number. Pro		t of soch with s	Scurity Classia	Icalian Code	**)
24. (U) Cell culture experiments using biochemical, light microscopy and electron micrographic technique. 25. (U) None. New study.	23. (U) Qua reas clos	intitate changes o sonable means ca sure of wounds.	effected on main be found to	ammalian ceir stimulate cel	is by n ll grow	yperton /th and (divisi	atment i ion which	n oraer i 1 would b	o deter æ appli	icable to
25. (U) None. New study.	24. (U) Cell	culture experime	ents using bio	chemical, ligh	t micr	oscopy	and e	lectron	micrograp	phic tec	zhnique.
25. (U) None. New study.	05 (II) N	No									
	25. (U) Nor	he. New study.									
	l l										
	l										
	l										
	l i i i i i i i i i i i i i i i i i i i										
	l										
	i i										
	l l										
	l l										
	ł –										
	i i										
	i										

2

ないないのでもないないないないない

X 68-574210

la Venite ne fou carada

とないである。ないないとうのないであれたのでないで

Control of

No.

15.7

Anoliable to contractors upon originators oppravel DD, serie 1498 PREVIOUS EDITIONS OF THIS FORM ARE DESOLETE DD FORME 1488A 1 NOV 48 AND 1498-1, 1 MAR 40 (FOR AKMY USE) ARE OBSOLETE.

LAND & California

DERMATOLOGY RESEARCH DIVISION

Program Element 6.21.10.A Bio-Medical Irvestigations

Project Number 3A062110A822 Military Internal Medicine

Task Area Number 00

Project Number 3A062110A831 Tropical Medicine

Task Area Number 00

and a second second

1440.7

and the second second second second

DERMATOLOGY RESEARCH DIVISION

The Dermatology Research Division studies the interrelated effects alone and in combination of water immersion, friction, heat and humidity, fungal and bacterial infections, and insect repellents on man's skin: The multi-disciplinary team approach is used (5 M. D. 's, 5 PhD's, 7 M. S. 's) in seeking solutions to pressing military dermatological problems.

One group designs instruments for producing and measuring various degrees of friction under scientifically controlled conditions and develops ways to prevent and treat blisters on the palms and soles of soldiers.

Another group studies prickly heat rash, its cause and prevention. Prickly heat rash is produced by putting Saran Wrap patches on a man's back for 2 to 4 days.

Mosquito repellents are being developed and tested on men that resist sweat-off and wash-off substantially longer than those now available.

Volunteers are infected on the forearm with a fungus that causes 'athletes foot'. Their response to the infection is closely studied, particularly the way they develop immunity. Such studies should lead to a vaccine, a better medicine to prevent such a skin disease, and more rapid, accurate, and economical methods to diagnose fungal infections.

Numerous basic scientific studies concern the way substances penetrate the skin barrier via the stratum corneum, and developing antifungal, antibacterial, antifriction, insect repellents, and skin waterproofing substances tc'stay in the skin.

Dermatological research has been advanced greatly by having 30 full-time military medical research volunteers, permitting long, closely controlled experiments in the laboratory and field. 34

REJEARLI	AND TECHNOLOGY	WORK UNIT S	UMMARY	I. AGEN	NCV A	CCESSION	8. DATE C	7 500	WARY	REPOR	T CONT	ROL SYND
					<u>OI</u>	3 6800	720	7 01		00.	DRAE	(AR)030
71 07 01	D. Change	U U	LI II	N	A A		NI.		CONTRACTO			WORK UM
NO./CODES:*	PROGRAM ELEMENT	PHOJECT	I NUMBER	TASK	AREA	NUMBER	1		WORK UNI	TNUM	ER.	
PRWARY	62110A	34062110	A822	(00			15	5			
CONTRIBUTING				<u>†`</u>			× 38					
										: **	•	• •
TITLE (Procodo mith	Somethy Classefication Code	•				•.						
CO MORE EII SCIENTIFIC AND TEL 003500 Cl	CHHOLOGICAL AREAS ^a Linical Medicine	epelients Aga	iinst malaria b		g Ivi		es (05	<u>)</u>	·····			
67 11		CONT	PLETION DATE	DA	DING	AGENCY			C. In-ł	IOUSE	ETHOD	
CONTRACT/ BRANT				10. RES	OURC			FESS		3 3 1	UN DE (n shows and
DATES/EPPECTIVE:	NA	EXPIRATION:				AA		•			-	
NUMBER *	11 7 8	• • • • •		FISCAL	·	72	_				20	
TYPE:		& ANDUNT:		I YEAR		73		1			35	
RIND OF ATARD:	086 ANI 7 / T-0-	F. CUM. AMT		-		/ J					r	
		L							L			
Lette Presi	erman Army Inst dio of San Franc	itute of Rese isco, CA 941	arch 29	HAME;"	86 .*	Letter Derm Presid	rman A atology lio of S	rmy / Re an I	/ Institut search D rancisco	e of l ivisio , CA	Resea n 9412	ırch 29
				PRINCI	РАЦ II 11 ⁰ 1911 ан	Akers	, W.A.	нан , СО 1	LMC	e jpelitu	Nanj	
AKCI	5, 11.7., COL MC	•					0UNT NUM	T DCA:				
GENERAL USE				-					•			
					~							
				-		Brode	el, C., S	P-4				_
				NAME NAME	la la	Brode	el, C., S	P-4				DA
. KEY WORDS (Procedo	BACH with Security Classifi	cation Code) (U) 1	wash-off; (U) :	uane uane sweat-	n -off	Brode	el, C., S man vo	P-4	teers	*		DA
. НЕЧИСАСЬ (Рисси) (U) repellent тесниісаь овласт	EACH of Seath Clauth t; (U) mosquito; tive." 26 APPROACH, 26	collan Codo) (U) ((U) skin; (U) PROCRESS (Purilia	wash-off; (U) : stratum corne intriduci program to	wawe wawe sweat- cum; (-off (U)	Brode ; (U) hu persiste	man vo nce; (L	P-4	teers olymer to	ormul	ation	DA
(U) repellent TECHNICAL ORJECT 25. (U) 71 0 of a	EACH of Board Claude t; (U) mosquito; (Tive." 24 APPROACH, 28 17 - 72 06 Wash repellents' wash t	collen Code) (U) 1 (U) skin; (U) PROGRESS (Pumle -off vs sweat- resistance tha	wash-off; (U) s stratum corne off testing rev off testing rev in sweating.	vane sweat- eum; (wained a	-off (U)	Brode ; (U) hu persiste	man vo nce: (L	P-4	teers blymer to the second sec	more	ation 	DA 115; ere test

10-01 Ser.

a familie a familie a

and a second second

More Effective Topical Repellents Against Malaria-Bearing Mosquitoes

William A. Akers, COL MC Charles Brodel, SP4

PROBLEM:

Our objective is to develop a broad spectrum topical preparation which will repel malariabearing mosquitoes and other disease vectors, which will persist one or more days resisting removal by excessive evaporation, skin penetration, sweat and water, and abrasion. This year we had a 7-month gap in replacing the principal investigator so our activity was lower than desired. We tidied up some loose ends in evaporation studies of repellent-polymer formulations and in vivo tests of a few new chemicals and other formulations from industrial and academic laboratories. Our main studies compare the repellent loss from man's skin from sweating and water wash-off. We wish to develop and quantitate simpler, faster, and more economical screening methods- preferably in-vitro.

A new repellent mentioned last year, diethylbenzenesulfonamide (DBS), a crystalline material at room temperature, was supplied by Dow Corning Corporation. A cosmetically acceptable formulation contained 2 parts of DBS and 1 part of silicone polymer. Applied to give 0.25 mg/cm² of DBS to non-sweating forearms, the formulation protected against biting 19 hours. When the formulation was applied to give 1 mg/cm^2 of DBS and the entire 105 cm² repellent-treated arm area was rinsed every hour with 250cc of water at room temperature, the repellent protected 8 hours. This was remarkably superior to the performance of the present standard repellent, diethyl-meta-toluamide (m-DEET) which protected 5 hours on dry skin and only 2-3 hours when subjected to hourly rinses.

36

Unfortunately, the USA Environmental Hygiene Agency (USAEHA) toxicological tests in 2 species, rats and rabbits, clearly showed DBS at oral dosage of 500 mg/kg to be teratogenic by producing smaller fetuses and limb abnormalities.

APPROACH:

1.

Formulating repellents with film-forming polymers, and additives in alcohol and other appropriate solvents will continue to be explored by cooperating industrial and academic laboratories; new systems showing water resistance, especially those showing both water resistance and cosmetic appeal, will be submitted to LAIR for mosquito challenge and water rinse testing on the arms of volunteers. LAIR feedback to cooperating polymer laboratories will aid in reformation to achieve the optimum compromise in necessary properties. Candidates showing improved sweat-off resistance (superior to simple DEET), cosmetic acceptability, and no skin irritancy will be considered for future field trials. Toxicological clearance will be obtained when necessary from the U.S. Army Environmental Hygiene Agency (USAEHA).

<u>Wash-Off vs Sweat-Off of DEET</u>: This pilot study compared the duration of DEET on men's forearms to washing with warm water and to sweating. DEET, 0.31 mg/cm², was applied to a 7x15 cm area on 4 volunteers' volar forearms, then was washed with water (temperature 34°C, one liter per minute) for 3 minutes. The standard mosquito repellency test was conducted immediately. If the volunteer did not receive 2 bites, the 3 minute washing was repeated with subsequent repellency testing until the repellent failed.

The volunteer then had DEET, 0.31 mg/cm², applied to the 7x15 cm area on the opposite forearm. To cause sweating, he entered a controlled environment room (temperature 40°C, relative humidity 48%) for 10 minutes, then exercised on a stationary bicycle for 10 minutes. On leaving the room, and without drying his forearm, he had the standard mosquito repellent testing performed. If the

volunteer did not receive 2 bites, he remained outside the chamber for 10 minutes, reentered the hot room, sat 10 minutes, bicycled 10 minutes, left the room, and was tested again. If he failed to receive any mosquito bites, he had the standard insect repellent test performed every 30 minutes until the repellent failed.

Ranking 4 Repellents: We wished to rank the 4 best mosquito repellents in use as to their persistence and resistance on man's skin against sweating, since this information is not available. We tested (1) DEET, (2) dimethyl phthalate, DMT, (3) Rutger's 612, R-612 (2 ethylhexanediol - 1, 3) and (4) Indalone. These were tested in 2 groups of 4 Repellents were applied to 2 rectangular volunteers. areas, 7x10 cm² on the volar wrist and proximal forearm. The site of application of each repellenc was rotated within each group, resulting in a 4x4 Latin square design. Each half-hour after application the repellent treated areas were exposed to 200 Aedes aegypti mosquitoes. The tests were conducted in a controlled-environment room at 32°C and 90% RH. To induce and maintain sweating, the men participated in 3 ten-minute exercise periods each hour, usually on bicycles.

ないないのでものないないないないです。

RESULTS AND DISCUSSION OF RESULTS:

We did <u>in vivo</u> and <u>in vitro</u> testing on approximately 20 chemicals or formulations supplied by contractors or industrial laboratories. One new chemical and a new formulation concept revealed distinct promise; but patent applications are underway so we cannot discuss them.

Wash-Off vs Sweat-Off of DEET: Three men received 2 bites after a single 3 minute warm water wash. The other volunteer was bitten after the second wash. After 40 minutes of 40°C and 48% RH, only one volunteer received 2 bites although all had sweat running-off the treated area at the end of each test period. One hour after they left the chamber 2 of 3 remaining men were bitten. These results confirm that water wash-off is a much more severe test of a repellents' wash resistance than sweating. Wash tests are also simpler, faster, and more economical to perform.

Ranking 4 Repellents: The sweat test could not clearly separate DEET and Indalone as to their resistance to removal by sweating. No significant difference between DMT and R-612 was demonstrated. Both dry and sweating tests revealed no apparent difference between the sites of application on the wrist and proximal forewarms, but the difference between individuals still persisted.

Duration of Repellents

Means in Hours

1

international contents of the state of the state of the state of the state of the state

Dry

	DEET	DMT	Indalone	R-612
Dry	6.2	2.9	2.2	3.9
Sweating	3.6	2.2	5.1	1.9

Ranking of Repellents

							•
Gr	oup 1	G	iroup 2	G	roup 1		Group 2
1. 2. 3.	DEET R-612 DMT	1. 2. 3.	DLET R-612 DMT	1. 2. 3.	DEET Indalone DMT,R~612	1. 2. 3.	Indalone DEET,DMT R-612
4.	Indalone	4.	Indalone				

Sweating

Group 1 was tested in the morning; group 2 in the afternoon.

We plan in vivo wash studies to rank these repellents. It is impossible to have people sweat the same amount using only heat or exercise as the stimulus. Sweat tests are more difficult to do than dry protection time tests, while wash tests are the quickest.

The previous principal investigator is working on the second draft of his technical report.

FUTURE PLANS:

Much information concerning the evaporation rate of DEET, when applied independently or in combination with various polymers, has already been gathered by utilizing a radio-labelled repellent and a sophisticated detecting apparatus. Operating this instrument manually demands around-the-clock attention so the apparatus is being automated. When completed the setup will permit more rapid screening of potential repellents with the most promising being tested on volunteers' forearms for data verification. Besides evaporation rates, repellent penetration rates through the stratum corneum will be studied. Basic studies concerning how polymers bind to the skin will be undertaken. 絲

40

C. T.

RESEARCH	AND TECHNOLOGY	WORK UNIT S	UMMARY	1. AGEN DA (CV ACCER DB 680)4	2. DATE OF SUI 72.07.0	MARY ⁸	REPORT (DD-DI	CONTROL STREO REE(AR)\$36
71 07 01	K Complete	r summary scyv ^a	N. WORK SECURITY	7. AEGA	NA		irn instan NE	ISA SPECIFIC		A VORE UNIT
NO./CODES:*	PROGRAM ELEMENT	PROJECT	HUMBER	TASK A	REA NU	MBER		WORK UN	THUNDER	1
PRIMARY	62110A	3A062110A	822		00		15	6		
CONTRIBUTING							849 - C - P		~~	· · · · · · · · · · · · · · · · · · ·
CONTRIBUTING							(NgGroot)			
(U) Investig	ation on the Path	nogenesis, Pre	vention and N	lanage	ement	<u>^f Tr</u>	opical Ac	ne (05)		
STAAT DATE		4. ESTINATED CON	LETION DATE	15 PUH	NHG AGEI	ICY				HOD
67 09		CONT		DA			1	C. In-h	ouse	
CONTRACT/GRANT				10. RES	DURCES E	STINAT	A PROFESS	IGNAL MAN YI		(06 (In these ands)
MATES/EFPECTIVE:	NA	EXPINATION:		-		72	1	0		0
TYPE:		& APOUNT:		YEAR CUNNENY						
KIND OF AWARD:		f. CUM. AMT.		1	l '	73	0			0
RESPONSIBLE DOD	DRGANIZATION			50. PER	ORMING	RGANI	ATION			
Leti Pres	erman Army Ins idio of San Franc	titute of Rese cisco, CA 941	arch 29	HAME!®	8: ⁰	Lette Derm Presid	rman Arm atology R lio of San	y Institu esearch 1 Francisc	te of R Division o, CA 9	esearch 94129
ESPONSIBLE INDIVIC		c		PRINCIP NAME:	AL INVER	Lewis	5, C.W., L	" U.S. Acade FC MC	le protibudes	•
TELEPHONE: 415	-561-5181	C		SOCIA	L SECURI					٠
		······································		-		TIGATO				
				NAME	4	Griffi Henn	ing, T.B., M	I.D. h.D		~
KEVBOADS /Procede	EACH with Senatity Classifi	Lation Codej		NAME:						UA
(U) acne: (U) skin: (U) trop	ical acne: (U)	skin lipids							
25. (U) 71 trop had and che prev whi seve spre con ship and or I valu clar	07 – 72 06 The bical acne evacuation never served in the routine laborato mistry and (6) apprious history of mistry ch developed in the ere pustular, cystic and distribution, it trol acne patient to the serum test the 17-ketostered Decadron suppress thes in patients with ification.	study has be ted from the he tropics. T ry studies, (2 oplied heat, hu nild to moder these patients ic acne patien including bot were found t stosterone lev bids were norn ssion testing. th acne. The	en completed Republic of V he following :) endocrinolo umidity and f ate acne vulga were clinical ts. The striki h the arms an o have low ur els in these pa nal and no pa One can only role played b	. The lietnan aspect gy, (3 riction aris pr ly and ing dif d the inary atients attern specu y and y and	study n and s of tr) histo ior to histo ference legs. I testos s. In g or trer late o rogens	grou 3 pat opica patho ess. A their patho e is the roatho enerand wa n the in th	p consiste ients with 1 acne wer ology, (4) 11 of the t tour in Vi logically i he sparing f the trop e levels. 7 1, the urin s apparen se paradoz e pathoge	d of 11 p severe a re investi microbic tropical a letnam. dentical of the fa ical acne there was hary 17-h t with th kical find nesis of a	patients cne vul gated: blogy, (cne patient to those patient to those patient to dir ydroxy e ACTF lings of to cne sti	with activ garis who (1) clinical 5) bio- tients had a bes of lesion e seen in the wide- ts and one ect relation corticoids 1 stimulation testosteroon awaits
Areilleble to contract DD, vorm 145	1015 Upon erifinatoris appr 98 PREVIOUS 38 AND 1455-1	erei Editions of ti 1 Mar es (for	115 FORM ARE D	850L E	TE. OD	FORM	8 1488A, 1 N			

gerts.

F

53.74 AV

Chinas had been had

.

Bether Constants

*জ্যা*য়ে হ

•

:

•

.

.,,

Investigation on the Pathogenesis, Prevention and Management of Tropical Acne

> Charles W. Lewis, LTC MC Tommy B. Griffin, MAJ MC David R. Henning, CPT MSC

The designation "Tropical Acne," is used to describe a severe form of cystic acne that typically affects military personnel assigned to a hot, humid climate. Recently, tropical acne became the major cause for evacuation for skin disease from RVN. It differs from acne vulgaris in that individuals affected are generally considered to be past the acne The onset is often explosive in nature invol. age. ving the posterior neck, chest, back, buttocks, proximal extremities but sparing the face. Clinically the individual lesions resemble acne vulgaris in its severest form with primarily deep seated, painful cystic lesions that frequently result in severe scarring and is extremely resistant to therapy under the adverse tropical climate. Upon returning to a temperate climate, many cases resolve spontaneously.

The existing literature contains no detailed studies on the disease or the possible similarities and differences between tropical acne and common acne vulgaris.

Therefore, in April 1967 this collaborative study to investigate various parameters of tropical acne was undertaken at the Dermatology Service of Letterman General Hospital with the Letterman Army Institute of Research, Presidio of San Francisco, California.

APPROACH:

The study group was composed of 11 patients with active tropical acne evacuated from the Republic of Vietnam, and 3 patients with severe acne vulgaris who had never served in the tropics. All patients were admitted to the Dermatology Service at Letterman General Hospital for comparative studies, received the standard hospital diet, were not allowed to bathe or shower until initial bacterial and lipid samples were obtained. The following aspects of tropical acne were investigated: (1) clinical and routine laboratory studies, (2) endocrinology, (3) histopathology, (4) microbiology, (5) biochemistry and (6) applied heat, humidity and frictional stress.

Clinical and Routine Laboratory Studies: Each patient received a complete history and physical examination, including an epidemiological family survey. Routine laboratory studies included complete blood count, urinalysis, Wintrobe erythrocyte sedimentation rate, urine culture, Venereal Disease Research Laboratory test for syphilis, fasting blood sugar, serum protein electrophoresis, total serum lipids and lipid fractionation, blood urea nitrogen, serum cholestrol, calcium, phosphorus, lactic dehydrogenase, serum glutamic oxalacetic transaminase, uric acid, bilirubin, alkaline phosphatase, serum vitamin A, and carotene. A chest xray was also obtained on each patient. CBC, ESR and urinalysis were repeated weekly times 3 and any abnormality of the above studies was evaluated as necessary.

Endocrinology: Thyroid evaluation included a T3 uptake, RAI 131 thyroid scan and serum cholesterol. Additionally, several patients received PNI determinations. The pituitary and pancreas ware evaluated by a glucose tolerance test with a concomitant plasma growth hormone level determination. Adrenal and gonadal evaluation was done by collecting an initial 24 hour urin for testosterone as described by Weigienka, et al., 17 ketosteroids, and 17 hydroxycorticosteroids and creatinine.

<u>Ristopathology</u>: Biopsies of acne lesions in various phases of development were histologically processed and stained with hematoxylin and eosin, toelucidate the histopathology of the disease process.

Microbiology: The primary objective of the bacteriological studies was to compare skin surface flora

ためにおいていたので、「「「「「」」」

and o extension he statistic that he was the

of patients with tropical acne, who had just returned from Vietnam, with the skin surface flora of patients who have severe cystic acne but who have not lived in a tropical environment.

Quantitation of microorganisms were obtained by serial dilution and spread plate techniques. Anaerobic culture was accomplished by evacuating and flushing Case amerobe jars three times with a mixture of 95% nitrogen and 5% cambon dioxide. <u>Corynebacterium</u> <u>acnes</u> were identified by typical colony morphology.

Biochemistry: Various skin sites of the tropical acne, control acne patients and uninvolved volunteers were extracted with ethyl acetate. The extract was evaporated to dryness and the residue quantitatively determined.

Results and Discussion:

Tropical acne developed in this group of patients after 2 weeks to 5 1/2 months (average 2.8 mos.) of exposure to a tropical climate. The average age at onset was 24.7 years (S.D.=8.27 yrs) with a range of 18 to 43 years. These men had all experienced acne vulgaris in their teens with an average age of onset of 15.5 years (S.D.=1.78). Mone of the patients previously had been completely free of acne, and 7 of the 11 patients had active acne lesions upon arrival in the tropical environment. Except for 1 patient, these 7 patients had minimal acne involving primarily the face or the face and upper back. ł

The severe cystic lesions developed on the skin over the neck, back, shoulders and chest in all patients. Eight of the 11 patients had involvement of the upper arms usually ending at the antecubital fossae, but one patient had lesions extending to his wrists. Five of the 11 also had cystic lesions over the buttocks and thighs. The skin surface of the face remained remarkedly clear of lesions in all patients.

A variety of tropical acne medications, soaps and systemic antibiotics (mainly Tetracycline) were uniformly unsuccessful in halting the progression or inducing a remission of this disease process as long as the patient remained in RVN. However, upon departing RVN to a temperate climate, 3 patients experienced rapid clearing of lesions within 2 to 3 weeks.

The second se

reinterenter heren som attenteren ereten som attenter inder enter attenter inder til staten attente bestaten so

the second more and the second states and the second states and the second second second second second second s

Negative or normal values were obtained for the following: urine analysis, urine culture, serology, chemistry scan (SMA-12), glucose tolerance test, thyroid scan and chest xrays.

One-half of the patients have an elevated white blood cell count. The erythrocyte sedimentation rate was elevated in all patients studied, ranging from 13 to 37mm/hour. This finding plus the elevation of the gamma globulins in 11 of 14 patients and reversal of the A/G ratio in 4 of the 14 patients most likely represents the chronicity and the extensive low grade infection of acne lesions seen in these individuals. There was no consistent abnormality demonstrated by the electrophoretic pattern and most cases had normal findings.

Thyroid evaluation was essentially normal in all patients studied. Two individuals had borderline low values for the 1^{131} , but gave normal results for PBI, T₃ and thyroid scans.

Vitamin A and carotene levels were normal except for 1 patient who had been taking one capsule daily of Vitamin A, 50,000 units for the past 6 months on his own initiative.

Only 4 patients with tropical acne had completely normal findings for serum lipids and fractionation. Various abnormalities were found primarily reflecting low values: total lipids low in 5 of 13; phospholipids low in 6 of 13; triglycerides low in 3 of 1? and elevated in one case; and cholesterol low in 3 of 13. There does not appear to be any specific pattern to these abnormally low . values as some patients had only one fraction decreased, while others had 2 or 3 low values.

The baseline urinary testosterone value was low in 6 of the 14 patients. The one control patient with an extremely low level proved to have acquired gonadal dysfunction manifested by oligospermia and low testosterone levels in his urine. Unfortunately, at the time this patient was studied, serum testosterone determinations were not available to us. The follicle stimulating hormone in this patient was less than 50 mouse units, and his chromosome karyotype was normal.

46

Five of 11 tropical acne patients had low urinary testosterone levels; patients #5 and #11 having extremely low values on repeated determinations. Patient #5 had a normal serum testosterone and a low follicle stimulating hormone level of <15 mouse units. Patient #11 had a borderline low serum testosterone. The other 3 men with low urinary testosterone values had a low serum testosterone level, an elevated level, and in the third the test was not available at the time the patient was studied. An additional patient had a normal baseline urinary testosterone, but low values following ACTH stimulation and Decadron suppression studies. The baseline urinary hydroxy- and ketosteroid determinations were normal in all but one who had a low value for 17-ketosteroids.

The ACTH stimulation tests were normal in all men studied except one, who also had low urinary testtosterone and normal serum testosterone levels. This patient did not show normal stimulation, but he did have normal suppression values.

The Decadron suppression tests were normal in all patients except two. These 2 men did not suppress below 4mg level of 17-hydroxycorticoids, which is considered to be the normal level for suppression. One of these patients, #8, also had the lowest serum testosterone value in this study.

Histopathology: Examination with the light microscope of biopsy specimens of comedos, including cysts and inflammatory lesions of various degrees of severity from seven tropical acne patients revealed no apparent differences in the basic histopathologic changes when compared with biopsies taken from similar control patients with acne or with previously reported findings for acne vulgaris.

All biopsies from inflamed cystic lesions represent the end results of severe acne. When the follicular structure becomes dilated with a keratin plus to the point of rupture, the keratin fragments, lipid material and bacteria are dislodged into the dermal tissue. An intense foreign body reaction develops that is usually accompanied by some degree of abscess formation. Fibrosis was also noted in several specimens representing evidence of chronicity. None of the changes appear to be distinctive and can be seen in any severe type of acne.

Staphylococcus epidermitis and gram positive diphtheroids are resident organisms on all body sites examined. Corynebacterium acnes was isolated at least once from all body sites examined except the buttocks area. All Proteus species were isolated from only one of the patients.

A significant number of gram negative organisms were recovered from acne lesions, normal appearing skin and the nares. E. coli was recovered from 4 tropical acne patients in 13 of 72 cultures and in 1 control patient in 5 of 20 cultures. Proteus mirabilis was identified in one culture from 2 tropical acne patients and Aerobacter aerogenes(Enterobacter aerogenes) on 4 cultures from one tropical acne and one control patient. Staphylococcus aureus, coagulase positive, was isolated in 6 of these 10 patients from at least one or more acne lesions.

Conclusion:

All of the tropical acne patients had a previous history of mild to moderate acne vulgaris prior to their tour in Vietnam.

The types of lesions which developed in these patients

ないたいになるというないであるというないであるという

were clinically and histopathologically identical to those seen in severe pustular, cystic acne patients. The striking difference is the sparing of the face and the widespread distribution, including both the arms and the legs.

Five of the tropical acne patients and one control acne patient were found to have low urinary testosterone levels. There was no direct relationship to the serum testosterone levels in these patients. In general, the urinary 17-hydroxycorticoids and the 17ketosteroids were normal and no pattern or trend was apparent with the ACTH stimulation or Decadron suppression testing.

One can only speculate on these paradoxical findings of testosterone values in patients with acne. The complexities of androgen metabolism are currently being extensively investigated by many research laboratories. The role played by androgens in the pathogenesis of acne still awaits clarification.

Future Plans:

The study is concluded. The final report is being prepared.

No.	Age	Total Lipids 500 - 800 mg%	Phospholipias 200 - 350 mg%	Triglycerides 50 - 250 mg%	Cholesterol 150 - 250 mg%
C	ntrols				
1	20	472*	181•	122	169
2	23	457 *	208	70	179
3	20	300*	236	12*	200
Tro	pical Ac	ne			
4	39	805	205	207	256
5	20	354*	228	8*	118
6	21	-	-	-	-
7	18	640	162•	152	127
8	43	560	257	151	233
9	24	480*	196	118	147
10	24	688	164*	26*	163
11	21	727	134*	422•	200

LABORATORY DATA

*Abnormal values for LGH Laboratory

	AND TECHNOLOG	Y WORK LINIT S		1 AGEN		ACCESSION	2. DATE OF SU	NWARY	REPORT	CONTROL SYP OL
DATE PREVIUMEN	I A KIND OF SUMMARY	S. SUMMARY SCTY	A BORE SECURITY	DA	OB	6814	72 07 0		DUID	KALARISJE
71 07 01	D. Change	U	U	1	NA		NL	CONTRACTOR	ACCESS	A WORK UNIT
9 NO./COE 15.*	PROGRAM ELEMENT	PROJECT	NUMBER	TASK /	ARE	A HUMBER		WORK UNIT	NUMPZ	
	62110A	3A06211	0A822		00)		59		
. CONTRIBUTING							· .· ·			
I TITLE (Procede W/S	Security Cleasification Code							rt		
Agents: Ki	netics of Blister F	(U) Studies	(05)	Produ	uce	a b; mee	cnanical,	i nermai ar		
002300 - Bi	ochemistry; 003	500 - Clinical	Medicine	TIS FUN	DING	AGENCY	·			400
68 12		CONT		DA		1	1	C. In-h	ouse	
T. CONTRACT/GRANT				18. MES	OUR	CES ESTINAT	A PROPES	HONAL MAN YRS		i Di (In theusands)
A DATES/EFFECTIVE	¹ NA	EXPIRATION:			T	ECEDING				
. NUMBER:*				FISCAL	-	72		.1	<u> </u>	0
C TYPE:		& ANOUNT:		TEAN		73		1	1	1
. RESPONSIBLE DOD	ORGANIZATION	T.CUM. AMT	· · · · · · · · · · · · · · · · · · · ·		FOR	HING ORGANIS	ATION	·	4	
NAM2: ⁹ =	A 8		i	-	,	T atta		 4	Dere	 arch
ADDRESS:* Lett	erman Army Inst idio of San Franc	itute of Kesei isco, CA 941	arch 29	ADORES	 	Dermato Presidio	in Army I logy Resc of San Fr	arch Divisi ancisco, C/	n N 941	arch 29
		•		PRINCIP	AL I	INVESTIGATO	R (Furnish SEAR	II U.S. Accidente	jne i i kuntan	v
RESPONSIBLE INDIVIO	NAL	_		NAME	•	Schmid,	P., Ph.D.			
Ake	rs, W.A., COL MO	2		TELE	рнох 1 ар	*** 415-5	61-5485			
TELEPHONE: 415.	-561-5181			ASSOCIA		INVESTIGATO	na nungen.			
				-						
				NAME:						DA
(II) higher	• BACH with Somethy Classifi mictory • (\$1) blietor	fluid · (11) all	umin•(II) fih	rinog	-n·	(II) imm	unoglobu	lins		
I. TECHNICAL OBJE	TIVE, 24 APPROACH, 25	PROGRESS (Furnish	Individual paragraphs Id	inilled by		ther Procede I	at of each with	Socurity Clocolite	tion Cod	
25. (U) 71 (fibr	07 – 72 06 Radi inogen, immunog	al gel immun lobulins IgG a FY 72.	odiffusion mi and IgM. Beca	cro te ause o	chr f n	niques ha nanpowe	ve been p r limitatio	erfected fo ons the pro	or albi ject w	umin, vas held
	in mactive state in									
	in mactive state in		·							

19¹⁹

11

*** *

. . .

;

to a state and a state of the s

televenter estruction in a file

a a series and a series and a series and a series and a series of the series of the series of the series of the series and the series of the ser

ž

1. 11/1 1

111

ŧ

Studies on Blistering Produced by Mechanical, Thermal, and Chemical Agents: Kinetics of Blister Fluid Proteins

Peter Schmid, Ph.D.

PROBLEM:

A variety of bullous and vesicular diseases are regularly seen in military populations. At Fort Ord, every day more than 1% of the population of this training center reports to sick call because of friction blisters. Various insects and plants throughout the world have chemicals which, when they come in contact with skin of soldiers, produce blisters. Other bullous and vesicular diseases seen by military dermatologists are pemphigus vulgaris, erythema multiforme and dermatitis herpetiformis. Once formed, bullae rupture or are torn more or less rapidly and may become secondarily infected by fungi, staphylococci or streptococci.

In previous investigations in this laboratory, new microtechniques have been developed to determine four specific proteins: albumin, fibrinogen, immunoglobulin IgG and IgM. Subsequently, the concentration of these proteins were determined in friction blister fluid and cantharidin blister fluid. The mechanisms and dynamics of friction blister fluid formation are largely unknown. Little is known about the repair process, i.e., the reconstitution of the epidermis following trauma.

APPROACH:

For friction blister studies, friction blisters are made on each palm and heel with our latest friction blister machine, and the kinetics of formation of the blister recorded. Friction blister fluid is withdrawn at 1, 4, 8, 16, 24, and 72 hours following blistering. Two cantharidin blisters are made and the fluid harvested at 8 and 24 hours and a small sample of vencus blood collected. The blister fluids and serum are then analyzed for albumin, fibrinogen and immunoglobulin IgG and IgM by the radial immunodiffusion technique.

The protein content of blister fluid in skin diseases like poison ivy dermatitis, tinea pedis, and erythema multiforme can be analyzed in the same manner.

RESULTS AND DISCUSSION:

Because of manpower limitations, the project was held in an inactive state in FY 72.

FUTURE PLANS:

どうちょうれ ある

Kinetic studies for albumin, fibrinogen, IgG and IgM proteins can begin when manpower is available and trained.

Initiate determination of albumin, fibrinogen and immunoglobulins in blister fluid obtained from suction blisters of normal skin and skin exposed to various aqueous solutions.

Initiate determination of albumin, fibrinogen and immunoglobulins in clinically important bullous eruptions.

The 2500 watt solar simulating xenon lamp and monochromator can now be used to raise sunburn and phototoxic blisters. Initiate analysis of blister fluid proteins obtained from phototoxic blisters.

Develop microtechniques for the determination of glucose and other small molecules.

RESEARCH	AND TECHNOLOG	Y WORK UNIT S	UNHARY	I AGEN	OD CO	1.01	DATS OF SU	MARY I	DD.D	CONTROL STMR
DATE PREV SUNAT	4. KIND OF SUMMARY	S. SUMMARY SCTY	. WORK SECURITY	DA 7. nean	OB 68	15 04 044	72 07 (1'* insta'n	IN SPECIFIC D	ATA	S. LEVEL OF SU
71 07 01	D. Change	U	U		NA		NL	THE L	CCESS NO	A TORE UNI
NO./CODES *	PROGRAM ELEMENT	PROJECT	NUMBER	TASK /	AREA NUM	BER		WORK UNIT	NUMBER	
	62110A	<u>3A062110</u>	A822		00			160		
CONTRIBUTING	}			+		 !:		· · ·	· .	· , ·
TITL. "ede #1th	Isturily Classification Cod	l				E		······	دسينش	
(U) Cunical	Evaluation of Al	pha-Cyanoacr	vlates and Tr	eatme	nt of F	rictio	n Blisters			
003500 - C	chnological Areas* linical Medicine;	012600 - Ph	armacology				•			
START DATE		14. ESTINATED CONF	LETION DATE	-	HIG AGEN	CV			ICE MET	HOD
CONTRACT/GRANT		CONT						C. In-hou	se	
DATES/EFFECTIVE.		EXPIRATION		10 AES	PRECEDIN	TIMATE	A PROFESS	OHAL MAN YRS	1 PUN	CS (In these ands)
NUMBER *	NA			PISCAL	72	2	,			3
TVPE.		& ANOUNT:		YEAR	CUMMENT		<u> </u>		†	
KIND OF AWARD.		f. CUM. AMT.			73	}	.1		L	2
RESPONSIBLE DOD	DRGANIZATION	L		20. PERI	ORMING OF	NGAN.	7108			1
une:" Lette Presioness:"	erman Army Inst dio of San Franc	titute of Resea cisco, CA 9412	rch 19	NAME: ⁰ ADDREM	Le De Pr	etterm ermat esidio	an Army ology Re of San H	Institute search Div Francisco,	of Re ision CA 94	search 1129
				PRINCIP	AL INVEST	GATOR	Furnish SEAR I	I U.S. Acodonic 5	ne i leu stany)
SPONSIBLE INDIVIDU	AL COT BA	~		NAME-	A	kers, V	N.A., CO	L MC		
415-	561-5181			SOCIAL	HONE. 41	3-36	1-5181			
GENERAL USE				ASSUCIA	TE INVESTI	CATORS				
				HAMEI	Le	onard	l, F., Ph.!	D.		
				NAME:					_	DA
(U) isoamyl-	cyanoacrylate; (l	U) toxicity; (U) topical; (U)) syste	mic: (U	l) voli	inteer: (U) pentyl: J) blister f	(U) f	luoralkyl v
25. (U) 71 0 home initia cyane ment select comf ment Neos Podia foot cyane conti	7 – 72 06 Phase plogues to raw fr lly: n-butyl, iso pacrylate proved ally produced bl ted were liquid is fort and less halo was compared t porin Cream and try Service, US a blisters during th pacrylate. The re nuation of traini	I. Cutaneous iction blister t butyl and n-he to be the mon isters of the he sobutyl and iso of inflammati o the usual tre moleskin. Ph Army Hospital e march and 3 csults were exc ing.	reactivity and bases were eva- ptyl spray, an nomer of cho- cels with cyano bamyl cyanoa ion than the i atment for fr ase IV. Field I, Fort Ord, C 5 recruits wi cellent for rel	d senso aluatec nd iso: ice. Pi noacry icrylat isobuty riction i trial Californ th 39 l ieving	ory resp t utilizionyl ar hase II. late ho e. Isoa yl mone blisters was cor nia. Fo blisters pain, p	oonse ing the d iso Vari molo myl c omer. s and nducte orty-se volur reven	to apply e followi butyl liqu ous meth uges were yanoacry Phase II proved n ed in coll even of th teered to ting infe	ing cyanoz ng cyanozo uid. Liquid ods for tro tried. The late produ I. Cyanozo ore satisfa aboration te 119 solo be treated ction, and	crylat crylat crylat e mon ced g crylat ctory with liers d g with permi	e m

State State La

STORES OF

A GUILDER STERRE FOR FRANK

Clinical Evaluation of Alkyl Alpha-Cyanoacrylates and Treatment of Friction Blisters

Colonel William A. Akers, MC, LAIR and Fred Leonard, Ph.D., USA Biomechanical Research Laboratory

PROBLEM:

We need a practical treatment for a medical corpsman or the soldier to use to lessen the pain and to minimize or prevent infection of torn or denuded blisters of the hands and feet. Cortese (1966) chose to test the alpha-alkyl cyanoacrylates since they offered some desirable characteristics which may be useful to accomplish our objective. ز دسته

Cyanoacrylates were first developed as "tissue glues" to provide a quick method of closing wounds without sutures. A tissue adhesive should (1) wet and spread freely on the tissue surface and (2) polymerize rapidly to form a solid with sufficient deformability to reduce the buildup of elastic stresses during formation of the bond. The higher members of the n-alkyl a-cyanoacrylate homologous series (n-butyl to n-octyl) wet, spread freely, and rapidly polymerize on protein surfaces like the liver, kidney, spleen, and omentum. The lower members of the homologous series - methyl, ethyl, and propyl show a greater affinity for non-protein surfaces like distilled water, saline, and dextrose solutions.

Polymerization occurs at room temperature without additional components such as special catalysts, external heat, or solvents. Bonding action results from anionic polymerization which is initiated by weakly basic substances including alcohols, amines, and water. Water is an excellent initiator; and in most bonding applications monomer polymerization is caused by trace amount of water on the adherent surfaces. Polymerization is mildly exothermic. To stabilize a monomer in a tube, bottle, or can sulfur dioxide (SO₂) is added in trace quantities to inhibit premature polymerization.

APPROACH:

Subjects: The volunteers were all soldiers on active duty and ranging in age from 18 to 28.

Phases: The study was divided into four phases. As different monomers became available they were tested in a similar manner.

Phase I: Cutaneous reactivity and sensory response to applying cyanoacrylate homologues to raw friction blister bases were evaluated utilizing the following cyanoacrylate monomers initially: n-butyl, isobutyl and n-heptyl spray, and isoamyl and isobutyl liquid. Experimental friction blisters were rubbed on volunteers' palms and the inner surface of their heels. The blisters were de-roofed at 2 hours and each monomer was applied to a single blister base in at least 5 volunteers while intact and de-roofed blisters on each volunteer served as controls. The volunteers' subjective response to applying the adhesives was recorded. Observations were made almost daily for 12 days then at 3-4 day intervals until the film fell off, noting the persistence and physical characteristics of the polymerized film, and untoward cutaneous reactions including signs of local and regional inflammation and infection of the blister base.

Phase II: Various methods for treating experimentally produced blisters of the heels with cyanoacrylate homologues were tried. The monomers selected from Phase I were the liquid isobutyl and isoamyl cyanoacrylate. Blisters were rubbed on paired symmetrical sites on the inner heels (2 sites each heel) of each volunteer in order to compare the monomers. Three separate studies were done. First the liquid cyanoacrylates were applied to the tops of blisters in 5 volunteers immediately after blistering in an effort to prevent filling of the blisters; in a second group of 5 volunteers the blister tops were removed 2 hours after blistering, and the liquid cyanoacrylate monomers were applied to the denuded A third group of 5 volunteers had the blister bases. tops partially removed and reflected; the liquid cyanoacrylates were applied to the entire blister bases, and the tops were then replaced. Daily evaluation of test sites were made as in Phase I.

Phase III: Cyanoacrylate treatment was compared to the usual treatment for friction blisters at all welling as bediet and a second

Fort Ord, California. Bilateral, symmetrical blisters were raised on the inner surface of the heels; and isoamyl cyanoacrylate was applied to the blister bases on the right heel, and Neosporin Cream (R) covered with moleskin (later Bandaids (R)) was applied to the blister bases on the left heel. Follow-up examinations were made almost daily as in other studies.

Phase IV: A field trial was conducted in collaboration with the Podiatry Service, US Army Hospital, Ft. Ord, California. One company of new recruits, prior to their first 12 mile march which occurs during their 4th week of basic training, were examined and only those without foot blisters before the march were used in the study. With the soldier's permission, at the end of the march all torn or denuded blisters were treated with the liquid plastic. Intact blisters were not treated. The soldiers were followed for 7 days at the routine sick call. If any soldier developed an infected blister he would have been admitted to the hospital, treated appropriately, and his course documented. During the 7 days follow-up period, the recruits made several 3-1/2 miles marches and one 5 mile march.

RESULTS AND DISCUSSION:

Twelve studies involving 90 volunteers with 265 blisters were done in the laboratory. In the Phase I study, if the blister top was ruptured, torn, or removed, applying a cyanoacrylate proved to be the most satisfactory method of management. Of the various cyanoacrylates tested in the early studies liquid isoamyl cyanoacrylate proved to be the moment of choice for the following reasons: (1) it produced the least amount of stinging when applied to the raw blister base, (2) it was the easiest to apply (just put a drop on, spread with a cotton-tipped applicator), (3) it produced the least halo of inflammation and (4) one application lasted 6 to 30 days, with a mean of 20 days before peeling off.

In the Phase II experiment isoamyl cyanoacrylate produced greater comfort and less halo of inflammation than the isobutyl monomer. Applying the cyanoacrylate to the intact blister top did not prevent the blister from filling. Attempts to cement a partially detached roof smoothly to the raw blister base failed, because the cyanoacrylate rapidly polymerized. This worked only with pentyl cyanoacrylate

55

Salar Salar

Э

which polymerizes more slowly, 3-5 seconds. The re-attached top was generally uncomfortable, feeling like a rock in the shoe.

For the Phase III experiment, the cyanoacrylate method proved more satisfactory than Neosporin Cream and moleskin since: (1) moleskin was extremely difficult to keep in place on walking and had to be replaced by Bandaids^(R) after 48 hours, (2) local evidence of inflammation occurred at the sites treated by moleskin but did not occur at any sites treated with cyanoacrylate.

In the field trial (Phase IV), 47 of the 119 soldiers developed foot blisters during the march and 35 recruits with 39 blisters volunteered to be treated with isoamyl cyanoacrylate. The results were excellent for relieving pain, preventing infection, and permitting the continuation of training. On one large blister (4x5.5cm) on the sole of one recruit, the plastic film failed to adhere to 1/3 of the base so he had the plastic re-applied the next day. No infections resulted. Usually the infection rate in a training company after a 12 mile march is 8 percent.

Cyanoacrylate films are freely permeable to oxygen. The film is also permeable to water as evidenced by stinging of the blister base when the volunteers took showers or washed their hands. Until we noted the above, cutaneous sensitivity was tested by applying 70 percent ethanol to the treated and raw blister bases, and the bases treated with plastic became less sensitive than the control by 72 hours. The palms proved more tender to pressure than the heels, but the heels developed halos of erythema which were infrequently seen on the plams. The palms and heels were scored separately to reflect such differences. Volunteers noted a gritty sensation of the heel blister bases on walking when the adhesives were sprayed on. Evidently the spray splatters some thicker droplets which a man can perceive on walking which was not appreciated when only palmar blisters were used. Simply applying a drop of isoamyl, spreading with a cotton-tipped applicator, produces a thinner and more comfortable film.

Raw blister bases become more inflamed than an intact blister or a blister treated with cyanoacrylate. A drained, intact blister is the most comfortable, but

a blister base treated with cyanoacrylate is less painful on walking than a raw blister base or a blister base treated with Neosporin Cream (R) and Bandaids (R).

The only infection occurred during the second day of Experiment 11 when one patient developed increased tenderness, oozing, and erythema of all 4 blister bases. Staphylococcus aureus (3/4) and Staphylococcus epidermitis (1/4) were recovered from his blisters. Healing was rapid using soap and water cleansing and Neosporin Cream^(R).

Cracking occurred less frequent and less deep with the plastic film than with the natural crust of a bli i.er. A flexible film that does not crack readily makes the best artificial top. Isoamyl and pentyl cyanoacrylates are superior in this respect (no cracks up to 144 hours) whereas butyl and isobutyl crack and begin to peel within 48 hours.

Healing of the raw blister bases occurred within 120 hours despite the monomer used and we never observed any interference with healing. Volunteers always preferred cyanoacrylate therapy to no treatment; and only in Experiment 11 was therapy with an antibiotic cream and a dressing equal to the cyanoacrylate application.

FUTURE PLANS:

Larger scale field trials will be done. Also, other viscosities of isoamyl cyanoacrylate will be prepared and tested.

TA	BLE
----	-----

EXPERIMENT	DATE	PHASE	SITE	MONOMER	VOLUNTEERS	BLIS	TERS
1	Apr 67	1	Palms	n-butyl spray # 96 n-butyl spray # 99 n-heptyl spray # 149**	16 (5) (4) (7)	3	48
			Heels	n-butyl spray	4	3	12
2	Feb 68	I	Palms	n-butyl spray isobutyl spray isoamyl spray isoamyl** n-heptyl spray	5	5	25
3	Feb 68	u ,	Heeis	isoamyl** control	5	2	10
4	Feb 68	п	Heels	isoamyl** reattached	5	2	10
5	Feb 68	u	Heels	isoamyl** intact control	5	2	10
6	Feb 68	.m	Heels	isoamyl** neospori + bandage	5	2	10
7	Mar 68	п	Palms	isoamyl	5	2	10
8	Apr 68	I	Hæls	isoamyl** isob.ttyl	5	2	10
9	Sep 68	I	Hcels	isobutyl 125 c.p.† isobutyl 215 c.p.† isoamyl ²⁴	8	3	24
10	Oct 68	I	Heels	isobutyl isobutyl + Na(HCO ₃) ₂ isoamyl**	7	3	21
11	Jul 69	ſV	Feet	isoamyl	35		39
12•	Mar 71	1,11,111	Palms Heels	isoamyl** pentyl** fluoralkyl neosporin + bandage**	12	4	48
13•	Jun 71	I, III	Palms Heels	isoamyl 200 c.p.† isoamyl 300 c.p.† ** pentyl** neosporin + bandage	8	4	32
					125		309

Hemograms, urinalyses, and blood chemistries (SMA-12) done pre-application, 1 week, and 1 month later on all volunteers revealed no evidence of systemic toxicity from topical application.
 Best of test
 \$ c.p. - centipoise

Shell Charling in the Instantion

ť,

ŝ

I after party Journet 1 & NUPD OF SUMMARY 12: 10000001 1: 10000000000000000000000	1 attra party summer is this one tomanary is the sona steeparty in the sona attraction accurate in the sona part of the sona par	k gatte batty surver 1: Non-anviett ^{ak} k wonk security ^{ak} L wonk (1) work (2) L w	1 2470 240 Y 1000 AV 1 2400 AV UNLARY 1 1000 AV	Tarte story course (a timb or countary (a time and terms) La time and terms (a time and terms) La time and terms (a time and terms) T 07 01 D. Change U U NA NI Events (a time and terms) th to course PROCENT water Take and a worker NI Events (a time and terms) La time and terms) to course PROCENT water Take and a worker U NA NI Events (a time and terms) La time and terms) to course PROCENT water Take and terms) PROCENT water Take and terms) La time and terms) La tin	Extra data control is the data of the series o	RESEARC	H AND TECHNOLOG	Y WORK UNIT	UMMARY	DA OR COLL	1 2. DATE OF	SUMMARY®	REPORT CONTR DD-DR&E(
11 U/ 01 U/ Contrast D NA NL Lives	In the contrast of the contrast	International content of the second	Indication Description Description Description if we decompare the second classification of the second classi	Indext of the contract of the c	No. D. Change D NA NL Day 1 - 2 0 no 200024 PROJECT NUMBER TASA ATA AUMOR PROMETATION PROJECT NUMBER PROMETATION x remain 621 10A 3A062110A822 00 161 PROMETATION x constructive	A DATE PREV SUMA	Y 4. RIND OF SUMMARY	S. SUMPARY SCTY	A. WORK SECURITY	7. REGRADING	DIEB'N INSTA'	N OL SPECIFI	C DATA - P. LEV
a manan 62110A 3A062110A822 00 161 b. contraturting in in in in in b. contraturting in in in in in in it Trick fighted with Standing Code in in in in in it Trick fighted with Standing Code in in in in in it Trick fighted with Standing Code in in in in in it it it it it it it it it it <t< th=""><th>And A Contractions Contractions</th><th>Additional and the second second</th><th>Advance of the second sec</th><th>Adversion of the second control of the</th><th>A sensary 62110A 3A062110A822 00 161 Contrantine Contrantine</th><th>71 U/ U1</th><th>D. CRANGE</th><th>U PROJECT</th><th></th><th></th><th>NL</th><th>KI YES</th><th><u>Uно î ~</u></th></t<>	And A Contractions	Additional and the second	Advance of the second sec	Adversion of the second control of the	A sensary 62110A 3A062110A822 00 161 Contrantine	71 U/ U1	D. CRANGE	U PROJECT			NL	KI YES	<u>Uно î ~</u>
Contransuring Contran	b contrangurus c contrangurus i True, frances was transformed was transform	b contrangutures c contrangutures i triction frame and heading Chearthington Code? (U) Biosynthesis of Proteins and Lipids in Human Skin with Particular Emphasis on Prickly Heat (05) (1) triction frameworks and heading chearthington Code? (1) triction frameworks and trip chearthington Code? (2) trip trip trip trip trip trip trip trip	b. contranguting c. contranguting i. trendstate of the testing Characterization (Market Control of the testing Control of testing Control of the testing Control of the testing Control of testicon of testing Control of testing Control of testing Cont	Lesterman Army Institute of Research Ansult: Lesterman Army Institute of Research Presidio of San Francisco, CA 94129 Assourt: Akers, W.A., COL MC recervate: 415-561-5181 the service of manpower limitations the project was held in an inactive state in FY 72. 25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	Letterman Army Institute of Research Senset* Letterman Army Institute of Research Presidio of San Francisco, CA 94129 Senset* Letterman Army Institute of Research Schmid, P., Ph.D. Tusersents accurate water alto-Sell-Sell Senset* Tusersents accurate water alto-Sell-Sell Senset* Tusersents accurate water alto-Sell-Sell Senset* Tusersents accurate water accurate water alto-Sell-Sell Senset* Schmid, P., Ph.D. Tusersents accurate water accurate accurate water acurate accurate water ac		62110A	3A062110	A822	00		161	
c. conversion 1 <	Contract and second character and second character and the second	Control of the second sec	Construction of the second consecond construction construction of the second construction constru	Contract of the sense of t	Contractive and second se	. CONTRIBUTING							
(05) Dissynthesis of Proteins and Elpids in Fruntian Skin with Particular (05) (05) Dissynthesis of Proteins and Elpids in Fruntian Skin with Particular (05) (05) (05) (05) (05) (05) (05) (05) (05) (05) (05) (05) (05) (16) (16) (16) (16) (17) (18) (18) (18) (10) (10) (11) (11) (21) (21) (21) (21) (21) (21) (21) (21) (21) (21) (21)	(0) Diosynthesis of Proteins and Explos in Hullian Skill with Particular	(0) Dissynthesis of Proteins and Lipids in Hullian Skill with Particular	(1) Didy intersis of Froteins and Lipits in Futural Skin with Faithan (1) External Colspan="2">(1) External Lipits in Futural Skin with Faithan Skin with Faithan (2) External Lipits in Futural Skin with Faithan (2) External Lipits in Futural Skin with Faithan (2) External Lipits in Faithan	Control of Soloy interests of Proteins and Explose in Futurian Skin with Particular (C) Soloy interests of Proteins and Explose in Futurian Skin with Particular (C) Soloy interests of Proteins and Explose in Futurian Skin with Particular (C) Soloy interests of Proteins and Explose in Futurian Skin with Particular (C) Soloy interests of Proteins and Explose in Futurian Skin with Particular (C) Soloy interests of Proteins and Explose in Futurian Skin with Particular (C) Soloy interests of Proteins and Explose in Futurian Skin with Particular (C) Soloy interests of Proteins and Explose in Futurian Skin with Particular (C) Soloy interests of Proteins and Explose in Futurian Skin with Particular (C) Soloy interests of Proteins and Explose in Futurian Skin with Particular (C) Soloy interests of Proteins and Explose in Futurian Skin with Particular (C) Soloy interests of Proteins and Explose in Futurian Skin with Particular (C) Soloy interests of Proteins and Explose in Futurian Skin with Particular (C) Soloy interests of Proteins and Particular Soloy interests of Proteins and Particular (C) Soloy interests of Particular Soloy interests of Proteins and Particular Soloy interests of Particular Soloy interests of Proteins and Particular Soloy interests of Particular Soloy interests of Proteins and Particular Soloy interests of Particular Soloy interestsologenergial interests of Particular Soloy inte	Emphasic on Prickly Heat (0) Dioynthesis of Proteins and Explose in Fundarios in Fundario	C. CONTRIBUTING	A Security Chapstillcollan Cade	(II) Riorum	thesis of Prot	l	in Home	Skin with	Destigular
11. ECENTRIC AND TECHNOLOGICAL AREA* 002300 - Glochemistry; 003500 - Clinical Medicine 14. FYATC 14. EVANCED COMPLETION DATE 15. FORTANCE DE THOLOGICAL AREA* 14. EVANCED COMPLETION DATE 16. EVANCES AND TECHNOLOGICAL CARACT 14. EVANCES AND TECHNOLOGICAL CARACT 16. EVANCES AND TECHNOLOGICAL CARACT 14. EVANCES AND TECHNOLOGICAL CARACT 17. CONTANCES AND TECHNOLOGICAL CARACT 14. EVANCES AND TECHNOLOGICAL CARACT 18. FORMERCE THE NA 2XFINATION 19. FORMERCE DOD ORDANIZATION 14. EVANCES AND TECHNOLOGICAL CARACT 18. REFORMULE COOL ORDANIZATION 19. FORMERCE DOD ORDANIZATION 19. REFORMENCE DOD ORDANIZATION 19. FORMERCE DOL ORDANIZATION 10. AND TECENTIAL COLOR ORDANIZATION 19. FORMERCE DOL ORDANIZATION 10. AND TECENTIAL COLOR ORDANIZATION 19. FORMERCE DOL ORDANIZATION 10. AND TECENTIAL COLOR ORDANIZATION 19. FORMERCE DOL ORDANIZATION 10. AND TECENTIAL COLOR ORDANIZATION 19. FORMERCE DOL ORDANIZATION 10. AND TECENTIAL COLOR ORDANIZATION 19. FORMERCE DE COLOR ORE	1: E Elektrine AND VECHNOLOUICAL AREAN ² 002300 - Biochemistry; 003500 - Clinical Medicine 1: E MARTONE	It. Selferfore and reconductive and reconducting recondereconducting reconductive and reconductive and reconduc	It setterfore and reconducted aneade 002300 - Sinchemistry; 003500 - Clinical Medicine 15 Front Dart 16 Bold 17 CONTRACT/ONANY 18 Contract/ONANY 19 Contract/ONANY 19 Contract/ONANY 19 Contract/ONANY 10 Contrant/ONANY 10	It. Scientific and recomplexity: 003500 - Clinical Medicine 68.06 CONT DA C. In-house 1. CONTRACT/GRAVY It. FUNCTION CONTRACT ON THE SCIENCE ASTIMUTE A PROFESSIONAL AND THE SCIENCE ASTIMUTE AST	It Scientifield and recently Sudday Assess 002300 - Giochemistry; 003500 - Clinical Medicine 1 1 68 0 1 0 1 0 1 0 1	Emphasis (n Prickly Heat	(05)		ems and Lipius		I SKIIL WILL	raiticulai
002300 - Silochemistry; 003500 - Clinical Medicine 68 06 Is Function agency Is Function agency 0 a rest/errective: NA Extratice converting a professional way vis bruike a carest/errective: NA 0 a rest/errective: NA Extratice converting a professional way vis bruike a carest/errective: NA 0 a rest/errective: NA Extratice converting a professional way vis bruike a carest/errective: NA 1 converting a rest of the state of the s	02.2300 - Silochemistry; 002300 - Clinical Medicine 16 SYMATOR 16 Symathic Struct 16 Symathic Struct 17 Contract/Cromm 18 Symathic Struct 19 Contract Struct 19 Contract Struct 19 Contract Struct 10 Contract/Cromm 10 Contract/Cromm 10 Contract/Cromm 10 Contract/Cromm 10 Contract/Cromm 10 Contract/Cromm 11 Contract/Cromm 12 Contract/Cromm 13 Contract/Cromm 14 Contract/Cromm 15 Contract/Cromm 16 Contract/Crom 16 Cont	002300 - Silochemistry; 002300 - Clinical Medicine 16 FMADYE 17 CONTRACT/GRAFT 18 FMADYE 18 FMADYE 18 FMADYE 19 FMADYE 19 FMADYE 10 FMADYE 11 FMADYE 12 FMADYE <	02200 - Sinceemstry; 002500 - Clinical Medicine 16 Fride String Store Character in Store St	022303 - Silochemistry; 002300 - Clinical Medicine 16 Friedmander Bethol 16 Friedmander Bethol 16 Friedmander Bethol 17 Contract/romant 18 Friedmander Bethol 18 Friedmander Bethol 18 Friedmander Bethol 18 Friedmander Bethol 19 Contract/romant 18 Friedmander Bethol 19 Contract/romant 18 Friedmander Bethol 19 Contract/romant 19 Contract/romant 10 Friedmander Bethol 11 Friedmander Bethol 11 Friedmander Bethol 12 Friedmander Bethol 13 Friedmander Bethol 14 Friedmander Bethol 14 Friedmander Bethol 15 Friedmander Bethol 16 Friedmander Bethol 16 Friedmander Bethol 17 Friedmander Bethol 18 Friedmander Bethol 19 Friedmander Bethol 19 Friedmander Bethol	CO2303 - Since mistry; CO2300 - Clinical Medicine Software convertion date of the structure of of t	12. SCIENTIFIC AND T	TECHNOLOUICAL AREAS						
68 06 CONT DA C. In-house 1. CONTENCEY/ORANY a professional man yns b runmer a dately/prective: NA 2xPINATION b runmer b nuessan c tyre: A amount: b runmer c tyre: d amount: c tyre: a moresumer c tyre: a two of ANARD f. Cum. AMT. 73 1 make:* Letterman Army Institute of Research Presidio of San Francisco, CA 94129 Dermatology Research Division about:** Akers, W.A., COL MC testponistic fill of San Francisco, CA 94129 nessponistic molecular make:* Letterman Army Institute of Research Dermatology Research Division nessponistic: Akers, W.A., COL MC testponistic fill of San Francisco, CA 94129 nessponistic: 415-561-5181 scial security account numere: ii. estrement: 415-561-5181 scial security account numere: ii. estrement: 41.5-561-5181 scial security account numere: ii. estrement: 41.5-561-5181 scial security account numere: ii. estrement: 41.5-561-5181 scial security account numere: synthesis: (U) biochemistry: (U) prickly he	68 06 CONT DA C. In-house In account of contract/contract In account of contract	68 06 CONT DA C. In-house th contract/creature A macrometer struct a processional way visit b purple of the contract of the contr	68 06 CONT DA C. In-house a DATE SUPERATION b. RESOURCE STUART & A PROFESSIONAL MAN YES & FUNDER a DATE SUPERATION b. RESOURCE STUART & A PROFESSIONAL MAN YES & FUNDER b NUMBER* c. TYPE. A ADDUNT: c. TYPE. A ADDUNT: to RESOURCE STUART & A PROFESSIONAL MAN YES & FUNDER r. REFORMED COD GRAMMETATION f. CUM. AMY. To RESOURCE STUART & A PROFESSIONAL MAN YES & FUNDER make* Letterman Army Institute of Research Presidio of San Francisco, CA 94129 Presidio of San Francisco, CA 94129 address Presidio of San Francisco, CA 94129 Presidio of San Francisco, CA 94129 address Responsister INDIVIDUAL Presidio of San Francisco, CA 94129 address Responsister MAN HULL Amount (PS) Stitute of Research Dermatology Research Division address Presidio of San Francisco, CA 94129 address Schmid, P., Ph.D. address Schmid, P., Ph.D. make* Schmid, P., Ph.D. address (Proves Access and Proves (U) MC reservate at 115-561-5181 Presidio of San Francisco, CA 94129 address (Proves Access and Proves (U) MC reservate at 115-561-5181 Proves (U) MC to address (Proves Access and Proves (U) MC synthesis: (U) Skin: (U) human volunteers to technick, Object (V)* 24 PPEROACH, is PROVES	68 06 CONT DA C. In-house In reconnect view NA Strinktron In network a strinktron In network a strinktron In users* A MOUNT: In network a strinktron In network a strinktron In network a strinktron In address In the strinktron In network a strinktron In network a strinktron In network a strinktron In address In the strinktron In network a strinktron In network a strinktron In network a strinktron In address In the strinktron In network a strinktron In network a strinktron In network a strinktron In address In the strinktron In network a strinktron In network a strinktron In network a strinktron In address In the strinktron In network a strinktron In network a strinktron In network a strinktron In address In address In network a strinktron In network a strinktron In network a strinktron In address In address In address In network a strinktron In network a strinktron In address In address In address In an inactive state in FY 72. In address In an inactive state in FY 72. In an inactive state in FY 72.	68 06 CONT DA C. In-house 1. CONTRACT/GRANY 2. SPERATION 2. SPERATION 2. SPERATION 2. SPERATION 2. OUTRACT/GRANY 4. ABOUNT: 2. SPERATION 2. SPERATION 2. SPERATION 2. NUMBER 4. ABOUNT: 4. ABOUNT: 2. SPERATION 2. SPERATION 4. NUMBER 4. ABOUNT: 4. ABOUNT: 2. SPERATION 2. SPERATION 4. NUMBER 4. ABOUNT: 4. ABOUNT: 2. SPERATION 2. SPERATION 4. ABOUNT: 4. ABOUNT: 4. ABOUNT: 2. SPERATION 2. SPERATION 4. MARC 4. ABOUNT: 4. ABOUNT: 2. SPERATION 2. SPERATION 4. ABOUNT: 4. ABOUNT: 4. ABOUNT: 3. SPERATION 3. SPERATION 4. MARC Letterman Army Institute of Research 3. SPERATION 3. SPERATION MARE.* Letterman Army Institute of Research Dermatology Research Division ADDRESS.** Presidio of San Francisco, CA 94129 Sechnid, P., Ph.D. ADDRESS.** Schmid, P., Ph.D. Sechnid, P., Ph.D. RESPONSE: 415-561-5181 Second Preside MART NUMBER: 3. GEREAL UNE ALSOCALE (WOUNDAL HOUT NUMBER: Second Preside MART NUMBER: 3. GEREAL UNE Second Preside MART NUMBER: Second Preside MART NUM	002300 - 19	liochemistry; 003	1500 - Clinica 14. Estimáted con	Medicine	15 FUNDING AGENCY		14. PERFOR	MANCE METHOD
IV: CONTRACT/GRANY a Darest/errective: NA a Darest/errection	If: CONTRACT/GRANT In RESOURCES ESTIMATE In PROFESSIONS In Department of the second secon	If: CONTRACT/ORANT 9. RESOURCE STUATE A PROFESSIONAL BAN YES & FUNRE A STURME A CONTRACTOR In UNDERAGE 1	IP: CONTRACT/OWANT B. RESOURCES ENTIANTE A PROTEMBER L AND YES NUMBER* CONTRECTOR Image: State of the	IP: CONTRACT/OWANT IP: RESPONSE STUDY IP: A PROFEMENT IN TO A PROFEMENT IN THE APPROX PROFEMENT APPROX PROFEMENT IN THE APPROX PROFEMENT IN THE APPROX PROFEMENT IN THE APPROX PROFEMENT	IP: CONTRACT/ORANT IP: REPORTED INTEL IP: REPOR	68 06		CON	<u>T</u>	DA		C. In-	house
Image: Product in the standy classification code; Image: Product in the standy classification code; Image: Presidio of San Francisco, CA 94129 Image: Presidio of San Francisco, CA 94129 Image: Presidio of San Francisco, CA 94129 Image: Presidio of San Francisco, CA 94129 Image: Presidio of San Francisco, CA 94129 Image: Presidio of San Francisco, CA 94129 Image: Presidio of San Francisco, CA 94129 Image: Presidio of San Francisco, CA 94129 Image: Presidio of San Francisco, CA 94129 Image: Presidio of San Francisco, CA 94129 Image: Presidio of San Francisco, CA 94129 Image: Presidio of San Francisco, CA 94129 Image: Presidio of San Francisco, CA 94129 Image: Presidio of San Francisco, CA 94129 Image: Alternation (Provide Addet (Provide (Provide Addet (Provide Addet (Provide (Provide Addet (Provide (Provide Addet (Provide (Provide Addet (Provide (Provide (Provide (Provide (Provide Addet (Provide (Prov	NUMBER* Image: Stream (Stream (S	NUMBER* Image: Structure in the structure in	Image: Structure in the st	Numeric Image: Second Seco	a number of the standard of the	17. CONTRACT/GRAN	7	34844444		W. AESOURCES ESTIN	ATE & PROP	ESSIGNAL MAN Y	AS E FUNDE (TH
c tvre. a tind of AWARD: a tind of AWARD: t. CUM. AMT. t. RESPONSIBLE DOD ORGANIZATION NAME: ² Letterman Army Institute of Research Presidio of San Francisco, CA 94129 ADDRESS: ² RESPONSIBLE INDIVIDUAL NAME: Akers, W.A., COL MC TELEPHONE: 415-561-5181 1. REMERAL USE TELEPHONE: 415-561-5181 1. REMERAL USE TELEPHONE: (U) skin: (I) human volunteers 1. REVended (Proceds Each with Security Classification Code) (U) biochemistry; (U) prickly heat; (U) protein synthesis; (U) lip synthesis: (U) skin: (I) human volunteers 1. TECHNICAL ODIECTIVE. ² 24 PEPERACH, 34 PROCESS (Provide Letter for the project was held in an inactive state in FY 72.	c tvpr. a tind of AVARD: a t	c TYPE. a KIND OF AWARD: a K	c TYPE. a KIND OF AWARD a KIND OF AWAR	c TYPE. a MOUNT: a MOUNT	c TYPE. a MBOUNT: * (U) OF ANARD: * (U) OF ANARD: * (U) ANT. * (U) ANT. * (C) OF CONTRAINED * (C) OF CONTRA	& NUMBER.*		SAMITA LION		PISCAL 72		1	18
e. KIND OF ANADO f. CUM. AMT. 73 1 W. RESPONSIBLE COOLORGANIZATION in. PERFORMING ORGANIZATION in. PERFORMING ORGANIZATION NAME.* Letterman Army Institute of Research Presidio of San Francisco, CA 94129 in. Performing Organization DDRESS.* Presidio of San Francisco, CA 94129 NEEPONHISLE INDIVIDUAL Dormatology Research Division MARE: Akers, W.A., COL MC TELEPINCHE: 415-561-5181 DI. GEMERAL USE Schmid, P., Ph.D. TELEPINCHE: 415-561-5181 DI. GEMERAL USE Schmid, Provide Back of the Standby Closelffictume Code) U. BERERAL USE NAME: MARE: NAME: MARE: NAME: Synthesis: (U) skin: Synthesis: (U) skin: Synthesis: (U) skin: Social SECURITY Account VINDER: Synthesis: (U) skin: Social SECURITY Account VINDER: Synthesis: (U) skin: Social SECURITY Account VINDER: Social SECURITY Account VINDER: Synthesis: (U) skin: Social SECURITY Account VINDER: Social SECU	a timb or AMARD: 1 W. REFORMENCE ODD ORDAMIZATION W. PERFORMENC ORDAMIZATION WAME.* Letterman Army Institute of Research Presidio of San Francisco, CA 94129 ADDRESS.* Dermatology Research Division Presidio of San Francisco, CA 94129 MARE.* Letterman Army Institute of Research Presidio of San Francisco, CA 94129 ADDRESS.* Dermatology Research Division Presidio of San Francisco, CA 94129 MARE.* Letterman Army Institute of Research Dermatology Research Division Presidio of San Francisco, CA 94129 MARE.* Akers, W.A., COL MC MARE.* Schmid, P., Ph.D. MARE.* Schmid, P., Ph.D. MARE.* Schmid, P., Ph.D. MARE.* Schmid, P., Ph.D. MARE.* AttoCiate Investication MARE.* Schmid, P., Ph.D. MARE.* AttoCiate Investication MARE.* AttoCiate Investication MARE.* AttoCiate Investication MARE.* AttoCiate Investication MARE.* Club Schmidt Commented AttoCiate Investication MARE.* Lettermone the state of the state	k KIND OF ARAAD' 73 1 W. RESPONDENCE DOO GROAMITATION In PERFORMING ORGANITATION In PERFORMING ORGANITATION MAME** Letterman Army Institute of Research Presidio of San Francisco, CA 94129 In AME** ADDREM** Presidio of San Francisco, CA 94129 MAME** Letterman Army Institute of Research Dermatology Research Division NOME** Presidio of San Francisco, CA 94129 MAME* Schmid. P., Ph.D. MAME* Alsocate transmemory account number: MAME* Alsocate transmemory account number: MAME* Schmid. P., Ph.D. MAME* Alsocate transmemory account number: MAME* Alsocate transmemory account number: MAME* Schmid. P., Ph.D. MAME* Schmid. P., Ph.D. MAME* Schmid. P., Ph.D. MAME* Schmid. P., Ph.D. MAME* Schmid. Schmid. P., Ph.D.	K KIND OF ARAAD' 73 1 W. REFORMUSCE GOO GROAMIEATEON In. PERFORMUSCE GROAMIEATEON In. PERFORMUSCE GROAMIEATEON MAME** Letterman Army Institute of Research Presidio of San Francisco, CA 94129 In. Performusce Groam Army Institute of Research Dematology Research Division ADDREM** Presidio of San Francisco, CA 94129 Interformusce Groam Army Institute of Research Dematology Research Division MARE** Schmid, P., Ph.D. MARE* Schmid, P., Ph.D. VIELEPHONE: 415-561-5181 II. SERERAL USE Investigation II. SERERAL USE Interformation II. SERERAL USE Inte	x NULD OF ANALO: 1 w. RESPONSING & GOO GRAMITATION 1 name:* Letterman Army Institute of Research Presidio of San Francisco, CA 94129 Dermanology Research Division aconess.* Presidio of San Francisco, CA 94129 actionation of San Francisco, CA 94129 Presidio of San Francisco, CA 94129 actionation of San Francisco, CA 94129 Presidio of San Francisco, CA 94129 actionation of San Francisco, CA 94129 Presidio of San Francisco, CA 94129 actionation of San Francisco, CA 94129 Presidio of San Francisco, CA 94129 actionation of San Francisco, CA 94129 Presidio of San Francisco, CA 94129 actionation of San Francisco, CA 94129 Presidio of San Francisco, CA 94129 actionation of San Francisco, CA 94129 Presidio of San Francisco, CA 94129 actionation of San Francisco, CA 94129 Presidio of San Francisco, CA 94129 actionation of San Francisco, CA 94129 Presidio of San Francisco, CA 94129 actionation of San Francisco, CA 94129 Presidio of San Francisco, CA 94129 actionation of San Francisco, CA 94129 Presidio of San Francisco, CA 94129 actionation of San Francisco, Californation of San Francisco, Californation of San Francisco, CA 94129 Presidio of San Francisco, CA 94129 actionati	* KUB OF ARAD: 1. 73 1 ** RESPONSELE DOO ORGANIZATION	G TYPE.		4 ANOUNT:		VEAR CUNNERY			
NAME:* Letterman Army Institute of Research Presidio of San Francisco, CA 94129 ADDRESS:* Presidio of San Francisco, CA 94129 NEEPONSIBLE INDIVIDUAL Dermatology Research Division Presidio of San Francisco, CA 94129 REEPONSIBLE INDIVIDUAL Presidio of San Francisco, CA 94129 NAME: Akers, W.A., COL MC TELEPHONE: 415-561-5181 11. BERERAL USE Schmid, P., Ph.D. TELEPHONE: 415-561-5181 11. BERERAL USE Audociate Investigation of Mark II U.S. Audomic Provided Mark II U.S. Audomic Provide Mark II U.S. Audomic Provided Mark II U.S. Audomic Proversity II U.S. Audo	ANNE:" Letterman Army Institute of Research Presidio of San Francisco, CA 94129 ADDRESS." Letterman Army Institute of Research Dermatology Research Division Presidio of San Francisco, CA 94129 PRINCIPAL INVESTIGATOR (PURION BACH IN U.S. Anotheric providential MARE: Schmid, P., Ph.D. TELEPHONE: 415-561-5181 ADDRESS." Schmid, P., Ph.D. TELEPHONE: 415-561-5181 ADDRESS." COL MC TELEPHONE: 415-561-5181 ADDRESS. TELEPHONE: 415-561-5181 ADDRESS." COL MC TELEPHONE: 415-561-5181 ADDRESS. TELEPHONE:	ANNEL [®] Letterman Army Institute of Research Presidio of San Francisco, CA 94129 ADDRESS. [®] Letterman Army Institute of Research Dermatology Research Division Presidio of San Francisco, CA 94129 ADDRESS. [®] Presidio of San Francisco, CA 94129 Pathecipal, investigation (Provide Back II U.S. Automatic provide Water Akters, W.A., COL MC TELEPHONE: 415-561-5181 I. CEMERAL USE I. CEMERAL USE	Anne de le terman Army Institute of Research Presidio of San Francisco, CA 94129 ADDRESS. ² ADDRESS. ² ALECTERMA Army Institute of Research Dermatology Research Division DDRESS. ² Presidio of San Francisco, CA 94129 Presidio of San Francisco, Ca 94129 Presid	ANNE** Letterman Army Institute of Research Presidio of San Francisco, CA 94129 ACCOMENT ARE** Letterman Army Institute of Research Dermatology Research Division Dermatology Research Division Presidio of San Francisco, CA 94129 PRINCIPAL INVESTIGATOR (PRINT SEARCH 10.2. Automatic printment NAME:* Schmid, P., Ph.D. TELEPRONE: 415-561-5181 ACCOUNT NUMBER: ALSOCIATE INVESTIGATORS NAME: TELEPRONE (Discrimination Code) TELEPRONE (Discrimination Code	Anse: Letterman Army Institute of Research Presidio of San Francisco, CA 94129 Actionative Individual Inter Akers, W.A., COL MC Telephone: 415-561-5485 Social Security Account Name II St. Auddenic Pollution Mate: Akers, W.A., COL MC Telephone: 415-561-5485 Social Security Account Numbers: Account Numbers: Att Security Account Numbers: Autor Account Numbers: Att Security Account Numbers	A KIND OF AWARD	O GRANIZATION	f. CUM. AMT	· 	73	ANIZATION		<u></u>
ADDRESS:* Dermatology Research Division ADDRESS:* Dermatology Research Division ADDRESS:* Dermatology Research Division RESPONSIBLE INDIVIDUAL Dermatology Research Division MANE: Akers, W.A., COL MC TELEPHONE: 415-561-5181 al. GENERAL USE Schmid, P., Ph.D. TELEPHONE: 415-561-5181 al. GENERAL USE Schmid, Presidio of San Francisco, CA 94129 Presidio of San Francisco, CA 94129 NAME: NAME: Akers, W.A., COL MC TELEPHONE: 415-561-5181 al. GENERAL USE Social Security Account HUMBER: Associate Investigators NAME: NAME: NAME: State: 10 protein synthesis; (U) lip State: 11 human volunteers State: 12 eppendach, 21 eppendach, 21 eppendach, 10 eregraphe (dmilling) protect test of each with Security Classification Carbor State: 12 eppendach, 21 eppendach,	Internant Army institute of Research Presidio of San Francisco, CA 94129 ADDRESS:* According to the second	Detterman Army institute of Research Presidio of San Francisco, CA 94129 ADDRESS:* According to the second	And Army institute of Research Presidio of San Francisco, CA 94129 Aboness: According for the second of San Francisco, CA 94129 <td>Presidio of San Francisco, CA 94129 aconess: Meter Akers, W.A., COL MC Telephone: 415-561-5181 Ale estenal use Akers, W.A., COL MC Telephone: 415-561-5181 Ale estenal use Akers, W.A., COL MC Telephone: 415-561-5181 Ale estenal use Associate investigators associate in FY 72.</td> <td>Presidio of San Francisco, CA 94129 ADDRESS.* Presidio of San Francisco, CA 94129 ADDRESS.* Presidio of San Francisco, CA 94129 PHINCIPAL INVESTIGATOR (POWER DAWN IV 2.4 Andress: politicitary HARE: Akers, W.A., COL MC TELEPHONE: 415-561-5181 ADDRESS.* TELEPHONE: 415-561-5181 ADDRESS.* TELEPHONE: 415-561-5181 ADDRESS.* TELEPHONE: 415-561-5181 ADDRESS.* TELEPHONE: 415-561-5181 ADDRESS.* TELEPHONE: 410 Solution of the Second Construction of the Second Constructi</td> <td>NAME:⁰ T</td> <td>· · · · · · · · · · · · · · · · · · ·</td> <td></td> <td>I</td> <td></td> <td>·····</td> <td>سیسیا مدینه:میرون</td> <td></td>	Presidio of San Francisco, CA 94129 aconess: Meter Akers, W.A., COL MC Telephone: 415-561-5181 Ale estenal use Akers, W.A., COL MC Telephone: 415-561-5181 Ale estenal use Akers, W.A., COL MC Telephone: 415-561-5181 Ale estenal use Associate investigators associate in FY 72.	Presidio of San Francisco, CA 94129 ADDRESS.* Presidio of San Francisco, CA 94129 ADDRESS.* Presidio of San Francisco, CA 94129 PHINCIPAL INVESTIGATOR (POWER DAWN IV 2.4 Andress: politicitary HARE: Akers, W.A., COL MC TELEPHONE: 415-561-5181 ADDRESS.* TELEPHONE: 415-561-5181 ADDRESS.* TELEPHONE: 415-561-5181 ADDRESS.* TELEPHONE: 415-561-5181 ADDRESS.* TELEPHONE: 415-561-5181 ADDRESS.* TELEPHONE: 410 Solution of the Second Construction of the Second Constructi	NAME: ⁰ T	· · · · · · · · · · · · · · · · · · ·		I		·····	سیسیا مدینه:میرون	
ADDRESS. ⁴ ADDRESS. ⁴ ADDRESS. ⁴ ADDRESS. ⁴ Presidio of San Francisco, CA 94129 PRINCIPAL INVESTIGATOR (PUMIAN BAAN II U.S. Anomanic prolinging NAME: Akers, W.A., COL MC TELEPHONE: 415-561-5181 AMME: 415-561-5485 Social SECURITY ACCOUNT NUMBER: ASOCIATE INVESTIGATORS NAME: NAME: PT REVENDES (Proceeds EACH with Security Classification Code) (U) biochemistry; (U) prickly heat; (U) protein synthesis; (U) lip synthesis: (U) skin; (U) human volunteers TE TECHNICAL OBJECTIVE. ⁴ 24 OPPROACH, 25 PROCEESS (Pumine Least of and Proceed test of each with Security Classification Code.) 25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	ADDRESS.* ADDRESS.* Presidio of San Francisco, CA 94129 PRINCIPAL INVESTIGATOR (PUMAR BAAN II U.S. Aurdenic prolimited MARE: Akers, W.A., COL MC TELEPHONE: 415-561-5181 TELEPHONE: 415-561-5485 TELEPHONE: 415-561-5485	ADDRESS. ⁴ ADDRESS. ⁴ ADDRESS. ⁴ Presidio of San Francisco, CA 94129 PRINCIPAL INVESTIGATOR (PURIS MARK IV.E. Ascannes (POSITIVE NAME: Akers, W.A., COL MC TELEPHONE: 415-561-5181 1. GEREGAL USE TELEPHONE: 415-561-5181 1. GEREGAL USE TELEPHONE: (U) protein synthesis: (U) protein synthesis: (U) lip synthesis: (U) skin: (I) human volunteers 1. TECHNICAL ODICTIVE. ⁴ 24 APPROACH, 16 PROCASS (Purish Instrume Propagate Contified by maker Proteor Instructed and the Source Continue Control 25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	ADDRESS. ⁴ Presidio of San Francisco, CA 94129 Presidio of San Francisco, CA 94129	ADDRESS. ⁶ Presidio of San Francisco, CA 94129 Presidio of San Francisco, CA 94129	ADDRESS. ⁴ DISTRICT OF CALL IN THE DESCRIPTION OF CALL OF CAL	Pre	sidio of San Fran	cisco. CA 941	earcn 129	Derm	rman Arm atology Re	y institute esearch Div	of Researc
RESPONSIBLE INDIVIDUAL NAME: Akers, W.A., COL MC TELEPHONE: 415-561-5181 1. GENERAL USE PRINCIPAL INVESTIGATOR (PUMICH SEAN II U.S. Audded: Principal AME: Schmid, P., Ph.D. TELEPHONE: 415-561-5485 SOCIAL SECURITY ACCOUNT NUMBER: AME: NAME: NAME: NAME: PE REVEOROS (Procedo EACH with Soundly Clearlifection Code) (U) biochemistry; (U) prickly heat; (U) protein synthesis; (U) lip synthesis; (U) skin; (U) human volunteers PE TECHNICAL OBJECTIVE, 24 OPPROACH, 24 PROCRESS (Pumich Individue Priopreparts identified by master Proceed test of each with Security Clearlifection Code.) 25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	RESPONSIBLE INDIVIDUAL NAME: Akers, W.A., COL MC TELEPHONE: 415-561-5181 N. GERERAL USE REVEORDE (Process EACH of the Breadly Clear Research of the State of	RESPONSIBLE INDIVIDUAL NAME: Akers, W.A., COL MC TELEPHONE: 415-561-5181 1. GENERAL USE 2. GENERAL USE 2. GENERAL USE 2. GENERAL USE 2. GENERAL USE 2. GENERAL USE 2. (U) Skin: (U) human volunteers 2. TECHNICAL BUILDETUR. 2. Andrewick provide and the second of the second o	RESPONSIBLE INDUVIDUAL HARE: Akers, W.A., COL MC TELEPHONE: 415-561-5181 1. GENERAL USE REVENDE: 415-561-5181 1. GENERAL USE REVENDE: 415-561-5181 1. GENERAL USE REVENDE: 415-561-5181 1. GENERAL USE RAME: HAR	PRINCIPAL INVESTIGATOR (Periode MAR II U.2. Andrew (Printed II U.2. Andrew (Printed II U.2. Andrew (Printed II U.2. Andrew (Printed Printed II U.2. Andrew (Printed II U.2. Andrew	PRINCIPAL INVESTIGATOR (POWNAN ADAM II U.S. Anderse (Principal MARE: Akers, W.A., COL MC VELEPHONE: 415-561-5181 1. SEMERAL USE I. SECONT (U) protein synthesis; (U) biochemistry; (U) prickly heat; (U) protein synthesis; (U) lip synthesis: (1) skin; (1) human volumteers I. TECHNICAL GENERAL (SECONT VIEW SAME Prese Interference Interf	ADDRESS:				ADDRESS!* Presid	lio of San	Francisco,	CA 94129
RESPONSIBLE INDIVIBUAL NAME: Akers, W.A., COL MC TELEPHONE: 415-561-5485 SOCIAL SECURITY ACCOUNT NUMBER: AME: SOCIAL SECURITY ACCOUNT NUMBER: AME: NAME: NAME: NAME: NAME: Synthesis: (U) skin: (U) human volunteers Synthesis: (U) Because of manpower limitations the project was held in an inactive state in FY 72.	REEPONSIBLE INDIVIDUAL MARE: Akers, W.A., COL MC TELEPUCHE: 415-561-5181 1. GENERAL USE TELEPUCHE: 415-561-5181 1. GENERAL USE TELEPUCHE: 415-561-5485 DOCIAL SECURITY ACCOUNT NUMBER: ALBOCIATE INVESTIGATORS NAME: NAME: TELEFUCHES: (U) skin: (U) human volunteers 25. TECHNICAL OBJECTIVE. ⁶ 24. PPPROACH, 24. PPOCRESS (Pumite Individual perspape identified by number preserve test of sector test of sector in Security Classification Code.) 25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	RELPONNELE INDIVIDUAL MARE: Akers, W.A., COL MC TELEPHONE: 415-561-5485 Social SECURITY ACCOUNT NUMBER: ALSOCIAL SECU	nessonnible individual wame: Akers, W.A., COL MC relephone: 415-561-5485 bocial security account number: associate investigators name: 1: essenal use security account number: hate: name: 1: essenal/ use security account number: hate: name: 1: essenal/ use security account number: hate: name: 1: essenal/ classification code; (U) skin; (U) human valuateers security (U) prickly heat; (U) protein synthesis; (U) lip synthesis: (U) skin; (U) human valuateers 2: technical objective, account number of manpower limitations the project was held in an inactive state in FY 72. 25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	nessonkible individual where: Akers, W.A., COL MC relephone: 415-561-5485 scial security account number: Associate investigators n: eeneral use	MARE: Akers, W.A., COL MC TELEPHONE: 415-561-5485 TELEPHONE: 415-561-5485 Social SECURITY ACCOUNT HUMBER: Astocial SECURITY ACCOUNT HUMBER: ALUE Astocial SECURITY ACCOUNT HUMBER: Synthesis: (U) biochemistry: (U) prickly heat; Structure.* Structure.* ALUE ACCOUNT.** Structure.*					PRINCIPAL INVESTIG	ATOR (Fundah Si	AN ITUS. And	nic jestikulieni
HANG: Akers, W.A., COL MC TELEPHONE: 415-561-5485 SOCIAL SECURITY ACCOUNT NUMBER: ASSOCIATE INVESTIGATORS NAME: NAME: NAME: Synthesis: (U) skin: ASSOCIATE INVESTIGATORS NAME: NAME: Synthesis: (U) skin: ASSOCIATE: PROCESS: ASSOCIATE INVESTIGATORS NAME: NAME: Synthesis: (U) skin: ASSOCIATE: PROCESS: ASSOCIATE INVESTIGATORS Synthesis: (U) skin: ASSOCIATE: PROCESS: ASSOCIAL: PROCESS: ASSOCIAL: PROCESS: <	NAME: Akers, W.A., COL MC TELEPHONE: 415-561-5485 Scial SECURITY ACCOUNT HUNDER: ALL SECURITY ACCOUNT HUNDER:	MANE: Akers, W.A., COL MC TELEPHONE: 415-561-5485 DOCIAL SECURITY ACCOUNT HUMBER: Autociate Investigators MARE: MARE: Synthesis: (U) skin; (U) human volunteers Process (doc) for synthesis; (U) lip Synthesis: (U) skin; (U) human volunteers Process (doc) for synthesis (consilhustion Cons.) 25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	NAME: Akers, W.A., COL MC TELEPHONE: 415-561-5181 N. GENERAL USE SOCIAL SECURITY ACCOUNT NUMBER: N. GENERAL USE ALE: NAME: NAME: Synthesis: (U) skin: Synthesis: (U) skin: NAME: NAME: Synthesis: (U) skin: Synthesis: (U) human volunteers Synthesis: Stockets (Period test of each win property classifier deriver property classifier deriver) 25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	NAME: Akers, W.A., COL MC TELEPHONE: 415-561-5485 Social SECURITY ACCOUNT NUMBER: ALSOCIATE INVESTIGATORS NAME: NAME: NAME: NAME: NAME: NAME: Synthesis: (U) skin: Synthesis: (U) skin: Notical Security Clearify Clearify Clearify Clearify Intervention Code; NAME: NAME: Synthesis: (U) skin: Synthesis: (U) skin: NAME: NAME: NAME: NAME: NAME: <t< td=""><td>MAREL Akers, W.A., COL MC TELEPHONE: 415-561-5485 Social SECURITY ACCOUNT NUMBER: Associate Investigators N. GENERAL USE Associate Investigators Synthesis; (U) skin; (U) human volunteers NAME: St. TECRNICAL OSIECTIVE." 24 PPPROACH, 24 PROCRESS (Purity Industries Presson Inst of soft with Security Classification Code;) 25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.</td><td>RESPONSIBLE INDIVI</td><td>IDUAL</td><td></td><td></td><td>HANE:* Schm</td><td>id, P., Ph.!</td><td>D.</td><td>• • • •</td></t<>	MAREL Akers, W.A., COL MC TELEPHONE: 415-561-5485 Social SECURITY ACCOUNT NUMBER: Associate Investigators N. GENERAL USE Associate Investigators Synthesis; (U) skin; (U) human volunteers NAME: St. TECRNICAL OSIECTIVE." 24 PPPROACH, 24 PROCRESS (Purity Industries Presson Inst of soft with Security Classification Code;) 25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	RESPONSIBLE INDIVI	IDUAL			HANE:* Schm	id, P., Ph.!	D.	• • • •
TELEPHONE: 415-501-5181 SUBJECTIVE: 415-501-5181 SUBJECTIVE	TELEPHCHE: 415-501-5181 11. GENERAL USE 11. GENERAL USE 12. KEVednos (Precede gach with Semerity Cleasification Code) (U) biochemistry; (U) prickly heat; (U) protein synthesis; (U) lip synthesis: (U) skin: (U) human volunteers 12. TECHNICAL OBJECTIVE." 24. PPPROACH, 25. PROCRESS (Permith Individue perspecto Identified by masker presede test of each with Security Cleasification Code.) 25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	TELEPHONE: 415-501-5181 BOCIAL SECURITY ACCOUNT HUMBER: 11. GENERAL USE ALGO INTY ACCOUNT HUMBER: 11. GENERAL USE HAME: NAME: HAME: Synthesis: (U) skin: (U) human volunteers HAME: 12. TECHNICAL OBJECTIVE." 24 OPPROACH, 25 OPPROACH, 25 OPPROACH, 25 OPPROACH, 26 OPPROACH, 26 OPPROACH, 27 OPPLICATIONS INSTITUTE INTERIOR OF Project was held in an inactive state in FY 72. 25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	TELEPHONE: 415-501-5181 Director reinvestigation Associate investigation State Name: NAME: NAME: NAME: NAME: Synthesis: (U) skin:	TELEPHONE: 415-501-5181 DECIAL BECURITY ACCOUNT NUMBER: 11. GERERAL USE Associate investigators 11. GERERAL USE NAME: NAME: NAME: NAME: NAME: Synthesis: (U) skin: (U) human volunteers Name: 12. TECHNICAL OBJECTIVE: 216 APPROACH, 216 PROCAELS (Period head paragraphs idmitified by number process issue in security classification Code) 25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	receptione: 415-501-5181 it. secontry accounty number: nit.	HANE: Ak	ers, W.A., COL M	IC		TELEPHONE: 41	5-561-548	35	
NAME: NAME: NAME: NAME: NAME: NAME: NAME: NAME: NAME: NAME: 25. (U) skin; (U) human volunteers 25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	NAME: NAME: NAME: NAME: NAME: Synthesis: (U) skin: (U) human volunteers RECHNICAL OBJECTIVE." 24 PPPROACH, 24 PROCRESS (Provide Instituted perspecto Identified by number Protoce Identification Security Classification Code.) 25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	PI KEVSGAGE (Proceds EACH with Security Closelfication Code) (U) biochemistry; (U) prickly heat; (U) protein synthesis; (U) lip synthesis: (U) skin: (U) human volunteers. 23. TECHNICAL OBJECTIVE.* 24. OPPEROACH, 24. PROCAESS (Provide Independent independent interface) property for a start of each with Security Closelfication Code) 25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	PL REVERINGE (Procede gach with Beauthy Clearitheation Code) (U) biochemistry; (U) prickly heat; (U) protein synthesis; (U) lip synthesis; (U) skin; (U) human volunteers 13. TECHNICAL OBJECTIVE.* 24 PPPROACH, 24 PPROACH, 24 PROCEEDS (Formion Inder recorregence identified by number Proceed test of each with Security Clearitheation Code.) 25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	NAME: NA	NAME: NA	TELEPHONE: 41	2-201-2181			ASSOCIATE INVESTIG	CCOUNT NUMBE	(A :	
NAME: 12 KEVWOND (Proceds EACH with Somethy Closellhiethen Code) (U) biochemistry; (U) prickly heat; (U) protein synthesis; (U) lip synthesis: (U) skin: (U) human volunteers 12. TECHNICAL OBJECTIVE.* 34 PPEROACH, 34 PROGRESS (Puriod Induitriani perspecto Constituted by number Protect test of each with Security Closellhiethen Code.) 25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	NAME: 12 KEVWORG (Proceds EACH with Sourthy Closellitenter Code) (U) biochemistry; (U) prickly heat; (U) protein synthesis; (U) lip <u>synthesis; (U) kin; (U) human volunteers</u> 21. TECHNICAL OBJECTIVE. [*] 24. PPPROACH, 24. PROCRESS (Pumleh Industant perspected to the infinite of and the second to the second	NAME: 12 KEVEORGE (Proceeds EACH with Secondly Closed Histman Code) (U) biochemistry; (U) prickly heat; (U) protein synthesis; (U) lip synthesis: (1) skin: (1) human volunteers 2. TECHNICAL OBJECTIVE." 24 PPPROACH, 24 PROCRESS (Pumith Individual purgraphs identified by number proceeds test of each with Security Closed Historian Code.) 25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	NAME: PL REVERAGE (Precede dack with preachy Clearlifecture Code) (U) biochemistry; (U) prickly heat; (U) protein synthesis; (U) lip synthesis: (U) skin: (U) human volunteers PL TECHNICAL OBJECTIVE. ⁹ 24. PPPROACH, 25. PROCRESS (Pumleh individual perspective identified by number presede test of each with security Clearlifection Code.) 25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	NAME: TEREVERAGE (Proceede EACH with Sciently Closelficiance Code) (U) biochemistry; (U) prickly heat; (U) protein synthesis; (U) lip synthesis; (U) skin; (U) human volunteers TECHNICAL OBJECTIVE." 24 OPPROACH, 25 PROCEESS (Provide Industrian) propagate identified by maker Protect test of each with Sciently Closelficiation Code.) 25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	I REVERING (Procedu EACH with Somethy Clearlifestion Code) (U) biochemistry; (U) prickly heat; (U) protein synthesis; (U) lip synthesis; (U) skin; (U) human volunteers 12. TECHNICAL OBJECTIVE.* 24. OPPROACH, 24. PROCRESS (Printed Internal perspecto Identified by masker procedu Ital of each with Security Clearlifestion Code;) 25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.					NAMEI			
(U) biochemistry; (U) prickly heat; (U) protein synthesis; (U) lip synthesis: (U) skin; (U) human volunteers B2 TECHNICAL OBJECTIVE." 28 CPPROACH, 28 PROGRESS (Purior infinite property identified by maker protoco that of each of a security closelikesian Code.) 25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	(U) biochemistry; (U) prickly heat; (U) protein synthesis; (U) lip synthesis: (U) skin: (U) human volunteers B2 TECHNICAL OBJECTIVE." 24 OPPROACH, 24 PROCHESS (Pomish Instrume) property limited by maker protoco (u) of each ord scorely classification code.) 25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	(U) biochemistry; (U) prickly heat; (U) protein synthesis; (U) lip synthesis: (U) skin: (U) human volunteers RE TECHNICAL ODJECTIVE." 24 OPPROACH, 24 PROCAELS (Permits instruent property instruments for the of the second rest of the off second rest o	(U) biochemistry; (U) prickly heat; (U) protein synthesis; (U) lip synthesis; (U) skin: (U) human volunteers 21. TECHNICAL CONTECTIVE." 24 FFFROACH, 21 PROCRESS (Frmite infinite programs france procedures to a state of a source constituentian cons.) 25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	(U) biochemistry; (U) prickly heat; (U) protein synthesis; (U) lip <u>synthesis: (U) skin: (U) human volunteers</u> 12. TECHNICAL OBJECTIVE. ⁶ 22. PEPROACH, 22. PROCRESS (Purnish Individue) perspective identified by number protoco test of each with security Classification Code.) 25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	(U) biochemistry; (U) prickly heat; (U) protein synthesis; (U) lip synthesis: (U) skin; (U) human volunteers 25. TECHNICAL OSIECTIVE. ⁹ 24. OPPROACH, 24. PROCHESS (Purilies Inder paragraphic dentified by number proteor test of each with security classification Control 25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.		the descent miles the second second	Realized Codes		NAME:			
25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.			(U) b	oiochemistry;	(U) prickly hea	t; (U) pro	tein synthe	esis; (U) lip
25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	TL XEVODAGE (Pres synthesis:	(U) skin: (U) hu	man voluntee				In Security Class	Illeallan Code.)
25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	25. (U) Because of manpower limitations the project was held in an inactive state in FY 72.	TI KEVBORGE (Free synthesis: 23. TECHNICAL OBJE	(U) skim: (U) hu Igtive." 24 opendach, 20	man voluntee	Individual paragrapha i	dentified by muster press	de tost ef oath a		
						ET KEVBORGE (Pres) 	(U) skim: (U) hui active." 24 oppmaach, 20	man voluntee PROGRESS (Furnish	ladiria,si peregraphe i	dentified by number proc	to test of each a		
						25. (U) Be	(U) skin: (U) hu convert at epermann, an cause of manpow	man voluntee PROGRESS (Pumish er limitations	the project w	as held in an in	active stat	te in FY 72	2.
						12 xtvodace/press synthesis: 23. TECANICAL 00/0 25. (U) Be	(U) skin; (U) hu crive, a preson, a ccause of manpow	man voluntee L process (source er limitations	the project w	/as held in an in	active stat	te in FY 72	2.
						22 xEvedade (Presi synthesis: 21. TECHNICAL OBJE 25. (U) Be	(U) skin: (U) hu convert an epermann, an ecause of manpowe	man voluntee L PROGRESS (Pumion er limitations	the project w	as held in an in	active stat	te in FY 72	2.
						25. (U) Be	<u>(U) skin: (U) hu</u> cerive. [•] as epphonen, an ecause of manpowa	man voluntee	the project w	/as held in an in	active stat	te in FY 72	2.
						25. (U) Be	(U) skin; (U) hu crive, a preson, a ecause of manpow	man voluntee Process (2000) er limitations	the project w	vas held in an in	active stat	te in FY 72	2.
						25. (U) Be	<u>(U) skin: (U) hu</u> cerive. [•] 24 oppmach, 20 ceause of manpow	man voluntee	the project w	vas held in an in	active stat	te in FY 72	2.
						25. (U) Be	<u>(U) skin; (U) hu</u> cerive [,] as <i>epperdoce</i> , and ecause of manpow	man voluntee	the project w	vas held in an in	active stat	te in FY 72	2.
						25. (U) Be	<u>(U) skin; (U) hu</u> ccrive [,] a <i>opp</i> roach, a ecause of manpow	man voluntee	the project w	vas held in an in	active stat	te in FY 72	2.
						25. (U) Be	<u>(U) skin: (U) hu</u> cerive. ⁹ 24 oppmach, 20 ceause of manpow	man voluntee	the project w	vas held in an in	active stat	te in FY 72	2.
						25. (U) Be	<u>(U) skin: (U) hu</u> cerive. ⁹ 24 <i>opp</i> roach, 24 ecause of manpow	man voluntee	the project w	vas held in an in	active stat	te in FY 72	2.
						25. (U) Be	<u>(U) skin: (U) hu</u> cerive [,] as <i>epphone</i> , and ecause of manpowa	man voluntee	the project w	vas held in an in	active stat	te in FY 72	2.
						25. (U) Be	<u>(U) skin; (U) hu</u> cerve [,] a <i>opp</i> roach, a ecause of manpow	man voluntee	the project w	vas held in an in	active stat	te in FY 72	2.
						T KEVEGAGE (Proce synthesis: 23. TECANICAL 0011 25. (U) Be	(U) skin; (II) hu crive, a presonan, a ecause of manpow	man voluntee	the project w	vas held in an in	active stat	te in FY 72	2.

- .---
60

Biosynthesis of Proteins and Lipids in Human Skin With Particular Emphasis on Prickly Heat

Peter Schmid, Ph.D.

PROBLEM:

No adequate hypothesis presently exists which explains the primary events causing miliaria. Much data suggests that bacteria may be involved, but contrary evidence exists indicating that bacteria are not important. Other work suggests that high level of salt in the sweat is responsible for producing miliaria but experimental testing did not confirm this hypothesis. Still other work suggests that lack of adequate lipid in the stratum corneum permits keratin to swell thereby blocking the sweat duct orifice.

From measuring the sweat rate per gland and the dimensions of the duct, linear flow rates of sweat secreted through an unobstructed duct to the surface can be calculated to reach values up to 100 mm/min. Physically obstructing the duct and/or lowering the sweat flow rate may have far reaching consequences on the metabolism of the sweat gland apparatus because solutes such as ammonia may no longer clear the duct rapidly and may become toxic to the sweat gland apparatus.

This work unit attempts to test a new hypothesis: that the differential rate of protein and lipid synthesis of the cells lining the sweat duct, spinous and granular layers of the epidermis leads to distortion and occlusion of the sweat duct and thus to miliaria.

APPROACH:

Miliaria is produced on one-half of the body surface by the method of Sulzberger, Griffin, et al. Volunteers are injected intravenously with a sterile solution of 200 μ C³H glycine and 100 μ C¹⁴C acetate. The experimental and control area on the back are scraped lightly to remove the outermost layer of stratum corneum and the dust-like scales collected. Scrapings are performed every second day over prolonged periods of time. The dry scales are extracted with lipid solvents and phosphate buffer. Lipid, soluble proteins and insoluble material is analyzed for ³H and ¹⁴C by liquid scintillation spectrometry.

RESULTS AND DISCUSSION:

Because of manpower limitations, the project was held in an inactive state in FY 72.

FUTL . PLANS:

Continue and terminate development of methodology.

Initiate measurement of samples from pilot study.

If necessary, modify procedures developed.

Measure protein synthesis and lipid synthesis of volunteers who were subjected to the induction procedure for experimental miliaria.

	H AND TECHNOLOGY	Y WORK UNIT	SUMMARY	DA	DA 6912	72 0	7 01	REPORT C	ONTROL STRE &E(AR)636
DATE PAEV SUMAY	D.Change	S SUMMARY SCTV	· · · ································	Y 7. ALO		ila'n insta NL	H BA SPECIFIC CONTRACTOR	ACCESS	-
NO./CODES.	PROGRAN ELEMENT	PROJEC	TNUMBER	TASK			WORK UNI		
PRIMARY	62110A	3A0621	10A822	00)		162		
CONTRIBUTING									·····
CONTRIBUTING	I								••••••••••••••••••••••••••••••••••••
Carticular En SCIENTIFIC AND T 103500 - Clin	nphusis on Prickly ECHNOLOGICAL AREAS [®] nical Medicine	Heat & Con	es on the Effense asequent Disa	ects of H abling D	leat & Hum ermatoses	idity U (05)	pon the Hur	nan Ski	in with
STAAT DATE		IN ESTIMATED CO	MPLETION DATE	IL FUN	DING AGENCY	1	C. In I		100
CONTRACT/GRANT						-+	[C. m·n	ouse	
DATES/EFFECTIVE		EXPIRATION		14 1465	PARCEDINE	E & PRO	FESSIONAL MAN VR	S B FUN	DS (In thousand
NUMBER *	NA			FISCAL	72		2	1	23
TYPE'		& ANOUNT:		YEAR	CURRENT				
KIND OF AWARD		f. CUM. AM	T.		73		1		20
RESPONSIBLE DOD	ORGANIZATION	L			FORMING ONGANI	ZATION			
Presi	dio of San Francis	sco, CA 941	29	ADDRES	S.* Derr Presi	natolog idio of !	y Research I San Francisc	Division o, CA 9	esearch 94129
SPONSIBLE INDIVISIONEL AND ANDE. AKET ELEPHONE 415-2	^{dyal} s, W.A., COL MC 561-5181			NAME. TELEI SOCIAI	• Harr PHONE 415- L SECURITY ACC	is, D.R. 561-54	, MAJ MC 85 ^{En:}		
GENERAL USE					TE INVESTIGATO				
				NAME					DA
ALY WORDS (Fritte	to BACH with Isocarity Classifi	collon Code) (11	N	NAME: NAME	·			(1) 1	DA
(U) heat rete	b each all fragily crowth ention; (U) stratus crive," 24 APPROACH. 26	(U M CORNEUM PROGRESS (Pumile) miliaria; (U	HAME: HAME-) prickly	/ heat; (U)	rash; (U) sweating; ((U) hea	DA t fatigue
U) heat rete TECHNICAL OUTE 25. (U) 71 (ther expo acce swea pric rem	ention; (U) stratus ention; (U) stratus crive," a APPROACH. 24 07 – 72 06 A sens apeutic studies. The erimental prickly l elerate the recover t delivery. Cellop kly heat, will affect oval of the stratur	itaina codo) (U m corneum sitive silicon fopical antib heat. Peelin y of sweatin hane tape st ct only a pai n corneum () miliaria; (U h (ndv/ two) personant pointics and co g agents, caus ig. However, tripping, either trial recovery horny layer)	ession te oling lon these ager preced in swea or topic	wheat; (U) echnique w tions do no quamation gents initial ding or folk t delivery. cal antibiot	rash; (U as devel t affect of horn ly cause owing t These s ics will	b) sweating; loped and ut the rate of y layer in 5 e profound d he induction studies indic; not provide :	(U) hea ilized for sweat re to 7 da lecrement of exp ate that satisfac	DA t fatigue
Attible to contra	ention: (U) stratus ention: (U) stratus crive.* at APPROACH. at 07 - 72 06 A sense apeutic studies. The enimental prickly le elerate the recover it delivery. Cellop kly heat, will affect oval of the stratus	sitive silicon Proceeding (U Proceeding (Popical Sitive silicon Copical antib heat. Peelin hane tape st ct only a pai n corneum () miliaria; (U h individual personan biotics and co g agents, caus g. However, iripping, either tial recovery horny layer)	ession te oling lot sing desc these ager precect in swea or topic	y heat; (U) echnique w tions do no quamation gents initial ding or folla t delivery. cal antibiot	rash; (U as devel t affect of horn ly cause owing t These s ics will	I) sweating; Ioped and ut the rate of y layer in 5 profound d he induction studies indic: not provide	(U) hea ilized for sweat re to 7 day lecrement of exp ate that satisfac	DA t fatigue or covery fro ys, nts in erimenta simple tory the

and the state of the

ELEVINE CONTRACTOR CONTRACTOR OF THE OWNER OF THE CONTRACTOR OF T

The second state and the second state and the second

*

***.*

Port the Presentes

a

. . . .

Studies on the Effects of Heat and Humidity Upon the Human Skin with Particular Emphasis on Prickly Heat and Consequent Disabling Dermatoses: Summary of 3 Years of Studies

Major David R. Harris, MC

PROBLEM:

The torment of itching that precludes sleep is familiar to everyone who has suffered from prickly heat rash (miliaria). Recently, a laboratory model for producing experimental miliaria, using occlusive polyethylene wraps over a 72 hour period, was developed at the Letterman Army Institute of Research (LAIR). Using this model, it was shown that clinical and experimental prickly heat is associated with longlasting decrements in sweat delivery. Significantly, in World War II investigators observed that heat fatigue and exhaustion were associated with transient reductions in sweating. Subsequent collaborative experiments by LAIR personnel at the U.S. Army Research Institute of Environmental Medicine, Natick, consistently demonstrated profound heat fatigue associated with widespread post prickly heat sweating deficiencies. Prickly heat caused disability in both combat and support personnel in RVN. The results of questionnaires submitted by LAIR to most battalion surgeons in RVN engaged directly in military patient care revealed neither an effective treatment nor a unified approach to the treatment of miliaria or other sweating disorders. Moreover, prickly heat rash serves as a prototype to investigate cutaneous diseases associated with assaults of heat and humidity upon the stratum corneum including: the sweat retention syndrome associated with heat fatigue, disabling disorders of the feet, including warm water immersion foot and paddy foot, bacterial and fungal infections, and tropical acne. All of these diseases are closely linked with the occupational hazards of the fighting man in a tropical climate.

With this background, the main thrust of this miliaria investigative program has been toward: (1) development of a human model; (2) elicitation of the causal mechanisms; (3) investigation of preventive and therapeutic modalities.

Carlo and an

E.E.

APPROACH:

Development of the human model 1. A technique was perfected to produce experimentally the clinical equivalent of miliaria rubra over multiple sites on the backs of volunteers. Tes+ sites were dressed for 72 hours with a 3" x 5" occlusive dressing composed of polyethylene film and 1/4" thick polyurethane foam, held in close proximity to the skin with an adhesive bandage. Following a sweat stimulus, these occluded sites revealed confluent prickly heat for 24 to 48 hours followed by sweating decrements lasting up to 3 weeks (Sulzberger, M.B. and Harris, D.R.: Miliaria and anhidrosis. III. Multiple small patches and the effects of different periods of occlusion. Arch Derm, in press).

2. Elucidation of causal mechanisms

Development of a sweat impression technique. Initially, increments and decrements in heat lamp stimulated sweating were measured by air flow hygrometry. Subsequently, our studies showed that with this method, day-to-day measurements varied greatly at the same control sites over the back and were dependent on a large number of variables. These included the ambient air temperature and humidity, skin color and distance of the skin from the heat lamp, the moisture content in and the flow rate of the air passing over the sweating site, and the length and temperature of the hygrometry tubing. Because these factors were difficult to control, we evaluated a number of sweat indicator and impression techniques which measure the number of actively secreting eccrine units and not the rate of sweat delivery. A technique was developed utilizing a thin silicone film sweat impression and a constant humidity chamber for a controlled sweat stimulus. Subjects are heated for 25 minutes in an environment of 118°F and 30% RH. A 10 minute active exercise program is carried on during the stimulus period. With vigorous sweating continuing in the chamber, 1 cc of a type II silicone base, class 3 light body impression material (Kerr Manufacturing Co., Romulus, Michigan 48174) is mixed with 1 drop of catalyst and spread in a thin film over the skin with a wooden applicator stick. This hydrophobic material withdraws from emerging sweat droplets and as polymerization occurs, an impression of active eccrine units is fixed (Harris, D.R.; Pclk, B.F. and Willis, I.: Evaluating sweat

64

gland activity with imprint techniques. JID 58: 78-84, 1972). In this manner, an accurate quantitation of day-to-day eccrine sweating over the same site can be achieved.

Three approaches were Histological studies. b. utilized for the histological evaluation of experimental prickly heat. Six volunteers had pairs of symmetrical occlusive dressings affixed for 8, 24, 48 and 72 hours (total of 8 dressings per man). At the end of each occlusive period, test sites were biopsied, formalin fixed, cut and prepared for light microscopy in the usual manner. Each specimen was serially sectioned, stained with the H&E and the PAS techniques and compared with control specimens. Second, number 15 gauge needle specimens were prepared in the usual manner for electron microscopy, being fixed with gluteraldehyde and osmic acid and slowly dehydrated in increasing concentrations of alcohol to 100%. This tissue was embedded in plastic, cut in thin 1 micron sections, stained with methylene blue and examined with both light and electron microscopic techniques. Third, 1 cm² free hand-split thickness shave specimens were fixed in sodium bromide and dehydrated in 70% alcohol solution. This tissue was prepared and examined under the scanning electron microscope at Johnson and Johnson Research Division, New Prunswick, New Jersey.

Selection and Characterization of Individuals C. Two field studies were conducted Prone and Resistant. in which each of 29 volunteers was physical y stressed in a warm environment (average 83°F) for a 72 hour period after being wrapped over 1/2 of the trunk with an occlusive dressing. Twice each day, volunteers engaged in strenuous exercise by marching at a brisk rate over hilly country for a total of 5 miles. All subjects developed dripping sweats. Following removal of the occlusive dressings, the severity of miliaria was determined clinically. Then, at 4 consecutive weekly intervals each volunteer was evaluated for Sweat delivery at control and miliaria sites in the Individuals who manifested manner previously outlined. sweating decrements at miliaria sites over the test period significantly greater than the group mean were designated "prone to miliaria." Conversely, individuals who had decrements significantly below the norm were designated "resistant to miliaria." These 2 groups were then compared with one another with regard to severity of experimental miliaria, past history and family history of the disease, sweat electrolyte

concentration (measured by flame photometry and skin chloride electrode), skin pH with and without occlusion and total cutaneous microflora counts.

d. Role of the stratum corneum (horny layer). To determine the possible role of a horny layer blockade in the induction of experimentalmiliaria and hypohidrosis, several cellophane tape stripping experiments were performed. In each, the technique was the same. Individual lengths of cellophane tape were applied to the test site with 2 firm thumb strokes and then gently peeled off. Separate pieces of tape were used for each stripping. In separate trials employing 5 volunteers each, the following experiments were performed:

(1) Separate sites stripped 3, 6, 9, 12 and 18 times immediately before induction of miliaria;

(2) Separate sites stripped 3, 6, 9, 12 and 18 times immediately after the induction of miliaria;

(3) Separate sites stripped 12 times 24 hours after induction of miliaria;

(4) Separate sites stripped 6 and 1.2 times immediately after the induction of miliaria;

(5) Separate sites stripped to glistening and 1/2 glistening 4 hours after induction of miliaria.

3. Therapeutic Trials. Multiple patches of miliaria were induced in groups of 5 volunteers each. The following classes of topical agents were then applied by the investigator at control and test sites twice daily for 7 days:

a. Topical antibiotic (Neosporin-GR cream)

b. Peeling solutions (resorcinol 14, salicylic acid 14, lactic acid [85%] 14, ethanol qs 100 and Retinoic Acid 0.1% in ethanol [55%])

c. Cooling lotion (Witch Hazel NF)

Each subject was evaluated for decrements or increments in sweat delivery at test and control sites at 3 day intervals for periods of 15 to 20 days.

RESULTS AND DISCUSSION:

1. Causal Mechanisms

Histological Studies. Examination of multiple a. sites occluded for periods between 8 and 72 hours, revealed neither clinically apparent experimental miliaria or long lasting sweat decrements before 48 hours of occlusion. The development of miliaria and hypohidrosis following this period correlated closely with the development of changes within the epidermis and the stratum corneum as determined with light The epidermis showed edema and acute and microscopy. chronic inflammation around the eccrine duct at the epidermal-dermal junction. These findings were identical to previous histological reports of the naturally occurring disease. At the same time, specimens fixed for electron microscopy showed varying degrees of edema within the granular layer of the epidermis and in the fully formed stratum corneum. In some specimens the cellular ultrastructure within the horny layer was dispersed. Pioneer studies using surface scanning electron microscopy (SEM) revealed no uniform picture. While some miliaria samples showed apparent surface plugs at the ostea of sweat ducts, some control site specimens also showed plugged After examining several thousand scans, this ostea. investigator, collaborating with Dr. Christopher Papa of Johnson and Johnson Research Division, concluded that baseline SEM studies should be undertaken first defining the range of normal sweat gland ostea.

Characterization of individuals prone and b. resistant to miliaria. Eight individuals, in 2 groups of 4 each, were selected from a group of 30 volunteers either as "prone" or "resistant" to experimental miliaria on the basis of being at the extremes of sweating decrements at test sites. Whether prone or resistant, there were no group differences in the expression of clinical disease when the occlusive wraps were removed. Nor were there significant differences between the 2 groups in reporting a past history of miliaria, in sweat electrolyte concentrations, or in the skin pH and bacterial flora at control and occluded sites. Overall, differences in skin pH were seen in both the prone and resistant groups at control compared to unwrapped miliaria sites. An average rise in pH from 5.6 to 6.4 was noted from the unoccluded to the occluded patches. Similarly, a 2-1/2 log average increase in aerobic bacteria was

seen in all the volunteers after 72 hours of occlusion. We conclude for the present that we have no clear picture of what factor or factors dispose a "prone" individual to prickly heat. Nor do we have assurance, given any set of environment circumscances, that the same individual will remain consistently "prone" or "resistant" to experimental or naturally occurring prickly heat.

entra en social de prédicion de la constitut de la constitue de la constitue de la constitue de la constitue de

Stratum corneum stripping studies. C. When multiple strippings of the horny layer were taken either before or after occlusion, a consistent trend toward greater sweat gland counts was seen. In one experiment, stripping 72 hour occluded sites 9, 12 or 18 times returned the sweat gland count to 29% of normal from a baseline of 9% of normal (p<.05). Similar increments were noted at sites stripped 3, 6, 12 or 18 times before occlusion. Subsequent experiments showed that the effect of stratum corneum removal on sweat delivery was most apparent at 7 days following stripping to glistening when a brisk desquamation of stratum corneum was seen. However, a factorial analysis of the effects of stripping following induction of experimental prickly heat revealed statistically significant increases in sweat delivery in only 1 of 4 experiments (F<0.05). In summary, stripping can increase sweat impression counts at miliaria sites from 8 to 20% depending on how and when it is done. Certainly, normal sweat delivery is not reinstituted.

Nonetheless, these stripping experiments coupled with the histological studies showing edematous disruption of the horny layer and deeper epidermal-dermal junction inflammation only in association with sweat decrements, strongly suggest that at least a partial horny layer blockade to the free egress of sweat is the anatomical event initiating prickly heat.

d. Therapeutic trials. Two considerations dictated the selection of agents for therapeutic trials. First, historically, a multitude of so-called "peeling" agents have been advocated for prickly heat since World War II. There efficacy has always been in doubt because most of these agents contain substances which, while causing drying and peeling, also evaporate in warm climate, cooling the prickly skin. Since a stratum corneum blockade apparently plays a role in the etiology, two peeling agents which were found to cause a brisk desquamation in from 5 to 7 days were chosen for initial clinical trials. Results showed

that this type of agent initially causes a decrement in sweat delivery ranging from 30 to 70% of baseline at both control and previously occluded sites. Subsequently, return to normal sweat counts at miliaria sites was accelerated over the 14 to 21 day normal and coincided with the onset of horny layer desquamation at 5 to 7 days. Whether these agents will beneficially effect either comfort or performance in the field has yet to be determined. Certainly, routine use of any agent which can initiate profound sweat decrements cannot be advocated.

The use of topically applied antibiotics has been a standard therapeutic approach since O'Brien, Acton and Lyson implicated staphylococci in the etiology of miliaria. We have shown, as have others, a tremendous increase in cutaneous microflora both in the naturally occurring state and after induction of experimental miliaria and hypohidrosis under occlusive wraps. With this background, MAJ T. Griffin and COL W. Akers of LAIR proceeded to demonstrate some beneficial effect using either topical neomycin or chloramphenicol prophylactically to prevent post-miliarial hypohidrosis. The only controlled therapeutic study of topical antibiotics showed neomycin and Kanomycin^R lotions to be clinically effective when only the clinical expression of disease and patient comfort were evaluated. Thus, we chose to evaluate a readily available preparation, Neosporin- G^R cream, containing the same concentration of neomycin as in previously reported studies. There was absolutely no effect on sweat delivery either at control or miliaria test sites over a 2 week period of evaluation.

We conclude that effective therapy as defined by the reestablishment of normal sweating at a physiological level may be impossible to achieve by means presently available. If the initiating event in miliaria is damage to the structural integrity of the stratum corneum, then a complete turnover in the horny tissue averaging 14 days will be necessary for return to normal sweat delivery. All of our results thus far serve to substantiate this premise. On the other hand, if effective therapy is to be defined by relief of discomfort through the natural course of the disease, then a unified approach to therapy will be more readily obtainable.

FUTURE PLANS:

Work will be directed toward more accurately defining and initiating effective therapy. Present prophylactic means of prevention are unrealistic in terms of the massive number of personnel at risk in certain environments. The following research priorities are offered:

1. Development of a long-lasting model. To test the effectiveness of therapeutic modalities in terms of patient comfort, performance, and long-lasting hypohidrosis, experimental prickly heat must be maintained without significant clinical or physiological recovery for at least 10 days to 2 weeks. To achieve this goal, the research subject will be placed in an environment of 85°F, 80-90% RH, with controlled daily exercise immediately after induction of experimental miliaria.

2. <u>Consideration of potential therapeutic agents</u>. Included for consideration are agents which buffer skin pH (citric and ascorbic acid), anionic wetting agents, antibholinergic substances (hexopyrronium bromide and Probanthine^R solution), and substances demonstrating duel solubility (cholesterol containing immulsions, polyethylene glycol). In addition, a number of newer, more potent broad spectrum topical antimicrobials bear consideration. These include Miconazole^R cream, Haloprogin^R cream, zinc and sodium Omadine and isoquinalinium bromide.

Normal and Abnormal Variations in Eccrine Sweat Delivery and Distribution

Major Isaac Willis, MC

PROBLEM:

Utilizing our new silicone imprint technique for identifying and counting active eccrine units, the objectives of this study were to determine the following: (1) if imprints of the same anatomical site were obtained at werkly intervals over 4 to 8 weeks, would significant variability in the function of a particular unit be detected, and (2) the use fulness of this technique in delineating the borders of skin tumors and evaluating the progression and/or regression of skin lesions.

Accomplishing the first objective would validate the superiority of this technique over conventional methods and would also serve to resolve previous questions concerning the possibility of "cyclic" or "periodic" functioning of sweat units that would render a single imprint using any technique unreliable. Accomplishing the second objective would provide not only a clinical means to uncover subclinical invasion or presence of tumors, but will be of use in "permanently" recording the spread or healing of lesions either under clinical or investigative therapy or simple observation, provided that they interfere with sweat delivery.

APPROACH:

1. To accomplish our first objective, 5 adult volunteers were utilized. To insure that imprints were taken from the exact same sites each time, a flexible plastic triangular mold bound by 3 permanent skin lesions (nevi, scars, etc.) was made for each test area and a 2 cm square was cut from the center of the mold where the imprint material was to be applied to the skin. Test areas included the forehead, flexor surface of the forearm, upper back, and medial surface of the leg. Sweating was induced and imprints were taken as described in our manuscript.

Initial imprints were projected onto sheets of paper where sweat ostia "light spots" could be outlined. Subsequent projected imprints could then be superimposed on old outlines to see if the same ostia were

71

functioning. Each ostia was coded and its weekly activity was recorded. A total of 4 to 8 weeks of imprints was obtained for each site in each subject.

2. The second objective was accomplished using patients with the following skin lesions: (a) superficial basal cell epithelioma, (b) sclerosing basal cell epithelioma, (c) epithelial nevus, (d) early keloid, (e) borderline tuberculoid leprosy.

These impressions were examined by direct inspection since ostia openings are easily seen and this observation would be sufficient for our purposes.

RESULT AND DISCUSSION:

1. The numbers of active eccrine units determined by repeated skin imprints of the same anatomical site did not vary by more than 5 percent. Approximately 10 percent of all units identified were found to function poorly in the initial imprint. This pool of poorly functional units remained poorly functional throughout the study.

We concluded that a single impression using this technique could be relied upon to detect >90% of all functional sweat units. These data indicate that sweat glands do not undergo cyclic or periodic function. Counts obtained with this method agree closely with those of Kuno who did in vitro histologic studies to determine the number of sweat glands.

2. The findings from imprints taken in areas of skin lesions revealed that each lesion interfered with sweat delivery. In the case of both basal cell epitheliomas that were later removed, areas of nonfunctioning sweat units corresponded to areas of actual tumor involvement. In the case of the borderline tuberculoid leprosy lesion, a partial return of sweat function was found after two months of treatment.

Results indicate that this is a useful clinical technique.

In State Page supervise 1 tousant state 1 tousant state 1 tousant state 10 70 01 D. Change U U V NA NI Entering to the state 10 07 01 D. Change U U V NA NI Entering to the state 10 07 01 D. Change U U V NA NI Entering to the state 10 07 01 D. Change Washed Formation Formation Total State Formation	RESEARCH	I AND TECHNOLOG	Y WORK UNIT	SUMMARY	1. ASE	ACCES	17	77 07 0	WARY	REPORT DD-D	cont R&E
71 07 01 D. Change U U NA NL Event and the subscription of the second with number and the second with number and second seco		4. KIND OF SUMMARY	S. SUMMARY SCTY	. WORK SECURIT	V 7. REGR	ADING ⁴	12 A DIS	7 <u>2070</u>	A SPECIFIC	C DATA -	9. LI
100.20021* PROJECT NUMBER TASK ARA NUMBER WORK UNIT NUMBER PREMARY 62110A 3A062110A822 (*) 163 CORTANTIA 62110A 3A062110A821 (*) 163 CORTANTIA 62110A 3A062110A821 (*) 002 CORTANTIA 62110A 3A062110A821 (*) 002 CORTANTIAL 62110A 0402 002 002 CORTANTIAL CONT 04 002 003500 C.In-house. CONTONIC AND TREMELOGICAL AREAS CONT DA C.In-house. C.In-house. CONTONIC AND TREMELOGICAL AREAS CONT DA C.In-house. C.In-house. CONTONIC AND TREMELOGICAL AREAS CONT DA C.In-house. Seconstant of the seconce in the	71 07 01	D. Change	U	U		NA		NL	K ves	0	•
Contraction Contraction <thcontraction< th=""> <thcontraction< th=""></thcontraction<></thcontraction<>	6. NO./CODES:*	PROGRAM FLEMENT	PROJEC	TNUMBER	TASK	AREA NUN			WORK UN	IT NUMBE	
Construint in the second second second second generation high pressure liquid characteristic and the second s		62110A	<u>3A06211</u> 3A06211	0A822 0A831							
11. Util growthe state stating classifier (U) Composition of Lipids (05) 12. Exclusion of Lipids (05) 12. Exclusion of Clipids (05) 13. Francisco of Clipids (05) 14. Exclusion of Clipids (05) 15. Francisco of Clipids (05) 16. Exclusion of Clipids (05) 11. Utility of Clipids (05) 11. Other of Clipids (05) 11. Exclusion of Clipids (05) 12. Exclusion of Clipids (05) 12. Exclusion of Clipids (05) 13. Exclusion of Clipids (05) 14. Exclusion of Clipids (05) 15. Exclusion of Clipids (05) 16. Exclusion of Clipids (05) 16. Exclusion of Clipids (05) 17. Exclusion of Clipids (05) 18. Exclusion of Clipids (05) 19. Exclusion of Clipids (05) 19. Exclusion of Clipids (05) 19. Exclusion of Clipids (05)	C. CONTRIBUTING	1	5700211		-	• • • •		•	002	·····	
10 Continue of the second	U) Comp	somity classification con	»• (۵۶)								
003500 - Clinical Medicine 12 Frant Darte 14 ESTIMATED COMPLETION DATE 15 FUNDING AGENCY 19 FEATOMMARCE BET 68 67 CONT DA C. In-house 14 RESOURCY CORNEY 14 RESOURCY CORNEY 14 FEATOMMARCE BET 15 Contract/Consert 14 RESOURCY CORNEY 14 FEATOMMARCE BET 16 Contract/Consert 15 FUNDING AGENCY 16 FEATOMMARCE BET 16 Contract/Consert 16 CONT 17 Clinical Marce Bet 17 Contract/Consert 16 CONT 17 Clinical Marce Bet 18 Contract/Consert 16 Contract/Consert 10 FEATOMMARCE BET 18 Contract/Consert 16 Contract/Consert 10 FEATOMMARCE BET 18 Contract 16 Contract 10 FEATOMMARCE BET 18 Contract 16 Contract 17 Contract 10 FEATOMMARCE BET 18 Contract 16 Contract 10 FEATOMMARCE BET 10 FEATOMMARCE BET 18 Contract 10 FEATOMMARCE BET 10 FEATOMMARCE BET 10 FEATOMMARCE BET 18 Contract 10 FEATOMMARCE BET 10 FEATOMMARCE BET 10 FEATOMMARCE BET 18 Contract 10 FEATOMMARCE BET 10 FEATOMMARCE BET 10 FEATOMMARCE BET 18 Contract <t< td=""><td>L SCIENTIFIC AND TE</td><td>CHHOLOGICAL AREAS</td><td>(03)</td><td></td><td>······</td><td></td><td></td><td></td><td></td><td>••••••</td><td></td></t<>	L SCIENTIFIC AND TE	CHHOLOGICAL AREAS	(03)		······					••••••	
Contract of Control Contenter Control Control Control Control Control Control Control Con	003500 - C	linical Medicine			-						
It Contract/Construct It Contract/Contract It Contract/Contract It Contract/Contract It Contract/Contract It Contract/Contract It Contract/Contract It Contract It	68 07	·	CONT	PLETION DATE		A Ì	C V	1	C I	MANCE NE	- 10
A DATEARPFECTIVE: NA EXPINATION: A BAUGUST: C TVPE: C	P. CONTRACT/GRANT					SOURCES 21		A PROPER	LICHAL MAN Y	AS N PU	N D
 A MAREANE C TYPE: C TYPE:	A DATEL/EFFECTIVE:	NA NA	EXPIRATION:			TRANCION	H&	1			
a wild of parado 1. CLUM. AMT. 73 1 a wild of parado 1. CLUM. AMT. 73 1 a wild of parado 1. CLUM. AMT. 73 1 a wild of presidio of San Francisco, CA 94129 1 1 1 about the state of	n nurser:*		4		PISCA	- 72	2	·	1		
37. REFORMENCE DOD ORGANIZATION Do PERFORMING ORGANIZATION WARE* Letterman Army Institute of Research Presidio of San Francisco, CA 94129 ADDRESS.* Presidio of San Francisco, CA 94129 ADDRESS.* Presidio of San Francisco, CA 94129 REFORMENCE INDUIDAL Presidio of San Francisco, CA 941 REFORMENCE Its Componence REFORMENCE Presidio of San Francisco, CA 941 REFORMENCE Its Componence REFORMENCE Its Componence REFORMENCE Its Componence REFORMENCE Its Componence <t< td=""><td>S KIND OF AWARD.</td><td></td><td>CUM. AMT</td><td></td><td></td><td>7</td><td>3</td><td>}</td><td>1</td><td>i</td><td></td></t<>	S KIND OF AWARD.		CUM. AMT			7	3	}	1	i	
 HARE* Letterman Army Institute of Research Presidio of San Francisco, CA 94129 ADDRESS.* Letterman Army Institute of Rese Dermatology Research Division ADDRESS.* Presidio of San Francisco, CA 941 PRINCIPAL INVESTIGATOR (PURITY BARK II U.S. ADDRESS (PALL MARE ALESS, W.A., COL MC TELEPHONE. TELEPHONE. 	I. RESPONSIBLE DOD	ORGANIZATION	1	<u> </u>	- 20 PE	AFORMING O	RGANIZ	A TION			-
41.5-301-3181 SOCIAL SECURITY ACCOUNT NUMBER: II. GENTRAL USE ASSOCIATE INVESTIGATORS NAME: NAME: II. GENTRAL USE III. GENTRAL USE III. GENTRAL USE Sciently Classification Code) III. GENTRAL USE III. GENTRAL USE III. GENTRAL USE Sciently Classification Code) III. GENTRAL USE III. GENTRAL USE III. GENTRAL USE Sciently Classification Code) III. GENTRAL USE III. GENTRAL USE III. GENTRAL USE IIII. GENTRAL USE III. GENTRAL USE IIIIII. GENTRAL USE	RESPONSIBLE INCIVIC NAME: AKERS,	W.A., COL MC			PRINCI NAME TELE	Pre PAL INVEST E* SC EPHONE.41	51010 1162707 hmid 5-56	or San Fi (rumish Han , P., Ph.D 1-5485	rancisco, / # u.s. Acadea),	UA 94 nis (notificitie	1 . ~)
 Associate investigators <l< th=""><th>415-56</th><th>51-5181</th><th></th><th></th><th>5001</th><th>AL SECURIT</th><th>Y ACCO</th><th>INT NUMBER:</th><th></th><th></th><th></th></l<>	415-56	51-5181			5001	AL SECURIT	Y ACCO	INT NUMBER:			
 12. KEVBOROG (Privade BACH with Sciently classification code) (U) biochemistry; (U) lipids; (U) fatty acids; (U) glycerides; (U) tropical acne; (U) soldiers 25. (U) 72 07 - 72 06 We have developed a second generation high pressure liquid chromato separation of complex skin lipids. Concurrent with this work, many solvent systems v tested to optimize solvent properties with regard to skin irritation, toxicity, solubility, corrosion properties as well as solvent mixture stability. 	21. GENERAL USE				ASSOCI	ATE INVES	TIGATOR	\$			
 (U) biochemistry; (U) lipids; (U) fatty acids; (U) glycerides; (U) tropical acne; (U) soldiers (U) biochemistry; (U) lipids; (U) fatty acids; (U) glycerides; (U) tropical acne; (U) soldiers (U) 72 07 - 72 06 We have developed a second generation high pressure liquid chromato separation of complex skin lipids. Concurrent with this work, many solvent systems tested to optimize solvent properties with regard to skin irritation, toxicity, solubility, corrosion properties as well as solvent mixture stability. 					NAM	 L:					
 (U) blochemistry; (U) lipids; (U) fatty acids; (U) glycerides; (U) tropical acne; (U) soldiers 78 TECHNICAL OBJECTIVE.* 24 APPROACH. 24 PROGRESS (Partial Individual programs idmitted by mater. Protect test of orth vio security classification core separation of complex skin lipids. Concurrent with this work, many solvent systems v tested to optimize solvent properties with regard to skin irritation, toxicity, solubility, corrosion properties as well as solvent mixture stability. 	IT. KEY BORDS (Friesde	BACH with Security Class	llicellan Cade)								
25. (U) 72 07 – 72 06 We have developed a second generation high pressure liquid chromato separation of complex skin lipids. Concurrent with this work, many solvent systems v tested to optimize solvent properties with regard to skin irritation, toxicity, solubility, corrosion properties as well as solvent mixture stability.		ocnemistry; (U)	lipids; (U) fat	ty acids; (U)	glyceri	des; (U) trop	ical acne	; (U) solo	liers	
	25. (U) 72 07 – 72 06 separation of c tested to optim corrosion proj	5 We have dev complex skin nize solvent pr perties as well	veloped a sec lipids. Conc roperties wit as solvent m	ond gei urrent h regard hixture	neratior with thi I to skin stability	n high is woı n irrit y.	pressure k, many ation, to	e liquid cl solvent s xicity, so	hromat systems plubility	0) \ \ /,

A Share was and

in the second second

<u> ALLESSER</u>

20020000

والمعادية المتحد والاستالية والمتكافية فالمراد والمحاصي

Composition of Lipids

Peter Schmid, Ph.D.

PROBLEM:

Tropical acne and severe acne conglobata were leading causes of evacuation for skin disease (varying between 20-30%) of U.S. soldiers from the Republic of Vietnam. New LAIR statistics indicate quite clearly (Army and Navy data) that acne outpatient visits are consistently above 10% of total visits and are thereby the most time consuming and costly item in military dermatology.

The role of lipid metabolism of sebaceous gland cells during the various stages of differentiation is largely unknown and very little modern data is available which does or does not suggest changes in lipid composition and lipid metabolism in acne. In FULLY WARTER COMPACTION

If progress in understanding the normal function of this lipid secreting organ is to be made, new techniques for analyzing microquantities of lipid components of human sebaceous glands must be developed.

APPROACH:

Thirty samples of 18 hospitalized patients with tropical acne have been collected and are analyzed at present by conventional analytical methods by an Army contractor.

New and more effective treatment methods for acne vulgaris and tropical acne depend on progress in understanding the regulation of the metabolism of sebaceous glands. To understand lipid metabolism of sebaceous glands requires knowledge of the composition of sebaceous lipids. Analysis of surface lipids, pooled from many people or from individuals, have been performed. However, it is essential to analyze the contents of a small number of individual sebaceous glands and comedones. This in turn requires handling, separating, and quantitating very small amounts of exceedingly complicated lipid mixtures into its myriad components.

RESULTS IND DISCUSSION:

Quantitative removal of very small amounts of lipid from the skin and subsequent meaningful analysis

required an exceptional amount of work on new solvents in FY 72. For optimization of collection and analysis of lipids, skin irritation, toxicity, solubility properties of lipid components, corrosion problems with "inert" stainless steel, stability of solvents as well as reactions of solvents with lipid components had to be studied.

Our lipid solubility studies indicated that methods currently in use for removal of non-lipid matter from lipid extracts are totally inadequate. For this reason, we have developed, tested and integrated a system to collect, purify and separate small quantities of lipids quantitatively from skin.

In continuation of work begun in FY 71, a comparison of several solvent mixtures to extract lipids from the skin surface of human volunteers was performed. We now have the basic knowledge to formulate effective solvent systems which show little skin irritation. Our results confirm our previous suggestion that most skin lipid analysis in acne patients were performed with inadequate lipid extracts.

FUTURE PLANS:

The acne and tropical acne project is discontinued at the end of FY 72, however, several publications will be prepared in FY 73. and the second states and the second states and

REJEARUN	AND TECHNOLOG	Y WORK UNIT	SUMMARY	1. AGENC	ACCEMION	1 DATE 0		a yê	DD DI	CONTHOL SYM
BATE PALY SUCRY	L KIND OF SUMMARY	L SUMMARY SCTY	. WORK SECURITY	7. ALGRAI	DING* P*	DISB'N INST		SPECIFIC	DATA-	. LEVEL OF
71 07 01	D.Change	U	<u> </u>	N	<u>A</u>	NL	X	YES	. NO	A WORK U
NO./CODES:"	PROGRAM ELEMENT	PROJEC	TNUMBER	TASK A	NEA NUMBER	·	······································	RORK UNI	TNUMBER	<u> </u>
POMARY	62110A	<u>3A06211</u>	0A822		00			57,		
CONTRIEUTING						-				
ITLE (Procode with	Locurity Closed Heatlan Cod	<u></u>								
(U) Evaluatio	n of Promising /	Antifungal Ag	gents in Soldie	ers in a (Combat	Zone	(05)			
SCIENTIFIC AND TE	CHHOLOGICAL AREAS									
003500 – Cli	nical Medicine									Exc. 0
START DATE		14. ESTIMATED CO	WPLETION DATE	IL UND	ING AGENCY		"			
0010		CONT		DA				<u> </u>	<u>house</u>	N D5 /20 Should
	NA			H. RESC	PRECEDINE	ATE APA	OPESSION			
				PISCAL	72		1			0
TYPE.	• *	4 AMOUNT:		YEAR	CUNNERT					
		f.CUM. AM	т.		73		1			7
RESPONSIBLE DOD	ORGANIZATION	1		20. PERF	ORMING ORG	NIZATION				
we:" Lette	rman Army Inst	itute of Rese	arch	HAME:*	Lette	erman A	rmv I	nstitute	e of Ro	search
Presid	lio of San Franc	isco. CA 941	29		Dern	natology	Rese	arch D	ivision	
DRE 15:8				ADDRES	Presi	dio of S	an Fra	ncisco	. CA 9	4129
									ale inalifuit	
				HANE		e H F		40		
		~		TELE	JUIIC	s, m.e., 561-548	5			
1AMC: / 10/010	561-518 1	0			115					
415-3				50CIAI	L SECURITY A	CCOUNT NU	****			
TELEPHONE: 413-3			<u> </u>	ASSOCIA	L SECURITY A	CCOUNT NU	****			
TELEPHONE:413-3				4350CIA NAME:	L SECURITY A	CCOUNT NU	* #C A:			F
TELEPHONE: 410-3 1. general use					L SECURITY A	ATORS	40CR:			E
TELEPHONE: 413-3	BACH of Sourthy Class	Ificetion Code)	1) Amos: (II)	ASSOCIA NAME: NAME:	L SECURITY A		(11) ns		(U) di	E (U) s
REVERAL USE	ogy; (U) derma	income codo) tophy tosis; (l	U) drugs; (U)	therapy	; (U) my	cology;	(U) pa	ntients;	(U) di	E (U) s agnoses;
ELEPHONE: 413-3	o BACH with Security Class logy; (U) dermat	Incellion Code) LOPhytosis; (26. PROGRESS (Pumi	U) drugs; (U)	ABOCIA NAME: NAME: therapy	; (U) my	COLOGY ;	(U) pa	ntients;	(U) di	E (U) s agnoses;
RELEPHONE: 413-3	ogy; (U) dermat	Income codo) tophytosis; (1	U) drugs; (U)	therapy	; (U) my	COLOGY ;	(U) pa	ntients;	(U) di	E (U) s agnoses;
тесерноне: 415-3 . венеяац изе (U) dermatol 3 тесинисац овјес 25. (U) 71 0	ogy; (U) dermat tive." 14 Approach.	Interior code) tophytosis; (1 16 PROGRESS (Furnit tening deman	U) drugs; (U)	therapy	; (U) my	cology;	(U) pa	the con	(U) di	(U) s agnoses; , one. Da 95th Fy
TELEPHONE: 415-3 DENEMAL USE (U) dermatol TECHNICAL OBJEC 25. (U) 71 0 on in Hosn	Dack of Second Class Dogy; (U) dermat TIVE. ⁹ 14 APPROACH. 177 – 72 06 Less scidence on skin sital RVN and	Theorem code) tophytosis; (1 as process (power ening deman diseases in 2 William Beau	U) drugs; (U) th instructure peragraphi ds resulted in 0-30 year old mont General	therapy no field active d	; (U) my , (U) my , number. proc l studies luty sold al. El Pas	cology; cology; conduct iers was	(U) pa (U) pa h win av ed in obtain s. The	the conned fro	(U) di	[(U) s agnoses; , one. Da 95th Ev. fungal
CALEPHONE: 415-3 ORMERAL USE (U) dermatol TECHNICAL OBJEC 25. (U) 71 C on in Hosp infec	TIVE. ⁹ 14 APPROACH. 07 – 72 06 Less 16 dence on skin 16 dence	tophytosis; (I tophytosis; (I tening deman diseases in 2 William Beau in both RVN	U) drugs; (U) ds resulted in 0-30 year old mont General and El Paso.	no field active d Hospit:	; (U) my ; (U) my ; number. gree l studies luty sold al, El Pas ed for ep	cology; cology; conduct iers was io, Texa:	(U) pa ed in obtain s. The ogical	the conned fro e incide data to	(U) di mbat zo m the ence of o predic	(U) s agnoses; one. Da 95th Ev. fungal ct epider
25. (U) 71 0 of the second states (U) dermatol 7 TECHNICAL OBJEC 0 n in Hosp infec of sk	ogy; (U) derma ogy; (U) derma Tive. [•] 14 APPROACH. Trive. [•] 14 APPROACH. Trive. [•] 14 APPROACH. Trive. [•] 14 APPROACH. To a constant of the	tophytosis; (I tophytosis; (I tening deman diseases in 2 William Beau in both RVN phasized.	U) drugs; (U) th individual paragraphs ds resulted in 0-30 year old mont General and El Paso.	no field active d Hospit	; (U) my ; (U) my ; latudies luty sold al, El Pas ed for ep	cology; cology; conduct iers was io, Texa: idemiol	(U) pa ed in obtain s. The ogical	the conned fro e incide data to	(U) di mont zo m the ence of o predic	(U) s agnoses; one. Da 95th Eva fungal ct epider
25. (U) 71 0 On in Hosp infections (Proceeding)	Dogy; (U) dermai Tive. ⁹ 24 APPROACH. 107 – 72 06 Less icidence on skin bital, RVN, and vitions was third i in sidease is emp	tophytosis; (tophytosis; (tening deman diseases in 2 William Beau in both RVN phasized.	U) drugs; (U) th individual paragraphic ds resulted in 0-30 year old mont General and El Paso.	no field active d Hospit:	; (U) my ; (U) my numer. cross luty sold al, El Pas ed for ep	cology; cology; conduct iers was idemioli	(U) pa ed in obtain s. The ogical	the conned fro e incide data to	(U) di	E (U) s agnoses; , one. Da 95th Ev; fungal ct epider
CELEPHONE 415-3 ORMERAL USE (U) dermatol TECHNICAL OBJEC 25. (U) 71 C on in Hosp infec of sk	TIVE. ⁹ 14 APPROACH. 07 – 72 06 Less 10 dermation 10 d	tophytosis; (I tophytosis; (I the process (point diseases in 2 William Beau in both RVN phasized.	U) drugs; (U) th instructor program ds resulted in 0-30 year old mont General and El Paso.	no field active d Hospit	; (U) my ; (U) my numer. pro- l studies luty sold al, El Pas ed for ep	cology; cology; conduct iers was io, Texa: idemiol	(U) pa ed in obtain s. The ogical	the conned fro e incide data to	(U) di most zo m the ence of p predic	E agnoses; one. Da 95th Eva fungal ct epider
25. (U) 71 0 of hermical objection of the second states of sk	7 – 72 06 Less cidence on skin tital, RVN, and tions was third i in sidease is emp	Antenion code) tophytosis; (1 tening deman diseases in 2 William Beau in both RVN phasized.	U) drugs; (U) th individual paragraphs ds resulted in 0-30 year old mont General and El Paso.	no field active d Hospit	; (U) my ; (U) my ; number proc l studies luty sold al, El Pas ed for ep	cology; cology; conduct iers was io, Texa: idemiol	(U) pa ed in obtain s. The ogical	the conned fro e incide data to	(U) di mont zo m the ence of predic	[(U) s agnoses; one. Da 95th Eva fungal ct epider
EVERAL USE (U) dermatol TECHNICAL OBJEC 25. (U) 71 C on in Hosp infec of sk	ogy; (U) dermation ogy; (U) dermation (U) de	theorem code) tophytosis; (I sening deman diseases in 2 William Beau in both RVN phasized.	U) drugs; (U) an individual paragraphic ds resulted in 0-30 year old mont General and El Paso.	no field active d Hospit:	; (U) my ; (U) my number: prot l studies luty sold al, El Pas ed for ep	cology; cology; conduct iers was idemioli	(U) pa ed in obtain s. The ogical	the conned fro data to	(U) di	I agnoses: , one. Da 95th Ev. fungal ct epider
CLEPHONE: 415-3 ORNERAL USE (U) dermatol TECHNICAL OBJEC 25. (U) 71 C on in Hosp infec of sk	TIVE. ⁹ 14 APPROACH. 07 – 72 06 Less 10 cidence on skin 11 cidence on skin 11 cidens was third i 11 sidease is emp	tophytosis; (tophytosis; (the process (point diseases in 2 William Beau in both RVN phasized.	U) drugs; (U) th individual paragraphi ds resulted in 0-30 year old mont General and El Paso.	no field active d Hospit	; (U) my ; (U) my numer. proc laty sold al, El Pas ed for ep	cology; cology; conduct iers was idemiol	(U) pa ed in obtain s. The ogical	the conned fro e incide data to	(U) di model 20 m the ence of predic	I agnoses one. Da 95th Ev fungal ct epide
CELEPHONE: 415-3 ORNERAL USE (U) dermatol TECHNICAL OBJEC 25. (U) 71 C on in Hosp infec of sk	7 – 72 06 Less cidence on skin bital, RVN, and v tions was third in sidease is emp	Antenion code) tophytosis; (1 tening deman diseases in 2 William Beau in both RVN phasized.	U) drugs; (U) an individual paragraphic ds resulted in 0-30 year old mont General and El Paso.	no field active d Hospit:	; (U) my ; (U) my ; number. proc l studies luty sold al, El Pas ed for ep	cology; cology; conduct iers was io, Texa: idemiol	(U) pa ed in obtain s. The ogical	the conned fro e incide data to	(U) di mont zo m the ence of predic	I agnoses one. Da 95th Ev fungal ct epide
REVUONDS (Presed (U) dermatol TECHNICAL OBJEC 25. (U) 71 C on in Hosp infec of sk	ogy; (U) dermation ogy; (U) dermation (U) de	Aleanian codo) tophytosis; (I tening deman diseases in 2 William Beau in both RVN phasized.	U) drugs; (U) an individual paragraphi ds resulted in 0-30 year old mont General and El Paso.	no field active d Hospiti	; (U) my ; (U) my ; studies luty sold al, El Pas ed for ep	cology; cology; conduct iers was idemioli	(U) pa ed in obtain s. The ogical	the conned fro e incide data to	(U) di	I agnoses , one. Da 95th Ev fungal ct epide
RELEPHONE: 415-3 BENERAL USE (U) dermatol TECHNICAL OBJEC 25. (U) 71 C On in Hosp infec of sk	Digy; (U) dermai Tive. ⁹ 24 APPROACH. 107 – 72 06 Less in side on skin in side ase is emp	tophytosis; (tophytosis; (the process (point diseases in 2 William Beau in both RVN phasized.	U) drugs; (U) th individual paragraph ds resulted in 0-30 year old mont General and El Paso.	no field active d Hospit	; (U) my ; (U) my number proc laty sold al, El Pas ed for ep	cology; cology; conduct iers was idemiol	(U) pa ed in obtain s. The ogical	the conned fro e incide data to	(U) di	I agnoses one. Da 95th Ev fungal ct epide
CELEPHONE: 415-3 ORNERAL USE (U) dermatol TECHNICAL OBJEC 25. (U) 71 C on in Hosp infec of sk	7 – 72 06 Less cidence on skin tital, RVN, and v tions was third in sidease is emp	Thesium code) tophytosis; (I tening deman diseases in 2 William Beau in both RVN phasized.	U) drugs; (U) th instruction program ds resulted in 0-30 year old mont General and El Paso.	no field active d Hospit	; (U) my ; (U) my numer. pro-	cology; cology; conduct iers was idemiol	(U) pa ed in obtain s. The ogical	the conned fro e incide data to	(U) di mont zo m the ence of predic	[(U) s agnoses one. Da 95th Ev fungal ct epide
CELEPHONE: 415-3 ORMERAL USE (U) dermatol TECHNICAL OBJEC 25. (U) 71 C on in Hosp infec of sk	7 – 72 06 Less cidence on skin bital, RVN, and v tions was third i in sidease is emp	Antenian code) tophytosis; (1 te paganess (pan) tening deman diseases in 2 William Beau in both RVN phasized.	U) drugs; (U) an individual paragraphi ds resulted in 0-30 year old mont General and El Paso.	no field active d Hospit:	; (U) my ; (U) my neter from l studies luty sold al, El Pas ed for ep	cology; cology; conduct iers was io, Texa: idemiol	(U) pa ed in obtain s. The ogical	the conned fro e incide data to	(U) di	I agnoses: one. Da 95th Ev fungal ct epide:
TELEPHONE 415-3 . GENERAL USE (U) dermatol TECHNICAL OBJEC 25. (U) 71 C on in Hosp infec of sk	7 – 72 06 Less decidence on skin vital, RVN, and v tions was third i in sidease is emp	tophytosis; (tophytosis; (tening deman diseases in 2 William Beau in both RVN ohasized.	U) drugs; (U) th individual paragraphic ds resulted in 0-30 year old mont General and El Paso.	no field Attornet	; (U) my ; (U) my numer. cross luty sold al, El Pas ed for ep	cology; cology; conduct iers was idemiol	(U) pa ed in obtain s. The ogical	the conned fro e incide data to	(U) di	I agnoses: , one. Da 95th Ev fungal ct epide
TELEPHONE 415-3 . GENERAL USE (U) dermatol . TECHNICAL OBJEC 25. (U) 71 C on in Hosp infec of sk	TIVE. ⁹ 24 APPROACH. (Ogy; (U) dermation (U) der	Theorem code) tophytosis; (1 the proceeding deman diseases in 2 William Beau in both RVN phasized.	U) drugs; (U) an instructure peragraphi ds resulted in 0-30 year old mont General and El Paso.	no field active d Hospit	; (U) my ; (U) my number proc l studies luty sold al, El Pas ed for ep	cology; cology; conduct iers was idemiol	(U) pa ed in obtain s. The ogical	the conned fro e incide data to	(U) di	I agnoses one. Da 95th Ev fungal ct epide
TELEPHONE 415-3 . GENERAL USE (U) dermatol 3 TECHNICAL OBJEC 25. (U) 71 C on in Hosp infec of sk	7 – 72 06 Less cidence on skin bital, RVN, and v tions was third i in sidease is emp	Antonia code) tophytosis; (1 tening deman diseases in 2 William Beau in both RVN phasized.	U) drugs; (U) th instructed program ds resulted in 0-30 year old mont General and El Paso.	no field active d Hospit	; (U) my ; (U) my ; tudies luty sold al, El Pas ed for ep	cology; cology; conduct iers was idemiol	(U) pa ed in obtain s. The ogical	the conned fro e incide data to	(U) di mont zo m the ence of predic	I agnoses
TELEPHONE 415-3 . GENERAL USE (U) dermatol TECHNICAL OBJEC 25. (U) 71 C on in Hosp infec of sk	7 – 72 06 Less cidence on skin bital, RVN, and v tions was third i in sidease is emp	Antenian code) tophytosis; (1 te paganess (pan) diseases in 2 William Beau in both RVN phasized.	U) drugs; (U) an individual paragraph ds resulted in 0-30 year old mont General and El Paso.	no field active d Hospit: The net	; (U) my ; (U) my ; studies luty sold al, El Pas ed for ep	cology; cology; conduct iers was idemioli	(U) pa ed in obtain s. The ogical	the conned fro e incide data to	(U) di	I agnoses
VELEPHONE: 415-3 OUNDES (Proceed (U) dermatol VECUNICAL OBJEC 25. (U) 71 C on in Hosp infec of sk	7 – 72 06 Less icidence on skin ital, RVN, and v tions was third i in sidease is emp	tophytosis; (tophytosis; (the process (point diseases in 2 William Beau in both RVN phasized.	U) drugs; (U) th individual paragraphic ds resulted in 0-30 year old mont General and El Paso.	no field active d Hospit	; (U) my ; (U) my numer. proc d studies luty sold al, El Pas ed for ep	cology; cology; conduct iers was idemioli	(U) pa ed in obtain s. The ogical	the conned fro e incide data to	(U) di	I agnoses one. Da 95th Ev fungal ct epide
ELEPHONE 415-3 ORMERAL USE (U) dermatol TECHNICAL OBJEC 25. (U) 71 C on in Hosp infec of sk	TIVE. ⁹ 24 APPROACH. (0)7 – 72 06 Less icidence on skin bital, RVN, and vitions was third i in sidease is emp	tophytosis; (I tophytosis; (I tening deman diseases in 2 William Beau in both RVN phasized.	U) drugs; (U) th individual paragraphic ds resulted in 0-30 year old mont General and El Paso.	no field active d Hospit	; (U) my ; (U) my number proc laty sold al, El Pas ed for ep	cology; cology; conduct iers was idemiol	(U) pa ed in obtain s. The ogical	the conned fro e incide data to	(U) di	l agnoses one. Da 95th Ev fungal ct epide

00 1408

Evaluation of Promising Antifungal Agents in Soldiers in a Combat Zone

Dermatology Outpatient Data System

LTC H. Earl Jones, MC

Biographical and clinical data are collected on each patient seen in certain Army dermatology outpatient clinics. The individual data cards are coded, key punched, sorted, and then analyzed by computer to determine the incidence of each disease seen. Using available climatological information from the Environmental Control Center and the biographical information from the data cards, the incidence of disease can be correlated with the age, sex and race of the surveyed population and the environment. The effect of the individual's occupation and factors pertinent to the local elevation and terrain can also be analyzed.

RESULTS AND DISCUSSION:

An 18 month study has been completed from William Beaumont General Hospital (WBGH) in El Paso and the 95th Evacuation Hospital in DaNang, Vietnam. The incidence of skin disease in both dermatology clinics is listed in decreasing order in Table 1. Dependent women, children, and elderly retired individuals seen at WBCH are being compared to a young, healthy male population in Vietnam. Thus, the incidence of skin disease cannot justly be compared and this is reflected in the high indicence of disease prevalent in dependents and the elderly at WBCH and the reverse in Vietnam. Utilizing the computer, 20-30 year old, active duty males can easily be compared; and by so doing, differences in disease incidence can be attributed to factors peculiar to each locality. Table 2 lists such a comparison and demonstrates that the diseases frequently seen in the total WBGH population attributable to dependents and retired patients are thus eliminated. Certain diseases are apparently more common in the tropics than the arid El Paso area and vice versa. Some diseases seen in RVN can be attributed to the war-time situation in RVN.

WBGH is located in a desert with a persistent low humidity (20-30%) and temperatures fluctuating from 30° to 100° F while the 95th swelters in the tropics with the humidity rarely falling below 80% and reaching 99% almost daily. From the climatological data and the specific age-sex disease incidence, certain conclusions can be reached.

Humidity seems to greatly favor the development of infectious diseases of the skin, i.e., both fungal and bacterial. This hypothesis is supported by the incidence studies observed in this study. Comparing the incidence of fungal infection by type and anatomic area involved in the opposite climatic types, no increased incidence of tinea pedis is observed in the humid tropics. This may be explained by the fact soldiers wear boots and socks which always provide a local, very high relative humidity for the feet irrespective whether the man is in the desert or the crc ns. The ambient relative humidity that "bathes" the glabrous skin in the tropics converts the skin into a fertile garden for fungal growth. Ringworm of the glabrous skir increased 11-fold as noted from analyzing this data reflecting the change in moisture content of the glabrous skin.

Miliaria is seen at the 95th during the hot, humid summer but never in Fl Paso, where the temperature is as great, if not greater, than in DaNang. The low relative humidity in El Paso does not permit hydration of the stratum corneum and resultant plugging of the sweat pores because of rapid evaporation of surface water that arises from either transepidermal loss or sweat thus no miliaria occurs in the desert climate. That such an environment affects the hydration dynamics of the stratum corneum seems confirmed by the reverse dry air situation present in El Paso. Dry skin A CONTRACTOR OF A LONG NOT A CONTRACT AND A CONTRACT AND A CONTRACT AND A CONTRACT OF A CONTRACT AND A CONTRACT

dermatoses are frequent in El Paso but never seen in the tropics of DaNang (see Table 3). The incidence of miliaria in DaNang and dry skin dermatosis in El Paso are cyclic and both diseases can be related to the opposite relative humidity and/or temperature changes.

Certain other diseases may be more frequent in Vietnam (see Table 4), such as vitiligo, alopecia areata and urticaria, and it is generally believed that these disorders relate in some way to anxiety or other emotions. This may relate to the wartime stress on the soldiers. Warts, atopic dermatitis, psoriasis, seborrheic dermatitis and numerous other disorders do not show any different incidence (see Table 2). Acne vulgaris does not show any great difference in incidence, but the tropical-type cystic acne of the trunk and extremities was seen much more frequently at the 95th.

This data is also being analyzed for the effect of occupation (MOS) on the incidence of skin disease but the results are not available at this time.

FUTURE PLANS:

1. The data obtained from the WBCH and the 95th Evac study will be completely analyzed.

2. A similar data collection system will be used to determine the incidence of skin disease at 4 large Army dermatology clinics (WRAMC, BAMC, FAMC, LGH). This trial study will operate for 2 years and will accomplish 3 goals presently beyond the scope of any Army data system:

a. Both biographical and linical data on the incidence of skin disease in veral large military clinics will be available for the first time. A disease outbreak and/or epidemics at an early stage can possibly be detected by monitoring this system.

79

さんちょうい ちょうちょうちょう ひろう

É.

b. Numerous valuable research studies will be conducted on the accumulated data.

c. A review of a physician's progress will be provided to his chief of service.

nen provinsi kana dahara da manana mana dahara da baran kanana kanana kanana kanana da kanana kanana kanana kan

Since the 4 hospitals are situated in widely different climatic types we should be able to analyze the age, sex, occupation specific incidence of any skin diseases and determine the effect different ambient temperature and humidity combinations may have on the frequency of skin disease.

From this unique experience we shall be able to construct a predictive temperaturehumidity graph from which the risk of developing various skin diseases can be predicted. This should be of great interest to the Army and other American military components.

TABLE 1

DISEASES CODED ALL CLINIC VISITS

WBGH, El Paso, Texas Jan 1970 – Jun 1971

95th EVAC, Da Nang RVN May 1970 - July 1971

ないに、何ちまであってかい

いなかりないればなどののであったかったかっ

Ň

ために、「たいい」という

というというよう

いたいためたいかたいました

N. H

TOTAL	9.819		9	
DISEASES	NO. % TOTAL	DISEASES	1,605 <u>NO</u> .	%TOTAL
 Warts, all Acne, all Actinic keratosis Nevi Dermatophytosis, all Contact derm Atopic derm Basal cell carcinoma Psoriasis Dry skin Dyshidrosis Seborrheic derm Seborrheic keratosis Hurticaria Misc. dermatosis & dermatides Pityriasis rosea Sebaceous cyst Skin tags Psecatodiculitis barbae Lichen simplex chronicus Alopecia areata Hyoderma, all Tinea versicolor 	1896 19.03 1082 11.02 505 5.14 442 4.50 371 3.78 360 3.67 288 2.93 274 2.79 258 2.63 234 2.38 222 2.26 202 2.06 174 1.77 162 1.65 154 1.57 139 1.42 115 1.17 114 1.16 110 1.12 108 1.10 104 1.06 93 0.76 75 0.76 75 0.76 75 0.76 75 0.76	 Warts, all Acne, all Dermatophytosis, all Fseudofolliculitis barbae Penile ulcer (? chancroid) Miliaria Pyodermia, all Contact derm Urticaria T. versicolor Psoriasis Atopic derm Dyshidrosis Alopecia areata Monilia Herpes - progenitalis Seborrheic derm Misc. dermatosis & dermatides Insect bites Molioscum contagiosum Sebaceous cyst Lichen planus Pityriasis roszcea Hand & foot eczema 	729 466 371 289 221 199 178 167 126 123 106 95 95 82 71 68 56 51 48 41 40 40 39 37	15.83 10.19 8.06 6.28 4.79 4.32 3.86 3.63 2.74 2.67 2.30 2.06 2.06 1.78 1.54 1.48 1.22 1.11 1.04 0.89 0.87 0.87 0.85 0.85
			10	AL 81.24

81

ويصدقوه جاي الأرام المراجع

いいま しつう

š

4

;

- Jahr Statistics No.

en etainin tenihiten etaineataininten etainin Silabaren ruuten eta hititta

1000

 $\Delta \gamma_{\rm c}$

Q-700-74-5

							82		
	ТА	ABLE 2							
DISEASES C	ODED 20-3	0 YEAR OL	D A	CTIVE DUTY MALES					
WBGH, El Paso, Texas				95th EVAC, Da N	Nang R	VN			
TOTAL 1,752	NO	. TOTAL		TOTAL 3,01	15 NO	% TOTAL		•	
arts, all	335	22.37	1	Warts, all	560	18.57			
icne, all	150	8.56	2	Acne, all	317	10.50			
ermatophytosis, all-	103	5.88	3	Dermatophytosis, all	243	8.06		•	
ouoromeustis paroze	85 61	4.85 3.48	4	Penile ulcer, chancroid	145	1.95 4.83			
ševi, all	60	3.42	6	Miliaria	141	4.68			
Contact derm	52	2.97	7	Pyoderma, all	122	4.05			
eporrheic dermatitis Inticaria	40	2.28	8	Contact derm	105 Q4	3.48 3.12			
Dyshidrosis	37	2.17	10	Tinea versicolor	89	2.95			
soriasis	36	2.05	11	Alopecia areata	63	2.09			
iebaceous cyst	36	2.05	12	Psoriasis	62	2.06			
luica versicolor Irv skin, xerosis	33	1.88	13	Atopic derm	60 60	1.99			
lityriasis rosea	31	1.77	15	Monila	• 46	1.53			
lise, dermatosis & dermatides	31	1.77	16	Seborrheic derm	38	1.26			
Herpes - progenitalis	29	1.66	17	Herpes - progenitalis	37	1.23			
Lichen simplex chronicus	26	1.48	18	Molloscum contagiosum	32 29	0.96			
yoderma, all	20	1.14	20	Sebaceous cyst	29	0.96			
Holloscum contagiosum	20	1.14	21	Hand & foot eczema	25	0.83			
Skin tags	14	0.80	22	Misc.dermatosis & dermat	ides 25	0.83			
Alopecia areata	14	0.80	2:	Erythema multiforme	29	0.66			
Bala nitis	13	0.71	2	5 Vitiligo	20	0.66			
Erythema multiforme	9	0.51	20	5 Balanitis	19	0.63			
Pediculosis pubis	8	0.46	27	Lichen planus	18	0.60			
Leug cruptions Lyphograpuloma U.	7	0.39	21	Drug eruptions	18	0.49			
Lichen planus	, , , , , , , , , , , , , , , , , , , ,	0.39	3() Keloids	14	0.47			
Ulcer, other	6,	0.34	31	Lichen planus	13	0.43		-	
Basal cell carcinoma	6	0.34	32	Corn & callouses	13	0.43			
Granuloma annulate	•	0.34	3	Nummular eczema	- 11 10	0.30			
Nammular eczeina	5	0.28	3	5 Syphilis, infection	8	0.27		•	
Dermatolibroma	5	0.28	3	5 Syphilis, late	8	0.27			
Envilis Notocensitive deem -11	5	0.28	3	7 Lymphogranuloma U.	7	0.23			
Insect bites	3	0.17	3	9 Privitis	5	0.14			
Corns & callouses	2	0.17	4) Striae	4	0.12			
Milipria Manila start (Calendaria)	2	0.12	4	Polymorphic light euption	4	0.12			
renue ucer, (r chancroid) Vicilizo	1	0.06	- 4) - 4	2 Unychomycosis 3 Photocontact derm.	3 2	0.05			
	i	0.06	4	No diagnosis	-	1.29			
	-								
	TOTAL	81.40				94.89			į

abeta ve watte and a state of the state of t

	Incidence per 10	00 clinic visits	Vietnam as
	WAGH	95th Evac	% of WBGH
Dermatophytosis, all	5.88	8.06	137%
T. pedis	3.88	2.82	73%
T. cruris	1.08	1.56	144%
T. corporis	0.24	2.65	1105%
Other tines	0.68	1.03	152%
Pyoderma, all	1.14	4.05	356%
Impetigo	0.24	1.39	580%
Ecthyma	0.74	0.63	263%
Furuncles	0.5.	1.76	309%
Cellulitis	0.12 (2 cases)	0.27	225%
Miliaria, all	0.12 (2 cases)	4.68	3900%
Dry Skin Dermatosis	1.83	0	absolute

Table 3. Effect of Climate and/or Elevation on Incidence of Disease in 20-30 year/old Males

WHEN AND AN ALMAN AND AND AND A STREET OF

Table 4. Effect of Climate and/or Elevation on Skin Disease in 20-30 year/old Active Duty Males

and states and an and a second states of the states of the second states

	Incidence per	100 clinic visits	Vietnam as
	WBGH	95th Evac	% of WBGH
	•		
Pseudofolliculitis Barbae	4.85	7.93	164%
Contact Dermatitis	2.97	3.48	117%
Atopic Dermatitis	1.14	1.99	175%
Tinea Versicolor	1.88	2.95	157%
Urticaria	2.17	3.14	145%
Alopecia Areata	0.80	2.09	262%
Vitiligo	0.05 (1 case)	0.63 (20 cases)	1260

A CONTRACTOR OF A DOLLAR CONTRACTOR OF A DOLLAR OF A

ないないとないというないというないないないないである

RESEARCH AND TEC	HNOLOGY	WORK UNIT	SUMMARY	i agen Dá		uica*)13	72 07 0	HWART [®]	RSPORT DD-D	CONTROL SYNBOL R&E/ARJ636
1. BATE PREV SUWAY & KIND OF SU 71 07 01 D.Chan	NWARY LEC	S SUMMARY SCTY	A. WORK SECURITY	P. REGR	A	PA DI	NL	BE SPECIFIC CONTRACTOR	DATA+ ACCESS	S LEVEL OF SUM
10. NO./CODES ^{.0} PROGRAM E	LEMENT	PROJEC	TNUMBER	TASK A	REA NU	UBER		WORK UNI	T NUMBER	
· PRIMARY 62110A		3A06211	0A822		00		10	58	********	
I. CONTRIBUTING								· .		
e. CONTRIBUTING		•		i						
(U) The Effects of Pro	tonged	Water Exno	sure on Huma	. Skin	(05					
18 SCIENTIFIC AND TECHNOLOGICAL 003500 - Clinical Medi	AREAS*	<u>, 11161 2200</u> 2	sure (or frumu	<u>I Skiii</u>						
11. START DATE		14 ESTIMATED CO	NPLETION DATE	IS FUNC	HIG AGE	ICY		16. PERPOR	ANCE WET	нов
11 U4		1212		D.	Á		4	C. In-	house	
A DATES/EFFECTIVE. NA		EXPIRATION		16. RES	PARCES .	STINAT	L & P30FEM	HONAL MAN YA	5 5 50	HDS (In theusands)
h numren +				FISCAL	7	2		1	1	17
C TYPE.		4 ABOUNT:		YEAR	RUNNEN					
& KIND OF AVARD		f. CUM. AMT	r.		7	3		1		20
IT. RESPONSIOLE DOD DRGANIZATION	• [L		20. PER	FORMING	DRGANI	MOITA ION	L		
Letterman Arr ADDRESS.* Presidio of Sar	ny Insti n Franci	tute of Rese sco, CA 941	earch 29	NAME:*	r. D P	etter erma residi	man Army tology Re io of San I	y Institute search Di Francisco	e of Re vision , CA 9	esearch 4129
AELPONSIBLE INDIVIDUAL NAME. AKETS, W.A., C	COL MC	•		PRINCIP NAME: TELEP	AL INVES • W PHONE:	116ATO /illis, 415-	I., MAJ N 561-5485	11 U.S. Academi [C	t (nelikulia	ry
TELEPHONE, 413-301-3101		·····			TE INVES	TIGATO	NURT NUMBER:			
				NAME:						
				NAME:						DA
IL REVOORDS (Procede BACH +18 See	wily Classifi	(U)	warm water im	mersio	n foo	t; (U) paddy fe	oot; (U) l	uman	volunteers;
(U) SKIN; (U) SKIN DAN	12ge; (L	Pagaess (Pumin	nposition	initiad in	number, i	retede (est of each with	Security Cinesis	Latin Ced	• •
25. (U) 71 07 - 72 0 niodel is now	6 The e availabl	experimenta le for use in	l model utilizii evaluating the	ng the relativ	small 'e effe	cups ctive	has been (ness of po	perfected. tential pr	The ophyla	experimental otic agents.
PAnallable to contractore upon origi	nat_da opera	276)								

The Effects of Prolonged Water Exposure on Human Skin

Major Isaac Willis

PROBLEM:

Warm water immersion foot and its acute, severe variant "paddy foot" caused severe disability among troops fighting in the Meking Delta of Vietnam and previously in troops located in the Pacific Islands during World War II. Oddly, warm water immersion foot also occurs in artic areas among soldiers wearing waterproof foot-The severity and extent of morbidity in both gear. instances were found to be related to unavoidable prolonged water exposure under combat conditions. Field trials revealed that temporary restoration of the skin's integrity occurred when predisposed areas were daily removed from inundated conditions and allowed several hours to dry. However, a lack of knowledge as to underlying pathologic changes induced by water exposure not only limited attempts at specifically effective prophylactic and therapeutic methods, but also knowledge as to the exact extent of temporary or permanent skin damage in those so exposed.

APPROACH:

Design of a Method for Continuous Water Exposure. This was accomplished by using clear Plexiglass^R to make a cup of 5 ml capacity that covered a surface area of 3.97 cm². Each cup also contains an approximately 16-gauge flexible plastic tube connecting from its side for use in introducing and removal of water samples while the cup is affixed to the skin. This flexible tube may be bent upon itself or plugged to seal off the cup and its contents. The open end of the cup is first affixed to a 2 x 2-inch strip of pliable cellophane tape (Mystik TapeR) using plastic rubber (Duro-Plastic RubberR) allowing 24 hours for the rubber to " dry. After sterilizing the cup in ethylene oxide, the cellophane tape covering the open end of the cup is cut-away immediately prior to use. Two coating of aerosol Medical Adhesive BR are sprayed on the skin around the test site and 30 second later the test cup, affixed to its cellophane tape, is placed in position. ElastoplastR is used to cover and support the entire base and edges of the test site.

Method of Testing. Subjects: Thirty normal young adult volunteers were utilized. The legs and backs served as test sites. A maximum of either 3 sites on each leg or 10 sites on the back could be tested simultaneously.

Water Samples: These consisted of (1) sterile water for injection, USP, and (2) sterile buffer solutions of 0.1 M N-2 Hydroxyethylpiperaxine-N'-2 Ethanesulfonic Acid. (HEPES) at pH 3.5 and pH7.5.

Preparation of Subject and Application of Test Materials: A 14-day period in which the use of all antibacterial soaps and cosmetics was proscribed preceded application of test materials. Volunteers discontinued all bathing for 24 hours immediately prior to testing. Water cups that had been prepared and gas-sterilized with ethylene oxide, were then affixed to the skin. Using sterile 5 ml syringes, 4 ml water samples were divided via Swinnex 25 Millipore^R filters to the test cups, leaving a lml air space inside the cup to allow the water to move about. Water samples delivered in this manner were placed on culture media to detect any bacteria contamination that may have occurred despite careful handling of The tube used for delivery of water to each cample. cup was bent upon itself and secured in position using tiny winding strips of adhesive tape. Test sites were randomized and each sample was tested in duplicate. One of each duplicate sample was changed every 6 to 12 hours while others remained unchanged for the duration of the test period (72-144 hours).

Controls: These consisted of (1) an empty water test cup affixed and sealed as above and (2) a $3.97 \text{ cm}^2 \text{ Saran}^R$ wrap occluded site affixed at its edges in the same manner as the cup.

Methods of Evaluating Test Responses. Clinical: Preliminary observations for erythema were made at 12-hour intervals through the transparent plastic. Edema could not be adequately evaluated until the cups were removed. Final test responses recorded at 2 hours after removal of test materials were graded on a 5-point scale:

0 - no reaction

1+ - mild diffuse erythema or moderate spotty erythema 86

こうちょう いっかい くろう ひなかないない いちもつ へいちつ

- 2+ = moderately intense confluent erythema
- 3+ = moderately intense erythema plus. moderate edema
- 4+ = erythema, intense edema, and vesiculation

Histology: Biopsy specimens obtained from 72 and 144 hour test and control sites were formalin fixed and prepared by routine hematoxylin-eosin staining for light microscopic examination.

Bacterial: Baseline bacterial samples were obtained in 18 subjects from 4 different sites located between areas demarcated for water testing and controls. These were obtained immediately prior to application of the test and control materials. Samples from the test and con trol sites in 9 of these subjects were obtained at 72 hours and in the remaining 9 subjects at 144 hours. Water samples from the cups were also cultured at this time.

Samples were collected using a mechanical scraping technique (detailed later in this report) in which phosphate buffered saline, pH 7.9, containing 0.1% Triton X-100 served as the collecting medium. Total bacterial counts were calculated from diluted samples grown after 5 days of aerobic and anaerobic inculbation on Casman agar. MacConkey agar was used to isolate gram negative bacteria, and Baird-Parker agar to isolate staphylococci and micrococci.

Method of Assaying the Effects of Antibacterials on Test Responses. Ten subjects were utilized in this experiment. One of each duplicate test site received 0.1 ml of syringe-delivered Neosporin-G^R cream both at 12 hours and immediately preceding testing. The cream was spread evenly over each 3.97 cm² test site using sterile wooden applicator sticks.

In 10 other subjects, crystalline Chloromycetin OphthalmicR was added to one of each duplicate set of water samples to give a concentration of 0.5 mgm/ml.

Observations were recorded as in the previous studies.

Method of Demonstrating Changes in Eccrine Sweating. The numbers of freely functioning eccrine sweat units de de la seconda de la desta de la seconda de la second

per cm² were determined at water test, control, and adjacent normal untested skin sites in every subject. Within 15 minutes after removal of test materials, subjects were first placed in an environmental chamber at a temperature of 110° F and 50% relative humidity. Fifteen minutes later, functioning sweat units were "permanently" recorded using a silicone impression material (Kerr Syringe Elasticon). Repeated imprints were taken at 24 hour intervals for 3 days and then at weekly intervals for 2 weeks to detect any delayed change in the number of functioning sweat units.

RESULTS AND DISCUSSION:

新聞のためという世界があるのとなるのでは、「「

errene agagyaran darah Wilayan dara sa darah ta

Clinical Responses. Observations revealed that simple continuous exposure to water for 72-144 hours, without any additional potentially adverse environmental factors, induced striking inflammation in skin. The degree of inflammation seen at water test sites could not be correlated with the pH of test samples. The pH of the buffer solutions did not vary by more than 0.5 unit throughout testing, while that of water changed from a pH of 6.7 to a more acidic pH of about 5.0.

The degree of clinical inflammation due to water exposure was 2 to 3 times greater than that observed at hydrated Saran^R and empty cup control sites (Table 1). These control sites showed only mild to moderate maceration, and diffuse inflamed pin-point papules that became accentuated upon attempts to induce thermal sweating (typical of miliaria). In contrast. the water test sites showed moderate to marked maceration, confluent erythema and edema. Pyoderma was never observed at any of the test sites. Hairs were thickly coated with a yellowish waxy material at almost all water and pH 7.5 buffer exposed sites. The same type but a much lesser amount of material was seen on hairs of pH 3.5 buffer exposed sites.

Skin responses after changing water samples every 6 to 12 hours were just as intense as those induced at sites where water samples remained unchanged for 72 to 144 hours.

The induction of dermatitis was not influenced by location, i.e., leg versus back. However, the back

89

proved to be a more suitable test area because of more available testing space and less chance of trauma to the cups.

Histological Observations. Histologic studies of specimens from water-induced dermatitis revealed the following: (1) a swollen thickened horny layer, (2) moderate acanthosis, (3) moderate to marked edema of the upper dermis, (4) a mild to moderate increase in perivascular mononuclear cells throughout the dermis, and (5) scattered pigment and pigment-laden macrophages in the upper dermis. These findings were quite different from those seen in specimens from the Saran^R and empty cup control sites.

Observations of Deposits on Hairs: Microscopic examination of gram-stained smears of the yellowish waxy material seen on hairs in water and buffer test sites revealed only masses of predominantly gramnegative rod-shaped bacteria.

Observations of Antibacterial Treated Sites: Water exposed skin sites that were either pre-treated with Neosporin- G^R cream or treated with Chloromycetin^R during the test developed inflammation at the same time and to the same degree as untreated test sites.

Eccrine Sweat Function: The most striking and unexpected finding was in regard to sweat delivery. While both of the control, empty cup and Saran^R, test sites showed moderate to severe decrements in the number of freely functioning sweat units after only 72 hours of occlusion, not a single water test site showed a decrement after even 144 hours of exposure. In fact, most water test sites showed a slight increase in the number of freely functiong sweat units (Table 2).

Bacteriology: The total numbers of aerobic and anaerobic organisms cultured from water test sites and from the Saran^R covered and empty cup control sites were compared with the numbers of organisms cultured from adjacent normal skin areas prior to testing. Except for the pH 3.5 buffered water test site where the bacterial counts ranged from approximately the same to a slight decrease in number, all other test sites showed manifold qualitatively

、ちょうかんなどなどないないないないとうないないないない

similar increases in the numbers of both aerobic and anaerobic organisms. In general, the greatest increase in counts occurred at the sterile water test sites followed by counts from the pH 7.5 buffer sites, the empty cup controls and Saran^R covered sites. Although sterile water and pH 7.5 buffer showed the greatest increase in bacterial counts, the degree of inflammation at these sites were greater in only a few subjects than that seen at the lower pH 3.5 site where bacterial counts were much lower (Table 1). Except at all test and control sites in two subjects, Staphylococcus aureus organisms were not isolated on selective media. Although retrieved water samples grew out organisms in numbers of 1×10^1 to 1×10^7 per cc of sample, these were not consistently higher for one sample over another.

SUMMARY:

Continuous 72 to 144 hour exposure to water using the experimental model described in this study resulted in a clinical and histologically proven subacute dermatitis. This dermatitis differs notably from responses induced by conventional Saran^R wrap type hydrating methods in the following ways: (1) Its onset and severity were not found to be dependent upon increases in skin pH and bacterial population. (2) Although hydration and maceration of the horny layer were marked, evidence of neither post-hydration anhidrosis nor miliaria could be found.

Results of this study indicate the need for re-evaluating our concepts concerning the pathogenetic relationship of prolonged hydration to such clinical dermatoses as warm water immersion syndromes (paddy foot), dyshidrotic eczema, miliaria rubra, housewive's eczema, contact irritant dermatitis and infections seen in tropical climates and warm inundated terrains. It is proposed that water, itself, may induce an irritant dermatitis through its direct toxic effect on viable cells following sufficient hydration and maceration of the horny layer.

FUTURE PLANS:

Utilizing this experimentally induced dermatitis to serve as a model for water-induced dermatoses, this technique may now be used to evaluate and compare the

effectiveness of potential water protective agents for prophylactic use in predisposed individuals.

Table 1

121142

Test Responses to Hydration

Test Site	Reaction <u>Rate</u>	Reaction Intensity
Sterile Water	25/30	3+
	5/30	2+
Buffer (pH 3.5)	19/30	3+
-	11/30	2+
Buffer (pH 7.5)	6/30	4+
	20/30	3+
	4/40	2+
Empty Cup Occlusion	3/30	2+
	27/30	1+
Saran ^R Wrap Occlusic	on 6/30	2+
	24/30	1+

Table 2

Effects of Hydration on the Number of

Functioning Sweat	Units per cm ²
<u>Test Site</u>	Percent Change (Range)
H ₂ O for Inj., USP	+1 to +10%
Buffer at pH 3.5	+3 to +10%
Buffer at pH 7.5	-2 to +8%
Empty Cup	-30 ito -80%
Saran	-75 to -100%

and the

Bacterial Sampling Technique

Major Isaac Willis, MC

PROBLEM:

While practically every available technique for sampling the cutaneous bacterial flora will give satisfactory qualitative information, almost none of these have been proven reliable for quantitative In our investigations where quantitative data study. was desired, it became occessary to have a reliable sampling technique. The only currently available technique for "reliable" quantitative sampling requires a trained technician who can skillfully duplicate his manual scrubbing method. We have no such person; and at the same time, I believed that a mechanical rather than manual method of sampling could be developed that would permit consistent replication thereby giving more reliable quantitative data.

APPROACH:

The horizontal arm of a linear friction blister machine was modified so that its rubbing end would contain an aperature for vertical insertion of a Teflon^R spatula. A rectangular plexiglass cup was devised to hold the bacterial collecting medium (phosphate buffered saline, pH 7.9, containing 0.1% Triton X-100). With the horizontal arm (adjustable by using a level on the arm) holding the vertical spatula in place, a given number of strokes (scrubs) could be made at a given skin site. The amount of downward pressure on the spatula tip touching the skin could be adjusted by sliding a metal weight along the horizontal arm of the machine.

RESULTS AND DISCUSSION:

Quantitative data obtained from samples of adjacent and bilateral normal skin sites using this new mechanical sampling technique have repeatedly demonstrated that the bacterial counts generally do not vary nearly as much as reported in the literature where other techniques have been used. Moreover, the sampling technique can be employed by almost any person without special training.

うちょうしんちょう ひとかたかがい ちょうろう

and the second second

のためでいたのであって、メートのかど

and the second se

and a stratevery

This technique fulfilled my needs for bacterial analysis is test sites in the study of the effects of prolonged water exposure on human skin. Since the initial studies, machined stainless steel spatulas and sampling cups have been made so that this equipment is more durable and can be sterigized more quickly (autoclaving).

This technique will also be of use in quantitative and qualitative studies of corneocytes

19. The second of the second s

RESEARCH	AND TECHNOLOGY	WORK UNIT S	UMMARY	1. AGEN	CV ACCESS OB 679	10H ^A	2. DATE OF SU 72 07 0	1	REPORT DD-D	CONTROL SYNBUL R&E(AR)636
PATE PREV SUMAY 71 07 01	6. KIND OF SUMMANY D. Change	S SUMMARY SCTY ³ U	a. work security* U	7. REGRI	IDING [®]	-	B'H INSTR'H NL	CONTRACTO	C DATA-	. LEVEL OF SUM
. NO./CODES.*	PROGRAM ELEMENT	PROJECT	NUMBER	TASK A	REA NUM			WORK UN	T NUMBE	
PRIMARY	62110A	3A062110	A831		00			001		
. CONTRIBUTING								•••		
. CONTRIBUTING				L						
(U) Delayed 1	Type Skin Reacti	on and Lymp	hocyte Tran	sforma	ntion in	n Cui	taneous E	Diseases	(05)	
003500 - Clin	ical Medicine; 0	10100 - Immi	inology							
67 04		CONT	LETION DATE	DA	NING AGEN	CV	1	C. In-	MANCE ME	THOD
				10. RES	JUNCES ES	TIMATE	A PROFESS	HONAL MAN Y	RS L FU	IN DE (In thousands)
DATES/EFFECTIVE:	NA	EXPIRATION:		<u> </u>	PRECEDIN		1	-		
				FISCAL	72		1	3		51
• TYPE.		4 ANOUNT:		YEAR	73			3		50
KIND OF AWARD	DREAN ZATION	T.CUM. AMT.			ORMING O	RGANIZ	ATION			
ANE." Totto		L		HANE:*	I		· · · · ·	سبيا مىدەندەسا		l
Presid	io of San Francis	sco, CA 9412	9 9	ADORES	De: De:	rmat sidio	ology Res	search D	ivision	search 4179
					110	-31UIU	o o San I	Tancisco	, 04 3-	4127
				PRINCIP	AL INVEST	-	(Fumish SEAN	H U.S. Acades	nic (nellmik	
				NAME:	Joi	nes, I	H.E., LTC	CMC		
HANE ARCIS	5, W.A., CUL MC			TELES	HOKE: 4	12-21	01-0400			
415-	301-3101			L SOCIAL	ARCHAIT					
TELEPHONE: 415-5				50CIA	L SECURIT	Y ACCO	UNT NUMBER: 19			
TELEPHONE: 415-5				SOCIAI ASSOCIA NAME:	L SECURIT	Y ACCO	UNT NUMBER: IS			
TELEPHONE: 415-5	501-5181			SOCIAI ASSOCIA NAME: NAME;	L SECURIT	Y ACCO	UNT NUMBER: 16			DA
TELEPHONE: 415-5	EACH of South Classic	168'100 Codo) (U) d	elayed hyper	SOCIAI ASSOCIA NAME: NAME: NAME:	security TE INVEST	J) hu	unt huapen: 15 Iman volu	ințeers; (U) skin	DA
TELEPHONE: 415-5 . GENERAL USE E. ELYBORIS (Process (U) intraderm Tremment Object	ACH -IN Smally clouds	(U) d <u>lymphocyte t</u>	elayed hypers	SOCIAN ASSOCIAN NAME: NAME: NAME: Sensitiv n: (U)	ity; (U	J) hu	iman volu (U) phyl	inteers; (ohemage	U) skin glutinin	DA
TECHPHONE: 415-5 . GENERAL USE E. REVIDERIE (Proceed (U) intraderm D. TECHNICAL OBJECT	EACH of Sector Classics Tal skin test; (U) TIVE." 24 APPROACH, 23.	(U) d (U) d lymphocyte t PROGRESS (Pumish (elayed hypers ransformatio	socia Associa NAME: NAME: NAME: NAME: NAME: NAME:	/ity; (U	J) hu ytes:	unt huzeen: man volu (U) phyl al of coch with	inteers; (johemagi security class	U) skin glutinin Interior co	DA
TELEPHONE: 415-5 . GENERAL USE E. ELYBORISE (Processon (U) intraderm D. TECHNICAL OBJECT 25. (U) 71 07	1115.° 14 100000 1110000000000000000000000000	(U) di <u>lymphocyte t</u> procress (Pumier (hocyte transfe	elayed hypers ransformatio advised programs to pormation has	socia associa name: uame: censitiv n: (U) been p	vity; (U leukoc	J) hu ytes:	uny huzpen: man volu (U) phyl af of each sta	nteers; (ohemage proving close h tuberci	U) skin glutinin Meetter cer slin (PP	DA , , , , , , , , , , , , ,
TELEPHONE: 415-5 . GENERAL USE E ALTEDRISE (Process (U) intraderm L TECHNICAL OBJECT 25. (U) 71 07 funga	EACH -18 South Cloud nal skin test; (U) Tive,* 24 Appendicu, 28 7 - 72 06 Lympi 1 (Trichophytin)	(carlan codo) (U) d <u>lymphocyte t</u> Prograsss (Pumiat) hocyte transfo antigens. The	elayed hypers ransformatio retrievel engraphy to ormation has e antigen dose	social AMOCIA NAME: NAME	vity; (U leukoc number pr perfecte ure tim	J) hu ytes: ed fo e, cu	unt huzsen: man volu (U) phyi if of each with r use with fture volu	inteers; (ohemage arcuity close th tubercu	U) skin glutinin Meeter co ilin (PP other p	DA D) and barameters
тесерноне: 415-5 . беневац изе <u>(U) intraderm</u> . тесниюсы орлоса 25. (U) 71 07 funga that e	Tack of Incide Charles Tack of Incide Charles Tal skin test; (U) Take, a approach, as 7 - 72 06 Lympi 1 (Trichophytin) affect the test's re-	(U) d lymphocyte t process (pumie) hocyte transfe antigens. The producibility	elayed hypers ransformatio ormation has e antigen dose and reliabilit	been p been y have	vity; (U leukoc oerfecte been e	J) hu ytes: ed fo e, cu optim	man volu (U) phyl a' d sech via r use with fture volu nized.	nteers; (ohemagy search close n tubercu ume and	U) skin <u>glutinin</u> meeter co Ilin (PP other p	DA D) and parameters
теснинся 415-5 . «Еневация (U) intraderm L теснинсац област 25. (U) 71 07 funga that e Usine	Tach of Local Chants Tach of Local Chants Trive," 24 Appendicut, 21 Trive," 24 Appendicut, 21 Triv	hocyte transfe antigens. The producibility	elayed hypers ransformatio advised exception for commation has e antigen dose and reliabilit in skin test a	social name: na na na na na na na na na na na na na	vity; (U leukoc meter production perfecto are tim been o F in 25	J) hu ytes: when to ytes: when to e, cu optim	man volu (<u>(U) phy</u> of use with lture volu nized. man subji	nteers; (ohemagy security closer tubercu ime and ects we f	U) skin glutinin meeter co ilin (PP other p aave sho	DA D) and parameters
TECLEPHONE: 415-5 . GENERAL USE (U) intraderm L TECHNICAL OBJECT 25. (U) 71 07 funga that e Using 1. Th	The second secon	(1) di <u>lymphocyte t</u> <u>phocyte transf</u> antigens. The producibility d Trichophyt kin test is a c	elayed hypers ransformatio retribut eregenetic ormation has e antigen dose and reliabilit in skin test a ontinuum and	been p c, culto y have	vity; (U leukoc meter fecto are tim been o F in 25 bitrary	J) hu ytes: of fo e, cu optim 0 hu	man volu (<u>()</u> phyl (<u>v) phyl</u> (<u>v) st of seth sith</u> r use with lture volu nized. man subj off of 5 m	inteers; (tohemage security close to tubercu ime and ime and ects we f im or 10	U) skin glutinin meeter co ulin (PP other p nave sho mm fo	DA D) and parameters own: or a positive
VELEPHONE: 415-5 . GENERAL USE L ALVERAUE (Parcel (U) intraderm . TECHNICAL OBJECT 25. (U) 71 07 funga that e Using 1. Th test c	The second secon	(U) d <u>lymphocyte t</u> <u>PROGRESS</u> (Pumiet i hocyte transfe antigens. The producibility d Trichophyt kin test is a co interpret read	elayed hypers ransformatio ormation has e antigen dos and reliabilit in skin test at ontinuum and ction from th	social nauocia nauocia nauocia naucia	vity; (U leukoc are time been o F in 25 bitrary unolog	J) hu ytes: ed fo e, cu optin 0 hu cuto ic vie	man volu (U) phys r use with lture volu nized. man subjo off of 5 m wpoint.	nteers; (ohemage prently close in tubercu ime and ects we f im or 10	U) skin <u>glutinin</u> Ilin (PP other p nave sho mm fo	DA D) and barameters own: r a positive
TECHNONE: 415-5 . SEMERAL USE E SEVERAL USE E SEVERAL USE (U) intraderm (U)	TACH of a second characteristic that $\frac{1}{1000}$ and $\frac{1}{10000}$ and $\frac{1}{10000000000000000000000000000000000$	(U) d <u>lymphocyte t</u> <u>process</u> (Pumlet (antigens. The producibility d Trichophyt kin test is a co interpret reac ost or possibl	elayed hypers ransformation ormation has e antigen dose and reliabilit in skin test an ontinuum and ction from th y sensitize the	been p e, culto y have hd LT an ar e imme	vity; (U leukoc verfecto verfecto verfecto re tim been o F in 25 bitrary unolog ptible	J) hu ytes: d fo e, cu optim 0 hu cuto ic cuto	man volu (U) phyl (U) phyl of eeth via r use with lture volu nized. man subj off of 5 m ewpoint. ient and	nteers; (ohemage really closed to tubercu ume and ects we f im or 10 in experi	U) skin glutinin alin (PP other p nave sho mm fo mentai	DA D) and parameters own: r a positive and/or
TECHNONE: 415-5 . GENERAL USE (U) intraderm . TECHNICAL OBJECT 25. (U) 71 07 funga that e Using 1. Th test c. 2. A clinic. 3. Ty	Act of Local Contents The second sec	to the set of the set	elayed hypers ransformatio antion has antigen dose and reliabilit in skin test a ontinuum and ction from th y sensitize the permissible, in may occur to	been p c, culto y have the susce o vitro	vity; (U leukoc meter erim e been o F in 25 bitrary unolog ptible tests st me an	J) hu ytes: wed fo e, cu optin 0 hu cuto ic vie recip uch a	man volu (<u>()</u> phyl (<u>()</u> phyl () of set with hized. man subj off of 5 m (wpoint. jent and is LTT m and with	nteers; (ohemage result close to tubercu ume and ects we f om or 10 in experi- ust be su trichop	U) skin glutinin mental nave sho mental bstituto hytin th	DA D) and parameters own: r a positive and/or ed. te immediate
TECLEPHONE: 415-5 . GENERAL USE E dEVEDRES (Partice (U) intraderm L TECHNICAL OBJECT 25. (U) 71 07 funga that c Using 1. Th test ci 2. A clinic: 3. Tw reacti	The second secon	(U) d <u>lymphocyte t</u> <u>hocyte transfe</u> antigens. The producibility d Trichophyt kin test is a co interpret reac ost or possibly re this is not p rgic reactions c to the delay	elayed hypers ransformatio retrievel eregreete ormation has e antigen dose and reliabilit in skin test at ontinuum and ction from th y sensitize the permissible, in may occur to ed reaction.	been p c, culto y have hd LT t an ar e imm e susce vitro the sa	vity; (U leukoc perfecto perfecto te time been o F in 25 bitrary unolog ptible tests si me ant	J) hu v Acco leator J) hu vtes: vtes	man volu (U) phy((U) phy(of even vie r use with fure volu nized. man subjo off of 5 m ewpoint. ient and is LTT m and with	inteers; (<u>iohemag</u> in tubercu ime and ects we f im or 10 in experi- ust be su trichopl	U) skin glutinin incollen cou llin (PP other p nave sho mm fo mental bstituto hytin th	DA D) and barameters bwn: r a positive and/or ed. re immediate
velephone: 415-5 . demenal use (U) intraderm (U) intraderm 25. (U) 71 07 funga that e Using 1. Th test c. 2. A clinic: 3. Tv reacti 4. Th	TACK - IN INCIDENTIAL TACK - IN INCIDENTIAL	to the delay (U) discrete the formation (U) distribution (U) discrete the formation (U) discrete the formation (U) discrete the formation (C) discrete the f	elayed hypers ransformatio ormation has e antigen dose and reliabilit in skin test at ontinuum and ction from th y sensitize the permissible, if may occur to ed reaction. hytin protect	been p ensitive mane: wantive wensitive mane: wantive been p e, culto y have had LT i an ar e imm e susce to vitro the sa s the h	vity; (U leukoc are tim e been o F in 25 bitrary unolog ptible tests st ime and	J) hu y test of fo e, cu optim 0 hu cuic ic vie recip uch a ligen from	man volu (U) physic r use with fture volu nized. man subju off of 5 m wpoint. ient and is LTT m and with experime	nteers; (ohemage really close to tubercu ime and ects we h im or 10 in experi- ust be su trichopl ental info	U) skin glutinin Ilin (PP other p nave sho mental bstituto hytin th ection v	DA D) and barameters own: r a positive and/or ed. re immediate with
velephone: 415-5 . seneral use L atvesdes (Purce (U) intraderm L TECHNICAL OBJECT 25. (U) 71 07 funga that e Using 1. Th test c: 2. A : clinic: 3. Tw reacti 4. Th Trichy 6. Vi	The response to a sannot be used to skin test may bo all situations when we classes of aller to presence of DT ophyton be the response to a sannot be used to skin test may bo all situations when the response to a still be the test of all situations when the response to a still be the test of all situations when the response of aller to the test and the test may bo all situations when the response of aller to the test of all situations when the test and test	(U) di <u>lymphocyte t</u> <u>ivmphocyte t</u> <u>ivmphocyte t</u> <u>ivmphocyte t</u> <u>ivmphocyte t</u> <u>integns.</u> The producibility d Trichophyt kin test is a cu- interpret react ost or possibly re this is not p rgic reactions c to the delay I'm to trichophytes. <u>ivmphytes.</u>	elayed hypers ransformation permation has antigen dose and reliabilit in skin test an ontinuum and ction from th ysensitize the permissible, in may occur to ed reaction. hytin protect	been p ensitive manage been p e, culto y have nd LT t an ar e imm e susce t be sa s the h	vity; (U leukoc perfecto perfecto perfecto prin 25 bitrary unolog ptible tests si me and puman 1	J) hu ytes: www.wed fo e, cu optim 0 hu cuto ic vie recip uch a tigen from	man volu (U) physical r use with lture volu nized. man subjo off of 5 m expoint. ies LTT m and with experime	nteers; (ohemage really closed in tubercu ume and ects we f im or 10 in experi- ust be su trichopl ental info	U) skin glutinin metal nave sho mental bstitute hytin th ection v	DA D) and parameters own: r a positive and/or ed. re immediate with
TELEPHONE: 415-5 . demenal USE L developies (Proceed (U) intraderm (U) intrad	A car of a sector chants nal skin test; (U) Tive," at a person con, and (Trichophytin) effect the test's re- multiple PPD and the response to a s- annot be used to skin test may bo- al situations when we classes of aller- tion is antagonistic the presence of DT ophyton mentagon right subjects acquiring antipiction the presence of DT ophyton mentagon the p	(U) di <u>iymphocyte transf</u> antigens. The producibility d Trichophyte kin test is a co interpret reactions c to the delay I'H to trichophytes. uire DTH from but the species of the c to the species of the conterpret reactions to the delay to trichophytes. c to the species of the conterpret reactions to the delay the the trichophytes.	elayed hypers ransformatio ormation has antigen dose and reliabilit in skin test at ontinuum and ction from th y sensitize the permissible, if may occur to ed reaction. hytin protect m the 1st exp ific acquired i	been p c, cultu been p c, cultu been p c, cultu d an ar e imm e susce the sa s the fi erimen mmun	vity; (U leukoc metric fr perfecto are tim e been o F in 25 bitrary unolog ptible tests si ime and uman inf ity is d	J) hu ytes: wed fo e, cu optin 0 hu cuto ic vie recip uch a ligen from	man volu (U) phyl r use with lture volu nized. man subjo off of 5 m ewpoint. jent aud is LTT m and with experime on and are nstrated	inteers; (tohemage security close in tubercu ume and ects we f im or 10 in experi- ust be su trichopi ental info eresistan in the hu	U) skin glutinin mental mave sho mental bstitute hytin th ection w t to fur man.	DA D) and parameters pwn: r a positive and/or ed. re immediate with ther
TECLEPHONE: 415-5 . GENERAL USE E. deveral USE (U) intraderm (U) intraderm 25. (U) 71 07 funga that e Using 1. Th test c 2. A: clinic: 3. Tv reacti 4. Th Tricho 5. Vi exper 6. Th	The presence of impresence of	(U) d <u>lymphocyte t</u> <u>hocyte transfe</u> antigens. The producibility d Trichophyt kin test is a co interpret read ost or possibly re this is not p rgic reactions c to the delay FH to trichophytes. uire DTH from n. Thus, speci-	elayed hypers ransformatio ormation has e antigen dose and reliabilit in skin test an ontinuum and ction from th y sensitize the permissible, in may occur to ed reaction. hytin protect m the 1st exp fic acquired in rsensitivity to	been p ensitive in an are ensitive in (U) been p e, culto y have nd LT i an ar e imm e susce n vitro the sa s the h erimen o Trick	vity; (U leukoc oerfecto are time been o F in 25 bitrary unolog ptible tests si me and ntal infi ity is d nophyti	J) hu y <u>tres</u> : d fo ed fo e, cu optim cuto ic vie recip uch a ligen from ectio lemo in re	man volu (U) phy((U) phy(of orth right r use with lture volu nized. man subject off of 5 m expoint. ient and is LTT m and with experime n and are nstrated in ders the	inteers; (<u>cohemage</u> <u>arcently close</u> in tubercu ime and ects we f im or 10 in experi- ust be su trichopl ental infe eresistan in the hu host mo	U) skin glutinin intention con alin (PP other p other p nave sho mental bstitute hytin th ection v t to fur man. re susce	DA D) and barameters own: r a positive and/or ed. te immediate with ther eptible to
TECHNONE: 415-5 . GENERAL USE E. deverate of the (U) intraderm (U) intraderm 25. (U) 71 07 funga that e Using 1. Th test c. 2. A: clinic. 3. Ty reacti 4. Th Triche 5. Vi exper 6. Th natur	Act of local products and local	(U) d <u>lymphocyte t</u> <u>Proceeds</u> (U) d <u>lymphocyte t</u> <u>procyte transfe</u> antigens. The producibility d Trichophyt producibility d Trichophyt in test is a co interpret read ost or possibly re this is not p gic reactions c to the delay FH to trichophytes. uire DTH from h. Thus, speci- mediate hypen tal dermatop	elayed hypers ransformatio ormation has e antigen dose and reliabilit in skin test at ontinuum and ction from th y sensitize the permissible, if may occur to ed reaction. hytin protect m the 1st exp fic acquired if rsensitivity to hyte infection	been p ensitiv mane: mane: mane: mane: mane: mane: been p e, culto y have nd LT i an ar e imm e susce the sa s the h erimen mmun o Trict ns.	vity; (U leukoc perfecto are tim e been o F in 25 bitrary unolog ptible tests st me and ntal infi ity is d iophyti	J) hu ytes: d fo ed fo e, cu optim 0 hu cuíc ic vie recip uch a ligen from ectio in ret	man volu (U) physic r use with fure volu nized. man subju off of 5 m wpoint. ient and is LTT m and with experime on and are nstrated in ders the	inteers; (<u>cohemage</u> <u>brently close</u> in tubercu ime and ects we home or 10 in experi- ust be su trichople ental info resistan in the hu host mo	U) skin glutinin Ilin (PP other p nave sho mentai bstituto hytin th ection w t to fur man. re susce	DA D) and barameters own: r a positive and/or ed. the immediate with ther eptible to
TECHNONE: 415-5 . devenal use . devenal use (U) intraderm b. Technical Object 25. (U) 71 07 funga that e Using 1. Th test c 2. A clinic: 3. Tv reacti 4. Th Trichi 5. Vi exper 6. Th natur 7. At exper	TACH - 14 Include Chanter nal skin test; (U) TIVE," 24 APPROACH, 25 7 - 72 06 Lympi 1 (Trichophytin) effect the test's re- multiple PPD an the response to a s annot be used to skin test may bo- al situations when wo classes of aller ion is antagonistic the presence of DT ophyton mentagonistic the presence of im- ral and experimental topic humans are- fimental dermato	(U) d <u>lymphocyte transfe</u> antigens. The producibility d Trichophyt kin test is a co interpret read ost or possibly re this is not p rgic reactions c to the delay [H to trichophytes. uire DTH from bytes. uire DTH from the delay of the delay and the delay of the delay of the delay and the delay of the delay of the delay of the delay and the delay of the delay of the delay of	elayed hypers ransformatio ormation has e antigen dose and reliabilit in skin test at ontinuum and ction from th y sensitize the permissible, in may occur to ed reaction. hytin protect m the 1st exp fic acquired is rsensitivity to hyte infection redisposed to ons and accou	been p ensitive in an ar e in m e in the sa the firm o Trick ns. develo	vity; (U leukoc perfecto are time been o F in 25 bitrary unolog ptible tests si me and ntal infi ity is d ophyti	J) hu y Acco leated J) hu y tes: 	man volu (U) phy((U) phy(of each eight r use with fure volu nized. man subje off of 5 m expoint. ient and is LTT m and with experime n and are nstrated in ders the te sensitin aronic der	inteers; (<u>cohemage</u> to tubercu ime and ects we f im or 10 in experi- ust be su trichopl ental info resistan in the hu host mo vity from	U) skin glutinin incollen cou llin (PP other p nave sho mental bstituto hytin th ection v t to fur man. re susce natura yte infe	DA D) and barameters D) and barameters own: r a positive and/or ed. te immediate with ther eptible to al and ections
TECHNONE: 415-5 • GENERAL USE • GENERAL USE • GENERAL USE • TECHNICAL OBJECT 25. (U) 71 07 funga that e Using 1. Th test c. 2. A: clinic. 3. Ty reacti 4. Th Trich. 5. Vi exper 6. Th natur 7. Ai exper obser	Act of local products and local	taria codo) (U) d <u>lymphocyte t</u> hocyte transfe antigens. The producibility d Trichophyt kin test is a co interpret read ost or possibly re this is not p gic reactions c to the delay FH to trichophytes. uire DTH from h. Thus, speci- mediate hype tal dermatop genetically p phyte infectio 5.	elayed hypers ransformatio ormation has e antigen dose and reliabilit in skin test at ontinuum and ction from th y sensitize the permissible, in may occur to ed reaction. hytin protect m the 1st exp fic acquired i rsensitivity to hyte infection redisposed to ons and accou	social associal massicial	vity; (U leukoc perfecto are time been o F in 25 bitrary unolog ptible tests st me and ntal infi ity is d tophyti	J) hu ytes: ueator d fo e, cu optim 0 hu cuíc ic vie recip uch a ligen from from ectio in ret aedia of cf	man volu (U) physical r use with fure volu nized. man subju off of 5 m wpoint. ient and is LTT m and with experime n and are nstrated in ders the te sensitive aronic der	inteers; (<u>cohemage</u> to tubercume in tubercume in tubercume in experi- ust be sub- trichople ental info resistanti in the hu host mo vity from rmatophy	U) skin glutinin Ilin (PP other p nave sho mental bstituto hytin th ection w t to fur man. re susce natura yte infe	DA D) and barameters D) and barameters own: r a positive and/or ed. ther immediate with ther eptible to al and ections
velephone: 415-5 • demenal use • demenal use (U) intraderm • vechnical object 25. (U) 71 07 funga that e Using 1. Th test c: 2. A: clinic: 3. Tv reacti 4. Th Triche 5. Vi exper 6. Th natur 7. At exper obser	A car of a sector channel al skin test; (U) Tive," at approach, and al skin test; (U) Tive," at approach, and al (Trichophytin) al (Trichophytin) al (Trichophytin) al (Trichophytin) al (Trichophytin) al (Trichophytin) al (Trichophytin) al (Trichophytin) annot be used to skin test may bo al situations when yo classes of aller to is antagonistic to presence of DT ophyton mentagonistic imental infection we presence of im- al and experiment topic humans are simental dermato yed in our survey	(U) d <u>lymphocyte t</u> hocyte transfe antigens. The producibility d Trichophyt kin test is a co interpret react ost or possibly re this is not p rgic reactions c to the delay IH to trichophytes. uire DTH from anticophytes. uire DTH from anticophytes. DTH speci- mediate hype ital dermatop genetically p phyte infectio (U) d lymphocyte to the second the se	elayed hypers ransformation permation has e antigen dose and reliabilit in skin test at ontinuum and ction from th y sensitize the permissible, in may occur to ed reaction. hytin protect m the 1st exp fic acquired is rsensitivity to hyte infection redisposed to ons and accou	been p ensitiv mane: wan	vity; (U leukoc verfectu are time been o F in 25 bitrary unolog ptible tests si me ant ntal infi ity is d ophyti	J) hu ytes: yt	man volu (U) physical r use with liture volu nized. man subju off of 5 m exposint. is LTT m and with experime n and are nstrated in nders the te sensitive pronic den	inteers; (cohemage intubercu intubercu internet in	U) skin glutinin Ilin (PP other p nave sho mental bstitute hytin th ection w t to fur man. re susce natura yte infe	DA D) and barameters D) and barameters own: r a positive and/or ed. re immediate with ther eptible to al and ections
receptione: 415-5 . demenal use L. devector (mice (U) intraderm L. Technical Abject 25. (U) 71 07 funga that e Using 1. Th test c: 2. A: clinic: 3. Tw reacti 4. Th Tricho 5. Vi exper 6. Th natu/ 7. At exper obser	Act of the sector channel al skin test; (U) Tive," at approach, at 7 – 72 06 Lympi 1 (Trichophytin) effect the test's re- multiple PPD an the response to a s- annot be used to skin test may bo- al situations when wo classes of aller- ion is antagonistic to phyton mentagoristic ophyton mentagoristic ophyton mentagoristic to presence of im- al and experimental topic humans are- simental dermato- ved in our survey	(U) divergence (U) di	elayed hypers ransformation ormation has e antigen dose and reliabilit in skin test an ontinuum and ction from th y sensitize the permissible, in may occur to ed reaction. hytin protect m the 1st exp fic acquired in rsensitivity to hyte infection redisposed to ons and accou	been p c, cultu mane: wa	vity; (U leukoc verfecto verfe	J) hu ytes: www.we ed fo e, cu optin 0 hu cuto ic vie recip uch a tigen from ectio lemo in re-	man volu (U) physical r use with lture volu nized. man subju ff of 5 m expoint. is LTT m and with experime on and are nstrated in ders the te sensitive in onic den	nteers; (cohemage result close in tubercu ume and ects we f im or 10 in experi- ust be su trichopl ental info e resistan in the hu host mo vity from rmatoph	U) skin glutinin mentai bstitute hytin th ection w t to fur man. re susce natura yte in(e	DA D) and parameters parameters own: r a positive and/or ed. re immediate with ther eptible to al and ections
VELEPHONE: 415-5 . GENERAL USE E diversion (Provide (U) intraderm . TECHNICAL OBJECT 25. (U) 71 07 funga that e Using 1. Th test cl 2. A clinic: 3. Tv reacti 4. Th Tricho 5. Vi exper 6. Th natur 7. At exper obser	Aca of a local frequency of the second secon	(U) d <u>lymphocyte transfe</u> antigens. The producibility d Trichophyt kin test is a co interpret read ost or possibly re this is not p rgic reactions c to the delay FH to trichophytes. uire DTH from n. Thus, speci- mediate hypen tal dermatop genetically p phyte infection (U) d tal dermatop	elayed hypers ransformation and reliabilities and reliabilities and reliabilities in skin test and ontinuum and ction from the y sensitize the permissible, in may occur to ed reaction. hytin protect m the 1st exp ific acquired in resensitivity to hyte infection redisposed to ons and account	social assoc	vity; (U leukoc oerfecto are time been o F in 25 bitrary unolog ptible tests si me and ntal infi ity is d iophyti	J) hu y <u>tes</u> : d fo e, cu optim cuto ic vie recip uch a tigen from ectio lemo in re-	man volu (U) phy((U)	inteers; (<u>iohemag</u> <u>arcently close</u> in tubercu- ime and ects we f im or 10 in experi- ust be su trichopi ental infe eresistan in the hu host mo vity from- rmatophy	U) skin glutinin income ilin (PP other p nave sho mental bstituto hytin th ection v t to fur man. re susce natura yte infe	DA D) and barameters D) and barameters own: r a positive and/or ed. te immediate with ther eptible to al and ections

1,995,-572**,**-

- - - -

and the second of the

ave and a second with the second second and a source of the second

ALL ALLES TO SEE STATISTICS AND A DESCRIPTION OF A

.

.

A STATE STATE AND A STATE A

. . .

,

.

New Construction of the second

Delayed Type Skin Reaction and Lymphocyte Transformation in Cutaneous Diseases

less the start area and the

LTC H. Earl Jones, MC

PROBLEM:

To develop a reliable in vitro test for studying delayed type hypersensitivity (DTH) in certain cutaneous diseases (fungal infections, contact dermatitis) and the chronology of the immunologic response of subjects infected with the fungus Trichophyton mentagrophytes and/or other organisms.

Fungal antigens prepared from <u>T. mentagrophytes</u> will be screened by lymphocyte transformation (LT). Ideally we hope to look for antigenic fractions which could be used as immunogenic compounds to be administered to experimental animals and eventually to immunize humans to develop DTH and resultant immunity to infection with dermatophytic fungi.

APPROACH:

Prerequisite for all related and further research has been developing the LT technique as a reliable tool. Using the commonly accepted delayed hypersensitivity antigen, purified protein derivative of tuberculin (PPD), the LT technique has been studied at LAIR for three years. Applying the fundamental principles learned from the study of PPD-induced LT in subjects with and without tuberculin sensitivity, a similar study of trichophytin skin sensitivity and the response of the subject's lymphocytes to trichophytin will be accomplished. This will obviate the booster effect that repeated skin testing may have in analysis and interpretation of the fungal infection model.

The LT technique using lymphocytes from subjects infected with the fungus will be employed as a screening procedure to analyze new antigen preparations for immunologic reactivity.
RESULTS AND DISCUSSION OF RESULTS:

statisticki internetikation

Lymphocyte Transformation with Tuberculin. Numerous problems were encountered with the LT technique. One of the most serious was chemical contamination of glassware used in the experiment with chromic acid, detergents and/or other chemicals which affect the lymphocyte response. This difficulty was overcome by using plastic disposable containers whenever possible and the thorough, diligent washing of essential glassware. Purified protein derivative (PPD) of the tubercle bacillus as commercially available for skin testing contains phenylolic preservatives which are toxic to lymphocytes in vitro. We now use PPD prepared free of phenylolic preservatives by the Parke-Davis Company. This PPD has proven to be an excellent tuberculin for in vitro lymphocyte studies, is nontoxic, and does induce specific LT in subjects with DTH skin test reactions.

The dose response curve of lymphocyte cultures has been determined for the Parke-Davis PPD and the optimum concentration is 30 mg/cc of culture volume. From time-response studies we determined 6 days to be the optimal time for harvesting the PPD antigen-stimulated lymphocyte cultures. The optimum concentration of lymphocytes per unit volume of the culture is 5×10^5 per cc, using 30 mg of PPD/cc as a stimulus and a 6 day harvest time. The response of the individual's lymphocytes to PPD has been found to be consistent in replicate cultures performed on the same day, or weeks and months apart, and the accuracy range is within 10%.

Relationship of the Lymphocyte Transformation Response to the Skin Test Response. To determine the minimal PPD concentration necessary to elicit a D1^w kin test response and to quantify that response, multiple skin tests were done in patients at Letterman General Hospital and in volunteers at LAIR. Commercial available PPD, 1st and intermediate strength, were administered simultaneously to the volar surface of one forearm unless there was a history of tuberculin sensitivity in the past; if so, only the indicated dose of PPD was

used for skin testing. If no response to either skin test or only a minimal response to the intermediate test, 7 days later the individual was tested again using 2nd strength PPD on the opposite forearm. All skin tests were read at 20 minutes, at 24 and 72 hours, at 7 and 10 days following The results of these skin tests are testing. listed in Table 1. The LT was performed on each subject using various doses of PPD. Fach culture contained 5 x 10^5 lymphocytes per cc and.all cultures were harvested on the 6th day. Table 2 compares the degree of LT as related to the skin test reactivity. A direct linear relationship exists between the minimal strength of PPD required to elicit a skin test reaction, the size of the response, and the individual's LT response to PPD.

Because the individual's response to PPD is a continuous phenomenon with a normal curve of distribution in the population, there cannot actually be a cut-off of skin test positivity at any arbitrary level. The skin test responses were not labelled as positive or negative using the arbitrary 5 mm criteria for a positive test commonly used for epidemiologic testing of individuals for tuberculosis. We believe this is logical from an immunologic point of view since an individual at 4.5 mm would be negative according to those criteria, whereas someone with a similar quality skin test response measuring 5 mm in diameter would be positive. Our LT studies support this hypothesis in that any individual who manifests a response to any one of the concentrations of PPD, including 2nd strength, also had a significant degree of LT. Conversely, 2nd strength PPD negative individuals had no degree of LT. From this evidence, we recommend that the epidemiologic term positive and negative not be applied to skin test responses if this response is to be considered from the immunologic point of view. Rather, the individual's response should be measured in millimeters and characterized as to the erythematous, edematous, and/or indurated quality of the lesion.

From the above studies of sequential PPD skin testing we were suspicious that a booster effect 、それ、「したいこと」というないない。

any areas and areas and and an areas and and a shark and a basis that is a substantial a shark of a source

may have been obtained by the quantity of antigen injected. We retested part of the 36 subjects one week later and another group 2.5 months later. Using intermediate PPD for the followup skin test, 2 of 36 individuals manifested larger reactions which would have been interpreted as positive by epidemiologic criteria, whereas they were negative on the first test. Presently we are studying this phenomenon in experimental animals, but our Moen-Chase guinea pigs develop DTH so exquisitely that they all become sensitized to the minute quantities of phenylolic preservatives included in the commercial PPD preparation.

Trichophyton Skin Test and Lymphocyte Transformation. We previously determined that 10 ug of Cruickshank's trichophytin will elicit delayed hypersensitivity in subjects who have had fungal infections but does not elicit a skin response of any type in women and children with no history of fungal infection. We undertook a clinical-skin test survey of 180 men. Each volunteer in chis survey completed a questionnaire involving basic biographical data including his personal history of fungal infections, atopy, and other relevant skin conditions. The physical examination included examining the feet for possible tinea Each subject had his feet and groin pedis. cultured for dermatophytes and was skin tested on his arm with trichophytin, 10 ug. Test sites were examined at 20 minutes, at 24, 48, and 72 hours, and at 7, 10, and 14 days. The diameter of the response was measured and the presence of erythema, edema, induration, vesicles, papules and ulceration at the test site was noted. The skin test results (Table 1) permit the subjects to be divided into three classes by the response at the skin test site at 72 hours: Type I - nonreactors; Type II - immediate reactors, plus or minus delayed hypersensitivity; and Type III - delayed hypersensitivity of varying intensity.

Table 2 shows the distribution of DTH by size of the skin test response which follows a normal biological curve of distribution. Table 3 records at 72 hours the diameter of the skin test response and relates this to the presence or absence of 98

14 The Part Charles and the Rank ow Colors and the

erythema, edema, induration, and vesicles. This scatter-gram demonstrates that the intensity of the skin test response is directly related to the size of that response. This is to be expected. This again supports our concept that skin test responses are a continum and that an arbitrary value of 5 mm or 10 mm cannot be used for immunologic purposes as a criteria of positive or negative.

That the trichophytin skin test may have a booster effect is demonstrated by the fact 31% of those subjects showing no reaction at 72 hours later manifested some skin test reactivity when examined at 7 or 10 days. This later response was observed at the same skin test site that did not show any reaction at the 72 hour reading. The subjects manifesting the booster effect had a history of fungal infections more frequently than did the skin test nonreactors who did not boost with repeated trichophytin skin tests (see This suggests that the skin test acts Table 4). as a booster and not a primary sensitizer. Repeated skin tests in subjects who showed the booster effect at 7 days resulted in a larger diameter skin test response with each subsequentskin test. More importantly we observed that the intensity of the subsequent skin test was progressively greater . Experimental infections with T. mentagrophytes in these booster susceptible subjects behave similarly to subjects with manifested DTH reactions of even larger magnitude. This indicates that in the susceptible human the skin test may act as a booster and alter the immunologic status of the recipient.

Of the individuals susceptible to the booster effect from trichophytin, 50 percent have a personal history of respiratory atopy. Individuals with respiratory atopy comprise only 23% of the surveyed population. Therefore, it appears that subjects with atopy may more readily lose an acquired delayed hypersensitivity than normal individuals.

Lymphocyte transformation studies using our PEBC antigens have confirmed that individuals with weak reactions to trichophytin do undergo Sectores and actual sector between the same the same more than and an above to some on a sector of the

and the states of the states

specific lymphocyte transformation but to a lesser degree than subjects manifesting stronger skin test reactions.

Pelation of Immediate Skin Test Response to Delayed Skin Test Reactivity. Although the subjects in the immediate reactor subclass have obviously been infected with a dermatophytic fungus (i.e., they developed a specific allergic sensitivity) only 64% of them manifest DTH to the same antigen when the same skin test site is examined at 72 hours (see Table 1). The average size of the DTH reaction in the immediate reacting group is about one-half the size in the subjects with only delayed hypersensitivity. The immediate reactor subclass has approximately twice the frequency of atopy as do either nonreactors or the frequency of atopy as do either nonreactors or the group average. The DTH reactors are significantly below the overall average of personal atopy for all subjects. This suggests that in ediate reactions to trichophytin is associated with atopy; and when this occurs, the delayed reactions are less than in individuals without immediate reactions and atopy. Conversely, subjects with no history of atopy are likely to develop strong DTH following dermatophyte infection.

The effects of immediate reaction on the latter response (Table 5) was examined by dividing those subjects showing immediate reactions into two groups, those with a large size response and those showing only a moderate size reaction. There is a lesser frequency of DTH associated with the large size immediate reactions than with the moderate size immediate reaction. By mixing chlorophenaramine (CTM) with the trichophytin skin test antigen, we partially inhibited the immediate reaction, and noted the size and intensity of the delayed reaction to increase in 80% of the subjects with large immediate reactions. In subjects with large immediate reactions, CTM successfully unmasked an occult delayed hypersensitivity in 3 subjects. The only subject with a moderate reaction without some degree of delayed hypersensitivity had his occult DTH unmasked by CTM. Chlorophenaramine inhibits the effect of

histamine released from the trichophytin-IqE interaction; and by so doing, reduces the hyperemia of the immediate reaction with a consequent reduction in wash-out of the injected trichophytin. This illustrates one mechanism by which immediate reactions may inhibit or decrease the size and intensity of the DTH response.

Forty-three percent of individuals with an immediate reaction had a personal history of atopic respiratory disease. Those with no personal history of atopy more frequently had positive family histories of atopy than individuals who only manifested DTH response to trichophytin. Table 6 illustrates this amply and also depicts. the results of skin testing with a battery of antigens that frequently elicit immediate hypersensitivity in allergic subjects. As expected, those subjects with atopy reacted frequently and with multiple positive responses to the ten screening test antigens. whereas those individuals with no immediate reactions reacted infrequently. Persons with immediate reactions to trichophytin but no personal history of atopy reacted intermediately, indicating that they have a fundamental increased propensity to develop immediate type antibody upon immunization with the appropriate antigen. This tendency probably accounts for their immediate reactions to trichophytin as well.

Considering the history, physical examination, and the allergy skin test responses, the subjects can be classified into 3 types: 1. the skin test nonreacting group, the "fungal virgins"; 2. the delayed hypersensitivity reactive group who characteristically had a fungal infection in the past, but only rare occurrences: and 3. the immediate skin test reaction group, most of whom have persistent or frequent recurrent fungal infections. Individuals with immediate reactions to trichophytin may become infected at a younger age and these individuals have more persistent and/or recurrent fungal infections as substantiated on their physical examination (see Table 7). Dermatophytes were recovered 3 times more frequently from those subjects with immediate reactions compared to the DTH positive subjects or atopic subjects with no immediate reactions.

arra are and the and the arrange of the state of the

v 2. -

Experimental Fungal Infection. The experimental model dermatophyte infections described previously and discussed elsewhere in this report display 4 stages during the experimental infection: Stage 1 is the toxic phase, Stage 2 is the spreading infection stage, Stage 3 is the development of ringworm, and Stage 4 is the healing phase. When subjects of each of the clinical skin test subgroups described above are infected one sees strikingly different responses: 1. DTH positive subjects seem to be relatively immune to the experimental infection; 2. fungal virgins with no existing skin test reactivity undergo the same toxic phase of the infection and the lesions continue to spread until the onset of delayed hypersensitivity limits further enlargement of the lesions; 3. the skin test booster group seems to be protected in a manner identical to those subjects manifesting DTH; 4. subjects with immediate reaction to trichophytin and with a history of poor resistance to infection are susceptible to infection with small numbers of spores and the individual's lesions become large and persist several times longer than subjects with DTH almost following the protracted course seen in the primary infected virgin. This would not be expected since many of these individuals manifest both delayed hypersensitivity and immediate hypersensitivity. Perhaps the immediate hypersensitivity interferes with the coexisting delayed hypersensitivity in a manner similar to that observed in skin testing and thus fails to afford protection to the individual.

Some of the "fungal virgin" group had asthma or hay fever at younger ages. During the course of infection these subjects developed delayed hypersensitivity and appeared to be healing; however, at about 30 days, 2 of the 4 such subjects developed immediate sensitivity and concomitantly lost control of the infection and large, gyrate, serpiginous, ringworm lesions erupted that have persisted for at least 90 days. This confirms the concept that immediate wheal and flare sensitivity to trichophytin is a liability to the individual manifesting. 102

and a recent from the second states and

Of the 129 subjects in the survey on which complete data is available, 18 (14%) had chronic and/or persistent recurrent fungal infections. This is a familiar figure since most male populations surveyed have a 10 to 20% incidence of athletes foot. Since atopy is present in most populations at about the same frequency, it seems likely that the percentage of individuals found in surveys to have athletes foot may coincide with the percent of individuals in the population who manifest immediate reactivity to trichophytin. In this survey, two-thirds of the 18 subjects with chronic or recurrent tinea pedis had a personal history of either asthma or hay fever.

In summary, it seems that delayed hypersensitivity confers relative immunity to dermatophyte fungal infections in man. This immunity may be antagonized by coexistent immediate hypersensitivity to trichophytin. 1

2023 . I HAVE

아파 1919년 1 1919년 1919

Lymphocyte Transformation and Trichophytin Antigens. During this fiscal year LT tests with several antigens prepared from <u>T</u>. mentagrophytes was attempted. LT was obtained using Cruickshank's antigen at 400 ug/cc of culture; but such large amounts would soon exhaust our supply of trichophytin. A growth supernatant antigen and a propylene glycol extractable antigen similar to Cruickshank trichophytin were toxic to lymphocytes in vitro. A pyridine extractable glycoprotein antigen prepared from <u>T</u>. mentagrophytes was found to specifically stimulate lymphocytes of subjects with trichophytin sensitivity. Small quantities (ugm) of PEGB-Pl and PEGB-P4 would induce transformation in sensitive subjects.

<u>Cytotoxicity</u>. A technique was developed in which HeLa cells are cultured in T flask and aliquots of potential toxic materials are added to the flask to assay for cytotoxicity. From extracts of <u>T. mentagrophytes</u> grown in culture, 4 mycotoxinlike fractions have been prepared. Assaying these mycotoxin-like materials for their ability to destroy HeLa cells, we found that mycotoxin fraction 2 and 3 are as toxic if not more so than aflatoxin B_1 . Further progress with this system has been slow due to difficulties in quantitating the technique and in producing sufficient quantities of pure mycotoxins.

FUTURE PLANS:

We will continue to develop the LTT to detect DTH to trichophytin in vitro which is absolutely essential in understanding the developing immunologic phenomenon in virgin subjects infected with T. mentagrophytes. Obviously, multiple skin tests in these subjects may significantly influence their developing immune-mechanisms. The LTT will be used to select volunteers as experimental subjects to receive the model infection thereby avoiding skin testing and the consequent possibility of a booster effect.

The same state of the state of the second stat

The LTT will permit studying the intricate relationships between the sensitized lymphocyte and circulating antibody. We have demonstrated in subjects with immediate hypersensitivity and natural or experimental fungal infections that IgE antibody specific for trichophytin is antagonistic to delayed hypersensitivity in some manner. By isolating the lymphocyte, the IgE, and the fungal antigens in vitro and using the LTT as a detector of the interactions among these biologic materials, we should be able to define the mechanism by which IgE exerts its antagonistic effect on the cell mediated immune response.

Better understanding the above relationships will provide better ways to combat fungal infections such as treatment with antihistamines, desensitization, or the using of transfer factor. New screening diagnostic techniques will be developed to detect carriers of pathogenic dermatophytes and/or subjects prone to develop progressive or persistent dermatophyte infections prior to exposure in a high risk This will greatly reduce morbidity and duty area. time loss because of fungal skin diseases such as athletes foot, jocky itch and ringworm. This should culminate in the development of an immunization program for use in military and civilian populations.

104

45,43 CAP+ 2 -

다. 아파 1999년 1991년 1

Skin Test Class	*	Age	DTH	Average Size 72 hr Response	Personal Atopic History
Non-reactors	53	29.9	0	0	228
DTH reactors	66	31.5	100%	li mm	86
Immediate reactors	28	29.2	648	6 mm	43%
Average - all subjects	180	30.5	658	7 mm	238

Table 1. Trichophytin Skin Test Responses

9 7 7

more allabor braceworks

Structure of a static structure of a static structure of a structure ostructure of a structure ostructure of a structure ostructure of a structure ostructure of a structure ostructure of a structure ostructure ostr

•

•

~ ~

105

64533

くれていたいなどである

などくなどのないであったたいなどであるという

sensita ana cina any sana ana si kadala si kanada sana kata si kata si kata si kata si kata si kata si kata si

. .



••

and the second descent and the second

10-1

The second second second

Artonand mental spectratic state and the second

14.1.1

	Number	Historical or Physical Evidence of Fungal Infection	Personal Atopic History
Susceptible to booster	12.39 (31%)	10/12	6/12 (50%)
Not susceptible to booster	27/39 (69%)	17/27	4/27 (15%)

Table 4. BOOSTER EFFECT OF TRICHOPHYTIN SKIN TEST

I HAR BELLEVIE TO BE TO BE TO BE TO BE TO BE TO BE THE THE TAKEN THE T

Table 5. TRICHOPHYTIN: EFFECT OF IMMEDIATE REACTION ON THE DELAYED RESPONSE

zuran térsen pilitik

nutra and the fifth of the new reads

	Size of immedia	te Skin Test Rosponse	
	Large	Moderate	
Average Wheal/Flare	21/49 mm	13/29 mm	
Number Subjects	13	15	
72 hr Response Antigen Only Antigen & CTM	32%	235	
Antigen & CTM - 72 hrs Size & Intensity Unmask occult DTH	80% 3 subjects	30% 1 subject	

Table 6. IMMEDIATE SKIN TEST RESPONSE: RELATION TO ATOPY

Trichophytin I Class	Reactor	Family Hx	Atopy	10 Test # with	Allergy So + Test	reening Se Average	eries* +/Subjects
Immediate Re Personal Ho No Persona	actors Atopy	50% 21%		6/6 8/13		4.2/su	bject
No Immediate + DTH	Reactions	8%		4/14		0.9/su	ibject
*Antigens :	1. Mixed 2. Mixed 3. Plants	trees 4. grasses 5. in 6.	Mixed Mixed House	ragweed Western weedt dust	7. Mold 8. Egg 9. Milk	mixture	10. Wheat 11. Control

	DTH + Non-Atopic	Atopic Subjects (no immediate reaction)	Immediate Reactors <u>+</u> Atopy
Number Subjects	91	19	28
Average Age Onset	16.8	· 14.3	12.7
Reoccurrences None 2-5 Episodes Persistent or recurrent	76% 20% 2%	72% 11% 17%	19% 8% 73%
Physical Exam Normal Possible Tinea Tinea	40% 40% 19%	53% 16% 31%	11% 29% 61%
Culture +	26%	7%	63%

and a second and the second and a second a sec

Table 7. CLINICAL EVIDENCE OF FUNGAL INFECTION

the state of the second se

RESEARCH	AND TECHNOLOG	Y WORK UNIT S	UNMARY	DA C	x x A 7(CESCION®	1. DATE OF 72 07	01	REPORT DD-D	CONTROL STUBOL RALIARIA SO
71 07 01	D. Change	5. SUMUARY SC17*	L BORK SECURITY	7 REGR		10. 04. 04	is'n insta'n NL	ON SPECIFIC CONTRACTOR	ACCESS	F LEVEL OF SUN
0. NO./CODES *	PROCRAM ELEMENT	PHOJECT	NUMBER	TASK A	AREA	NUMBER		WORK UNIT	NUMBER	l
	62110A	34062110	DA831	1 0)0			004		
. CONTRIBUTING		1		1					*******	
-										
1. TITLE (Procode with)	Security Classification Code	,, e								
(U) Biochemi	cal Mechanisms	of Pathogenes	sis in Fungal S	<u>škin In</u>	fect	ions	(05)		_	
002300 - Bioc	chuologicali aneas" chemistry: 0101	00 - Microbio	logy; 003500) - Clin	nical	Medici	ne			
S. FTART BATE		14 ESTINATED COM	PLETION DATE	IS FUNE	HHG A	GENCY		16. PERFORM	ANCE WET	000
77 []		CONT		DA				C. In-	<u>house</u>	
7. 500TRACT/0840T	BI A			-		S ESTIMAT	A PRO70		6 FUI	DS (In theveards)
& DATES/EFFECTIVE:	NA	EXPIRATION.			-	10:×1				
				FISCAL	CURF	/ <u>/</u>		4		40
				1 VAR		73		5	1	50
RESPONSIALS AND		I.CUM. AMT.	······································	10	10==	10.09644	ATIC			
		L						L	·····	
Letter	man Army Insti	tute of Resear	rch	HALE:"		Lettern	ian Arm	y Institute	of Res	earch
Presid	io of San Franci	sco, CA 9412	У	ADDRESS		Dermat	ology R	esearch Div	ision	
		Microbiology Research Laboratory Presidio of San Francisco, CA 94129								
				PRINCIP	AL INV	F RESIGIO	oi San	r rancisco,	LA 94	129
		NAME.* Reinhardt, J.H., CPT MSC								
name: Akers	W.A., COL MC			NAME* Reinhardt, J.H., CPT MSC TELEPHONE: 415-561-3006						
415-5	61-5181			-		517 / ACCO		ŀ		
TELEPHONE: 415-561-5181 EDCIAL SECURITY ACCOUNT HUNDER										
TELEPHONE: TO SOL STOR TELEPHONE: TO SOL STOR TI GENERAL USE ABOCIATE INVESTIGATORS ASSOCIATE INVESTIGATORS ASSOCIATE INVESTIGATORS										
FI. GENERAL USE					7E INV	King, R		MSC		
EI. GENERAL USE				A36OCIA NAME: NAME:	7 E INV	King, R Jaeger,	". .D., CP1 J.R., DA	r MSC NC		DA
ET. REVERAL USE	BACH with Jonathy Closelly	Iconian Codoy	throderma be	A360CIA NAME: NAME: Dátami	YE INV 1 20: (King, R Jaeger,	.D., CPT J.R., DA	MSC C	mbyte	DA
EL REVEALE (Fride)	Each and Seath closed (U) antigens: (U	immunogen	throderma be s: (U) virulend	ABOCIA NAME: NAME: NAME: NAME: NAME:	10 100 10 100 10 100 10 100	King, R Jaeger, U) <u>Tric</u> nea pig	.D., CP1 J.R., DA hophyta ;; (U) sk	MSC Con mentogra	ophyte	DA SS:
С. Сеневаль чэе С. сечеваль чэе (U) €прушес; не чеснинса овист	LACH off Lowith Clouin (U) antigens: (U	(U) Ar immunogen	throderma be s: (U) virulen	AMOCIA NAME:	re	King, R Jaeger, U) <u>Tric</u> nea pigs	.D., CPI J.R., DA hophyte ;; (U) ski	MSC AC on mentogro in * security clocol to	ophyte	DA <u> <u> </u> </u>
(U) enzymes; 23. (U) 1) Elu	EACH OTH Second Closed (U) antigens: (U) (VE.* 14 APPROACH, 45 Icidate biochemi	(U) <u>Ar</u> <u>) immunogen</u> PROCEELE (Profile) cal mechanise	throderma be s: (U) virulent strong property ns of infection	n. 2) I	ve ae; (gui Perfe	King, R Jaeger, U) <u>Tric</u> nea pige	.D., CPI J.R., DA hophytc i: (U) sk	MSC AC <u>on mentogra</u> <u>n mentogra</u>	ophyto	DA S: ., iydrolyzing
U) CREATING	EACH OTH SCOTH COUNT (U) antigens: (U) (VC. ⁹ 24 APPROACH, 24 Incidate biochemi ates found in str	(U) <u>Ar</u> <u>) immunogen</u> PROCELLE (POLITE cal mechanise atum corneur	throderma be s: (U) virulent s: of infection n; characteriz	n. 2) I e isola	ae; (gui Perfe ted (King, R Jaeger, U) <u>Tric</u> nea pige ect assa enzyme	.D., CPI J.R., DA hophyto : (U) ski of each of y of enzy s by phy	MSC AC <u>on mentagra</u> * security closed to ymes capab /sical-chemi	ophyto	DA
(U) enzymes; U) enzymes; EE TECHNICAL OBJECT 23. (U) 1) Elu substr 3) Con	EACH ON SCOTH COUNT (U) antigens: (U) (VZ.* 20 APPROACH, 20 Incidate biochemi ates found in str rrelate virulence,	cal mechanism enzyme prod	throderma be s: (U) virulend s: of infection n; characteriz iuction, and n	n. 2) I e isola	ae; (gui Perfe ted (onal	King, R Jaeger, U) <u>Tric</u> nea pigs ect assa enzyme require	.D., CPI J.R., DA hophyto ; (U) ski st of ent s by phy ments of	MSC on mentagra in security closelve ymes capab /sical-chemi fungus wit	ophyto offer contraction le of h ical pro-	DA S: hydrolyzing occdures. phological
(U) enzymes; EL ARYBRALL USE (U) enzymes; EL YECHNICAL OBJECT 23. (U) 1) Elu substr. 3) Cor and pl S) End	EACH -18 Seats Cloud (U) antigens: (U) (ve.* 16 APPROACH, 18 Incidate biochemi ates found in str rrelate virulence, hysiological varia late and purify fo	(U) <u>Ar</u> <u>immunogen</u> <u>immunogen</u> cal mechanisr atum corneur enzyme prod ttions in <u>vitro</u> ungal antigen	throderma be s: (U) virulens (divide services of n; characteriz luction, and n and <u>in vivo</u> .	n. 2) I e isola utritio 4) Det	ae; (gui Perfe ted (onal erm	U) <u>Tric</u> <u>U) Tric</u> <u>nea pigs</u> ect assa enzyme require ine anti		MSC <u>on mentagra</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u>	ophyto eller con le of h ical pr h mor lated	DA S: nydrolyzing occdures. phological enzymes.
(U) enzymes; te action object (U) enzymes; te reconnical object 23. (U) 1) Elu substr 3) Con and pl 5) isol messa	(U) antigens: (U) (U) antigens: (U) (ve.* is approach, is icidate biochemi ates found in str rrelate virulence, hysiological varia late and purify fu late and purify fu	(U) <u>Ar</u> <u>) immunogen</u> <u>Paocatu (Paola</u> cal mechanisr atum coraeur enzyme prod ttions i <u>n vitro</u> ungal antigen antigen isolo	throderma be s: (U) virulent ins of infection n; characteriz iuction, and n and <u>in vivo</u> . s and fungal to tion procedure	n. 2) I e isola utritio 4) Det oxins.	Perfe ted (onal erm 6) 1	U) <u>Tric</u> U) <u>Tric</u> nea pige ect assa enzyme require ine anti Devise r in ime		MSC <u>on mentagro</u> <u>in</u> ymes capab vsical-chemi fungus with tivity of iso erapeutic an m studior	boothyto le of h ical pro- h mor- lated of d prev	DA Si aydrolyzing occdures. phological enzymes. ventive
TE REVEALE JE TE REVEALE JE (U) Enzymes; TE TECHNICAL OBJECT 23. (U) 1) Elu substr 3) Cor and pl 5) isol measu 24. (U) 1) Enzymes;	(U) antigens: (U) (U) antigens: (U) (ve. ⁹ as approach, as incidate biochemi ates found in str prelate virulence, hysiological varia late and purify for the by perfecting autors data	(U) <u>Ar</u> <u>) immunogen</u> <u>) immunogen</u> cal mechanisr atum corneur enzyme prod ations i <u>n vitr</u> o ungal antigen g antigen isola	throderma be s: (U) virulens ns of infection n; characteriz iuction, and n and <u>in vivo</u> . s and fungal to thisn procedu	n. 2) I e isola utritio 4) Det oxins. res for	Perfe ted (onal erm 6) l use	King, R Jaeger, U) <u>Tric</u> nea pige ect assa enzyme require ine anti Devise t in imm	D., CPT J.R., DA hophytc s:(U) ski y of enz s by phy ments of genic ac novel the unizatio	MSC on mentagro mentagro mentagro ymes capab ysical-chemi fungus with tivity of iso erapeutic an in studies.	ophyto of a contract le of h ical pro- h mor lated d prev	DA Si nydrolyzing occdures. phological enZymes. /entive
ст. сенепац use (U) спzутез; ст. тестноса, оваест 23. (U) 1) Elu substr 3) Cor and pl 5) Isol measu 24. (U) 1) En	<u>(U) antigens: (U</u> (<u>U) antigens: (U</u> (uc. [•] is approach, is incidate biochemi ates found in str trelate virulence, hysiological varia late and purify fources by perfecting zymes – determit	(U) <u>Ar</u> <u>) immunogen</u> <u>) immunogen</u> cal mechanist atum corneur enzyme prod ations i <u>n vitro</u> ungal antigen g antigen isola ine fungal enz 2) Antigen	throderma be s: (U) virulens ns of infection n; characteriz luction, and n and <u>in vivo</u> . s and fungal to tion procedur cymic activity (Voccina)	n. 2) I e isola utritio 4) Det oxins. res for against	ae; (gui Perfe ted (onal erm 6) I use	King, R Jaeger, U) <u>Tric</u> nea pige ect assa enzyme require ine anti Devise t in imm ratum c		MSC <u>on mentagro</u> <u>in</u> ymes capab vsical-chemi fungus with tivity of iso erapeutic an n studies. component	by the contract of the contrac	DA
CI. GENERAL USE CI. GENERAL USE (U) Enzymes; 23. (U) 1) Elu substr. 3) Cor and pl 5) Isol measu 24. (U) 1) Enzymes; putify ferine	(U) antigens: (U) (U) antigens: (U) (vz.* as approach, as incidate biochemi ates found in str rrelate virulence, hysiological varia late and purify four is by perfecting zymes – determit fungal enzymes immunity to exi	(U) <u>Ar</u> <u>) immunogen</u> <u>) immunogen</u> cal mechanist atum corneur enzyme prod ttions i <u>n vitro</u> ungal antigens g antigen isola ine fungal enz . 2) Antigens perimental an	throderma be <u>5: (U) virulens</u> ns of infection n; characteriz iuction, and n and <u>in vivo</u> . s and fungal to tion procedur cymic activity (Vaccine)	n. 2) I e isola utritio 4) Det oxins. res for agains isolate maton	Perfected (onal erm 6) I use ist stu-	U) <u>Tric</u> Neap 12 (U) <u>Tric</u> (U) <u>Tric</u> (U) <u>Tric</u> (C)	.D., CPT J.R., DA hophytc s:(U) ski of enzy s by phy ments of genic ac hovel the unizatio orneum cellular	MSC <u>on mentagra</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u>	le of h ical pro- h mor- lated of prevention of the lated	DA S: aydrolyzing occdures. phological enzymes. yentive late and of con- 3) Toving
CI. GENERAL USE (U) Enzymes; (U) Enzymes; 23. (U) 1) Elu substr. 3) Cor and pl 5) Isol measu 24. (U) 1) Enzymes; jsolate	(U) antigens: (U) (U) antigens: (U) (VZ.* as approach, as incidate biochemi ates found in str rrelate virulence, hysiological varia late and purify four late and purify four symes – determi fungal enzymes immunity to exp and characteriz	(U) <u>Ar</u> <u>) immunogen</u> <u>) immunogen</u> cal mechanism atum corneum enzyme prod ttions in vitro ungal antigens g antigen isola ine fungal enz . 2) Antigens perimental an e the mycoto	throderma be <u>5: (U) virulens</u> ns of infection n; characteriz iuction, and n and <u>in vivo</u> . s and fungal to tion procedur cymic activity (Vaccine) – d natural Der- xips producer	n. 2) I e isola utritio 4) Det oxins. res for agains isolate matop	Perfected (onal errn 6) l use st stri and hyte	U) <u>Tric</u> Nager, U) <u>Tric</u> nea pige ect assa enzyme require ine anti Devise r in imm ratum c l pruify e infect	b. D., CPT J.R., DA hophytc (U) ski (U) ski (U	MSC on mentagro in mentagro in studies capab sical-chemi fungus with tivity of iso erapeutic an on studies. component fractions ca nimals and prophytes to	boot to the second seco	DA S: aydrolyzing occdures. phological enzymes. yentive late and of con- 3) Toxins - rmine their
TC ACTIONAL USE (U) Enzymes; (U) Enzymes; (U) Enzymes; 23. (U) 1) Elu substr 3) Cor and pl 5) Isol measu 24. (U) 1) Enz putify fering isolate biolog	(U) antigens: (U) (U) antigens: (U) (U) antigens: (U) (U) antigens: (U) (U) antigense (U) a	(U) <u>Ar</u> <u>) immunogen</u> <u>raccats</u> (Frain atum corneur enzyme prod ations in vitro ungal antigens g antigen isola ine fungal enz . 2) Antigens perimental an e the mycoto their role in d	throderma be s: (U) virulend ins of infection n; characteriz iuction, and n and <u>in vivo</u> . s and fungal to ition procedure cymic activity (Vaccine) – d natural Der xins produced isease.	n. 2) I e isola utritio 4) Det oxins. res for agains isolate matop 1 by <u>Ti</u>	ae; (guin Perfe ted (onal erm 6) l use st stri st and hyte richo	U) <u>Tric</u> Nagger, U) <u>Tric</u> nea pige ect assa enzyme require ine anti Devise r in imm ratum c l pruify e infecti ophyton	D., CPT J.R., DA hophyta i. (U) ski y of enzy s by phy ments of genic ac novel the unizatio orneum cellular ions in a <u>menta</u>	MSC on mentagro in security closed ymes capab ysical-chemi f fungus with tivity of iso prapeutic an on studies. component fractions ca nimals and grophytes to	bophyto allon cont le of h ical pro- h mor- lated of pro- d pro- s; isola apable man. o deter	DA S: nydrolyzing occdures. phological enzymes. yentive late and of con- 3) Toxins - rmine their
TE REVEAL USE (U) Enzymes; (U) Enzymes; EL TECANICAL OBJECT 23. (U) 1) Elu substr 3) Cot and pl 5) isol measu 24. (U) 1) Enz putify fering isolate biolog	(U) antigens: (U) (U) antigens: (U) (U) antigens: (U) (U) antigens: (U) (U) antigens: (U) (U) antigense (U) antigense ((U) <u>Ar</u> <u>) immunogen</u> <u>easentii (restation</u> cal mechanism atum corneum enzyme prod ntions <u>in vitro</u> ungal antigens g antigen isola ine fungal enz . 2) Antigens perimental an e the mycoto their role in d	throderma be s: (U) virulens s: (U) virulens throad perspective ns of infection n; characteriz iuction, and n and <u>in vivo</u> . s and fungal to thion procedure cymic activity (Vaccine) – d natural Der xins produced isease.	n. 2) I e isola utritio 4) Det oxins. res for agains isolate matop	Perfected (onal errm 6) I use st str and hyte	U) <u>Tric</u> <u>U) Tric</u> <u>nea pigs</u> ect assa enzyme require ine anti Devise t in imm ratum c l pruify e infection ophyton	D., CPT J.R., DA hophyta (U) ski (U) s	MSC on mentagro in security closelve ymes capab /sical-chemi f fungus wit tivity of iso erapeutic an on studies. component fractions ca nimals and grophytes to	ophyto eller cell le of h ical pro- h mor- lated of prev s; isol apable man. o dete	DA S: nydrolyzing occdures. phological enzymes. yentive late and of con- 3) Toxins rmine their
CI. deneRAL use (U) €nzymes; (U) €nzymes; 23. (U) 1) Elu substr 3) Cor and pl 5) isol measu 24. (U) 1) Enz purify fering isolate biolog 25. (U) 71 07	(U) antigens: (U) (U) antigens: (U) (u) antigens: (U) (u) antigens: (U) (u) antigens: (U) (u) antigens (u) a	(U) <u>Ar</u> <u>) immunogen</u> <u>Process</u> (U) <u>Ar</u> <u>) immunogen</u> ratum cornens atum cornens enzyme prod tions <u>in vitro</u> ungal antigens g antigen isola inc fungal enz . 2) Antigens perimental an e the mycoto their role in d rains of <u>T. me</u>	throderma be s: (U) virulens ns of infection n; characteriz iuction, and n and <u>in vivo</u> . s and fungal to tion procedur cymic activity (Vaccine) – d natural Der xins produced isease. ntagrophytes	n. 2) I e isola utritio 4) Det oxins. res for agains isolate matop 1 by <u>T</u>	ac; (gui Perfe ted (onal erm 6) I use st str i and hyte riche	King, R Jaeger, U) <u>Tric</u> nea pige ect assa enzyme require ine anti Devise t in imm ratum c l pruify e infecti ophyton	D., CPI J.R., DA hophyta (U) ski (U) s	MSC on mentagro	ophyto elle of f ical pro- lated of prev s; iso apable man. o deter for th	DA by hydrolyzing occdures. phological enzymes. yentive late and of con- 3) Toxins rmine their eir ability
tt acveration use (U) enzymes; (U) enzymes; 23. (U) 1) Elu substr 3) Con and pl 5) isol measu 24. (U) 1) Enzymes; isolate biolog 25. (U) 71 07 to pro	EACH ON LOOM COMPACT (U) antigens: (U) (U) anti	(U) <u>Ar</u> <u>) immunogen</u> <u>) immunogen</u> cal mechanism atum corneum enzyme prod tions <u>in vitro</u> ungal antigens g antigen isola ine fungal enz . 2) Antigens perimental an e the mycoto their role in d rains of <u>T. me</u> ing enzymes:	<u>throderma be</u> <u>s: (U) virulens</u> ins of infection n; characteriz iuction, and n and <u>in vivo</u> . s and fungal to tion procedur cymic activity (Vaccine) – d natural Der xins produced isease. <u>ntagrophyte</u> s collagenase, o	n. 2) I e isola utritio 4) Det oxins. res for agains isolate matop 1 by <u>Ti</u> and <u>A</u> elastase	ac; (gui gui Perfe ted (onal erm 6) I use st stri- and hyte riche	King, R Jaeger, U) <u>Tric</u> nea pige ect assa enzyme require ine anti Devise r in imm ratum c l pruify e infecti ophyton nhamiae ratinas	D., CPI J.R., DA hophyta i.(U) ski i.(U) ski i	MSC on mentagra	ophyto even control le of h ical pro- lated of pro- lated of lated of lated of lated of lated of lat	DA S: hydrolyzing occdures. phological enzymes. yentive late and of con- 3) Toxins rmine their eir ability rotease and
Contract of the second	<u>ACH - IN Joseth Clouin</u> (U) antigens: (U) (U) antigens: (U) (Vz.* 24 APPROACH, 25 Incidate biochemi ates found in str rrelate virulence, hysiological varia late and purify fu- res by perfecting zymes – determi fungal enzymes immunity to exp e and characteriz ic function and the - 72 06 1) Str duce the followi 2. 2) A purified I	(U) <u>Ar</u> <u>) immunogen</u> <u>) immunogen</u> cal mechanism atum corneum enzyme prod ttions <u>in vitro</u> ungal antigens g antigen isola ine fungal enz . 2) Antigens perimental an e the mycoto their role in d rains of <u>T. me</u> ing enzymes: keratinase pre	<u>throderma be</u> <u>s: (U) virulen</u> ns of infection n; characteriz luction, and n and <u>in vivo</u> . s and fungal to tion procedur cymic activity (Vaccine) – d natural Der xins produced isease. <u>ntagrophytes</u> collagenase, o paration from	n. 2) H e isola utritio 4) Det oxins. res for agains isolate matop by <u>Ti</u> and <u>A</u> elastase <u>a</u> <u>Co</u>	ae; (gui gui erm 6) l use st str and hyte richs e, ke	U) <u>Tric</u> Ning, R Jaeger, U) <u>Tric</u> nea pigg ect assa enzyme required ine anti Devise t in imm ratum c l pruify e infection ophyton	base base base base base base base base	MSC <u>on mentagra</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u>	ophyto even control le of h ical pro- lated of pro- lated of lated of lated of lated o	DA
 In GENERAL USE It AEVERAL USE (U) Enzymes; (U) Enzymes; (U) 1) Elu substr (U) 1) Elu substr (U) 1) Enz substr (U) 1) Enz purify fering isolate biolog (U) 71 07 to pro urease sensiti cell w: 	<u>ACH - 18 Joosh Cloud</u> (U) antigens: (U) (U) antigens: (U) (U) antigens: (U) (U) antigens: (U) (U) antigens: (U) (U) antigens: (U) ant	(U) <u>Ar</u> <u>) immunogen</u> <u>Pacenti</u> (U) <u>Ar</u> <u>) immunogen</u> pacenti (Pate atum corneur enzyme prod tions <u>in vitro</u> ungal antigens g antigen isola ine fungal enz . 2) Antigens perimental an e the mycoto their role in d ains of <u>T. me</u> ing enzymes: keratinase pre guinea pigs a	<u>throderma be</u> <u>s: (U) virulen</u> ns of infection n; characteriz luction, and n and <u>in vivo</u> . s and fungal to tion procedur cymic activity (Vaccine) – d natural Der xins produced isease. <u>ntagrophytes</u> collagenase, o paration from	n. 2) H e isola utritio 4) Det oxins. res for agains isolate matop 1 by <u>Ti</u> and <u>A</u> elastase 1 <u>T. me</u>	ae; (gui gui gui erm 6) l use st str and hyte richs e, ke enta wal	Visition of the second	.D., CPI J.R., DA hophyta (U) ski (U)	MSC <u>on mentagra</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u>	ophyto even control le of h ical pro- lated of pro- lated of pro- man. of deter for th base, p tive de T. me	DA S: hydrolyzing occdures. phological enzymes. yentive late and of con- 3) Toxins runine their eir ability protease and layed hype ntagrophyt
(U) <u>enzymes;</u> (U) <u>enzymes;</u> (U) <u>enzymes;</u> (U) <u>1) Elu</u> substr 3) Con and pl 5) isoi measu 24. (U) 1) Enz purify fering isolate biolog 25. (U) 71 07 to pro urease sensiti cell wi olasmi	<u>(U) antigens: (U)</u> <u>(U) antigens: (U) antigens: (</u>	(U) <u>Ar</u> <u>) immunogen</u> <u>Pacenti</u> (U) <u>Ar</u> cal mechanism atum corneum enzyme prod ations <u>in vitro</u> ungal antigens g antigen isola ine fungal enz . 2) Antigens perimental an e the mycoto their role in d ains of <u>T. me</u> ing enzymes: ceratinase pre g guinea pigs a being characte been isolated	<u>throderma be</u> <u>s: (U) virulens</u> ns of infection n; characteriz luction, and n and <u>in vivo</u> . s and fungal to tion procedur cymic activity (Vaccine) – d natural Der xins produced isease. <u>ntagrophytes</u> collagenase, e paration from nd humans.	n. 2) I e isola utritio 4) Det oxins. res for agains isolate matop 1 by <u>Ti</u> and <u>A</u> elastase 1 <u>T. me</u> 3) Cell ally an charage	ae; (gui gui erm 6) l use st str and hyte st str and hyte e, ke enta wal d in cteri	U) <u>Tric</u> King, R Jaeger, U) <u>Tric</u> nea pige ect assa enzyme require ine anti Devise t in imm ratum c I pruify in fection ophyton maniae grophy Ils have imunol	.D., CPI J.R., DA hophyto (U) ski (U)	MSC <u>on mentagra</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u>	ophyto even control le of h ical pre- lated of pable man. o deter for th base, p tive de T. mc otiona	DA
II. deneñal, use (U) €nzymes; (U) €nzymes; 23. (U) 1) Elu substr 3) Con and pl 5) isol measu 24. (U) 1) Enz purify fering isolate biolog 25. (U) 71 07 to pro urease sensiti cell w; plasmi fungus	(U) antigens: (U) (U) antigens: (U) (U) antigens: (U) (u) at approach, as incidate biochemi ates found in str rrelate virulence, hysiological varia late and purify fu- irres by perfecting zymes – determi fungal enzymes immunity to exp and characteriz ic function and i (-72 06 1) Str duce the followi (-2) A purified I vity responses in all fractions are I ic antigens have is are being evalue	(U) <u>Ar</u> <u>) immunogen</u> <u>) immunogen</u> cal mechanist atum corneur enzyme prod ations in vitro ungal antigens g antigen isola ine fungal enz . 2) Antigens perimental an e the mycoto their role in d rains of <u>T. me</u> ing enzymes: keratinase pre guinea pigs a being characted been isolated ated for their	throderma be s: (U) virulens ns of infection n; characteriz iuction, and n and <u>in vivo</u> . s and fungal to tion procedur cymic activity (Vaccine) – d natural Der xins produced isease. <u>ntagrophytes</u> collagenase, of paration from and are being ability to com	n. 2) I e isola utritio 4) Det oxins. res for agains isolate matop 1 by <u>T</u> and <u>A</u> elastase 1 <u>T. mo</u> 3) Cell ally an charac	ae; (<u>guin</u> Perfeted (onal onal use t strue and hyter icho e, ke <u>eenta</u> wal d in cteri mur	Listicator King, R Jaeger, U) <u>Tric</u> nea pige ect assa enzyme require ine anti Devise r in imm ratum c I pruify e infecti ophyton hamias grophy lis have lis have simunol ized. Sj nity in e	.D., CPT J.R., DA hophyto s: (U) ski y of enz s by phy ments of genic ac novel the unizatio orneum cellular cellular orneum cellular e have be e, lipase, tes has e been iso ogically All sub	MSC <u>on mentagra</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u>	ophyto le of h ical previous lated of pable man. o deter for the base. p live de T. moran ctions s and	DA set: aydrolyzing occdures. phological enzymes. yentive late and of con- 3) Toxins runine their eir ability protease and layed hype ntagrophyt te and cyto of the in human
 CU) <u>enzymes;</u> <u>(U) enzymes;</u> <u>(U) enzymes;</u><td>EACH - 18 Loom, 2000 (U) antigens: (U) (U) antigens: (U) (u) a spendace, as incidate biochemi ates found in str rrelate virulence, hysiological varia late and purify fu- rres by perfecting zymes – determi fungal enzymes immunity to exp and characteriz ic function and (- 72 06 1) Str duce the followi (- 2) A purified 1 ivity responses in all fractions are 1 is antigens have is a re being evalua- ters in conjunct</td><td>(U) <u>Ar</u> <u>) immunogen</u> <u>) immunogen</u> cal mechanism atum corneum enzyme prod ations i<u>n vitro</u> ungal antigens g antigen isola ine fungal enz . 2) Antigens perimental an e the mycoto their role in d ains of <u>T. me</u> ing enzymes: keratinase pre guinea pigs a being characted ated for their ion with Proje</td><td>throderma be s: (U) virulens ns of infection n; characteriz uction, and n and <u>in vivo</u>. s and fungal to tion procedur cymic activity (Vaccine) – d natural Der xins produced isease. <u>ntagrophytes</u> collagenase, of paration from and humans. erized chemics and are being ability to con ect No. DA O</td><td>n. 2) I e isola utritio 4) Det oxins. res for agains isolate matop 1 by <u>T</u> and <u>A</u> elastaso <u>T. mo</u> 3) Cell ally an charac</td><td>ae; (ae; (auii Perfeted onal erm 6) l use st stu and hyte st stu any te st stu any te st stu any te st stu any te st stu any te stu stu stu stu stu stu stu stu stu stu</td><td>Visition of King, R Jaeger, U) <u>Tric</u> nea pige ect assa enzyme require ine anti Devise r in imm ratum c I pruify infection ophyton hamiae grophy lls have imunol- ized. S hity in e Vork Ur</td><td>.D., CPT J.R., DA hophyto s:(U) ski y of enz s by phy ments of genic ac novel the unizatio orneum cellular orneum cellular on in a mentage have be e, lipase, tes has e been iso ogically All sub experimo nit 006.</td><td>MSC <u>on mentagra</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u></td><td>ophyto le of h ical prev lated of apable s; isol apable man. o deter for th base, p tive de <u>T. mc</u> mbran ctions s and</td><td>DA S: aydrolyzing occdures. phological enzymes. yentive late and of con- 3) Toxins- rmine their eir ability rotease and layed hype <u>ntagrophyt</u> ne and cyto of the in human</td>	EACH - 18 Loom, 2000 (U) antigens: (U) (U) antigens: (U) (u) a spendace, as incidate biochemi ates found in str rrelate virulence, hysiological varia late and purify fu- rres by perfecting zymes – determi fungal enzymes immunity to exp and characteriz ic function and (- 72 06 1) Str duce the followi (- 2) A purified 1 ivity responses in all fractions are 1 is antigens have is a re being evalua- ters in conjunct	(U) <u>Ar</u> <u>) immunogen</u> <u>) immunogen</u> cal mechanism atum corneum enzyme prod ations i <u>n vitro</u> ungal antigens g antigen isola ine fungal enz . 2) Antigens perimental an e the mycoto their role in d ains of <u>T. me</u> ing enzymes: keratinase pre guinea pigs a being characted ated for their ion with Proje	throderma be s: (U) virulens ns of infection n; characteriz uction, and n and <u>in vivo</u> . s and fungal to tion procedur cymic activity (Vaccine) – d natural Der xins produced isease. <u>ntagrophytes</u> collagenase, of paration from and humans. erized chemics and are being ability to con ect No. DA O	n. 2) I e isola utritio 4) Det oxins. res for agains isolate matop 1 by <u>T</u> and <u>A</u> elastaso <u>T. mo</u> 3) Cell ally an charac	ae; (ae; (auii Perfeted onal erm 6) l use st stu and hyte st stu any te st stu any te st stu any te st stu any te st stu any te stu stu stu stu stu stu stu stu stu stu	Visition of King, R Jaeger, U) <u>Tric</u> nea pige ect assa enzyme require ine anti Devise r in imm ratum c I pruify infection ophyton hamiae grophy lls have imunol- ized. S hity in e Vork Ur	.D., CPT J.R., DA hophyto s:(U) ski y of enz s by phy ments of genic ac novel the unizatio orneum cellular orneum cellular on in a mentage have be e, lipase, tes has e been iso ogically All sub experimo nit 006.	MSC <u>on mentagra</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u>	ophyto le of h ical prev lated of apable s; isol apable man. o deter for th base, p tive de <u>T. mc</u> mbran ctions s and	DA S: aydrolyzing occdures. phological enzymes. yentive late and of con- 3) Toxins- rmine their eir ability rotease and layed hype <u>ntagrophyt</u> ne and cyto of the in human
 CU CREAL USE CU CREAL USE CU CREAL USE CU CREAL OBJECT COLORIZATION CU CREAL OBJECT <li< td=""><td>(U) antigens: (U) (U) antigens: (U) (u) antigens: (U) (u) a service of the ser</td><td>(U) <u>Ar</u> <u>) immunogen</u> cal mechanism atum corneum enzyme prod ations in vitro ungal antigens g antigen isola ine fungal enz. 2) Antigens perimental an e the mycoto their role in d ains of <u>T. me</u> ing enzymes: keratinase pre guinea pigs a being characted ated for their ion with Proje</td><td>throderma be s: (U) virulens ns of infection n; characteriz luction, and n and <u>in vivo</u>. s and fungal to tion procedur cymic activity (Vaccine) – d natural Der xins produced isease. <u>ntagrophytes</u> collagenase, of paration from and are being ability to con- ect No. DA O</td><td>n. 2) I e isola utritio 4) Det oxins. res for agains isolate matop i by <u>T</u> and <u>A</u> elastaso <u>T. mo</u> 3) Cell ally an charac fer im</td><td>ac; (ac; (ac; (ac; (and bonal erm 6) l use st str and hyte st str and hyte chai erm chai chai ac hyte st str and hyte chai ac hyte chai hyte hyte chai ac hyte chai hyte chai hyte hyte chai hyte hyte hyte hyte hyte hyte hyte hyte</td><td>Visition of the second second</td><td>.D., CPT J.R., DA hophyto i.(U) ski y of enzy s by phy ments of genic ac novel the unizatio orneum cellular in mentage have be e, lipase, tes has e been iso ogically All sub experimonit 006.</td><td>MSC <u>on mentagra</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u></td><td>ophyto le of h ical prev lated of apable man. o deter for th base, p tive de T. me mbrai ctions s and</td><td>DA S: ydrolyzing occdures. phological enzymes. yentive late and of con- 3) Toxins - rmine their eir ability protease and layed hype <u>ntagrophyt</u> ne and cyto of the in human</td></li<>	(U) antigens: (U) (U) antigens: (U) (u) antigens: (U) (u) a service of the ser	(U) <u>Ar</u> <u>) immunogen</u> cal mechanism atum corneum enzyme prod ations in vitro ungal antigens g antigen isola ine fungal enz. 2) Antigens perimental an e the mycoto their role in d ains of <u>T. me</u> ing enzymes: keratinase pre guinea pigs a being characted ated for their ion with Proje	throderma be s: (U) virulens ns of infection n; characteriz luction, and n and <u>in vivo</u> . s and fungal to tion procedur cymic activity (Vaccine) – d natural Der xins produced isease. <u>ntagrophytes</u> collagenase, of paration from and are being ability to con- ect No. DA O	n. 2) I e isola utritio 4) Det oxins. res for agains isolate matop i by <u>T</u> and <u>A</u> elastaso <u>T. mo</u> 3) Cell ally an charac fer im	ac; (ac; (ac; (ac; (and bonal erm 6) l use st str and hyte st str and hyte chai erm chai chai ac hyte st str and hyte chai ac hyte chai hyte hyte chai ac hyte chai hyte chai hyte hyte chai hyte hyte hyte hyte hyte hyte hyte hyte	Visition of the second	.D., CPT J.R., DA hophyto i.(U) ski y of enzy s by phy ments of genic ac novel the unizatio orneum cellular in mentage have be e, lipase, tes has e been iso ogically All sub experimonit 006.	MSC <u>on mentagra</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u>	ophyto le of h ical prev lated of apable man. o deter for th base, p tive de T. me mbrai ctions s and	DA S: ydrolyzing occdures. phological enzymes. yentive late and of con- 3) Toxins - rmine their eir ability protease and layed hype <u>ntagrophyt</u> ne and cyto of the in human
 CU) <u>enzymes</u>; (U) <u>enzymes</u>; <	(U) antigens: (U) (U) antigens: (U) (U) antigens: (U) (U) antigens: (U) (U) antigens: (U) (U) antigense (U) antigense ((U) <u>Ar</u> <u>) immunogen</u> <u>) immunogen</u> cal mechanism atum corneum enzyme prod ations in vitro ungal antigens g antigen isola ine fungal enz. 2) Antigens perimental an e the mycoto their role in d ains of <u>T</u> . me ing enzymes: keratinase pre guinea pigs a being characted been isolated ated for their ion with Proje	throderma be s: (U) virulens ns of infection n; characteriz luction, and n and <u>in vivo</u> . s and fungal to tion procedur cymic activity (Vaccine) – d natural Der xins produced isease. <u>ntagrophytes</u> collagenase, of paration from and are being ability to con ect No. DA O	n. 2) I e isola utritio 4) Det oxins. res for agains isolate matop i by <u>T</u> and <u>A</u> elastaso <u>T. mo</u> 3) Cell ally an charac fer im	ae; (ae; (auii) Perfeted (anal erm 6) l use st stri and hyte st stri hyte st stri hyte hyte hyte stri hyte hyte hyte hyte hyte hyte hyte hyte	King, R Jaeger, U) <u>Tric</u> nea pige ect assa enzyme require ine anti Devise r in imm ratum c l pruify e infecti <u>ophyton</u> mhamiae eratinas grophy lls have imunol ized. 5 nity in e York Ur	.D., CPT J.R., DA hophyta i.(U) ski y of enzy s by phy ments of genic ac novel the unizatio orneum cellular ions in a <u>mentag</u> have be e, lipase, tes has e been iso ogically All sub experimo it 006.	MSC <u>on mentagro</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u>	ophyto le of h ical prev lated of apable man. o deter for th base, p tive de T. me mbrai ctions s and	DA S: hydrolyzing occdures. phological enzymes. yentive late and of con- 3) Toxins - rmine their eir ability protease and layed hype <u>ntagrophyt</u> ne and cyto of the in human
 CU) <u>enzymes</u>; <u>(U) enzymes</u>; <	(U) antigens: (U) (U) antigens: (U) (U) antigens: (U) (U) antigens: (U) (U) antigens: (U) (U) antigense (U) antigense ((U) <u>Ar</u> <u>) immunogen</u> cal mechanism atum corneum enzyme prod ations in vitro ungal antigens g antigen isola ine fungal enz. 2) Antigens perimental an e the mycoto their role in d ains of <u>T</u> . me ing enzymes: keratinase pre guinea pigs a being characted been isolated ated for their ion with Proje	throderma be s: (U) virulens ns of infection n; characteriz luction, and n and <u>in vivo</u> . s and fungal to tion procedur cymic activity (Vaccine) – d natural Der xins produced isease. <u>ntagrophytes</u> collagenase, of paration from and are being ability to con ect No. DA O	n. 2) I e isola utritio 4) Det oxins. res for agains isolate matop i by <u>T</u> and <u>A</u> elastaso <u>T. mo</u> 3) Cell ally an charac fer im	ac; (ac; (King, R Jaeger, U) <u>Tric</u> nea pige ect assa enzyme require ine anti Devise r in imm ratum c l pruify e infecti <u>ophyton</u> mhamiae eratinas <u>grophy</u> lls have imunol ized. 5 nity in e York Ur	.D., CPT J.R., DA hophyta i.(U) ski y of enzy s by phy ments of genic ac novel the unizatio orneum cellular ions in a mentage have be e, lipase, tes has e been iso ogically All sub experimo it 006.	MSC <u>on mentagro</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u>	ophyto le of h ical prev lated of apable man. o deter for th base, p tive de T. me mbrai ctions s and	DA S: hydrolyzing occdures. phological enzymes. yentive late and of con- 3) Toxins - rmine their eir ability protease and layed hype <u>ntagrophyt</u> he and cyto of the in human
 ceneral use ceneral use <u>(U) enzymes:</u> <u>(U</u>	(U) antigens: (U) (U) antigens: (U) antigens: (U) (U) antigens: (U) antigens: (U) antigens: (U) (U) antigens: (U) antigens: (U	(U) <u>Ar</u> <u>) immunogen</u> cal mechanism atum corneum enzyme prod ations in vitro ungal antigens g antigen isola ine fungal enz. 2) Antigens perimental an e the mycoto their role in d ains of <u>T</u> . me ing enzymes: keratinase pre g guinea pigs a being characted ated for their ion with Proje	throderma be s: (U) virulens ns of infection n; characteriz iuction, and n and <u>in vivo</u> . s and fungal to ation procedur cymic activity (Vaccine) – d natural Der- xins produced isease. <u>ntagrophytes</u> collagenase, of paration from and are being ability to con ect No. DA C	n. 2) I e isola utritio 4) Det oxins. res for agains isolate matop 1 by <u>Ti</u> and <u>A</u> elastase <u>T. me</u> 3) Cell ally an charac fer im	ae; (ae; (ae; (ae; (anal erm 6) l use ist stu and hyte ist	King, R Jaeger, U) <u>Tric</u> nea pige ect assa enzyme require ine anti Devise r in imm ratum c I pruify e infecti <u>ophyton</u> hhamiae eratinas <u>grophy</u> Ils have imunol ized. 5) nity in e	.D., CPT J.R., DA hophyta i.(U) ski y of enzy s by phy ments of genic ac novel the unizatio orneum cellular ions in a mentage have be e, lipase, tes has e been iso ogically All sub experimo it 006.	MSC <u>on mentagro</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u>	ophyto le of h ical prev lated of apable man. o deter for th base, p tive de <u>T. me</u> mbrai ctions s and	DA S: hydrolyzing occdures. phological enzymes. yentive late and of con- 3) Toxins rmine their eir ability protease and layed hype <u>ntagrophyt</u> he and cyto of the in human
rt. ceneral use (U) <u>enzymes;</u> (U) <u>enzymes;</u> (U) <u>enzymes;</u> 23. (U) 1) Elu substr 3) Con and pl 5) iso measu 24. (U) 1) En: putify fering isolate biolog 25. (U) 71 07 to pro urease sensiti cell w: plasmi fungus volunt	(U) antigens: (U) (U) antigens: (U) (U) antigens: (U) (VZ.* 24 APPROACH, 25 (VZ.* 24 AP	(U) <u>Ar</u> <u>) immunogen</u> cal mechanism atum corneum enzyme prod ations in vitro ungal antigens g antigen isola ine fungal enz. 2) Antigens perimental an e the mycoto their role in d ains of <u>T. me</u> ing enzymes: keratinase pre guinea pigs a being characted been isolated ated for their ion with Proje	throderma be s: (U) virulens ns of infection n; characteriz iuction, and n and <u>in vivo</u> . s and fungal to tion procedur cymic activity (Vaccine) – d natural Der xins produced isease. <u>ntagrophytes</u> collagenase, of paration from and are being ability to con ect No. DA C	n. 2) I e isola utritio 4) Det oxins. res for agains isolate matop 1 by <u>T</u> I and <u>A</u> elastase 1 <u>T. me</u> 3) Cell ally an charac offer im	ae; (guin Perfeted (onal erm 6) I use st stri and hyte st stri e, ke enta wal d in cteri mur 4, W	King, R Jaeger, U) <u>Tric</u> nea pige ect assa enzyme require ine anti Devise r in imm ratum c l pruify e infecti <u>ophyton</u> hamias grophy lls have imunol ized. Sj nity in e Vork Ur	.D., CPT J.R., DA hophyta (J) Ski y of enzy s by phy ments of genic ac novel the unizatio orneum cellular ions in a <u>mentag</u> have be e, lipase, tes has e been iso ogically All sub- experimo it 006.	MSC <u>on mentagro</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u> <u>in</u>	ophyto allow control le of h ical previous lated of apable man. o deter for the base, p live de <u>T. me</u> mbran ctions s and	DA S: hydrolyzing occdures. phological enzymes. yentive late and of con- 3) Toxins runine their eir ability protease and layed hype <u>ntagrophyt</u> he and cyto of the in human
 CONTRACTOR OF CONTRACTOR OF CONTRAC	EACH ON LEAST, COUNT (U) antigens: (U) incidate biochemi ates found in str rrelate virulence, hysiological varia late and purify fi irres by perfecting zymes – determi fungal enzymes immunity to exp and characteriz ic function and the duce the followi (2) A purified to vity responses in all fractions are to is are being evalua- teers in conjunct	(U) <u>Ar</u> <u>) immunogen</u> cal mechanism atum corneum enzyme prod ations in vitro ungal antigens g antigen isola ine fungal enz. 2) Antigens perimental an e the mycoto their role in d rains of <u>T. me</u> ing enzymes: keratinase pre a guinea pigs a being characted been isolated ated for their ion with Proje	throderma be s: (U) virulens ns of infection n; characteriz iuction, and n and <u>in vivo</u> . s and fungal to tion procedur cymic activity (Vaccine) – d natural Der xins produced isease. <u>ntagrophytes</u> collagenase, e paration from and are being ability to con ect No. DA C	n. 2) I e isola utritio 4) Det oxins. res for agains isolate matop i by <u>Ti</u> and <u>A</u> elastase i <u>T. ma</u> 3) Cell ally an charace offer im	ae; (<u>guin</u> Perfeted (onal erm 6) l use st stri and hyte <u>icho</u> e, ke <u>enta</u> wal d in cteri mur	King, R Jaeger, U) <u>Tric</u> nea pige ect assa enzyme require ine anti Devise r in imm ratum c l pruify e infecti <u>ophyton</u> hamiae eratinas <u>grophy</u> lls have imunol ized. Sj nity in e York Ur	.D., CPT J.R., DA hophyta (J) Ski y of enzy s by phy ments of genic ac novel the unizatio orneum cellular ions in a <u>mentag</u> e have be e, lipase, tes has e been iso ogically All sub- experimon it 006.	MSC <u>on mentagro</u> <u>in</u> <u>in</u> <u>in</u> ymes capab /sical-chemia fungus with tivity of iso erapeutic and n studies. component fractions c: nimals and grophytes to een studied phospholip licited positi lated from <u>4</u>) Cell me -cellular fra ental animal	ophyto allow control le of h ical prev- lated of apable man. o deter for the base, p live de <u>T. me</u> mbrai ctions s and	DA S: hydrolyzing occdures. phological enzymes. yentive late and of con- 3) Toxins runine their eir ability rotease and layed hype <u>ntagrophyt</u> ie and cyto of the in human

CONTRACTOR CONTRACTOR AND CONTRACTOR

tatan menyenya sana para ata ang manganang menangkan panangan panangan nanganang tana satah tanang bang pang s

1

and a second and the second of the second of the second second second second second second second second second

and first the

......

4"26 . 7 Me-

RESEARCH	AND TECHNOLOGY	WORK UNIT SU	JANARY	DA	OC 6792	1. DATE 0	07 01	DD-D	CONTROL SYNBOL
71 07 01	. KIND OF SUMMARY	S. SUMMARY SCTY	. WORK SECURITY	7 REGRA	A I	NT.	CONTRAC	FIC DATA	A FORK UNIT
NO./CODES:*	PROGRAM ELEMENT	PROJECT	NUMBER	TASK A	REA NUMBER	T	WORK	UNIT NUMBE	I
PRIMARY	62110A	3A06211	0A831	0	0	1	005		
CONTRIBUTING						2000		· · ·	
CONTRIBUTING	and the strengtheness of the	• (TT)				<u></u>			botting
Susceptibi	lity to Funga	1 Infection	s (05)	wien		Diagn			
010100 -	Microbiology	14. ESTIMATED COM		TIL FUND	HA ASENCY		Tut Bear	OBMANCE ME	1000
70 04		72 02		D	A	1	C.	In-ho	use
CONTRACT/GRANT	NA	EXPIRATION:		10. AES	PRECEDING	TE & PRO	FESSIONAL MAI	YRS & FU	IX 86 (In thousands)
NUNDER:*	1 1 1 1			FISCAL	73		0		0
TYPE		& AMOUNT:		YEAR	CUNNERY		•		
KIND OF AWARD:		f. CUM. AMT.			72		1		10
RE. ANSIELE DOD	DRGANIZATION	· · · · · · · · · · · · · · · · · · ·		20. PER	FORMING OREAN	IZATION			
wailetterm _{boass:*} Pres	an Army Inst idio of San Fi	ancisco, (search CA 94129	HAME;*	Lettern Dermat Presidio	an Ar ology o of Sa	my Inst Resear in Fran	itute ol ch Divi cisco, (f Researd sion CA 94129
	JAL			HAME-	• Kornfe	ld, L.	Ph. D.	mare jaotikuli ,	
Aker	s, W.A., CO	L MC		TELES	HONE:				
TELEPHONE: 41	5-561-5181			SOCIAI	L SECURITY AC				
. GENERAL USE				ASSOCIA	TE INVESTIGAT	ORS			
				HAME:					D
L KEYBOAGS (PHION	EACE with Somerity Classin								
25. (U) 7	1 07 - 72 06	Study term	inated due	e to r	esignati	on of :	investig	ator.	

1

in the second se

sam and the second second second

and the short of the formation of the

などをというのです

North Computer

to a provide the second s

Development of Methods for Diagnosing and Combatting Susceptibility to Fungal Infections

Lottie Kornfeld, PhD

GENERAL PROBLEM:

Fungal infections of the feet, groin and trunk are among the most common military medical problems in the humid tropics. Clinical and experimental observations indicate that the inflammatory nature of dermatophyte infections is due to a state of delayed hypersensitivity to the infecting fungus and/or its products. The hypersensitive state may persist for long periods after remission of a primary infection, so that an intense and more rapid inflammatory response occurs following reinfection with the same or an antigenically related fungus.

If immunoprophylaxis of the dermatophytoses is to be successful, it must prevent, or at least reduce, the development of the hypersensitive state. Before approaching the ultimate goal, certain fundamental questions must be answered. To what extent does the immune response of the host affect the pathogenesis of the fungal infection? Does alteration of the host response alter the course of the disease? Which components/products of the fungus are responsible for eliciting the immunological responses? Is a sensitive and specific in vitro test available for detecting delayed hypersensitivity to dermatophytes?

ころうちょうち ちんこうちょう こうろうたい なんないない たちま ちょう

APPROACH:

A series of 4 experiments were performed to gain insight into these questions. The principle investigator departed in March 1972.

FROBLEM #1:

To evaluate various fractions prepared from <u>Tricho-</u> <u>phyton mentagrophytes</u> as potential skin test antigens for detecting delayed hypersensitivity to this fungus.

METHOD: Lyophilized materials prepared by CPT Reinhardt were dissolved in physiological saline and

sterilized by millipore filtration. Further dilutions to give the desired concentrations were prepared aseptically in sterile saline. The substances tested are listed in Table 1. Groups of normal guinea pigs and guinea pigs which had recovered from experimental infection with T. mentagrophytes were injected intradermally with 0.1ml quantities of all test materials. Skin reactions were observed 30 minutes later and after 24 and 48 hours. Reactions were scored by the usual criteria: the diameter of erythema was measured; intensity of erythema and intensity of induration were evaluated on a scale of 0 to 3. For comparison with a known skin test antigen, all animals were tested simultaneously with Cruickshank's trichophytin (CT).

RESULTS:

Immediate reactions to the test materials were never observed. Delayed reactions are summarized in Table 2. It can be seen that the following preparations exhibited both specificity and sensitivity under our experimental conditions and compared favorably with CT (100 μ g):

> Precipitate of culture supernate 100 ug Partially purified keratinase 100 ug 170-671-CT1 100 ug 170-771-SEP1 100 & 10 ug

PROBLEM #2:

To determine whether skin testing of normal guinea pigs with Cruickshank's trichophytin (CT) induces delayed hypersensitivity demonstrable by subsequent skin tests.

METHOD:

3 normal guinea pigs were each given 4 weekly intradermal injections of 100 ug CT. Skin reactions were recorded after 24 and 48 hours.

RESULTS:

Mild erythema without induration (mean diameter 9 mm) was observed 24 hours after the initial skin tests, but the réactions did not persist for 48 hours. However, intense erythema with induration (mean diameter

15.6 mm) was seen both 24 and 48 hours after the second set of skin tests. The severity of the skin reactions was essentially unchanged on further testing. Although only a small number of animals were used, the results of this study indicate that a single skin test with 100 ug CT was sufficient to induce delayed hypersensitivity to this antigen in our guinea pigs.

PROBLEM #3:

To test sera from volunteers and experimental animals for the presence of complement-fixing antibodies to Trichophyton mentagrophytes.

APPROACH:

Complement fixation tests were carried out essentially as outlined by Campbell, et al, in "Methods in Immunology," 1964. Overnight fixation at 4°C was found to be most suitable in this system. Lyophilized <u>T. mentagrophytes</u> "disrupted mycelium and cell sap," was rehydrated (1 mg/ml) and used in 1:8 dilution as antigen. Serum obtained from rabbits injected repeatedly with <u>T. mentagrophytes</u> mycelium was used for the titration of antigen and as a positive control. The titer of the immune rabbit serum was 1:128.

RESULTS:

a. Sera from 12 guinea pigs obtained 4 months after infection with <u>T</u>. <u>mentagrophytes</u> were negative in 1:2 dilution.

b. Sera from 6 guinea pigs obtained 7 months after fungal infection were negative in 1:4 dilution and showed slight complement fixation (of doubtful significance) in 1:2 dilution.

c. Sera from 6 human volunteers obtained before and during experimental fungal infection did not fix complement specifically in 1:2 dilution.

PROBLEM #4: •

To select breeders for the LAIR guinea pig colony on the basis of ease of acquiring contact sensitivity to dinitrochlorobenzene (DNCB).

METHODS:

The prospective breeders were brought to LAIR in October and December 1971 from the University of California at Davis, where a breeding colony had been maintained since March 1970. This colony was established with male and female Moen-Chase guinea pigs obtained directly from Dr. Merrill W. Chase of Rockefeller University, New York.

The methods employed for sensitization and skin testing were essentially those recommended by Dr. Chase, wit one notable exception. Dr. Chase tests and selects only prospective male breeders, we subjected both males and females to this procedure.

Sensitization:

A fresh solution of DNCB in alcoholic saline (42 ug DNCB/ml 0.83% ethanol in saline) was prepared by dissolving the chemical in an appropriate volume of 83% ethanol and diluting 100-fold with sterile saline. Three intradermal injections (0.1ml each) were given on the shaved right foreflank so that the three sites were approximately 1 inch apart and formed a triangle.

Skin Testing:

Ten days later, one drop (about 0.03 ml) of a 5% solution of DNCB (freshly prepared by dissolving a weighed amount of chemical in a small quantity of acetone and diluting with fresh corn oil to the required volume) was applied to the shaved back. Skin reactions were scored after 24 and 48 hours according to the following criteria:

- negative 0
- faint pink spots I+ faint pink - confluent 2+ pale pink
- 3+ bright pink
- 4+ deep pink, thickened

77 guinea pigs (Group 1) were sensitized on 29 October and skin tested on 8 November 1971; 53 guinea pigs (Group 2) were sensitized on 10 December and skin tested on 20 December 1971.

RESULTS:

24 and 48 hour skin reactions of all (130) animals were compared. 79 animals (61%) were selected for inclusion in the breeding colony

FUTURE PLANS:

Dr. Chase has stated that about one-third of the animals should be rejected. On this basis, the following tentative criteria for the selection of breeders have been adopted: at least a 2+ reaction either 24 or 48 hours after DNCB challenge. It may be advisable to apply more stringent criteria to the next generation of animals.

Table 1

Experimental T. mentagrophytes skin test antigens

Designation Description Disrupted mycelium and cell sap Precipitate of culture Ammonium sulfate preciptate supernate of extracellular supernate from fungus grown on plantar skin Partially purified DEAE column effluent of keratinase above material 170-671-CT1 Corresponds to Extract II described by Cruickshank, et al: JID 35: 219,1960 170-871 Nucleoprotein fraction 170-871-BCF1 "Cruickshank fraction" dialyzed, lyophilized, pH 9.5 borate 170-871-CAS1 "Cruickshank fraction" calcium acetate soluble 170-871-CT2 "Cruickshank trichophytin" 10 August 71 170-871-NPS1 Neutral polysaccharide fraction 18 August 71 170-771-SEP1 Schweizer's reagent of residue from two ethanol extractions

Skin reactions of infected and control guinea pigs to experimental *T. mentagrophytes* antigens

		Infe	ctcd s	auine	a pig	\$	Co	ontrol	guind	à pig	IS
Antigen µ	1) Dose 11/0.1 ml	Number Animals	l ryt 24 lur	48 hr	Indu 24 hr	48 hr	Noinest Animals	1.ryi 24 hr	hema 48 hr	Inde 24 hr	tation 48 hr
Cuickshank trichophytin	10	6	9.5	10.2	0	0	10	4.7	0.8	0	0
Disrupted mycelium and cell sap	500 100 10 10	6666	17.3 8.2 5.0 3,8	13.2 5.0 2.8 1.7	2.0 0 0	2.0 0.9 0	10 10 10 10	17.0 7.8 6.1 5.8	13.4 3.6 2.6 2.3	1.0 0 0	1.2 0 0 0
Cruickshank trichophytin	10	6	6.0	3.9	0	0	3	4.0	2.7	0	0
Precipitate of culture supernate	100 10 1	66	12.0 4.5 1.9	11.3 3.9 0.9	1.3 0.5 0	0.5 0 0	333	3.3 2.7 2.0	1.0 1.7 1.0	0000	0
Partially purified keratinase	100 10 1	666	10.0 5.2 2.6	10.0 3.6 1.6	1.7 0.7 0	1.0 0 0	333	2.7 2.0 1.7	3.0 2.0 1.0	000	000
Cruickshank trichophytin	100 10	66		12.5		1.8 1.0	4		1.8		0
176-671-CT1	100	6		12.5]	2.3	4		2.0		0.3
Cruickshank trichophytin	100	8	12.5	12.6	1.7	1.6				ŀ	
170-871-NPF1	100 10	4	6.25 4.25	5.75 0.50	8	8	1	5.00 4.25	3.25 1.50	00	00
170-871-BCF1	100 10	4	11.75 9.00	13.00 7.75	2.8 2.0	3.0 1.5	4	10.75 4.75	8.25 2.25	2.3 2.0	1.5 1.3
170-871-CAS1	100 10	1	9.75 4.75	6.25 2.00	0.8 0.5	0.8 0	1	3.75 4.00	1.00 0.50	8	8
170-871-CT2	100 10	1	5.00 4.25	1.75	0.	0	1	2.75	2.00 0	8	8
170-871-NPS1	100 10	11	3.75 5.50	1.75	0.5 1.5	00	1 1	1.75	0 2.25	8	8
170-771-SEPI	100 10	1	14.00 12.00	3.25 10.00	2.2 1.5	1.8 0.8	1	3.50 3.75	0.75 1.75	0.8 1.3	8

ĩ

CARLEN CARACTER CONTRACTOR OF CONTRACT

•Mean diameter in mm ••Mean.intensity (on scale of 0 to 3)

ana ang pangangan na pangangan ang pangangan ang pangangan ang pangangan ang pangangangan ang pangangangan ang

ALL CONTRACTOR OF A

1232.86

ait

		<u></u>							117		
RESEARCH	AND TECHNOLOGY	WORK UNIT S	UMMARY	1. AGEN	CV ACCESSION® OC 6794	2 DATE OF S	7 01	DD-D	CONTROL SYNBOL R&E(AR)036		
1. BATE PREV SUMPY 71 07 01	A. RIND OF SUMMARY D. Change	s. summary setv ^a U	U NORK SECURITY	P ARON	ADING ^e Ba C	^{hser} n insta'n NL	CONTRACTOR	ACCESS	. VORK UNT		
IN NO./COLIES.	PROGRAM ELEMENT	PROJECT	NUMBER	TASK A	REA NUMBER	T	WORK UNIT	NUMBER	R		
	ó2110A	3A062110	DA831		00	0)06				
b. CONTRIBUTING						1					
C. CONTRIBUTING							· · ·				
(U) Experime	ntal Fungus Infec	• tions in th e S	Skin of Man:	A The	rapeutic M	lodel (O	5)				
010100 - Micr	obiology: 00350	0 - Clinical M	ledicine	1							
69 11		CONT		DA		1	C. In-h	louse	40D		
17. CONTRACT/GRANT	N A			10. RES	OURCES ESTIMAT	E & PROFEL	SIGNAL MAN YRS	h FUI	105 (In thousands)		
& DATES/EFFECTIVE:		EXPIRATION.					•	2 25			
L NUNDER."		4		PISCAL	COMMENY		2				
G TVPE.					73		2	1	30		
A KIND OF AWARD.	ORGANIZATION	I.CUM. AMT.		NO. PER		ZATION					
name:" Letter adoress;" Presid		Letterman Army Institute of Research Dermatology Research Division Microbiology Research Laboratory Presidio of San Francisco, CA 94129 PRINCIPAL INVESTIGATOR (FUTHER SEAR II U.S. According for United)									
RESPONSIBLE INDIVIO NAME. AKERS VELEPHONE: 415-	, W.A., COL MC 561-5181			NAME	Jones, HONE415-50	H.E., LTC 51-5485 ount number:	C MC				
					Reinha	rdt, J.H.,	CPT MSC		DA		
IL KEYBORDS (Frecede	EACH with Someliy Classili	cation Code)		tin (II) human yahuttaan (II) human yahuttaan kutu							
(U)dermatoph	ytosis; (U) experi	mental infect	tion; (U) skin:	in; (U) human volunteers; (U) <u>Arichophytin mentagrophyte</u>							
23. (U) 1) Per minim pre-ex teers or min therap	rfect a reproducib num number of fu- tisting immunity with the severity nimize the severit peutic anti-fungal	ele, experiment angal spores r to dermatoph of the induce y of experiment agents.	ntal fungal inf equired to pro sytic fungi. 3 d infections. ental and natu	ection oduce) To co 4) To ral in	of the ski persistent orrelate the prepare a fections. 5	n of huma infections e degree o protective 5) To evalu	ans. 2) To a in humans of immunity vaccine th uate prophy	deterr with in hu at will ylactio	nine the and without Iman volun- I prevent and		
24. (U) 1) Pu cover evalua detern and th	rified spores of T ed with a wet gau ated using standar mined by skin tes merapeutic agents	richophyton ze patch and dized lesion g ting and by <u>is</u> are evaluated	mentagrophy a piece of Tel grading criteri <u>vitro</u> methoo using control	phytes RVN D-1 are inoculated onto normal skin and Teflon® film for 96 hours. 2) Resulting infections are iteria. 3) The immune status of human volunteers is thods such as lymphocyte transformation. 4) Prophylactic trolled double-blind studies							
 determined by skin testing and by in vitro methods such as lymphocyte transformation and therapeutic agents are evaluated using controlled, double-blind studies. 25. (U) 71 07 - 72 06 1) Over 300 persistent infections have been initiated on 140 humating natural history of the untreated lesions in volunteers with and wothout pre-existing carefully documented in all cases. 2) One (1) spore from Trichophyton mentagrophytic can produce severe, persistent ringworm (tinea corpus) in 100 percent of volunteers 3) Over fifty (50) spores per cm² of skin are required to produce progressive diseas pre-existing immunity. 4) The effectiveness of various immunogenic preparations immunization are being studied. Attempts to induce immunity by vaccination to prinfections (athletes foot and/or "Jungle Rot" are being persued in conjunction with DA OC 6783, Work Unit 004. 							0 human ve existing im <u>intagrophy</u> lunteers wi e disease in rations and ion to prev ion with Pr	olunte munit tes RV ithout volur volur meth ent do roject	ers. The iy has been 'N D-1 immunity ateers with ods of ermatophyte No.		

1.1

DD, FORM 1498

STRANSPACE AND

a construint said ditantana

States and

SAME PASSAGE

PREVIOUS EDITIONS OF THIS FORM ARE OBSOLETE. DD FORMS 1498A, 1 NOV 68 AND 1498-1, 1 MAR 68 (FOR ARMY USE) ARE OBSOLETE.

\$253.

	H AND TECHNOLOGY	WORK UNIT S	UMMARY	1. A68N	GY ACCESSION	2. BAYE OF BU	MARY.		OF TROL SYND
	IL SIND OF SUMMARY	S SUMMARY SCTY	A WORK SECURITY		OC 6921	72 07 0	A APRCIFIC	E DAT - TA	LEVEL OF SU
	K Complete	U	U	1	NA	NL	CONTRACTO		A DORK UM
	PROGRAM ELEMENT	PROJECT	NUMBER	TASK	REA NUMBER	1	WORK UN	IT HUNDER	
PRIMARY	62110A	3A062110	DA831		00		009		
CONTINOUTING						$\langle \langle \langle \langle \langle \rangle \rangle \rangle \rangle$	<u> </u>		
CONTRIBUTING	1						· ·		
TITLE (Protodo mid	h Somethy CloselHeatlan Codo	,• • • • • • •	-						
(U) Yeast F	lora of Interdigita	I Areas of the	e Foot (05)						
	inited Modining								
UUSSUU - CI	inical Medicine	14. ESTMATED CON	PLETION DATE		NIG ASENCY		TH. PERFOR		100
71.07		72 07				1 I	C In-	house	
CONTRACT/SRANT	,	1201		IN RES	DURCES ESTIMA			A A FUN	Di (In these and
	· NA	EXPIRATION:			PARCEDING				
	•••••			FISCAL	72		i		1
TYPE:		& ANDUNT:		YEAR	CONNERY				
KIND OF AWARD:		I. CUM. AMT.	•		73		0		I
RESPONSIOLE DOD	ORGANIZATION			20. PERI	ORMING ORGAN	TION			
ME:*			•	-	• • • •			6.0	
Letter	man Army Institu	ite of Keseard	n	1	Lettern	ian Army I	nstitute (DI Kesea	Ircn
poness:* Presidi	io oi san prancisc	0, CA 94129	,	ADDRES		ology Kese	arch DIV	ISION CA 0411	0
				1	r resiaio	or sau rr	mei sco , (UR 7417	.7
				PRINCIP	AL INVESTIGAT	is MD CL	HU.J. Auto	ic (nell iuilan)	
ESPONSIBLE INDIVID				MANE:	MCOUII	15, MI.R. CI	1 Mac		
(AME: / TRCID,	5.561.5181			TELEP	HONE: 415-	561-2921			
SENERAL MAR				AMOON	-	UUNT NUNDER:	•		
				MAMP.	Haide.	Carlyn, Ph.	D.		
									D
KEVIONES (Presed	· BACH with Somerity Classifi	cation Codes		-					
TECHNICAL OBJEC	TIVE," 24 APPROACH, 24	PROGRESS (Pumish)	individual paragrapha in a thaa taa suahi	be of 7	7 volunta	test of each with s	- Citto New	ication Code.	
vectimical ease 25. (U) 22: subjec 40% o and Ca recove species	53 cultures were of t to the next inva- f the fungi recove andida. The rema- ered were identifies s are in progress.	PROGRESS (Pointin obtained from lidating quan red were mer aining 60% co d to species to	n the toe web tative data. E nbers of the g onsisted prima using establish	bs of 2 Definiti enera wily of led tax	7 volunte ve mycolo <u>cryptococ</u> A <u>spergill</u> conomic cr	ers. Sample gy was per <u>cus</u> , <u>Torule</u> <u>is</u> and <u>Peni</u> iteria. Con	e size var formed. opsis, <u>Rh</u> cillium. np a rison	ied fron Approx addtor All org s of gen	n one timately <u>Ila,</u> anisms era and

and the second of the second second

* • *

Contraction that the distribution of

We want the star second to

ちったいちんち あませいしん ひたいろいいり

-ruc 0.15

Preservatoria

1.11 M. 17 1

Sec. A.F.

distriction of the state of the state

Yeast Flora of Interdigital Areas of the Foot

CPT Michael McGinnis, MSC

PROBLEM:

Objectives: (a) Determine both qualitatively and quantitatively the fungal flora of the interdigital areas of the "normal" human foot. (b) Determine which taxa shifts, if any, occur due to dermatophyte infected feet as compared to the "normal" foot. (c) Evaluate possible implications as regards the presence and types of yeast found versus a predisposing disease state, i.e., dermatophytosis.

Hypothesis: A representative survey of the fungal population of the "normal" human foot may or may not be relatively constant. If findings indicate a rather uniform population of fungi (taxonomically and numerically) then gross variations in these species or numbers might be correlative with the presence of dermatophytoses.

Background: While many investigators have studied the microbial flora of the human skin, few have indicated mycologically the full taxonomic range of fungi encountered. Former investigators have classified fungi recovered from various anatomical positions as Genera and Types. To our knowledge, the present investigation is the only study which has attempted to speciate all fungi recovered from the human foot.

APPROACH:

Experimental Design: In-house, informed, volunteers were utilized. Sampling involved the following procedures. The right and left interdigital spaces of each foot from each volunteer were scraped, and resulting scrapings diluted and placed upon the proper media for growth of yeasts and molds. Upon obtaining growth in pure culture of the organisms enumerated, each was identified to species by the appropriate methods.

Methodology: Using sterile technique, the interdigital spaces of both right and left feet from each volunteer were scraped by means of a sterile scapel. The scrapings from the interdigital spaces of the right foot were pooled in 10ml of sterile distilled water. The same procedure was followed for the scrapings of the left foot. In addition, scrapings were spread directly on Dermatophyte Test Medium (DTM), 2 plates per foot, to detect possible presence of dermatophytes.

The dilutions were shaken on a vortex mixer and a lml aliquot withdrawn from each tube. This aliquot was added to Oml sterile distilled water and shaken. The tubes were then diluted tenfold and ready for inoculation onto each of the various media to be used.

The media used for initial isolation of the yeast and mold fungi were as follows:

For isolation of mold forms: (1) Martin's Media; (2) Sabouraud's Dextrose Agar.

For isolation of dermatophytic fungi: Dermatophyte Test Medium

Physiological conditions were varied so as to include the entire temperature range for a maximum recovery of fungi.

Martin's Media and Sabouraud's Dextrose Agar (MM and SDA) were used primarily for isolation of the mold fungi. These media were incubated at room temperature, approximately 25°C.

Yeast extract mait extract agar (YM) was inoculated primarily for recovery of yeast fungi. Plates were incubated at both room temperature (25°C) and at 32°C.

Dermatophyte Test Medium (DTM) was inoculated directly from foot scrapings and incubated at 32°C.

Plates were inoculated by pipeting a 0.5 ml aliquot from the 10-fold dilution tubes directly onto the media desired and spreading the inocula out with a sterile glass spreader thus giving uniform dispersion of the fungi.

The plates and tubes were allowed 4-5 days growth time and then examined for growth of fungi. Each colony was then counted and subcultured on the basis of being either a yeast or mold. ALL REAL ALL SOME A PRIME PARTY IN

ちっち こうちんちょう うちょうたい いち いちょうちょう ちんちょう

Yeast fungi were subcultured to YM plates and incubated at the temperature from which the original isolate had been growing. If mold fungi were present, they were incubated at room temperature on SDA. Colonies appearing on DTM were likewise placed on the proper media at the correct temperature range.

These colonies were then allowed to develop; finally each was transferred to an appropriate medium for maintenance as a pure stock culture.

All yeast fungi were identified by the methods of Lodder*. All mold fungi were identified by the investigators with some speciations being accomplished through the use of additional texts.

RESULTS AND DISCUSSION OF RESULTS:

From the 26 volunteers sampled, 1886 specimens were recovered. Approximately one-half of these were yeast fungi, with the other 50% being mold forms. Of the mold forms, the vast majority of species were in the Genera Aspergillus and <u>Penicillium</u>. The remaining molds were representative of common saprophytes from all 3 classes of the eumycota. The yeast fungi have fallen into the following genera: <u>Candida</u>, <u>Cryptococcus</u>, Phodotorula, Torulopsis, and Trichosporon.

In general, all fungi recovered and identified are very constant from volunteer to volunteer.

121

^{*}Lodder, J. (ed.). The Yeasts - A Taxonomic Study. 2nd ed., North-Holland Publishing Co., Austerdam. 1970.

The presence of dermatophytes is being carefully examined for comparison of fungal recovery versus those volunteers having no dermatophytes. Until all data is fully analyzed, little correlation can be drawn.

An inverse relationship of population numbers between yeasts and molds is constant in each volunteer. Large yeast counts were associated with small mold counts, and low yeast numbers with high mold numbers. Further analysis is in progress.

FUTURE PLANS:

The same volunteers are being rescraped for a quantitative survey of fungi present. This will show if any population shifts have occurred in the individuals since the original sampling data. These results will indicate possible factors involved in explaining the relative constancy of species of yeasts and molds thus far encountered from individual to individual.

The future may hold promise for investigations of the virulence, pathogenicity, and infectious properties of dermatophytes as revealed by presence and types of yeasts found on the human foot via these ecological type studies.

Back the state and a state and show the surface

MAXILLOFACIAL SCIENCES DIVISION

South Providence of the low

interior and a station water and the second states and the second states and the second states and the second s

Program Element 6.11.02.A Defense Research Sciences, Army

Project Number 3A061102B71R Dentistry

Task Area Number 04

Program Element 6.21.10.A Bio-Medical Investigations

Project Number 3A062110A825 Oral & Maxillofacial Sciences

Task Area Number 00

with the second

CONTRACTOR OF THE OWNER OWNER OF THE OWNER OWNER

and the second second

123

1

いたちちちちいいのなどをしていたいとう

MAXILLOFACIAL SCIENCES DIVISION

THE BETHER THE THE PARTY CONFERENCE STREET BUILDENESS OF THE SAME STREET AND THE SAME STREET AND THE SAME STREET

This division's research program is directed toward developing methods for reducing the morbidity associated with traumatic injuries to the maxillofacial area and oral diseases prevalent in soldiers.

During the period covered by this report, research has been conducted in 16 different areas. Major advances have been made in the following research studies: Mandibular Bone Grafts; Reaction of Oral Tisgues to Suture Materials; Prevention of Post Extraction Alveolitis; Oral and Maxillofacial Wound Infection; and Survey of Oral and Maxillofacial Injuries in the Federal Dental Services.

A new mandibular bone grafting method has been developed employing a combination of surface decalcified lyophilized allogenic bone and autologous bone marrow. Laboratory findings show this technique to have distinct advantages over current clinical methods of mandibular bone grafting. Preliminary clinical trials on six patients indicate confirmation of laboratory findings.

Research on sutures has identified polyglycolic acid suture as the most satisfactory suture for oral wound closure currently available.

Studies on alveolar osteitis reveal that presence of adjacent soft tissue inflammation does not counterindicate the extraction of teeth and that patients receiving estrogen and progesterone therapy have a marked predilection for alveolitis subsequent to tooth extraction.

Cral and maxillofacial wound infections have a more diverse group of bacteria involved than previously reported and organisms previously considered not to be pathogens appear to be responsible for some of these infections. Additional findings suggest that prophylactic antibiotics may be contraindicated in maxillofacial surgery.

Studies have been initiated in the five Federal Services to identify the types of maxillofacial injuries and problems associated with the management of such injuries occurring in personnel deployed in various situations.

RESEARCH	AND TECHNOLOGY	WORK IINIT C	INNADA	I AGENCY	ACCESSION	2 DATE OF SU	MARY	REPORT	CONTROL STAR
		WORK ORT 3		DA O	B 6780	72 07	01	nD-DI	K&E(AR1636
DATE PREV SUMAY	4 KIND OF SUBMARY	S SUMMARY SCTY	4. WORK SECURITY	7 REGRAD	NG DE D		Sh SPECIFIC	DATA-	. LEVEL OF SU
<u>71 07 01</u>	D. Change	U	<u> </u>	NA	·	NL	XV YES C	Ĵ _{M0}	A. WORE UNIT
AB /CODES.	PROGRAM ELEMENT	PROJECT	NUMBER	TASK AR	EA NUMBER		WORK UNIT	NUMBER	2
, PRIMARY		3A061102	B71R	0	4		135		
. CONTRIBUTING						· ··			********
CONTRIBUTING						·	•		
I. TITLE (Procede with)	lecurity Classification Code,	•							
<u>(U) Oral D</u>	isease in Military	Populations	_(05)						
SCIENTIFIC AND TEC	HNOLOGICAL AREAS								
<u> </u>	<u>iology; 012900</u>	 Physiology; 	<u>010100 - Mi</u>	crobiole	<u>yev: 003</u>	500 - Clin	ical Medici	ine	
		IL ESTIMATED COMP	LETION DATE	15. FURDIN	G AGENCY		16. PERFORMA	NCE MET	NOD
66 07		CONT		DA			C. In-ho	ouse	
				18. RESOU	RCES ESTINAT	E & PROFESS	IONAL MAN YRS	& FUN	DE (In these and a
	NA	EAFINATION.					-		
L TYPE		d		FISCAL	72		7		65
					72		7		20
. RESPONSIBLE DOD O	REANIZATION	I.CUM. AMT.			13	1	/		//
		C D 1					_ L		
Peesidio	an Army Institut	e of Kesearch	l	HAME."	Letter	man Army	Institute	of Ke	search
E ICSIUIU	of San Francisco	, CA 94129			Maxill	otacial Sci	ences Divi	sion	
				AUUNESS:-	rresidi	o oi San I	rancisco,	CA 94	1129
								•	
	AL			MAME.*	T :11 4			[nelihulien)
HANE: Akers. V	A. COL MC			TELEPHO	LIIIY, V NE <i>A</i> 15.54	J.E., COL (1.5160	DC		
TELEPHONE: 415-5	61-5181			SOCIAL SI	CURITY ACCO				
I. GENERAL USE	<u></u>			AMOCIATE	INVESTIGATO				
				NAME:	Cutch		TC DC		
				NAME:	Tomne	I TP N			n
L REVIONDS (Procede)	LACH -Ids Somethy Classifi	allen Code) /11) e	ffect of elect	ric stim	ulation of	hone ror			U
(U) endode	ontics: (U) alveol	itis: (U) bacte	remia: (U) bo	ne rena	ir (11) m	ilitary nat	ient·(11)fl	Intern	ant hactor
1. TECHNICAL OBJECT	VE." 24 APPROACH, 25	PROGRESS (Parminh In	dividual paragraphs Ide	milled by nu	aber Procedo i	at of soch with 1	Hearing Classifier	Hen Code.	J Dacter
25. (U) 71 De Ex Sti	07 – 72 06 Inventistry; Preventi traction; Oral Fl mulation on Bon	estigations are on of Post-Ex uorescent Bac e Repair.	being condu traction Alve cteria in the N	cted in s olitis; C filitary	six sub-pi Control of Populatio	rojects: E Bacteren n; Bone l	ndodontic nia Associa Repair; Ef	s in M ited w fect o	, ilitary ith Tooth f Electric
See	e specific DD For	m 1498 for c	urrent status	of each	subject.				

GNERSE BEAM

Anoliane la contrectore upon originator's appreval DD PORM AR 401498
PREVIOUS EDITIONS OF THIS FORM ARE OBSOLETE. DD FORMS 1458A, 1 NOV 68 AND 1488-1, 1 MAR 68 (FOR ARMY USE) ARE OBSOLETE.

24.5

The stars in the second

5≠5

A. Land Street

~- · -

the product of the second sectors of the sectors of the second sectors of the sectors

Fari Di

A STATE OF A CALLER AND A

C GENERALIS

and the second secon

									126
DECEADON		WARE HUT	11UU AOV	1. AGEN	CY ACCES	NON [®]	2 DATE OF SU	MARY	ABPORT CONTROL SYMBOL
REJEARUN	AND TECHNOLOUT			DAC	<u>)C 680</u>	1	72 06 3	0	DD-DR&E(AR)636
L BATE PREV SUPRY	. KIND OF SUNMARY	S SUMMARY SCTY	A. WORK SETURITY	7. REGR		BP 04	10'N 1457X'H	CONTRACT	TOR ACCESS
71 07 01	K. Completed	11		1	NA		NL	LA YES	
A PRIMARY	61102A	3A062110	2B71R		04			137	
S. CONTRIBUTING	VIIVer	0.1002110							
C. CONTRIBUTING									
(U) Oral Flue	prescent Bacteria	a in Military	Populations	(05)				<u> </u>	
010100 - Mici	robiology; 0035	500 - Clinical	Medicine						
13 START DATE		14 ESTIMATED CON	PLETION DATE	IS PUN	NNG AGEN 1	CY	1	IS. PERFC	SAMANCE METHOD
17 CONTRACT/GRANT		12.00	······································	DA				<u> C. II</u>	1-nouse
& DATES/EFFECTIVE:	NA	EXPIRATION.			PARCEON	44	A PHOPESI	IONAL BAN	VRS E FUNDS (m Prouseanter)
-	INA			FISCAL	7	2		5	4
G TYPE.		& ANOUNT:	-	VEAR	CURRENT	-			
& KIND OF AWARD		L.CUM. AMT	•	L	7	3)	0
IS RESPONSIBLE DOD OF	RGANIZATION	L	<u>_</u>	20. PER	ronming o	RGANIZ	ATION		
HAME:" Lette	rman Army Inst	itute of Rese	arch	NANE."	Lett	erma	in Army I Incial Sciev	nstitute	of Kesearch
ADDRESS.	no of San Franc	isco, CA 941	29	ADDRES	Max • Pres	idio	of San Fr.	ancisco.	. CA 94129
						1010	01 0411 1 1		
				PAINCIP	AL INVEST	IGATO	(Furnish SEAN	II U S. Acod	baic Institution)
RESPONSIBLE INDIVIDUA	NL .			NAME	• Cut	cher,	J.L., LT(C DC	
name: Akers	s, W.A., COL MO	2		TELE	HONE 4	15-5	61-4042		
TELEPHONE: 415-5	61-5181	- <u></u>		ASSOCIA	TE INVEST	IGATO	**		
				-					
				-					DA
IL KEYBOADS (Frederic S	LACH with Semigity Classifi	callen Codej							
(U) oral: (U) bacteria; (U)	fluorescent;	(U) tongue; (U) dis	ease; (<u>U) w</u>	ound inte	ection	alification Code)
25 (1) 71 0	7 - 72 06 Bac	teriologic sar	nnles obtained	l from	the po	osteri	or half of	the tor	ngue dorsa of 202
subje	cts yielded cult	ures showing	orange-pink fl	uores	cence u	inder	ultraviol	et light	in 43.1 percent of
the p	opulation studie	ed. Current s	mokers accou	nted f	or 56.3	3% of	the total	positiv	e cultures obtained.
Prese	nt evidence indi	icates that the	ese fluorescing	g coloi	nies con	nsist	of a mem	ber of t	he genus Neisseria,
grow	ing in synergistic	c combinatio	n with a gram	positi liebed	ve pleo	mor	phic cell 1	orm. N	to relation of these
orgar	nisms to clinical	orai disease i	ias been estab	nsnea	, TAIS :	study	anas beer	compi	cicu.
[
l .									
1									
[
1									
1									
1									İ
1									
Available to contracto	us upen eriginetor'e epor	avet							

DALL STY LAS

the a possible and

2.15

DD, 1498

115.20

and the second

ģ

22.25

-

199

and the second
A CONTRACT OF A CONTRACT OF A CONTRACT OF A CONTRACT OF A CONTRACT OF A CONTRACT OF A CONTRACT OF A CONTRACT OF

PREVIOUS EDITIONS OF THIS FORM ARE OBSOLETE. DD FORMS 1488A 1 NOV 65 AND 1488-1, 1 MAR 68 (FOR ARM) USEI ARE OBSOLETE.

1. C. S. C. S. A. D.

Oral Fluorescent Bacteria in Military Populations

Lieutenant Colonel J.L. Cutcher, DC Judith B. Richey, B.S. Robert H. Heflich, B.S., M.S.

PROBLEM:

The human oral cavity is the site of one of the most luxuriant and varied bacterial floras known. The bacterial components of this flora have been specifically implicated in systemic and local diseases, e.g., bacterial endcuarditis, actinomycosis and alveolar osteitis. In general, however, practically nothing is known about the relationship of endogenous oral microorganisms to human diseases.

Recent dermatologic reports involving the implication of diphtheroid bacteria, which fluoresce under ultraviolet light, in the etiology of erythrasma have led to the observation that bacteria causing similar fluorescence are present on the dorsum of the tongue of some indiviuals. The purpose of this study is to determine the incidence, nature and significance of such fluorescent bacteria in the oral cavities of military personnel.

APPROACH:

A total of 200 subjects will be evaluated bacteriologically to determine the presence of bacteria which fluoresce under ultraviolet light when grown on a special laboratory culture medium containing porphyrin.

Bacteriologic samples are obtained by means of a calcium alginate swab from the posterior aspect of the dorsum of the tongue. Such samples are immediately streaked onto an enriched agar plating medium devised to enhance fluorescence of bacteria capable of metabolizing porphyrins. All cultures are incubated at 37° C in 4 percent carbon dioxide for a minimum of 24 hours, before fluorescent screening procedures with long-wave ultraviolet light (Wood's light) are performed. All cultures are screened at 24, 28, and 72 hours after initial incubation. Patients are questioned concerning current and prior smoking habits, in order to determine if such habits are related to the presence of these bacteria.

an in the second of the second s

Qualitative biochemical and morphological studies are also being conducted on selected fluorescent isolates in order to identify the specific microorganisms involved.

RESULTS AND DISCUSSION:

4

and the owner of the second states and the

Preserved and an and a second second second

alindura tata, kindarak

Bacteriologic samples obtained from the posterior half of the tongue dorsa of 202 subjects yielded cultures showing orange-pink fluorescence under ultraviolet light in 43.1 percent of the population surveyed.

When apparently well isolated, fluorescing colonies were carefully picked using a stereoscopic microscope, 2 different cell forms frequently could be seen following gram staining:

1. A gram negative coccoid form, often kidney-shaped and Neisseria-like in appearance. Oxidase testing of the mixed culture gave varying results.

2. A gram positive pleomorphic cell form, occurring in short chains of coccobacillary cells on solid medium. Fluorescent colonies could be subcultured onto serum agar plates, but this frequently resulted in loss of fluorescence. When a fluorescent colony was subcultured onto a trypticase soy agar blood plate, fluorescence was not observed.

With respect to tobacco smoking habits of the subjects:

1. Forty-nine of the 107 subjects classified as "current smokers" were positive for in vitro fluorescence (45.8 percent).

2. Nineteen of the 39 subjects listed as "previous smokers" were positive for fluorescence (48.7 percent).

3. Nineteen of the 56 subjects tested listed as "tobacco abstainers" were positive for colony fluorescence (33.9 percent).

These results do not indicate a statistically significant relationship between use of tobacco and presence of fluorescent bacterial colonies.

Operational circumstances prevented correlation of positive in vitro fluorescence with clinical fluorescence of each subject's tongue. Observations on a limited population, however, suggest that a tongue exhibiting clinical coral pink fluorescence will usually provide fluorescent laboratory cultures.

We have been unable to specifically identify these fluorescent organisms. While it is possible that diphtheroid bacteria may be involved, gram negative Neisserialike colonies appear to play a larger role in colony fluorescence in terms of occurrence and relative predominance within the colony. In any case, no lingual pathology was observed in any of the subjects studied.

In view of the relatively high incidence of these bacteria, it is probable that they are non-pathogenic members comprising the "normal flora" of many individuals. Consequently, no further studies to determine possible pathogenic complications of these bacteria are contemplated.

FUTURE PLANS:

This study has been completed.

RESEARCH AND TECHNOLOGY WORK UNIT SUMMARY				1 AGENCY ACCESSION®		2 DATE OF 1	2 DATE OF SUMMARY ⁴ 72 06 30		DD DR&F(AR)~3	
& DATE PREV SUMRY	. KIND OF SUMMARY	S SUMMARY SCTY	4. WORK SECURITY	7. REGRI	OING [®]	DIEG'N INSTR'N	CONTRACTOR	ATA .	. LEVEL O	
71 07 01	K. Complete	U	<u> </u>		NA	_NL	luives L	040	A VORK	
A POWARY	61102A	3A061102R71R		04		+	141			
. CONTRIBUTING		5/100110	20110	<u> </u>		1				
C. CONTRIBUTING										
I. TITLE (Procodo alda	Security Classification Code	•	n Tooth Extr	oction	(05)					
(U) Control	Of Bacterennia A:	Scotated with								
003500 - Cli	nical Medicine									
13. START DATE	I START DATE				ING AGENCY		16. PERFORMANCE METHOD			
68 06		72 06		DA			C. In-house			
17. CONTRACT/GRANT				IS AES	OURCES ESTIN	TE & PROFE	SIGNAL MAN YAS	L FUN	DS (In sheue	
A DATES/EFFECTIVE	NA	EXPIRATION			72		1		6	
C TYPE.		4 ANOUNT.		YEAR	CURRENT			+		
& KIND OF AWARD		f. CUM. AMT.			73		0		0	
IS. RESPONSIBLE DOD	ORGANIZATION	L	1	20 PERI	FORMING ORGA	POITATION				
RESPONSIBLE INDIVIDUAL NAME: AKERS, W.A., COL MC TELEPHONE: 415-561-5181 21. GENERAL USE					NAME * Cutcher, J.L., LTC DC TELEPHONE: 415-561-4042 SOCIAL SECURITY ACCOUNT NUMBER: ASSOCIATE INVESTIGATORS NAME. Jones, J.C., MAJ DC					
				-						
12 KEVBONDS (Preside	emia: (II) tooth e	extraction (1)) military nat	ionts:	(II) tonic	antisent	ics			
B. TECHNIGAL OBJEC	TIVE," 24 APPROACH, 25	PROGRESS (Furnish	indevidual paragrapha is	fenillied by	number proces	e test et eech mi	h Socurity Classific	ellen Code	• • • • • • • • • • • • • • • • • • • •	
23. (U) Ba Su der der ba	cteria are known ch bacteremias m veloping methods ntally-induced ba cteremias.	to invade the ay have serio which are pr cteremias and	e bloodstream us consequen actical in mili i thereby redu	of 50 ces in itary si icing t	-85 percer certain pa ituations the compl	nt of all pe itients. St for reducin ications w	cople who h udies are dia ng the incide hich may re	ave ter rected ence o sult fr	eth ext toward of such com suc	
24. (U) R an dif	eduction of the n tiseptic solutions. Terent local antis	umber of ora A collabora eptic solutior	I bacteria asso tive study with as on the incide	ociated h Leti lence (l with the terman Ge of bactere	tooth to eneral Hos mia subse	be extracted pital evalua quent to to	l, by u ting th oth ex	ise of lo le effec traction	
25. (U) 7 in sol stu Dr	1 07 - 72 06 Stud incidence of bact lution is employe idies on two gene ug Administratio cause the original	dies on 301 p eremia associ d as an oral r erically differen n actions relations relat	atients to data ated with too inse and as a sent commerci- ting to the ef-	e have oth ext sulcus al mou ficacy	demonstr raction w irrigating thwash so of these s	rated a sta hen a phe agent, pric plutions h polutions.	tistically signolated anti or to extract ove been del In view of t	nificat septic tion. layed this sit	nt redu mouth Additic by Foo wation	

The second secon

ż

in the subscription of the factor states and

المحالية كما الأربية للملاقة ومخرمات المارك منامعتهم والملائح سلطا لأطواح ممي

and a serie that the second and the same and a second second second second second second second second second s

DD, rotu 1498

and a market and the set of the state of the set of the

PREVIGUS ECTTONS OF THIS FORM ARE OBSOLETE DD FORMS 1498A 1 NOV 65 AND 1498 1 1 MAR 66 (FOR ARMY USE) ARE OBSOLETE

and the second and the second s

Control of Bacteremia Associated with Tooth Extraction

Lieutenant Colonel J.L. Cutcher, DC Major John C. Jones, DC

PROBLEM:

Transitory bacteremia, which is known to occur subsequent to as much as 85 percent of all tooth extractions, may have serious consequences in certain patients, particularly when the viridans group of streptocci are involved. Recent studies indicate that one-third of reported cases of subacute bacterial endocarditis can be directly associated with prior dental procedures.

It has been established that bacteremias associated with oral procedures are caused by the invasion of the vascular system by microorganisms present in the oral cavity. Previously reported investigations under this project conducted in this laboratory have demonstrated that applying a phenolated topical oral antiseptic solution can result in as much as a 72 percent reduction in incidence of bacteremia following tooth extraction. This study was undertaken to determine the effect of 2 different mouthwashes, each generically distinct from the solution used in earlier studies, on the incidence of postextraction bacteremia.

APPROACH:

A total of 201 patients will serve as subjects for this study. Patients will be selected from the routine daily workload of people presenting to the Oral Surgery Service, Letterman General Hospital. Patients are placed, by means of random selection, into one of 3 groups of 67 subjects, as follows: Control group--no oral rinse or sulcus irrigation is performed on these patients; Mouthwash group A--a mouthwash solution containing .05 percent cetyl pyridinium chloride is used as an oral rinse and for sulcus irrigation in this group of patients; Mouthwash group B--receives a mouthwash solution containing thymol, eucalyptol, methyl salicylate, boric acid, methol and ethanol.

131

CALL STREET, SALES ST
Laboratory bacteriologic evaluation of pre- and postoperative blood samples is employed to determine incidence of positive blood cultures.

RESULTS AND DISCUSSION:

Recent efforts to evaluate other selected commercial antiseptics (see Approach) have been hampered by uncertainty resulting from Food and Drug Administration (FDA) actions concerning efficacy of these formulations. A total of 48 patients had been surveyed prior to these FDA actions, but resultant data were insufficient for statistical analysis. In view of this situation, and because the original hypothesis and purpose of this investigation have been demonstrated on studies conducted earlier under this project title, this investigation is now classified as completed.

FUTURE PLANS:

This study is completed.

	WORK UNIT S		1 AGENCY ACCESSION ⁶ 2 DATE OF SUMMARY ⁶						
			DAC	<u>C 680</u>	5	/0.0/		1/1	
71 07 01 D. Change	U	U U	N REGRA	A		NL	CONTRACTOR	ACCESS	A WORK UNIT
B NO /CODES PROGRAM ELEMENT	PROJECT	NUMBER	TASK A	REA NUM			WORK UNI	-	
61102A	3A06110	2B71R	0	4		1	43		
. CONTRIBUTING									
C. CONTRIBUTING									
(U) Endodontics in Matitary D) entistry (05	5)							
SCIENTIFIC AND TECHNOLOGICAL AREAS									
003500 - Clinical Medicine									
IS STANT DATE	A. ESTIMATED COM	PLETION DATE	IS FUND	NG AGENC			14. PERFOR	ANCE MET	NOR
69 01			UA			1	C. In-h	ouse	·
- CONTRACT, GRANT			N. RESO	URCES EST	TIMATE		ONAL MAN YR	1 h 701	IDS (In theusands)
A DATES/EFFECTIVE: NA	EXPIRATION:				•				10
A HUMBER .	•		FISCAL	T2 Eugenear	2		1		10
C TYPE	C ANOUNT.			73	2		1	1	6
L KIND OF AWARD	S.CUM. AM7.			13			1 		
		l					L		
Letterman Army Insti Presidio of San Franci	tute of Resea sco, CA 9412	arch 29	ADDAESS	Lette Maxi Presi	erma illofa idio c	n Army I cial Scien of San Fra	nstitute o ces Divisi incisco, C	f Resc ion A 941	arch 29
RESPONSIBLE INDIVIDUAL			NAME *	Robi	ert. F	(e-min sear (R., CPT D	ity s. androi C	: [ns:1] u3iq	Ÿ
NANE: Akers, W.A., COL MC			TELEP	10HE: 4	15-5	61-4042	-		
TELEPHONE: 415-561-5181			BOCIAL	SECURITY	ACCOL	INT NUMBER			
ويستعديه والمستعدة وتستبعت وتستعيث والمتشارق والمستعد والمستعد والمستعد			-	-	GATOR	•			
I. GENERAL USE			MANEL	Lilly	, G.E	E., COL D	С		
DI. GENERAL USE							-		

mechanical syringes are the most promising for reducing the time necessary to accomplish root canal filling. Two papers have been presented at national scientific meetings.

DD, FORM 1498

たいたいないのである

ŝ

Endodontics in Military Dentistry

Colonel Gilbert E. Lilly, DC Captain Richard C. Robert, DC SP-4 Kenneth D. Freeze, B.S.

PROBLEM:

Endodontics involves the treatment of the internal portion of the tooth, and more specifically, the pulp chamber and root canal and their contents - the dental pulp. Due to the unique anatomy of the tooth when the pulp degenerates subsequent to bacterial invasion associated with caries or other forms of trauma, it has limited regenerative powers. The apical foramen of the tooth is the only avenue of entrance of vascular supply and viable mesenchymal tissue. This foramen is so narrow that when the pulp becomes nonvital, it prevents connective tissue ingrowth and thus precludes phagocytosis and regeneration. As a result, the nonviable root canal acts as a reservoir of irritating material which incites a chronic periapical inflammatory reaction.

Debridement and obliteration of the root canal space with a nonresorbable inert material will effectively eliminate this dead space and its irritating contents. Such treatment results in restoration of the periapical tissues to a normal status of health, and retention of the tooth as a functional member of the masticatory apparatus for a prolonged period of time. Currently, debridement and obliteration are accomplished by opening the pulp chamber through the crown of the tooth and debriding and enlarging the root canal with mechanical instruments. The two basic instruments used in the removal of the contents of the canal and its enlargement are small hand instruments, the reamer and file. These instruments are used to clean and enlarge the root canal prior to insertion of a filling material. Various raterials are employed in the filling and sealing of root canals. The most popular method contines the use of a sealing cement and a solid material, such as a silver point, with the use

dir energie werden in werden verscher verschlichen werden eine die einen als einen die die stelle stellen die s

of hand instruments.

Presently the treatment time associated with endodontic procedures averages a total of 3 to 5 hours per posterior tooth, and requires 2 to 4 or more separate dental appointments over a 7 to 14 day period. In addition, special professional skill, beyond the capability of many practicing dentists, is required to accomplish endodontic therapy on posterior teeth. These time and professional skill factors currently limit the application of endodontics in many military situations.

Endodontic treatment has the advantage of maintaining the individual tooth as a functional member of the dentition. Such a tooth, if properly treated, is superior to any prosthetic replacement. In military dentistry, it has the added advantage of obviating the need for exodontia and subsequent prosthetics; and by so doing reduces the dental workload and non-effective time for the patient.

The purposes of this study are to: 1) simplify endodontic treatment; 2) reduce the number of professional manhours required to accomplish such treatment; 3) increase the endodontic capability of the Army Dental Corps; and 4) reduce the number of tooth extractions required.

APPROACH:

Particular of the transport of the state of the second

Two aspects of endodontic treatment are under investigation:

a. Debridement and enlargement of the root canals.

b. Filling and obliterating the root canal space. Studies in each of these areas have been divided into 5 phases of investigation:

(1) In vitro studies on extracted human teeth.

(2) In vivo studies on animal teeth.

(3) In vivo toxicity studies on animals.

(4) Human clinical trials.

LIL COMPANY

(5) Feasibility studies on large troop populations.

In vitro studies on extracted human teeth and in vivo studies on animal teeth have been conducted in the following areas:

a. Debridement and enlargement of the root canal.

(1) Chelating agents, e.g., ethylene-diamine-tetracetic acid (EDTA) and ethylene-bis (iminodiacetic) acid, as well as other chemicals, such as HCl and H_2SO_4 to debride, decalcify, and enlarge the root canals.

(2) Mechanical means (rotary instruments and ultrasonic instruments) to debride and enlarge the root canals.

b. Filling and obliterating the root canal space.

Every and a second and and the second and the second of th

7

(1) Preformed materials (gutta percha, silver points) and liquid materials (zinc oxide-eugenol cements, polyketone cements, chloropercha and eucopercha pastes, iodoform pastes).

(2) Methods of delivering filling materials.

RESULTS AND DISCUSSION:

To date, studies have been limited to in vitro experiments on extracted human teeth and in vivo investigations on animals.

In vitro studies on extracted human teeth have evaluated various mechanical, ultra sonic, and chemical means for enlarging the root canal. None of these methods have proven feasible. Rapid mechanical methods for enlarging the root canal cannot be accurately controlled and frequently result in perforation of the root. Ultrasonic methods are not sufficiently efficient to remove adequate amounts of odontogenic material in a reasonable time frame. Chemical agents also require a prolonged time interval to be effective and then only facilitate other methods of enlargement. In addition, the in vivo tissue toxicity of effective chemical agents precludes their clinical use.

136(.

In vitro studies on extracted human teeth have been conducted in evaluating selected debriding agents. Debriding agents were retained in the tooth for 15 minutes prior to flushing with saling. Effectiveness of the debridement was determined by examination with a dissecting microscope after splitting the tooth. Detectable difference in debridement between various proteclytic enzymes and hydrogen peroxide could not be ascertained by this system.

In vitro studies with various filling materials and delivery methods have been conducted and a high pressure mechanical syringe has been designed and fabricated. Effective sealing of the root canal can be rapidly accomplished with fluid materials using the high pressure mechanical syringe without extensive debridement or canal enlargement. The particle size of resorbable root canal filling materials is too large to permit use in this system and the effect of nonresorbable materials on the periapical tissues has not yet been determined.

FUTURE PLANS:

In vivo laboratory studies to evaluate periapical toxicity of nonresorbable root canal sealers delivered with the high pressure mechanical syringe are planned.

RESEARCH	AND TECHNOLOG	Y WORK UNIT	SUMMARY	DA (CY Arcess		72 0	WWARY*	REPORT	cont KSE
DATE PAFY SUMAY	4 REND OF SUMMARY	S SUMMARY SCTY	S WORK SECURITY	T REGRI	DING	A DIE	8'H INSTR'N	ON TRACTO	C DATA - DA ACCESS	P
71 07 01	D. Change	U		TASK	A INTER NUMB	ER	NL	NORK UN		
	61102A	3A06110	2B71R		04			144		
. CONTRIBUTING						[
I TITLE (Procode with :	Security Classification Cade	l				<u>i</u>				
(U) Preven	tion of Post-Ext	raction Alve	olitis (05)							
003500 - C	linical Medicine									
START DATE		TIA. ESTIMATED CON	NPLETION DATE	DA	DING AGENC	Y		C I	MANCE NE	THO
7001 P. CONTRACT/GRANT			L		OURCES EST	INATE	A PROPAL	SIGNAL MAN Y		NDS
A DATES/EFFECTIVE.	NA	EXPIRATION:					1			
k runder * G Type,		& ANOUNT:		PISCAL	CUNNERT			1		1
& KING OF AWARD		f. CUM. AMT	г.		73			1		_
RESPONSIBLE DOD	DRGANISATION			20 PER	FORMING OR	GANIZ	ATION			
NAME: AKETS, V	V.A., COL MC			PRINCI NAME TELE	• Osboi Phone 4	GATO 1, D. 15-5	.B., COL 561-3061	DC	mic (nelikuli	29 ~~
nesponsible individ name: Akers, V telephone: 415- 21. general use	V.A., COL MC -561-5181			PRINCI NAME TELE SOCIA ASSOCIA	• OSDOI • OSDOI PHONE 4 L SECURITY	GATO A.D. 15-5 ACCO	B., COL 661-3061	DC	Dic (notikuli	29 ~~
RESPONSIBLE INDIVIOL NAME: AKETS, Y YELEPHONE: 415 81. GENERAL USE	V.A., COL MC -561-5181			PRINCI MAME TELE SOCIA ASSOCIA MAME NAME	• OSDOI • OSDOI PHOME 4 L SECURITY ATE INVESTING JONES LILLY,	GATO 1, D. 15- ACCO GATO G.E	R (Fumilies Bla B., COL 561-3061 5000 None 5000 None 500	ини 5. лан DC DC DC	mic (notifui)	29 m
аебронзівле іноїчіол наме: Акстя, У телерноне: 415- 21. денемал use 12. кеуболов /глиска (U) alveola 23. тесннісал овлу с	AL V.A., COL MC -561-5181 TEACH -TH Somethy Claused ar osteitis; (U) n TIVE," 24. APPROACH., 20	Activen code) nandibular th PROGRESS (Furnid	hird molar; (PRINCI NAME TELE SOCIA ASSOCIA NAME NAME U) EXTEC	AL INVESTI • OSDOI PHONE 4 L SECURITY TE INVESTI JONES Lilly, Inction: (G.E	B., COL 561-3061 C., MAJ I C., MAJ I C., COL E Intiseptic	DC DC e mouthw	vash; (U	29 mj) 1 je.j

12401200

Print 13 3200

والأخذر

.

 $\sim 2^{\circ}$ · · . · .

Prevention of Post-Extraction Alveolitis

Colonel Gilbert E. Lilly, DC Major J.C. Jones, DC Colonel Donald B. Osbon, DC

PROBLEM:

The incidence of alveolitis (dry socket) is not established in the US Army. Available data suggest that approximately 2 percent of all tooth extractions, and 5 to 6 percent of all mandibular third molar (wisdom tooth) extractions, are followed by this complication. Furthermore, 90 percent of the dry sockets that do occur are in the mandibular third molar region. Based on the current Army population and dental treatment required, 40,000 cases of alveolar osteitis are estimated to occur annually. This results in an annual loss of 160,000 patient man-hours and creates a dental workload of 80,000 separate additional appointments.

While the precise etiology of alveolitis has not been established, 3 contributory factors are recognized; (1) the general systemic status of the patient (age, nutrition, systemic disease, and medications); (2) local trauma; and (3) local microorganisms. The systemic status of the patient and the amount of local trauma are factors which are unique to each patient and each extraction. Because of this, their inherent variability makes them extremely difficult to control or standardize in studying a series of patients. Although the specific types and numbers of microorganisms vary from one case to another, their presence is constant. Topical oral antiseptics are known to drastically reduce the oral bacterial population for periods of up to 1 1/2 hours.

This study tests the hypothesis that a topical antiseptic can effect a reduction in the oral bacterial population during the time interval in which surgery and subsequent clot formation occur, and that such a reduction is a critical factor in preventing alveolar osteitis.

APPROACH:

Patients requiring mandibular third molar extractions are randomly placed in one of 2 groups: Experimental and Control. Patients in the experimental group have their mouths and gingival sulci in the mandibular second and third molar areas lavaged with an antiseptic mouthwash prior to third molar extraction. Patients in the control group receive no such pre-extraction lavage. In all other respects, patients in the control group and experimental group receive comparable treatment before, during and after surgery. Basic information concerning the patient, the extraction and group is recorded on a special card. Postoperatively, all patients are evaluated for alveolar osteitis. The investigator conducting the examination is not aware of the patient's group allocation (experimental or control), and findings are recorded on a separate data card. For the purpose of the investigation, alveolar osteitis is defined as any case with localized post-extraction pain which requires treatment with a local obtundent dressing. Collected data is processed with electronic data processing equipment as the basis for determination of the incidence of alveolar osteitis. Approximately 3,000 mandibular third molar extractions will be needed for a valid sample. This collaborative study involves Letterman Army Institute of Research, Letterman General Hospital, and Oakland Naval Hospital.

RESULTS AND DISCUSSION:

To date, data have been obtained on 912 patients and 1452 mandibular third molar extractions. Alveolitis was reported in 90 instances, or 6.2 percent of all. mandibular third molar extractions. At this time, the sample is not of sufficient size to provide significant Jata on the effectiveness of the topical antiseptic. Significant findings reveal: a) that the presence of pericoronitis at the time of extraction does not increase the incidence of alveolitis; the incidence of alveolitis in teeth with pericoronitis is 5.82 percent as compared to 6.33 percent in cases without pericoronitis; b) women taking oral contraceptives have a marked predilection for alveolitis; the incidence of alveolitis in women taking oral contraceptives is 17.2 percent as compared to an incidence of 4.82 percent for women not taking contraceptives.

140.

FUTURE PLANS:

This study will be continued until sufficient cases are included to permit statistical verification of findings. To further explore the hypothesis that lowering the bacterial count intraorally may lessen the incidence of alveolitis, an extension of the use of antiseptic mouthwash will be instituted on 1 July 1972. Patients in the experimental group will be provided with 8 ounces of mouthwash to be used four times a day for 2 days, beginning the day after surgery.

anister that the second

141

รสระสมันสร้างสมบรรมรับสมบริสมบส จากรรมสร้างให้น้ำ จากหรือมีสารให้บรรมสมบริสมปริภษณ์เป็นหนึ่งไม่

RESEARCH				TI LOOM		A SLOW					عد
	AND TECHNOLOGY	WORK UNIT SU	JMMARY	DA	00.69	910	72 07	01	DD-DE	антко г зүш к (b f (AR)536	in <i>t</i> ,
A BATE PREV SUMRY	. KIND OF SUMMARY	S. SUNMARY SCTY	. WORK SECUNTY	PREGR	ADING [®]	14 DI		AL SPECIFIC D	ATA -	LEVEL OF S	UH.
71 07 01	D. Change	U	U	NL			NL	V yes	40	A. WORK UN	11
IO. NO./CODES:®	PROGRAM ELEMENT	PROJECT	NUMBER	TASK /	REA NI	MBER		WORK UNIT	NUMBER		
. PRIMARY	61102A	3A061102	2B71R		04			146			
. CONTRIBUTING							. : .				
C. CONTRIBUTING											-
11 TITLE (Procede with 5	southy Classification Code	•									
(U) Effect of	of Electric Stimu	lation on Bon	e Repair (O)5)							
003500 - Cili	nical Medicine			Tis Post							
71.03		74.04			1		1			00	
11 US		/4.06		DA				C. In-ho	use		
	BT A			10. AES	PRECES	ESTIMATE	A PROPES	IONAL MAN YAS	L PUN	D's (In these and	<u>"</u>
	NA					72		1		10	
C TYPE		4 ANOUNT:		YEAR	CURREN	· · · · · · · · · · · · · · · · · · ·	+	· <u>·</u> ·····	+	10	_
A KIND OF ABARD.		f. CUM. AMT.				73		2		19	
19. RESPONSIBLE DOD G	RGANIZATION		<u> </u>		ORMING	ORGANIZ	ATION		L		
ume I attarma	n Army Institute	of Peseerch		-	L	ttorm	on Armu	Institute o	f Doco		
Presidio o	f San Francisco				M	avillat	an Army	mone Divici	i nese	aren	
ABOREN:"	a ban i tancisco,	CA 94129		ADDRES	ічі • п.			nices Divisi	011 A 041	20	
				1	r	estato	oi san r	rancisco, U	A 941	29	
				PRINCIP	AL INVE	STIGATO	t (Furnish SEAN	II U S. Academic (nellfullenj)	
RESPONSIBLE INDIVIDU	AL			-	т:	11 ₁₁ C	E COL	DC.	•		
NAME Alean W				TELEP	ы / :Знон'	119, G.	.E., CUL	UC			
TELEPHONE. 415.	561-5181			-	SECURI	TY ACCO	UNT NUMBER				
21, GENERAL USE				ASSOCIA	TE INVE	STIGATOR	15				
				NAME:	H	ackett	. P. SP4				
í				-	lo	nes. J	C. MAL	DC		I	DA
II. XEVWORCE (Frecede I	CACH with Semulty Classifi	callen Cade)									
(U) mandibi	ilar fractures: (I	<u>J) bone repair</u>	: (U) piezoe	lectric	ity:()	D wo	und heali	1 <u>g</u>			
23. VECHNICAL OBJECTI	VE," 24 APPROACH, 23	PROGRESS (Pumien In	an viausi pereditaphe in	MAN 1711 0 4 197	num.207	P/06080 14	nt of each with .	Becurliy Classifics	llan Code)	
20 (1) 21 (7 72 07 1										
25. (0) 71 0	7 - 7206 Init	ial studies are	being directe	ed tow	ard d	evelop	ing a labo	pratory mo	del an	d	
tech	nology. Prelimi	hary findings i	indicate that	direct	electi	ric cur	rent in th	e 10 micro	amp	range	
can a	accelerate bone i	repair.									
1											
ł											
ł											
ł											
1											
1											
!											
l											
1											
Į											
]											
Į											
Į											
1											
_											
1											
Parallable to series to	te u nne eridin atoria a n on	vel									

÷

2.12

and the second

のないないないのない

Same and and the second

VEN:

Effect of Electric Stimulation on Bone Repair

Colonel Gilbert E. Lilly, DC Major J.C. Jones, DC SP-4 Perry B. Hackett

PROBLEM:

Accepted treatment for fractures and bone grafts of the jaws usually involves wiring the jaws together. Because of this, it is necessary to hospitalize the patient until bone repair has progressed to the point that the wires can be removed and the patient can eat a normal diet and is not in danger of aspirating foreign material into the lungs. Such care requires prolonged hospitalization and results in loss of many A number of authors have reported and manhours. measured electric potentials which are apparently due to a piezoelectric effect in human and other mammalian bones when bones are subjected to mechanical stress in in vitro laboratory studies. More recently, in vivo laboratory studies and selected applications on humans have resulted in reports of increased and more rapid bone deposition in bones subjected to small amperage direct electric current. The exact amount of current necessary and the relation of bone formation to the implanted electrodes are not well established. This study is being undertaken to: (a) determine the effect of electric current on bone repair, (b) determine the most appropriate amount and method of delivering electric stimulation to the mandible to accelerate bone repair, and (c) reduce the hospitalization time and military manhours lost due to mandibular fractures.

APPROACH:

Five bilateral mandibular surgical defects were prepared by way of an aseptic extra-oral surgical approach on 8 dogs. Each defect was 1 mm wide and 1 cm apart, cut through the inferior border of the mandible. Each defect was extended to, but not through, the mandibular canal. Direct electrical current across the center defect was furnished by a circuit similar in design to that of Lavine et. al., using a 1.4 volt E400 Eveready Gh battery connected in series with a 170 K OHM 10

and the little state of the second second second

resistor (resistance measured prior to use). This power unit was sealed in Silastic Silicone A (Dow Corning Silicone, type A). The copper wire battery leads were fastened to the voltage source with conducting silver epoxy cement (Emerson & Cuming, Gardena, Calif.) One lead had a surface exposure for current monitoring after implant. Platinum electrodes (0.020 inch diameter) were soldered to the copper wire and insulated with shrink tubing. The electrodes were implanted in drill holes (0.5 cm diameter) on either side of the center cut of each defect series. A pair of electrodes were implanted on each side of the mandible, but only those on one side were connected to a power source. Osteogenic activity at the defects was evaluated radiographically and histologically. Dogs were sacrificed 2 and 4 weeks after surgery.

RESULTS AND DISCUSSIONS:

Numerous technical problems have been encountered in this study related to the electric circuitry and the animal model. The copper wire leads separated in 3 cases due apparently to metal fatigue, the result of the dogs' constant movement of the neck and jaws. In 2 other cases, circuit failure resulted from interruption of the platinum electrode-copper wire union. Inflammation and infection at the cutaneous entry site of the circuit has been a continual problem necessitating early sacrifice of some animals.

In 2 animals maintained for 4 weeks with intact electric circuits, we have microscopically observed increased osteogenic activity and osteoid formation in defects between the electrodes as compared to contralateral defects and bilateral defects not receiving electrical stimulation. The electric potential in these circuits varied from 5 ma to 10 ma during the course of this experiment. Due to the numerous problems encounttered, these findings have been fragmentary and cannot be considered meaningful.

In view of the problems encountered, primary effort has been directed toward developing more reliable and sophisticated electric circuitry and solving problems encountered in the animal model. In cooperation with Rosemount Engineering Corporation, Minneapolis, Minnesota, we have developed an electric power unit and circuitry which is dependable and capable of wider ranges of electric output. In order to avoid the problems encountered with electrode and wire lead failures, this system uses multi-stranded platinum leads and continuous electrodes. In cooperation with Tecna Corporation, Emeryville, California, we have modified a microporous polyurethane percutaneous lead for monitoring of the circuit. This system should permit prolonged exposure of the electric leads without local inflammation or infection.

FUTURE PLANS:

Employing newly developed technical and animal model modifications, a series of 20 dogs will be studied, evaluating osteogenesis at various electric stimulation rates.

とないのないないというないないないないです。

									146	
RESEARCH	AND TECHNOLOGY	Y WORK UNIT S	UMMARY	DA	OC 6911	2 DATE OF SUM 72 07	D1	DD DR6.E+AR)616		
S. DATE PREV SUWRY	A KIND OF SUMMARY	E SUMMARY SCTY	S BOAR SECURITY	T REGR	ADING [®] BA DI	89'N 1857A'A 3.13	A SPECIFIC C	ACCESS	LEVEL OF SUM	
710701	D. Change	U	U			NL	Nyes [] HO	A WORK UNIT	
A RAMARY	61102A	3406110	R71R	TASK	AREA NUMBER		WORK UNIT	NUMBER		
A. CONTRIBUTING	011024	5700110		<u> </u>	04		14/			
C. CONTRIBUTING										
11. TITLE (Procede with .	Socurity Classification Code	,•		L						
(U) Bone R	lepair (05)									
12 SCIENTIFIC AND TEL 003500 - C	Inical Medicine									
13 START DATE		TA. ESTIMATED COMP	LETION DATE	15 PUN	DING AGENCY		S. PERFORMA	NCE METHO	20	
71 03		74 03		DA			C. In-h	ouse		
17. CONTRACT/GRANT	N/ A			18. RES	OURCES ESTIMAT	-	HAL MAN TAS	L FUND	S (In these ands)	
& DATES/EFFECTIVE.	NA	EXPIRATION.			ARCEOINE					
N NUMBER:*			•	FISCAL	72	2.	5		25	
C TYPE		& ANOUNT:		YEAR					20	
& KIND OF AWARD		f. CUM. AMT.			/3	3		<u> </u>	38	
-	RUSHIZATION			20 PER	FORMING ORGANIZ	ATION				
HAHE!" Letterm	an Army Institut	e of Research		NANE:*	Lettermai	n Arnay Ins	titute of l	Researc	h	
Presidio	of San Francisco	, CA 94129			Maxillofac	ial Sciences	Division			
ADDRESS				ADDRES	Presidio o	f San Franc	cisco, CA	94129		
		•		PRINCIP	AL INVESTIGATO	Crumish SEAN II	U S. Acedemic (nelitu lian)		
RESPONSIBLE INDIVIDU				MANE.	[*] Robert, R	. CPT DC				
MANE: Akers, W	A., COL MC			TELEP	**** *4 15-561	-5181				
TELEPHONE: 414	5-561-5181			SOCIAL	SECURITY ACCO	UNT NUMBER				
				ASSOCIA	TE INVESTIGATO	N E COT DC				
				MAME:	rayne, 1.					
IL KEYBORDS (Procede	EACH with Sometily Classific	ation Code)		NAME:	Lilly, G.E	., COL DC			DA	
(II) avulsio	n wound: (1) bo	ne renair: (II)	radioisotone	e (11)	mandibula	r hone graf	ter (TI) for	aturas		
23. TECHNICAL OBJECT	IVE." 24 APPROACH. 25	PROGRESS (Purnish in		S. (U)	manurbura	r Uolle grat		ictures		
								nen Case.)		
24. (U) Lal	poratory studies	on does relatio	ng radioisoto	ne acti	ivity bloch	emical mic	rosconic	clinica	,	
rad	iographic and nh	vs., al strength	n findings	n act	wity, biech	cincai, niic	roscopic,	cinaca	•,	
160	ropraising and bu	ysical strength	i illiumga.		•					
25 (11) 71	07 - 72 06 Tw	o exneriment	al models are	heine	developed	to study m	andibula	. hono	and t	
20. (0) / 1	ength is correlated	d with the act	ual force requ	virod 1	a fractura	to stady m	andioulai	ulated	nhusio	
logi	ic stress. The def	ects are through	igh-and-throu	ah dai	focte analog	a grant site t	te which l	have he	physio-	
for	med in humans	The second m	odel correlat	er arai	ft strength	with the for	is which i	and to a	en per-	
era	ft plug from a rou	und-nunch de	fect This and	cs gra	allows con	marison of	vorious	cu iv s rofting	toobniques	
wit	hin a single hone	Presentiv t	he model is by	aina a	n allows con	nparison or	th model	s have l	leennigees	
ada	nted for strength	testing in the	Instrom Mai	orials	Testing Av	norotuc	in mouci	5 11440 1	Jeen	
	pica for strength	i testing in the		enais	resting Ap	paratus.				
*Aveileble is contracto	te u nen eri dinataria annos	**!								
Contraction of Contraction	CALIFORNIA AND AND AND AND AND AND AND AND AND AN	:-x						_		

į

10 - 11 - 114

and a second
DD, #07# 1498

وترجيع فالمراجع المداجة بتسطية وترقوه

a la sera da s

ner etter hatten hannet den sterre ander sterre atten atten atten atten

alternational tension and the second states of the

South States of the States of

法にい

Bone Repair

Colonel Gilbert E. Lilly, DC Major J.C. Jones, DC Captain Richard C. Robert, DC Captain Thomas F. Payne, DC

PROBLEM:

Accepted treatment for fractures and bone grafts of the jaws usually involves wiring the jaws together. In the military, the patient is hospitalized until bone repair has progressed to the point that the wires can be removed, the patient can eat a normal diet, and he is not in danger of aspirating foreign material into tight lungs. Such care requires prolonged hospitalization and results in many man-days lost. Currently, the most reliable clinical criteria for determining adequacy of bone repair are physical manipulation, and, in the laboratory, microscopic evaluation. Both of these methods are subjective.

This study is being undertaken to determine more reliable quantitative and qualitative methods for assaying bone repair to develop more objective laboratory and clinical endpoints for studying and evaluating bone healing.

APPRCACH:

Preliminary studies were undertaken to develop a suitable model for through-and-through bone defects in order to compare various grafting techniques on a histological, radiological, and physical basis. Defects were prepared on dog radii, tibias, and mandibles, and various graft and stabilization techniques attempted.

Graft strength has been datermined by two techniques. The first is based on the force required to fracture a graft plug from a round-hole defect 6 rm in diameter. This type of defect is small and uniform in morphology permitting different types of graft materials to be compared within a single bonc. Due to ease of access and surface area of bone available, the tibia has been used for this study.

en entre a servicitation and con

an and shared a bit has been and an an an and a start and a start and an and a start and an and an

The second strength determination has attempted to simulate the physiologic force required to fracture a through-and-through mandibular graft site. A downward force was applied to the anterior portion of the mandible, perpendicular to the body of the mandible.

Both of these strength determinations are being adapted to an Instrom flaterials Testing Apparatus.

RESULTS AND DISCUSSION.

Grafts were attempted on the radii of 4 dogs to determine the suitalility of the radius as a pocel for through-and-through defects. The radius vas found to be unsatisfactory because of overgrowth of fillrous connective tissue and bone. In addition, graft immobilization proved to be a significant problem. Mandibular grafts were attempted using an Iowa Bi-Phase Stabilization apparatus for external fixation. Two dogs received grafts and were stabilized with the Iowa Bi-Phase. Although through-and-through grafts on one of these dogs were successful, fixation again proved to be a problem. Most of the difficulty could be traced to the malfunction of teeth in the upper and lower arches due to misalignment of the mandible after grafting. It was determined that functional trauma to the grafts could not be overcome without removal of the mandibular teeth.

After the adoption of an edentulous mandible as the model for study, removal of teeth from mandibular arches of dogs was begun. To date, 7 dogs have had their lower teeth extracted. Similar procedures will be carried out on 13 more dogs in order to obtain a total of 20 for the study.

Tibiae from 2 dogs have been obtained for the preparation of round plugs for grafting. The plugs are obtained by cutting cores with a 6 mm trephine. These cores are presently being surface decalcified for use as grafts, according to procedures described in Work Unit No. 063, "Early Restoration of Mandibular Continuity".

Permission has been obtained from the U.S. Public Health Service Hospital of San Francisco to make use of their Instrom unit to make strength measurements on

the state and share and the first and a share and share and and

the grafts.

FUTURE PLANS:

Mandibles of the remaining dogs necessary for study will be made edentulous. Grafts will then be performed in order to determine the time-rate of healing of the various types of grafts. Attempts will be made to correlate through-and-through defects with the round punch defect in order to obtain comparison of grafts with the round punch model.

RESEARCH	AND TECHNOLOG	Y WORK UNIT S	UNHARY	T AGEN	CV ACCESSION®	2 DATE OF	10000AEV	REPORT C	ECARIA
1. DATE PREV SUURAV 71 07 01	D. Change	S SUMMARY SCTY	A. WORK SECURIT	P REGR	ADING [®] Part	NL	CONTRACTOR		A WORK
10. NO /CODES.*	PROGRAM ELEMENT	PROJECT	NUMBER	TASK	AREA NUMBER		WORK UNI	THUMBER	
b. CONTRIBUTING	02110A	<u></u>	04825		<u> </u>		Q6U		·····
C. CONTRIBUTING	Soturity Closeffication Cod	•,•				1			
(U) Early	Management of	Oral and Maxi	llofacial Wo	unds	(05)				
003500 - C	chnological Aneast Clinical Medicine	: 012900 - Pi	hysiology						
13 STANT DATE		CONT	LETION DATE	DA	DING AGENCY		C. In-ho	IANCE NETH	00
17. CONTRACT/GRANT		1	• <u> </u>	10 AES	OURCES ESTINA		STIDHAL MAN VA	S & FUN	4 (In these
B DATES/EFFECTIVE:	NA	EXPIRATION			PARCEOINS		••		77
G TY PE		4 ANOUNT-		VEAR	EUNNENV		10		
& CIND OF ASARD	ORGANIZATION	f. CUM. AMT.		20. PER	73	LA TION	12		90
				NANE:	Jones, J. Cutcher,	C., MAJ J.L., LT	DC C DC		
EL REVERADE (Frecedo	BACH with Security Clevel	hienen cede (U) bu	ne: (U) may	illofaci	al wounds:	(U) wou	nd inciden	ce;(U)	alloplas
(U) debrid 23 TECHNICAL OBJECT	ement; (U) surge	PROGRESS (Purnish)	trv: (U) avi	ISION W	ounds; (U)	feet of each with	h security Classifi	icellah Cada	,
25. (U) 71	07 – 72 06 Inv Maxillofacial Inj Restoration of M Infections; Rep See specific DI)	vestigations are uries: Early R fandibular Cor air of Salivary Form 1498 fo	e being cond lestoration (ntinuity: M Gland Duct r current st	lucted in of Oral I andibul as; Actin atus of o	n eight sub Integrity; ar Bone G nic Blockin each sub-pr	-projects Tissue Re rafts: Ora ng Agents roject.	: Incidence eaction to S al and Maxis for Protec	e of Ora Sutures: illofacia :tion of	l and Early I Wour Lip Mi

......

ういう ちょう アント

and a second second state and a second second and a second s

·

The second second the second

Sec. March

and the second second

DECEADOR	AND TECHNOLOGY	WORK HINT		I AGEN	CY ACCES	\$10H	DATE OF SUN	HARY I	EPORT	CONTROL STREES
REJEAKUT	AND TECHNOLOG	WURK UNIT 3	UNIAK I	DA C)C 68()7	72 07 ()1	ומ-ממ	CALIARIS IS
DATE PREV SUMAY	4 KIND OF SUMMARY	S. SUMMARY SCTY	S WORP SECURITY	REGR	DING	84 015	O'N INSTR'N	SE SPECIFIC D	ATA-	S LEVEL OF SUS
71 07 01	D. Change	U	U	N	A		NL	X ves C	HQ	A. WORK UNIT
NO./CODES.®	PROGRAM ELEMENT	PROJECT	NUMBER	TASK A	REA NUI	ABEN		WORK UNIT	NUMBER	1
PRIMARY	62110A	3A0621	10A825		00			061		
. CONTRIBUTING	<u> </u>									
. CONTRIBUTING								•		
1. TITLE (Procode with	Security Classification Code	,•								
(U) Early I	Restoration of Or	al Integrity	(05)							
SCIENTIFIC AND TE	CHNOLOGICAL AREAS									
0:7100 - W	eapons Effects;	(U) 003500 -	Clinical Medi	cine						
START DATE		14 ESTIMATED COM	PLETION DATE	IS PUNE	NHG AGE	104		16. PERFORMA	NCE WET	HÓD
65 11		CONT		DA				C. In-ho	ouse	
. CONTRACT/GRANT				18 RES	UNCES E	STIMATE	& PROFESSI	ONAL MAN VRS	b FUR	DS (In Knows anda)
N DATES/EFFECTIVE	NA	EXPIRATION		1	PAECEDI	M G			T	
N NUMBER *				PISCAL	7	2		1		6
C TYPE.		4 ANGUNT:		YEAR	CONNEN		1			•
KIND OF AWARD		f. CUM. AMT.		I	7	3		1		8
RESPONSIBLE DOD	ORGANIZATION	L		20 PERI	ORMANG	MGANIZ.	ATION		· · · ·	
Letterm:	an Army Institute	e of Research		HAME.*	Lette	rman	Army Ins	titute of F	lesear	ch
DODRESS · Presid	io of San Francis	co, CA 94129	9	ADDRES	• Max Presi	illofa dio of	cial Sciend San Fran	ces Divisio cisco, CA	n 9412	9
				PRINCIP	AL INVES		(Puminh SIAN	IUS. Academic ;	ne i i tu i ler	J
CSPONSIBLE INDIVID				NAME	Lilly	/, G.E	., COL DO			
HANE AKERS, W	A., COL MC			TELEP	HONE. 4	15-50	51-5160			
TELEPHONE: 415	-561-5181			SOCIAL	SECURIT	Y ACCO	UNT NUMBER:			
I. GENERAL USE				A330CIA	-	TIGATOR	1			
				NAME	Cut	cher,	J.L., LIC	DC		~
				HAME:	10	nes, J	.C., MAJ	DC		D.
	EACH with Steaming Classic									
(U) wound	s; (U) treatment;	(U) oral; (U)	maxillotacia!;	(U) v	eapor	<u>is effe</u>	<u>cts; (U) c</u>	<u>ombat; (U</u>) dim	ethylsiloxa
J TECHNICAL OBJEC	TIVE," 26 APPADACH, 25		iversienet bezeitebue in	entitie e oy	number p		si ai seca with 2	ecurity Classifics	.lan çadı	.,
AP /11	07 70 07 m									
25.(0) /1	0/ - 1206 10	date, a synthe	etic material h	as bee	n used	$\lim_{n \to \infty} 1^2$	i human t	attlefield	casua	lties, to
t	emporarily repla	ce missing soi	t tissue of the	maxi	lotaci	al area	a. Prelimi	nary findi	ngs m	dicate
1	nat this material	and method (or managemen	it are e	ellecti	ve in i	the treatm	ient of lar	ge ma	xillotacial
8	wuision wounds.	No evidence	of untoward	reaction	on has	iven.	iound. Pi	reliminary	labor	atory
S	itudies indicate ti	iat delayed p	nmary closure	or sel	ected	large	grossiy co	ntaminate	d max	killoracial
	wounds may be p	referable to i	nitial primary	closu	e.					

\$

É

And the fills of the case of the second second

The second s

Same and

DD PORM 1498 PREVIOUS EDITIONS OF THIS FORM ARE OBSOLETE. DD FORMS 1498A I NOV 48 AND 1498-1, I MAR 68 (FOR ARMY USE) ARE OBSOLETE

Early Restoration of · Oral Integrity

Colonel Gilbert E. Lilly, DC Lieutenant Colonel J.L. Cutcher, DC Major J.C. Jones, DC

PROBLEM:

When high velocity missiles strike the body, tissues are severely damaged, and large portions frequently are avulsed. Such large wounds in some cases cannot be closed primarily without severe distortion of anatomic features, and the traumatized tissues are not favorable sites for immediate grafts. When avulsion wounds involve the maxillofacial area, its integrity may be lost. This can lead to: problems in feeding; frequent requirements for intravenous or nasogastric nutrition; extensive nursing care; and psychologic problems, all being major factors in early patient management. Current initial therapy for such wounds, when they are large and primary closure is impossible, consists of suturing skin to mucosa with no attempt to close the defect.

The currently accepted treatment is to initiate immediate primary closure of maxillofacial wounds subsequent to debridement for esthetic reasons. In other areas of the body, battle wounds are usually closed several days after initial debridement, stabilization and initiation of tissue regeneration. Despite antibiotics and adequate debridement, some maxillofacial wounds break down after initial primary closure often increasing disfigurement and scarring. Advances in total patient care, antibiotic therapy, and materials to dress and support maxillofacial wounds suggest that delayed primary closure of selected maxillofacial wounds should be considered.

APPROACH:

Previous laboratory studies on dogs indicated that large orofacial avulsion wounds could be effectively managed by fabricating a silicone prosthesis directly in the wound to replace missing tissue and support the remaining tissues in their normal anatomic relation. To evaluate this method of management under realistic

152

and a second state of a second state of the second state of the second state of the second state of the second

conditions on patients with fresh battlefield wounds, permission was obtained to conduct a clinical study in the Republic of Vietnam.

Patients selected for this study had large orofacial avulsion wounds which could not be closed primarily or had orofacial wounds in which primary closure was considered inadvisable. Patients with concomitant injuries, which might compromise maxillofacial wound management, were not included in the study. Conversely, patients with concomitant injuries which might be adversely affected by the maxillofacial wound management, were also excluded. Wounds were debrided conservatively, consistent with accepted surgical principles for maxillofacial injuries. Fractures, if present, were treated in a conventional manner with reduction, fixation, and soft '.issue coverage. Soft tissues were closed in layers, taking care to preserve their anatomic position and relation as much as possible. Those portions of the wound which could be closed primarily, with skin to skin or mucosa to mucosa, were so managed. In areas of large avulsion, when possible, skin to mucosa closures were accomplished. Liquid RTV 382 dimethylsiloxane was then mixed with stannous octoate catalyst (10 drops catalyst/one ounce of RTV 382 dimethylsiloxane) and poured into the defect. This mixture self-vulcanizes in approximately 5 minutes. A prosthesis was formed which replaced the avulsed tissue and was well adapted Subsequent to vulcanization, the prosto the wound. thesis was trimmed with scalpel and scissors, if . necessary. In some cases, sutures were passed through the prosthetic device and into the soft tissues to insure adequate retention.

Patients received antibiotics postoperatively, usually consisting of parenteral penicillin and streptomycin for at least 10 days. Analgesics were prescribed as needed. Postoperatively, the wounds were irrigated twice daily with saline. This irrigation was accomplished by gently lifting the margins of the silicone prosthesis and flushing both intra- and extra-orally, using a large. Luer syringe. Early self-feeding was encouraged, except in cases where a nasogastric feeding tube was in place. In other respects, postoperative care was routine. Studies on delayed primary closure of maxillofacial wounds are in progress on rabbits. Bilateral maxillofacial wounds are produced on the cheek of each animal

with blank-shell explosive charges. These injuries traverse and destroy a portion of the masseter muscles but do not fracture facial bones.

Alternate methods of delayed primary closure managing the wounds are being evaluated. These methods include topical antibiotics, daily saline lavage, and no therapy other than the dressing. Five days postoperatively, the wounds are closed with sutures. The wounds are evaluated clinically and histologically for adequacy of wound healing 14 days after injury.

RESULTS AND DISCUSSION:

A total of 14 patients with combat maxillofacial avulsion wounds have been treated in the manner outlined, with a temporary prosthetic device prepared in the wound from RTV 392 dimethylsiloxane. The small number of patients treated in this preliminary study with wounds of such a diversified nature does not allow any valid conclusions to be reached concerning this method of management. We have not detected any evidence of local or systemic toxicity associated with the in vivo vulcanization and retention of RTV 382 dimethylsiloxane in the wound; nor have we observed any evidence that this material has contributed to wound infection or secondary breakdown. This is true even though the material was used in 3 patients subsequent to initial wound breakdown. The silicone prosthesis, fabricated in vivo, closely adapted to the wound and provided a splint which effectively replaced lost tissues and supported the remaining soft tis-This method of management is not intended to be sues. used to primarily close maxillofacial wounds. In selected maxillofacial avulsion wounds, however, where primary closure is impossible or cannot be accomplished without severe distortion of facial tissue, this method may prove valuable.

Dimethylsiloxane can be autoclaved and has a prolonged shelf life. Because it closely adapts to the wound with its rubbery consistency, support to the mobile soft tissues is provided.

Delayed primary closure of experimental wounds in rabbits indicates that, of the methods evaluated, topical treatment of the wound with bacitracin ointment and dressing with a thin sheet of silicone is the most acceptable method for delayed primary closure.

FUTURE PLANS:

The clinical portion of this study using RTV silicone prosthesis will be continued. Based on our experience this year, however, we anticipate that the number of wounds needing this type of management will be limited due to the reduced number of combat casualties.

Additional studies evaluating alternate methods of delayed primary closure are planned in the animal experimental model.

and the second
a Date Prev Sumay a Rind C 71 07 01 D 10. NO./CODES:* PROC a Primary 62 b. CONTRIBUTING C c. CONTRIBUTING C c. CONTRIBUTING C 11 TITLE (Proceds with Security C (U) Incidence of 1 12 SCIENTIFIC AND TECHNOLOG 003500 - Clinical 13 STARY DATE 66 09 14 CONTRACT/GRANY NA	r SUMMARY IS Change IN ELEMENT I TOA Dral and Mar CAL AREAS ⁶ Medicine	SUMMARY SCYY ⁴ (A. 0) PROJECT NUM 3A062110A8 Aillofacial Injur	DHK SECURITA U MER 25 ries (05)	AEGRA N TASK A O	DING ⁴ PA DI A REA NUMBER O		NORK UNIT N	TA- CCLSS HO LUMBER	CF SLM
71 07 01 D 10. NO./CODES:* PADC a. PRIMARY 62 b. CONTRIBUTING	Change MELEMENT 110A Accellication Codey* Oral and Mai Cal AREAS* Medicine	U PROJECT NUL 3A062110A8 Aillofacial Injur	U 25 ries (05)	N. 743K A 0	A REA NUMBER O		NORK UHIT A	IUNBER	R UHIT
10. NO./CODES: PADC a. PAIMARY 62 b. CONTRIBUTING 62 c. CONTRIBUTING 11 11 TITLE (Priced with Security C 12 SCIENTIFIC AND TECHNOLOG 13 SCIENTIFIC AND TECHNOLOG 003500 - Clinical 13 START DATE 66 09 17 CONTRACT/GRANT a. DATES/SPECTIVE NA	AN ELEMENT 10A 10A Dral and Ma: CAL AREAS ⁴ Medicine	PROJECT NUM 3A062110A8 Allofacial Injur	ries (05)	7A3K A 0	REA HUMBER		WORK UNIT N		
PRIVARY 62 CONTRIBUTING CONTRIBUTING CONTRIBUTING CONTRIBUTING CONTRIBUTING CONTRIBUTING CONTRIBUTING CONTRACT/ORANT CONTRACT/ORANT CONTRACT/ORANT	110A accellication Costs)* Oral and Mar CAL AREAS* Medicine 14	3A062110A8 Aillofacial Inju	25 ries (05)	0	0		062		
b. CONTRIBUTING c. CONTRIBUTING II TITLE (Precede with Security C (U) Incidence of 1 II SCIENTIFIC AND TECHNOLOG 003500 - Clinical II START DATE 66 09 I/ CONTRACT/GRANT A DATES/EFFECTIVE NA	analikanian Gudo) ⁶ Dral and Mai GAL AREAS ⁴ Medicine	xillofacial Inju	ries (05)						
e. CONTRIBUTING 11 TITLE (Procede with Security C (U) Incidence of 1 12 SCIENTIFIC AND TECHNOLOG 003500 - Clinical 13 START DATE 66 09 14 CONTRACT/GRANT • DATES/LEFECTIVE NA	Dral and Mar Cal areas ⁴ Medicine	xillofacial Inju	ries (05)						
(U) Incidence of a security of (U) Incidence of a scientific and technolog 003500 - Clinical 13 START DATE 66 09 17 CONTRACT/ORANT • DATES/EFECTIVE NA	Dral and Mai Cal aneas ^a Medicine	<u>Aillofacial Inju</u>	ries (05)						
(U) Incidence of B SCIENTIFIC AND TECHNOLOG 003500 - Clinical IS STATE DATE 66 09 CONTRACT/GRANT A DATES/EFECTIVE NA	Dral and Mai cal aneas* Medicine	Allofacial Inju	ries (05)						
003500 - Clinical 003500 - Clinical 0609 CONTRACT/GRANT A DAYES/EFFECTIVE NA	Medicine				·				
003500 - Clinical is start date 66.09 Contract/grant a dates/efective NA									
66 09 CONTRACT/GRANT DATES/LEFECTIVE NA		ESTIMATED COMPLET	ION DATE	IS FUND	ING AGENCY			CA METHOD	
A DAYES/LEFFECTIVE NA	i i	75.06	1	Ð٨	1	1	C. In-h	nuse	
A DATES AFFECTIVE NA	L.	75.00		10 .01%				h funds (in the	
110		EXPIRATION.	ł		PAECEDINE				
N NUMBER "				PISCAL	72	1 1		8	
G TYPE		4 AMGUNT.		YEAR	CURNENT		<u></u>	<u>~</u>	
& KIND OF AWARD		LCUM. AMT.			73	1	.5	12	
IS RESPONSIBLE DOD ORGANIZA	TION				ORMING ORGANI	EATION		·····	
NAME.* F	سا مىمەلەرمەت مىمە	uf Dament	·	-		A			
Letterman Ar	my institute	OF Kesearch			Letterman	Army Inst	nute of Ke	search	
ADDRESS:"	n rrancisco,	CA 94129		ADDRES	axiioiaci	ai Sciences	DIVISION	1100	
				ľ	resiaio of	san rranci	sco, UA 94	127	
				PRINCIP	AL INVESTIGATO	R (Pumish SBAN I	I U S. Academic J	alluilanj	
RESPONSIBLE INDIVIDUAL				HANE-	Lilly, G.	E., COL D	C		
NAME. Akers, W.A.,	COL MC			TELEP	HONE 415-	561-4042			
TELEPHONE. 415-561-51	81			SOCIAL	SECURITY ACCO	UNT NUMBER-			
21. GENERAL USE		** ** ***************		A550CIA	TE INVESTIGATO	R5			
				NAME:					
				-					DA.
21. KEYPORDS (Procede BACH +1	Security Clevellice	lan Codo)			• • •	(11)			
(U) oral; (U) m	ixillofacial;	(U) wounds; (U) injuries;	; (U)	incidence;	(U) treat	nent		
23. (U) This inv types of essential used as a research	estigation w maxillofacia for determin guide for st activities.	as undertaken il injuries treaten nation of the F affing, support	to obtain ir ed by the F ederal Den t required, c	nform edera tal Se prient	ation conc l Dental Se rvices' com ation of tra	erning the rvices. Th mitment i aining prog	relative ind is informat n this area rams and c	idence and ion is consi which may lirection of	idered be
24. (U) Survey submitte proc es si	of oral and 1 d through a ng equipmen	naxillofacial w ttending oral sı t.	ounds at sei urgeons. Da	lected ata ar	hospitals (tabulated	of the Fed and organ	eral Service ized by ele	es. Reports ectronic dat	are a
– 25. (U) 71 07 cards. N	72 ()6 To d o tabulation	ate, approxima of data has be	ately 1,000 een done as	cases of thi	have been is report.	reported a	nd transcri	bed to data	L

The state of the s

Incidence of Oral and Maxillofacial Injuries

Colonel Gilbert E. Lilly, DC Major J.C. Jones, DC Lieutenant Colonel J.L. Cutcher, DC

PROBLEM:

Previous studies conducted by this Unit based on data on over 10,000 oral and maxillofacial injuries in Vietnam; revealed that the incidence of such injuries is much higher than previously reported (as high as 24 percent of all admissions for trauma at one major hospital reporting over 1100 maxillofacial injuries in a one year period). In addition, the nature of these injuries and resulting complications required more sophisticated treatment and supportive care than that traditionally associated with oral and maxillofacial injur-These findings indicated: a) a greater dental ies. commitment than previously realized; b) a requirement for greater support by the Medical Department; c) the need for more extensive training) certain areas; d) a requirement for redirection of r a arch programs to deal with identified problems.

Current methods of reporting injuries incurred in the Federal Services are not sufficiently detailed to provide identifiable and usable data on maxillofacial injuries. Information on the type, number, treatment, and hospitalization time associated with maxillofacial injuries occurring within the United States is needed, since the majority of the population serviced by the Federal Dental Services is located within the United States. Such information is necessary to determine the Federal Dental Services' commitment in this area, which may be used as a guide for staffing, support required, orientation of training programs and direction of research activities.

The purpose of this study is to determine: 1) The commitments of the Federal Dental Services to the management of maxillofacial injuries and to establish the support required to meet these commitments. 2) The number and type of maxillofacial injuries at selected Federal hospitals. 3) The nature of maxillofacial

157

injuries, the treatment required, complications associated with such injuries and identification of specific problem areas.

APPROACII:

The oral surgery services at selected hospitals of the Air Force, Army, Navy, Public Health Service, and Veterans Administration would be furnished survey forms to be completed on all cases of maxillofacial trauma treated at their respective facilities. A representative from each service would be delegated as a coordina tor to collect and review the data and forward it to Maxillofacial Sciences Division, Letterman Army Institute of Research. The data would be processed and tabulated by electronic data processing equipment. Accrued information would be made available to the Chiefs of the Federal Dental Services and, upon their approval, promulgated in the usual manner. Subsequent to the approval by the Chiefs of the Federal Dental Services, it is proposed that this study be initiated 1 January 1972 and continue for a period of 3 years until 31 December 1974.

RESULTS AND DISCUSSION:

To date, over 1,000 cases have been reported and the forms returned to LAIR. Data on these have been transcribed to key punch cards. The data has not yet been tabulated since it is anticipated that this will be done on an annual basis.

FUTURE PLANS:

Tabulate and analyze accumulated data on an annual basis. Continue data collection for two more years.

Last Decret Using 1 (U) Do Change U U U NA NL Decret Using 1 (U) Do Change NA OLCOGES PROGRAM ELSERT PROJECT NUMBER TAKE AREA ANUMER PROVIDENT UNITED INFORMATION OF MANDING USING S. DECOMES PROJECT NUMBER TAKE AREA ANUMER PROVIDENT UNITED INFORMATION PROVIDENT UNITED INFORMATION S. CONTRACTING CONTRACT NUMBER TAKE AREA ANUMER PROVIDENT UNITED INFORMATION S. CONTRACTING CONTRACT NUMBER TAKE AREA ANUMER PROVIDENT UNITED INFORMATION OO3500 - Clinical Medicine: 017100 - Weapons Effects In PROFEMANCE NUMBER In PROFEMANCE NUMBER OO3500 - Clinical Medicine: 017100 - Weapons Effects In PROFEMANCE NUMBER In PROFEMANCE NUMBER OO3500 - Clinical Medicine: CONT DA C. In-house In PROFEMANCE NUMBER CONTENT A MOUNT ENTRACT NUMBER In PROFEMANCE NUMBER In PROFEMANCE NUMBER Names ^{AB} Letterman Army Institute of Research Presidio of San Francisco, CA 94129 In Presidio of San Francisco, CA 94129 New Sector NUMBER Internet Num Sector Number Internet Num Sector Number Internet Num Sector Number Internet Num Sector Sector Number Interenemance Internet Num Sector N	RESEARC	AND TECHNOLOG	Y WORK UNIT	SUMMARY	I. AGENO DA	CV ACCESSION [®] OC 6809	2 DATE OF SU	шляу ⁴)]	DD-DR&E	AR)
Image: Construction Image: Construction Image: Construction is not construction is not	L DATE PREV SUMAY	A KIND OF SUMMARY	S. SUMMARY SCTY	E BORK SECURITY	7. REGRA	-	158'N INSTR'N	SE SPECIFIC	C GATA - 9. LE	782
A paradar i G2TIDA 3A062110A825 00 063 Learnantina Communities Communit Communities C	/I U/ UI	PROGRAM ELEMENT	PROJEC	TNUMBER	TASK A	REA NUMBER		WORK UN	UND T	
Convention in the second	. PRIMARY .	62110A	3A062110	DA825	0	0		063		
c. constructions it. VTRLET/VIEW of a bandly Classifiering Cody it. VTR	. CONTRIBUTING							• • • •	•	••••
(U) Early Restoration of Mandibular Continuity	C. CONTRIBUTING	Somethy Classification Code			L		Lummer	. s 2000 .		فقيعر
Letterman Army Institute of Research Presidio of San Francisco, CA 94129 Response 415-561-5181 Letterman Army Institute of Research Presidio of San Francisco, CA 94129 Response 415-561-5181 Letterman Army Institute of Research Presidio of San Francisco, CA 94129 Response 415-561-5181 Letterman Army Institute of Research Presidio of San Francisco, CA 94129 Response 415-561-5181 Letterman Army Institute of Research Presidio of San Francisco, CA 94129 Response 415-561-5181 Letterman Army Institute of Research Presidio of San Francisco, CA 94129 Response 415-561-5181 Letterman Army Institute of Research Presidio of San Francisco, CA 94129 Response 415-561-5181 Letterman Army Institute of Research Presidio of San Francisco, CA 94129 Response 415-561-5181 Letterman Army Institute of Research Presidio of San Francisco, CA 94129 Response 415-561-5181 Letterman Army Institute of Research Presidio of San Francisco, CA 94129 Response 415-561-5181 Letterman Army Institute of Research Presidio of San Francisco, CA 94129 Response 415-561-5181 Letterman Army Institute of Research Presidio of San Francisco, CA 94129 Response 415-561-5181 Letterman Army Institute of Research Presidio of San Franci	(U) Early	Restoration of M	fandibular C	ontinuity (C)5)					
003500 - Clinical Medicine; UI 7100 - Weapons Effects 14 Franz Nate 14 Franz Nate 15 Franz Nate 16 Office 17 CONTRACT/GAMAY 1 Subject Struct I 1 Subject Struct III 1 Subject Struct IIII 1 Struct IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	12 SCIENTIFIC AND TE	CHNOLOGICAL AREAS	. 012100 14						**************************************	
66 06 CONT DA C. In-house "Conventer (analy) In RESOurces III inverse a Propertion of a properties of a propertion of a properties of the properties of a properties of a properties of the properties of a properties of a propertion of a properties of a properis properties of a properis of a propertis prop	003500 - C	Junical Medicine	; UI / LUU - W	PLETION DATE	S	HIG AGENCY		TIS PERFOI	MANCE METHOD	
 CONTRACT/GRANT CONTRACT/GRANT<td>66 06</td><td></td><td>CONT</td><td></td><td>DA</td><td>1</td><td>ŀ</td><td>C. In-</td><td>house</td><td></td>	66 06		CONT		DA	1	ŀ	C. In-	house	
L DATEARETTECTIVE: NA ELEMENTION: L DUMENT: L CUM. AMT. T. CUM. ALL INVESTIGATOR (PMIN MAN IU. J. AND T. MAR. AME. JONE, J.C., MAJ DC MAR. T. CULCHER, J.L., LTC DC T. CUCHER, J.L., LTC DC T. CUM. AMI. CULCHER, J.L., LTC DC T. CUM. AMI. T. CUM. ALL INT. T. CUM.	IT. CONTRACT/GRANT		*		18. RES	OURCES ESTIMAT		IONAL MAN Y	RS L FUNDS (
a mount: a mount: real provided cool one duitation a control: a mount: real provided cool one duitation a control: a mount: real provided cool one duitation a control: a mount: real provided cool one duitation a control: a mount: real provided control one duitation a control: a mount: real provided control one duitation a control: a mount: real provided control one duitation a control: a mount: real provided control one duitation a control: a mount: real provided control one duitation a control: a mount: real provided control one duitation a control: a mount: real provided control one duitation a control: a mount: real provided control one duitation a control: a mount: a mount: real provided control one duitation a control: a mount: a mount: real provided control one duitation a control: a mount: a mount: real provided control one duitation a control: a control one duitation a control one duitation real provide control one duitatin	A DATES/EFFECTIVE:	NA	EXPIRATION:			77		5		1
In RELEMENTAL OF AWARD: I. CUM. AWT. 73 .5 4 In RELEMENTAL OF AWARD: I. CUM. AWT. 73 .5 4 In RELEMENTAL OF AWARD: I. CUM. AWT. 73 .5 4 In RELEMENTAL OF OUR AWARD: Internation of Comparison of	- NUMBER:" G TYPE:		4 ANOUNT:		YEAR	CURNERY				
 The second statistication The second statistic statististic statistic statistic statistic statistic statistic statis	& KIND OF AWARD		f. CUM. AMT	r.		73		.5	5	
 (U) maxillofacial; (U) weapons effects; (U) early treatment: (U) mandible; (U) osseous avulsion were avulated of the second of the se	RESPONDELE INDIVID NAME: AKETS, V TELEPHONE: 415- 21. GENERAL USE DE REVEGAGE (Processi	W.A., COL MC -561-5181	lization Code)		TELEI SOCIA ASSOCIA NAME: NAME:	Jones, J. Cutcher,	-561-4042 COUNT NUMBER C., MAJ D J.L., LTC	C DC		<u> </u>
 24. (U) Laboratory studies on dogs and clinical studies to verify laboratory findings. 25. (U) 71 07 - 72 06 Laboratory studies have indicated that mandibular continuity can be effect temporarily restored, and soft tissues supported, with preformed silicone segments. Pref silicone mandibles have been fabricated and are being evaluated in clinical trials. Two pa have been treated with this device. Preliminary findings indicate that continuity has been effectively restored and the soft tissues supported without evidence of untoward reaction. 	(U) maxill 23. TECHNICAL OBJEC	lofacial; (U) weat	pons effects;	(U) early trea	dentitied by	: (U) man	dible; (U)	DSSCOUS	avulsion wo	íu —
	24. (U) L 25. (U) 71	aboratory studie 1 07 – 72 06 La temporarily rest silicone mandibl have been treate effectively resto	is on dogs and boratory stud ored, and so les have been ed with this d ored and the s	d clinical studi dies have indic ft tissues supp fabricated and levice. Prelimi soft tissues sup	ies to v cated ti orted, d are b inary fi oported	verify labor hat mandil with prefo weing evalue indings ind d without o	ratory find bular conti- ormed silico ated in clir licate that evidence of	ings. nuity ca one segm ical trial continui f untowa	n be effecti ents. Prefo ls. Two par ity has beer and reaction	ive)ri tic 1

in many and sha an in

ŝ

PREVIOUS EDITIONS OF THIS FORM ARE OBSOLETE. DD FORMS 1488A, 1 NOV 65 AND 1488-1, 1 MAR 68 (FOR ARMY USE) ARE OBSOLETE. DD, ***** 1498

Early Restoration of Mandibular Continuity

Colonel Gilbert E. Lilly, DC Major J.C. Jones, DC Lieutenant Colonel J.L. Cutcher, DC

PROBLEM:

When missiles strike the body, they frequently result in avulsion of tissues. The limited number of missile injuries experienced in civil life make such injuries essentially unique to the military.

Current information indicates that 96 percent of all maxillofacial injuries resulting from hostile action (RHA) in Vietnam are caused by missiles, and that 37 percent of these involve facial fractures. The mandible is the most common of the facial bones fractured (19 percent of all facial fractures). Seventy-five percent of these mandibular fractures are comminuted, and 55 percent involve avulsion of osscous fragments.

Major avulsion wounds of the mandible are usually treated by stabilization of the remaining osseous fragments and primary closure of the soft tissues. Such treatment does not usually provide adequate support for the soft tissues and results in their collapse into the defect and subsequent soft tissue deformity which is, because of scarring, difficult to reconstruct. Kirschner wires placed in the osseous stumps prior to soft tissue closure have been used in an attempt to provide support for the soft tissues. Such wires do not, however, provide sufficient support, and they literally cut through the tissues and usually become exposed in a period of 2 to 4 weeks.

This program is directed toward developing a method of management for large osseous avulsion wounds to reduce morbidity and man-days lost.

APPROACH:

Unilateral discontinuity defects were prepared surgically in the body of the mandible of 8 dogs. Each defect measured 3 cm in length. Immediately after preparation of the osseous defects, mandibular continuity 「こうないないないないないないないないないないないないないないないない

was restored with a block of precontoured vulcanized medical grade silicone, number 373, wired in place with trans-osseous stainless steel wires in 4 of the animals and a Kirschner wire in the other 4 dogs. The soft tissues were closed primarily over the silicone and Kirschner wire. The mandibles of each animal were then stabilized with an external pin fixation appliance. One animal from each group was sacrificed at 4, 6, 8, and 10 weeks after the surgical procedure. At sacrifice, radiographs were taken of each experimental site and the tissues recovered for microscopic study. Subsequent to fixation in formalin and decalcification, histologic sections were prepared from each surgical site.

Precontoured human mandibles have been prepared from vulcanized medical grade silicone and made available to selected oral surgeons in the United States and Vietnam for use on humans.

RESULTS AND DISCUSSION:

Clinically, the soft tissues overlying the osseous defects restored with preformed vulcanized silicone were supported in their normal anatomic position in all animals. The soft tissues overlying the silicone prosthesis appeared to heal normally even though in one case intraoral wound dehiscence occurred. Microscopically, the silicone prosthesis was surrounded by a thin fibrous connective tissue capsule containing a mild inflammatory infiltrate of lymphocytes and plasma cells. Later postoperative specimens obtained at 6, 8, and 10 weeks exhibited fewer inflammatory cells. The fibrous connective tissue capsules in these later specimens were well vascularized and did not show evidence of progressive fibrosis and thickening.

Clinically, the soft tissues overlying the defects restored with Kirschner wires initially appeared to heal in a normal manner. After 6 weeks, however, there was evidence of 'soft tissue deformities and, in one case; the wire became exposed into the oral cavity. In the latter instance, a severe inflammatory reaction was associated with the exposed wire necessitating its removal. Microscopically, there was a dense inflammatory infiltrate composed of plasma cells, lymphocytes, and neutrophils surrounding the wires. This inflammatory infiltrate was present in all specimens, but it was more severe in the specimen with wire exposure. There was increased soft tissue fibrosis and bone resorption surrounding the wire in later specimens.

To date, preformed silicone mandibles have been used in 2 humans. In both cases, the silicone prosthesis was placed at the time of removal of a large benign central tumor of the mandible (ameloblastoma and myxoma). Subsequent to placement of the prosthesis, the retained mandibles were immobilized with intermaxillary fix-In both cases, the postoperative period was unation. eventful and the silicone mandibles adequately supported the soft tissues in their normal anatomic position. There was no evidence of suppuration or other untoward In both of these cases, intraoral soft tisreaction. sue dehiscence occurred 2 months after the prosthesis This dehiscence was not associated with was placed. increased inflammatory reaction in either case and appeared to be directly due to excessive bulk of the silicone prosthesis. Three months after placement, both prosthetic appliances were removed due to persistent but uncomplicated intraoral dehiscence. In both cases, this removal and subsequent healing were uncomplicated. The soft tissues overlying the prosthesis were stabilized at this point and did not collapse after removal of the internal appliance.

Based on the animal studies and limited human clinical trials, the silicone prosthesis appears to more adequately support the soft tissue than does Kirschner wire and is associated with less local tissue reaction.

Although the clinical results have been less than ideal, due to intraoral dehiscence, this appeared, in the opinion of the surgeons, to be the result of inadequate soft tissue coverage of the appliance and could have been avoided by reducing the bulk of the prosthesis prior to placement. The lack of tissue reaction associated with intraoral dehiscence is a phenomenon which has been noted by other observers in association with intraoral submucous silicone prostheses. We are unable to explain this lack of reaction, but consider it to be an observation of great interest and of possible clinical significance.

FUTURE PLANS:

Based on the clinical and laboratory findings, this appliance and method of management appear to offer advantages to alternate methods for tenporarily restoring mandibular continuity. Additional clinical studies are planned with attention to method of coverage so as to avoid wound dehiscence.

The set of the set of

LASS CONTRACTORY NO.

				I. AGEI	CY ACCESSION	1	CATE OF SUMM	AP1* 1.8	LAURT C	164
RESEARCH	AND TECHNOLOG	Y WORK UNIT SU	IMMARY	DA	OC 6909	ľ	72 07 (01	rb pR	AFIAL In
S. BATE PREV SUMAY	4 KIND CP SUMMARY	S SUMMARY SCT	WORK SECURITY	7 REGR	ADING PA C	515 B'	N 1NST#'N 8	A SPECIFIC DA	in l	LEVEL De i D
71 07 01	D. Change	U	<u> </u>	N	A	NI	<u> </u>	Dres D	но	A WORK UNIT
10. NO./CODES:"	PROGRAM ELEMENT	PROJECY	UNBER	TASK	AREA NUMBER			WORK UNIT N	UMAER	
A, PRMARY	62110A	3A062110A	1825	 	00		(<u>)64</u>		
S. CONTRIBUTING	······					1				
11 TITLE (Procede with	Secutity Cleanilisation Code			1		1				
(U) Mandi	bular Bone Graf	ts (05)					······	·		
003500 - 0	linical Medicine									
11 START DATE		14 ESTIMATED CONPL	ETION DATE		DING AGENCY			- PERFORMAN		00
71 03		CONT		DA		1		C. In-ho	use	
17. CONTRACT/GRANT	······································		· · · · · · · · · · · · · · · · · · ·	14 821	OURCES ESTINAT	-	A. P. 0 (P. 1)			
& DATES/EFFECTIVE.	NA	EXPIRATION			PARCEDING					
* NUMBER.*	nn.			FISCAL	72			4		32
G TYPE:		4 ABOUNT.		YEAR	CONNERA	-				
& KIND OF AWARD:		f.CUM. AMT.			73		4	4		36
IS RESPONSIBLE DOD C	RGANIZATION			20. PER	FORMING ORGAN	ZAT	ION	T		1
NAME.* Letterm	an Army Institu	te of Research		-	Letterm	an .	Army Inst	titute of l	Resear	rch
Presidio	of San Francisco	. CA 94129		ł	Maxillof	aci	al Science	s Division)	
ADDRESS		.,		ADDRES	** Presidio	of	San Franc	cisco, CA	9412	9
				{						
				PRINCI	AL INVESTIGAT	0 n (#	umish SEAN II C) 5. Acadomic in	etterion)	
RESPONSIBLE INDIVIDU	AL			NAME	• Jones, J.	C.,	MAJ DC			
KANE: Akers, V	V.A., COL DC			TELE	MONE 415-5	61.	5160			
TELEPHONE: 415-5	61-5181			50CIA	L SECURITY ACC	OUN	T NUMBER.			
21, GENERAL USE				ASSOCI	TE INVESTIGATO	DRS				
				NAME	Lilly, G.	Ē.,	COL DC			
	A CH ALL LOOPIN Claudin			NAME	Osbon, I	D.B	<u>, COL D</u>	<u>C</u>		DA
(#1)		······································			Justans (1 1 \	laina -	wannela		
(U) mandi	bular bone gratts	5: (U) maxillo	aciai; (U) D	one in	auction; (0)	avuision	wounds		
					number, process		er eecu mim žeci	AILA CIDODINCON	lan Cede j	1
74 (U) La	horstory studies	on does invest	igating news	meth	nds for mai	ndi	bular bon	e oraftino	and o	linical
24. (U) La	idios to verify la	horatory findir	ngaring new i	metin		101		e Brarring	4110 V	minear
50	tules to verify ia	bolatory midi	iga.		•					
25 (II) 71	07 - 72 06 1	horstory studi	es on dogs ir	dicat	e that man	dib	ular bone	orafts wi	th su	face
23. (0) /1	calcified lyonhili	zed allogenic h	one and ant	nlogo	us marrow	are	well acce	nted by t	he ho	st. appear
to	be stronger micr	asconically the	n marrow g	afts	are easier to	n fe	abricate a	nd place t	han n	narrow
012	ofts and do not l	bave secondary	complicatio	ns rec	miring rem	ov	al of the r	netal fran	iewor	k used in
m	arrow grafts Cli	nical trials have	e been initiat	ed. S	tudies on f	5 n	atients po	int to pre	limin	arv
fin	dings which are	similar to labo	ratory result	s. Tu	vo papers h	invi	e been pro	sented at	natio	onal
sci	entific meetings	and a naner ha	s been nrese	nted a	it the 1972	. A	rmy Scien	ce Confe	rence.	
	entite meetings	and a paper na	B been prese				,			
l l										
ł										
ł										
1										
L		-								

- and the second s

by conting

Ť

ale se a la construcción de la cons

Butter and shear of a Salary or descended at the second

nsuit upstra stictin triin

Sector S

DD porm 1498 AND 14081.

Same and the second second

PREVIOUS EDITIONS OF THIS FORM ARE OBSOLETE. DD FORMS 1495A, 1 NOV 65 AND 1498-1, 1 MAR 65 (FOR ARMY USE) ARE OBSOLETE

And a second a second
Mandibular Bone Grafts

Colonel Gilbert E. Lilly, DC Major John C. Jones, DC Colonel Donald B. Osbon, DC

PROBLEM:

A survey of 9,439 patients with maxillofacial injuries received in Vietnam reveals that in 9.4 percent of patients with mandibular fractures due to hostile action, avulsion of a significant portion of the mandible occurred.

Mary of these patients required bone grafts to restore the mandibles. A review of 89 patients who required such mandibular bone grafts at selected army nospitals revealed that the hospitalization time for these patients averaged 509 days, with a range of 138 to 1,392 days. The patients in this group who were discharged from the military service had an average of 25 percent disability related to their mandibular wounds. Graft failures, or complications requiring additional grafts, occurred in 12.4 percent of these patients. These findings indicate the continued need for research directed toward reducing the morbidity and hospitalization time associated with mandibular bone grafts.

Recent work by Boyne and associates with autologous hematopoietic marrow has resulted in the development and clinical acceptance of a method for mandibular grafting that uses marrow fragments. Since the marrow fragments used in this technique have no inherent allostructural support, it is necessary to use a Vitallium metal framework to bridge the defect in order to support the graft and provide internal stability to the mandibular fragments. This framework is lined with a cellulose acetate micropore filter that serves to isolate the transplant from connective tissue invasion but allows for fluid interchange. Arthough rapid repair and earlier mobilization have been reported with this technique, the metal framework can be difficult to fabricate and adjust and may require surgical removal after the graft has healed.

Urist and associates recently have reported that

decalcified or surface decalcified allogenic bone or dentin will induce mesenchymal cell differentiation into osteoblasts and formation of new bone. They have labeled this process the "bone induction principle" (BIP) and have related it to the topochemistry of bone or dentin matrix collagen. With these findings, they have theorized that bones, unlike most human organs, retain the primordial capacity to induce regeneration of lost parts.

This study was undertaken to determine the feasibility of using surface decalcified allogenic bone for mandibular bone graft: and, if feasible, to develop methods for accomplishing such grafts.

APPROACH:

Bilateral osseous defects of the same size were created surgically in the inferior border of the body of the mandibles in 23 dogs. Each defect was 3 cm long and extended superiorly to the inferior alveolar canal. In group one, each of 17 dogs had one mandibular defect restored with fresh autologous marrow obtained from the iliac crest. These grafts were stabilized with a Vitallium crib lined with Millipore filter in the method described by Boyne. The contralateral defect in each of these animals was restored with surface decalcified allogenic bone obtained from the mandibles of other dogs and secured in place by intraosseous stainless steel wires.

Surface decalcified allogenic bone was prepared in the manner described by Urist by placing donor specimens in 0.6N HCL for 2 hours at 25 C. After surface decalcification, each specimen was washed for 30 minutes in normal saline solution and placed in neutral 70 percent ethanol at 20 C for 48 hours to defat the specimen. The specimens were then lyophylized after exposure to liquid nitrogen for 15 minutes and shored at -10 C in vacuum containers.

The dogs were sacrificed at 2, 3, 4, 5, 7, 9, 10, 11, 12, and 14 weeks postoperatively--2 dogs at each interval, except on the last 3 dates when only one animal was sacrificed. Selected animals received radioactive 18F intravenously (doses were calculated

to give 10µ curie/kg at time of sacrifice or photoscan) at various intervals before sacrifice and were scanned with a positron photoscanner. Osseous core samples were obtained from these animals after sacrifice and ¹⁸F activity was determined by well counting. The mandibles were recovered by block section and processed for histologic study. After decalcification, step serial sections, stained with hematoxylin and eosin, were prepared in all instances.

In group two, each of 6 dogs was treated in the same way as the first, except that the mandibular defects were restored with autologous marrow grafts on one side and with a combination of surface decalcified bone and autologous marrow fragments on the other side. in the latter instance, a hollowed-out tray was formed from the surface decalcified bone and the marrow cavity and the interface was packed with autologous marrow. The surface decalcified bone was held in position with stainless steel intraosseous wires. These dogs were sacrificed at 2, 3, 6, and 7 weeks after grafting. Two dogs were sacrificed at 3 and 6 weeks and one each at the other times. The specimens were prepared in the same manner as previously described for the animals in the first group. The animals were monitored by ¹⁸F photoscans at regular intervals and scintillation well counts at sacrifice.

RESULTS AND DISCUSSION:

TWO WEEKS POSTGRAFT--Surface decalcified grafts: Endosteal host bone proliferation had resulted in initial fusions between the graft and the host bone.

Marrow grafts: In some specimens, the transplanted marrow fragments were associated with early evidence of osteogenesis. Other specimens revealed no detectable osteogenic activity. None of the transplanted fragments was fused with each other or the host bone. Endosteal bone proliferation was comparable to that observed in surface decalcified specimens. An inflammatory infiltrate was observed at the external margins of the graft adjacent to the Millipore filter and Vitallium mesh.

Surface decalcified grafts with marrow fragments: The specimen showed early evidence of fusion with the host
bone associated with considerable endosteal prolife.ation. Osteogenic activity was noted around some of the marrow fragments. There was no evidence of all inflammatory inflltrate.

THREE WEEKS POSTGRAFT--Surface decalcified grafts: Fusion between the graft and host was more advanced. There was evidence of osteoclastic activity and initiation of graft replacement by the host. No inflammatory infiltrate was observed.

Marrow grafts: All grafts showed some evidence of osteogenesis in relation to the transplanted fragments. The amount of osteogenic activity varied considerably from one specimen to another. Fusion between the separate fragments and between the host bone and the marrow fragments was observed in only one instance. An inflammatory infiltrate was present at the margins of the graft associated with the Millipore filter and Vitallium mesh. In these areas, osteogenic activity was not evident.

Surface decalcified grafts with marrow fragments: Endosteal bone proliferation was evident, with fusion between the host bone and surface decalcified graft. Marrow fragments showed limited osteogenesis. No inflammatory infiltrate was noted.

FOUR TO SEVEN WEEKS POSTGRAFT--Surface decalcified grafts: Microscopic evaluation revealed progressive remodeling and fusion of the graft with the host bone. No inflammatory reaction was evident.

Marrow grafts: Marrow grafts showed fusion between the fragments and with the host bone at 4 weeks, with progressive osteogenesis and fusion at later dates. The grafts were trabecular in character and hematopoietic activity was present in some grafts. Endochondral ossification within the graft was noted frequently, and in some instances was extensive. The margins of the grafts adjacent to the Millipore filter and Vitallium mesh showed fibrosis and contained a chronic inflammatory infiltrate. In these areas, osteogenic activity was limited.

Surface decalcified grafts with marrow fragments: Sixand 7-week specimens showed fusion between the host

and a second of the second

bone and graft. Marrow fragments showed active osteogenesis with endochondral ossification in some areas. Extensive remodeling was present in some grafts: No inflammatory infiltrate was present. No further histologic evaluation of this type of graft was performed at longer postoperative time intervals.

NINE TO TEN WEEKS POSTGRAFT--Surface decalcified grafts: All specimens showed fusion of the graft to the host bone with extensive remodeling and progressive incorporation into the host mandible.

Marrow grafts: Although the grafts were undergoing progressive osteogenesis, they were still trabecular, and many contained areas of hematopoietic activity. Cartilage was observed in some areas. An inflammatory and fibrotic reaction to the Millipore filter and Vitallium crib was noted in most instances. There was no evidence of a cortical plate.

ELEVEN TO 14 WEEKS POSTGRAFT--Surface decalcified grafts: Grafts were well incorporated into the host mandibles and showed continued remodeling. There was no evidence of rejection.

Marrow grafts: Fusion with host bone was extensive. The grafts were trabecular and __matopoietic activity was noted in some areas. Some specimens exhibited reaction to the Millipore filter and Vitallium mesh, and only one graft had a well-developed cortical plate.

¹⁸F ACTIVITY--Positron photoscans of animals revealed increased ¹⁸F activity in all grafts at all intervals after 2 weeks. The resolution of these photoscans was not sufficient to permit quantitative or qualitative differentiation between the various grafts.

Scintillation well counts of core samples revealed increased ¹⁸F activity at all graft sites as compared to controls. Maximum ¹⁸F activity was observed in all types of grafts 4 weeks after placement of the graft. This level of activity appeared to correlate with microscopic findings as to maximum osteogenic activity. In general, ¹⁸F activity was higher in grafts composed only of marrow fragments, as compared with those containing surface decalcified bone. As remodeling progressed, grafts containing surface decalcified bone

Carbona and a state of the second second second

had ¹⁸F activities that more closely approximated activity levels observed in pure marrow grafts.

The surface decalcified allogenic bone grafts used in this study were well accepted by the host. We were unable to detect any evidence of rejection of this material. Microscopically, the decalcified material appeared to be tolerated in the same fashion as autologous nonviable bone. New bone fused directly to the allogenic graft, followed by gradual resorption of the nonviable graft and progressive replacement by new The microscopic, radioisotopic, and clinical bone. end points used in this study were not sufficiently sensitive to permit determining the induction effect of the surface decalcified bone on the mesenchymal tissue of the host. Conversely, they did not reveal any inhibition of host bone osteogenic activity. Therefore, from our results we cannot support or refute the induction principle reported by Urist for surface decalcified allogenic bone.

The transplanted marrow fragments did appear to maintain their viability, as shown by the microscopic presence of intact osteocytes within the lacunas of the fragments. The apposition of osteoid directly on these viable fragments, which were not directly associated with host bone, is in agreement with Boyne's findings that fresh autologous marrow has osteogenic potential. However, our findings would appear to show that this potential is retarded for a time after transplantation. The endochondral bone formation observed in association with transplanted marrow fragments has not, to the best of our knowledge, been reported previously for such grafts to the mandible. Endochondral bone formation occurs frequently in osseous repair in other parts of the body. This formation appears to be the result of incomplete vascularization of the repair site before osseous proliferation.

The inflammatory reaction associated with +he Millipore filter and Vitallium mesh, which was consistently observed in the first 9 weeks after grafting, appeared to inhibit osteogenesis in the local area. This finding conflicts with those of Boyne when he used a similar technique. We have conferred with Boyne on possible technical differences but have been unable to explain this variance.

Although the surface decalcified graft with autologous marrow fragments appeared to have little advantage over the grafts composed entirely of surface decalcified bone, in a human discontinuity defect the addition of autologous marrow fragments with osteogenic potential is considered desirable.

The use of surface decalcified allogenic bone with autologous marrow fragments has advantages over the autologous marrow graft supported with Vitallium mesh lined with Millipore filter. The surface decalcified bone unites structurally with host bone, is removed by physiologic processes, and has shown no evidence of inciting local inflammatory reactions. In addition, the use of allogenic human mandibles would simplify fabrication problems associated with metallic frameworks, and such mandibles are much easier to contour and adapt than metal frameworks.

The ¹⁸F activity at the graft sites, as measured by positron photoscans and scintillation well counts, is not yet a sufficiently sensitive measurement to relate the significance of emission variations to the total repair process.

FUTURE PLANS:

Additional studies have been initiated on the experimental animal model described in this report to determine if variations in the amount of surface decalcification have any effect on bone repair. Clinical studies have been initiated to verify laboratory findings.

RESEARCH	AND TECHNOLOG	WORK UNIT S	UMMARY	I AGEN	CY ACCESSION®	2 DATE OF SU	MARY [#]	REPORT C	он тв ог љ. I (AR)
TI 07 01	• KIND OF SUMMARY	B SUMMARY SCTY	4. NORE SECURITY	7 REGRI	IA	NI 1	AL SPECIFIC	DATA -	LEVEL
NO /CODES:*	PROGRAM ELEMENT	PROJECT	NUMBER	TASK A	AEA NUMBER	INL	WORK UNI	T NUMBER	
	6 <u>2110A</u>	3A062110	0A825	0	0		066		
. CONTRIBUTING				+		4			
1 TITLE (Procedo alth	Security Classification Code	,•		- h				*****	
(U) Tissue	Reaction to Sut	ures (05)				<u></u>			
003500 - 0	linical Medicine:	012900 - Ph	ysiology						
START DATE		14 ESTIMATED CON	PLETION DATE	TS FUNC	ING AGENCY		16 PEAFOM	ANCE METH	00
DO UD		/300		IJA 10 RESU	OUACES ESTINA		OHAL MAN 7		05 (In the
& DATES/EFFECTIVE	NA	EXPIRATION			PRECEDING			-	
. NUNBER *		4 AMOUNT		FISCAL	72		.5		4
L KIND OF ABARD		f. CUM. AMT.	•		73	1	.5		2
B RESPONSIBLE DOD	ORGANIZATION		<u> </u>	20 PER	FORMING ORGAN	TION			1
TELEPHONE. <u>4</u> II. GEMERAL USE IT REVUCENDS (Frieddi SUFGETY; (L IS TECHNICAL OBJEC 25. (U) 71	15-561-5181 <u>J) mouth: (U) m</u> tive. [•] at approach. 23 07 - 72 06 The tologically in dog material, polygly multifilament su with antibiotics. compared to unt polyglycolic acid sutures. Clinical and oral tissues.	e oral tissue re colic acid, we ture materials Antibiotic in reated nonres suture inhibi studies indica These finding	Maxillofacial ranes references ofilament sution ere associated is studied, eve mpregnation of sorbable multi its the transmate that polyg gs suggest that	wound wound different wound different with n n thoug did app ifilame ission glycolic t the n	Cutcher Jones, J Is; (U) sut ent suture terials and nilder tissu gh some of ear to imp ent sutures of bacteria cacid sutu olyglycolid	, J.L., LTC .C., MAJ I ures; (U) ti materials I the multifi re response the latter rove the re . Bacteriol compared res are wel	DC ssue reac as been e lament re s than the materials lative tiss ogy studi to other tolerated re is the r	tion; (U evaluate esorbable e nonres were in sue resp ies revez multifi d by the naterial	d his- d his- le suti sorbal npreg onse a lamer e patie

and the second states and the second states and the second states and the second states and the second states a

an inder the second second

WARTER CLEAN

New color restored and a second description of the second second second second second second second second seco

dis-sheet and

ł

a Alexandrian Tissue Reaction to Sutures

Colonel Gilbert E. Lilly, DC Colonel D.B. Osbon, DC Lieutenant Colonel J.L. Cutcher, DC

PROBLEM:

Because of military urgencies requiring evacuation and transfer of patients, and the frequent necessity to wire the jaws together, prolonged retention of oral sutures is often necessary. In such situations, particularly when battlefield wounds are involved, it is critical that the sutures used to maintain closure do not themselves contribute to tissue irritation and wound breakdown with resultant increased morbidity.

In previous studies on dogs, resorbable multifilament polyglycolic acid (PGA) sutures were associated with less severe tissue reactions histologically than multifilament nonresorbable sutures. The histologic rindings in these previous studies suggested that bacterial transmission by the PGA suture was less than with the other multifilament suture materials and that this was a factor accounting for the milder tissue reaction associated with the PGA sutures.

This study was undertaken to clinically verify the previous animal studies and to determine if the PGA suture did inhibit bacterial transmission.

APPROACH:

In the clinical portion of this study, 12 periodontal flaps and 220 surgical flaps associated with the bilateral removal of third molars were evaluated in 122 patients. Periodontal flaps were sutured with alternate 4-0 silk and 4-0 PGA sutures. Third molar flaps were sutured with 4-0 silk and on the contralateral side with 4-0 PGA sutures. All sutures were on swedged 3/8 circle cutting needles. Sixty-one percent of the patients were males and 86 percent of the patients were in the second and third decades of life (see Table 1). Slightly over 68 percent of the surgical procedures were in the mandibular area and 90 percent were third molar flaps. The sutures were removed four to seven days after they were placed and 88 percent were removed on either the fourth

neder verste verste het der der beinden verste bieden verste bieden der der der der der der beste beinder bei d

or fifth postoperative day. At the time of suture removal, the response of the tissues to the PGA and silk sutures was compared in each patient as to appearance, retention of sutures, flap position, evidence of complications, and patient complaints related to the sutures.

TABLE I

CLINICAL STUDY

Patient	s	Location of Sutures	Type Flap	Suture Removal
Males	61%	Maxilla 31.8%	Periodontal 9.8%	<5 days 88%
Age 15-30	86.2%	Mandible 68.1%	3rd Molar 90.2%	>6 days 12%

The ability of sutures to transmit bacteria was evaluated in vitro by a specially designed bacteriologic culture chamber. Sterile thioglycollate medium was placed in the central chamber and the exterior chamber was partially filled with a similar medium containing a mixed culture of oral microorganisms. The interface between the two chambers was impervious except at the site occupied by the suture. The chambers were incubated aerobically at 37° C and the presence or absence of growth determined by visual examination after twenty-four hours. The bacterial transmission features of PGA, silk, steel, and gut sutures were evaluated in this system.

RESULTS AND DISCUSSION:

All of the PGA sutures were retained in position in 96.7 percent of the cases and in no case were they all lost (see Table II). The flaps were maintained in their proper position in 95 percent of the cases. In comparison, contralateral flaps sutured with silk were retained in position in 95.9 percent of the cases, and some of the silk sutures were lost in 7.2 percent of the patients. Local complications related to the sutures were noted in five cases with PGA sutures and in nine cases with silk. Only one of the 122 patients had any complaints related to the PGA suture. In the clinical judgment of the surgeon, the reaction Associated with the PGA sutures was judged to be the same as that associated with silk in 78.7 percent, better than silk in 13.9 percent, and worse than silk in 7.4 percent of the patients surveyed. In the . laboratory study, steel and gut sutures exhibited no evidence of bacterial transmission at twenty-four hours (see Table III). Twenty-five percent of the PGA sutures and 74.1 percent of the silk sutures exhibited bacterial transmission. This difference in bacterial transmission was significant with a P value of < 0.01.

TABLE II

CLINICAL RESULTS

	Suture	Flap	Local Com-	Patient
	Retention	Retention	plications	Acceptance
PGA	119 (96.7%)	116 (95.1%)	5 (4.1%)	121 (99.2%)
Silk	112 (91.8%)	117 (95.9%)	9 (7.4%)	120 (98.4%)

TABLE III

BACTERIAL TRANSMISSION

Suture	Number of Trials	Negative	Positive	Percent Positive
Silk	27	7	20	74.1
PGA	24	18	6	25.0
Gut	12	12	0	0.0
Steel	12	12	0	0.0

The in vitro bacteriologic findings indicate that the PGA sutures do not transmit bacteria as readily as silk sutures. In our opinion, these findings add support to our previously expressed contention that bacterial transmission is a major factor responsible for the tissue reaction to intraoral sutures.

In view of the bacteriologic findings in this and previous studies, we are convinced that PGA does inhibit bacterial transmission and that this is the major

factor accounting for decreased oral tissue reaction as compared to multifilament nonresorbable sutures. Although neither polyglycolic acid or its in vivo hydrolytic breakdown product, glycolic acid, are bactericidal, it is theorized that within the microcosm between the interstices of the PGA suture, the glycolic acid concentration is sufficient to result in a pH that is not compatible with bacterial growth.

Although the clinical observations made in this study fail to demonstrate a clinical superiority of PGA suture as compared to silk, the nature of the population (predominately young adults), the procedures (elective surgery), and the suture retention time (usually five days or less) resulted in a situation where, in most cases, the host resistance was sufficient to preclude demonstration of clinical differences. The clinical findings indicate that PGA sutures are not toxic, are well tolerated by the patient, and technically provide and maintain tissue approximation.

Because of the microscopic and bacteriologic findings, in cases where longer suture retention is required and/or tissue resistance is lowered, we believe the PCA suture is preferable to silk.

The physical handling characteristics of the PGA suture are similar to silk and other multifilament suture materials and therefore make it clinically more acceptable than the monofilament suture materials currently available. Although the PGA suture is resorbable, the resorption time is sufficiently long (16-20 days in the oral cavity) to make suture removal necessary. The major disadvantage to the clinical use of PGA suture, in our opinion, is its pale color which makes visualization difficult.

This comparative clinical and bacteriologic study cf PGA and silk sutures revealed no significant clinical difference in the tissue reaction to the two sutures studied. The bacteriologic findings and previous histiologic findings indicated that PGA sutures inhibited bacterial transmission. This inhibition of bacterial transmission is thought to be a major factor responsible for reaction of oral tissues to sutures. The bacteriologic, histologic, and clinical handling features of PGA sutures appear to make them superior to silk for oral sutures which are retained for extended periods or in patients with lowered resistance.

FUTURE PLANS

At this time, no additional studies are planned. As additional suture materials become available for use in the oral cavity, they will be evaluated.

An how was a service and

たいというなどであるというないないですよう

	ND TECHNOLOGY	WORK HAIT C		1 ACEN	CY ACCES	SION®	2. DATE OF SU	WWARY [®]	REPORT	ONTHOL STREE
KEJEAKUN A				DA	<u>OC 69</u>	20	72 0	7 01		KAT (AK)636
DATE PREV SUM'RY 4.	KIND OF SUMMARY	S SUBBARY SCTY	4 BUAR SECURITY	7 REGRI	DING	-	88'N 1HSTA'N	OHTRACTOR	DATA+ ACCESS	I LEVEL OF SU
71 10 18 1	D. Change	U	U	N	<u>A</u>		NL	IKI YES] но	A VORK UNI
NO./CODES.	ROGRAM ELEMENT	PROJECT	NUMBER	TASK 4	REA NUN	IBER		WORK UNI	NUMBER	1
	621104	3A062110	0A825)0			067		
. CONTRIBUTING										
CONTRIBUTING										
. TITLE (Procode with Sec	willy Classification Code	,•								
(U) Repair of	of Salivary Glan	nd Ducts (0)	5)							
L SCIENTIFIC AND TECH	NOLOGICAL AREAS	<u> </u>								
0035 0 0 - Cli	nical Medicine									
& START DATE		4 ESTINATED COM	PLETION DATE	13. FUNT	ING AGEN	CY		16. PERFORM	ANCE MET	HOD
71 08		73 06		DA	1			C. In-	house	
. CONTRACT/GRANT						TIMAT	L & PROFES	SIONAL MAN YR		DS (In Housands
A DATES/EFFECTIVE.	NA	EXPIRATION			PARCEON			ببسنيا كلية وتسيلميا اسبنتا		
L NUNSER *				FISCAL		72		.5		2
		4 ANOUNT.		YEAR	CURNENT				_	
L KIND OF AWARD		L.CÚM. AMT.				73		.5	1	3
RESPONSIBLE DOD OR	GANIZATION	[20 PER	ORMINGO	RGANT	ATION			
		a of Bosoaral		-	1 attar	man	A may In	titute of i	Dougor	
Letterman	i Anny Institut	e of Research	1	1	Letter	111411	Aimy in:	situte of a	Nescan	. 0
DOALSS." Durat Ita		- CA 04120		ADDRES	"•Maxi	he a	cial Scien	ces Divisio	on	
Presidio C	of San Francisc	0, CA 94129		1	Presi	dio o	f San Fra	ncisco, C/	\ 9412	9
				PRINCIP	AL INVEST	IGATO	R (Fumish SEAN	ITUS Aradomi	: j=slitution)
	_			HANE!	Jone	s, J.C	.,MAJ D	C		
Akers, W.	A., COL MC			TELEP	HONE 4	15-5	61-4042			
415-56	51-5181			SOCIAL	SECURIT	Y ACCO	UNT NUMBER			
I. GENERAL USE	· · · · · · · · · · · · · · · · · · ·	······		ASSOCIA	TE INVEST	TIGATO	n \$			
				NAME:	Lilly	, G.E	, COL D	С		
				-	Hack	ett, l	P.B. SP4			Đ٨
				I TARES						DA

23. TECHNICAL OBJECTIVE, * 46 APPROACH, 25 PROGRESS (Purnish in Uridual peragraphe Ideniilied by number Precede test of each with Security Cleasification Code

25. (U) 71 10 - 72 06 Preliminary studies have indicated extreme difficulties in developing a laboratory model that is analogous to human clinical situations. A model has been developed but preliminary results on two dogs indicate further refinement is necessary.

Aveilable to contractors upon originator's approval

DD, 1084 1498

Repair of Salivary Gland Ducts

Colonel Gilbert E. Lilly, DC Major J.C. Jones, DC SP-4 Perry B. Hackett

PROBLEM:

High velocity missile wounds involving the face frequently result in the laceration or transection of major salivary gland ducts. Various methods have been suggested for the repair of these injuries to permit normal salivary drainage, promote normal gland repair and function and prevent salivary fistula formation Although the most frequently advocated on the face. and accepted method of repair is to suture the cut ends of the duct together over a polyethylene tubing stent, there is still a question as to how the stent should be placed. The adequacy of such repairs has not The treatment of a severed duct, where been defined. primary repair is not possible, is not well established. This study is directed toward developing methods for managing major salivary gland duct injuries that will decrease patient morbidity and promote normal salivary gland function.

APPROACH:

Adult mongrel dogs were used in this experiment. All dogs were anesthetized and both submandibular ducts were surgically exposed and transected approximately 2 cm from the orifice. In 6 dogs the ducts were repaired by suturing them over polyethylene tubing Three dogs had the tube removed from the stents. duct immediately on one side, and 2 weeks postoperatively on the other. Three other dogs had the tube removed from 1 side at 4 weeks and the other side at 6 weeks postoperatively. Three dogs did not have a primary repair of the severed duct. In these animals, one gland was drained by means of a tube through the distal end of the duct. The other side was drained by a larger diameter polyethylene tube through a stab The proximal stump of the duct was not surincision. gically approximated to the distal stump in these

dogs. The adequacy of repair and gland function was evaluated by sialography at weekly intervals, and by microscopic examination of the glands and ducts at sacrifice. All dogs were sacrificed at 12 weeks postoperatively.

RESULTS AND DISCUSSION:

Retention of the polyethylene catheter in the animals has been a major problem. Despite placement of deep sutures, the catheters frequently have been lost prior to the end of the experimental period for retention. This problem in the experimental model has precluded obtaining meaningful data on these different methods of management. Histologic and sialographic studies in animals that retained catheters for a minimum of 2 weeks indicated major differences in the catheterized salivary glands as compared to contralateral untreated control salivary glands with resected ducts.

Control glands histologically exhibited marked diffuse acinar degeneration and contained an inter- and intralobular inflammatory infiltrate of lymphocytes and plasma cells. Catheterized glands contained a mild intralobular inflammatory infiltrate and minimal acinar degeneration. Sialograms were essentially normal for the experimental glands. Sialograms of control glands revealed marked stricture of the salivary gland ducts and limited definitive filling of the glands with resection and are currently being evaluated in the experimental model.

FUTURE PLANS:

Additional studies are planned to develop a predictable animal model.

Preliminary trials with silicone catheters have indicated less problems with rejection and are currently being evaluated in the experimental model. A microporous polyurethane catheter has recently become available which may offer advantages to other types of catheters.

				I. AGENCY	ACCESSION®	2 DATE OF SU	MARY ⁰ R	PORT C	ONTROL SYN	-10 /01
RESEARCH	AND TECHNOLOGY	WORK UNIT	T SUMMARY	DA O	C 6923	72 07 0	1	DD.DH	LE(AR)630	•
71 10 18	D. Change	1. SUMMARY SCT	VA N. WORK SECURITY	7. REGRADI	NG ⁶ 84 DI	NI.	ON TRACTOR A	CCESS	A WORK U	IUW NIT
. NO./CODES	PROGRAM ELEMENT	PROJ	ECT NUMBER	TASK AR	CA NUMBER		WORK UNIT I	IUNBEA		
	62110A	3A062	10A825	00			068			
. CONTRIBUTING				1		·	~			
CONTRIBUTING						. <u></u>	×	, 		
(U) Oral a	nd Maxillofacial	• Wound Inf	ection (05)							
E. SCIENTIFIC AND TE 003500 - C	CHHOLOGICAL ARTAS [®]									
START DATE		14. ESTIMATED	COMPLETION DATE	IL FUNDIN	GAGENCY		16. PERFORMAN	CE NET	NOD	
71 08		CONT		DA			C. In-hou	ise		
. CONTRACT/GRANT				N. RESOU	ACES ESTINAT	E A PROFESI	IONAL MAR YRS	h PUN	DS (In shouse	(4)
A DATES/EFFECTIVE:	NA	EXPIRATIO	6:		75		•	ł	10	
N NUMBER "		A AMOUNT:		VEAR T	UNRENT		<u> </u>	<u> </u>	10	
& KIND OF AWARD:		f. CUM. A	MT.		73		3.5		20	
. RESPONSIBLE DOD	GAGANIZATION				RHING ORGANI	ZATION				
ADDRESS: [®] Presidi	an Army Institut o of San Francisc	e of Resea :0, CA 941	rch 29	HAME:" L	etterman Maxillofa residio of	Army Ins cial Science San Fran	titute of Recess Division cisco, CA 9	esearc 4129	:h	
				NAME:*	Cutcher,	J.L., LTC	DC		-	
HANE AKETS, V	V.A., COL MC			TELEPH	DHE: 413-30	DI-4042				
TELEPHONE: 413	-501-5181			ASSOCIATI	INVESTIGATO	RS				
				NAME	Osbon. D	.B., COL	DC			
				HAME:	Hutchins	on, R., LI	<u>CDC</u>			DA
IL REVIONDS (Freced	BACH with Somethy Classif	Ication Codej								
(U) wound	l infection; (U) a	ntibiotic s	usceptibility tes	sting: (U) pathoge	nic bacte	13	ittan Cod)	
24. (U) Cl mi of 25. (U) 71 iso wh ba pa un	linical and labora crobial genera cul all microorganism der to evaluate th 10 - 72 06 Prel lated from oral a nich are gram nego cteria. Gram pos tients. The diversi derlines the need	tory study ltured from ns involved e effect of iminary fu nd maxillo ative). Ove itive bacte se nature o for cultur	of infected hun n such infection l. Such informa drug therapy. ndings on 50 pa facial wounds (er half of all cul ria resistant to p of the antibiotic e and sensitivity	man oral as, and de ation is c atients in 30 differ tures con penicillin suscepti y testing	and maxi elineating ollated w dicate a w rent speci ntained at G were of bility pat in hospita	illofacial w the antib ith the cli wide spect es have be t least one cultured fi terns of the al practice	vounds, ide iotic suscep nical course rum of mic een isolated gram nega for 52 perc hese microc of oral sur	ntify otibili of ir roorg to da tive si cent corgani gery.	ing all ty patter ifection anisms ite, 15 o train of of all sms	ns in f

TRANSPORTATION (STRAFTS TRANSPORTATION TO THE TO THE TO THE CONTRACT OF THE CONTRACT OF THE TO THE STRAFT OF THE

*Aucilable to contracture eriginalerte esprevel

in the second state the second state of the second state of the second state of the second state of the second

. .

13000

State State States

\$Y.C.S.G.

<u>Aller Alteration</u>

Oral and Maxillofacial Wound Infection

Lieutenant Colonel J.L. Cutcher, DC Colonel Donald B. Osbon, DC Judith B. Richey, B.S. Lieutenant Colonel R. Hutchinson, DC

PROBLEM:

Gram negative bacteria play a major role in postoperative surgical infections of combat wounds in regions other than the oral cavity. Moreover, gram negative organisms are now partially supplanting the gram positive bacteria formerly regarded as the major factors in secondary breakdown of maxillofacial combat wounds, even in the presence of standard, accepted antibiotic therapy. Oral and maxillofacial wound infection results in prolonged hospitalization of affected patients since wound healing is invariably delayed. In addition, such infection frequently has a deleterious effect on restoration of facial function and esthetics which often have already been seriously compromised.

A meaningful approach to effective therapeutics should entail a comprehensive knowledge of the types of microorganisms involved in oral and maxillofacial wounds.

The purpose of this investigation is to survey the microfloras of oral and maxillofacial infections, and to establish guidelines for therapy by determining the microbial population characteristics and antibiotic sensitivity patterns of these infections. Were not a stratter that the shear of the shear of the second states and the second and the second strates of the second
APPROACH:

にないたいというないないであるというという

This study will be performed on selected patients having oral and maxillofacial infections who present for treatment at the Department of Dentistry, Letterman General Hospital.

Prior to definitive therapeutic measures or oral manipulations, bacteriologic samples will be obtained from the inflammatory site and inoculated directly into selected culture media for immediate incubation. Pertinent data relating to the patient and the-lesion will be recorded and forwarded to the Oral Microbiology Laboratory, Maxillofacial Sciences Division, Letterman Army Institute of Research, along with the bacteriologic specimen.

Specimens will be evaluated for identification of aerobic, facultative, and anaerobic microorganisms involved in these infections, and for determining bacterial antibiotic susceptibility and resistance patterns according to the Kirby-Bauer Method.

All laboratory findings relating to antibiotic sensitivity data and culture characterization will be collated with the clinical course of each infection.

RESULTS AND DISCUSSION:

Preliminary findings on 50 patients to date indicate that the spectrum of microorganisms isolated from eral and maxillofacial infections is broader than generally reported (30 different species, 15 of which are gram negative, have been isolated thus far).

Total pure culture isolations from these 50 cases number 182. Of these, 24.7 percent consist of gram negative bacteria, indicating the increasing significance of this type of bacteria in these infections. Fifty-two percent of all patients exhibit cultures containing gram positive bacteria resistant to penicillin G. To date, such bacteria have been exclusively members of the genus Staphylococcus, with S. epidermidis predominating.

At least one gram negative strain of bacteria was cultured in 56 percent of all samples obtained.

In general, the in vitro antibiotic susceptibility patterns and culture characteristics of these microorganisms are extremely varied, indicating the need for culture and sensitivity testing in the hospital practice of oral surgery. Moreover, it is becoming increasingly apparent that continued empirical use of antibiotics such as penicillin, in dental and maxillofacial infections, raises the distinct possibility of iatrogenic or nosocomial infections due to resistant bacteria. 183

an order of a second radiant we want to able the the second second second second second second second second s

a. Nitressociedes (stitution distributions conservation attractions and station and station of the transmission of the station of the

FUTURE PLANS:

Clinical and laboratory studies should be continued in FY 73 to obtain a comprehensive understanding of the culture characteristics and antibiotic susceptibility patterns of microorganisms involved in these infections.

DATA: DATA: DATA: DATA: NACCESS NO NO NO NO NO NO NO NO NO NO NO NO NO
IT NUMBER
•••
<u></u>
-house
as & FUNDE (In monement
4
<u> </u>
I
f Research on A 94129
n.
Reation Code.)
of commercially which emits an graded time tion when applied of the solar y in the field of mently underway

and in the State of the second state of

CERTER DE MORENCE (CERTE

...........

Carlor and a second

Actinic Blocking Agents for Protection of Lip Mucosa

Captain Thomas F. Payne, DC Colonel Gilbert E. Lilly, DC Major Isaac Willis, MC

PROBLEM:

Military personnel are frequently exposed to sun and wind for prolonged periods of time during combat or training exercises. Such exposure, particularly in light-complexioned individuals, can result in painful sunburned or chapped lips. Severely sunburned lips in addition to personal discomfort may interfere with speech and limit the effectiveness of military operations involving voice transmission. Moreover, actinic radiation received by chronic exposure to sunlight is known to be a causal factor of lip carcinoma. Commercial agents are available that are purported to effectively protect the lip mucosa from sun and wind. However, there are conflicting reports concerning the effectiveness of the various active ingredients. No comparative evaluation of the effectiveness of actinic blocking agents on the lip has been done. At present, no agent is available as a standard military formulary item.

The purpose of this study is twofold: first, to determine the effectiveness of selected commercially available actinic blocking agents for the protection of the lip mucosa against actinic radiation, and second, to evaluate additional vehicles for application should the penetrative features or adhesiveness of the commercial preparations prove unsatisfactory. 20. maint water a straight a straight a life at the second of the second atternation of the second of the

The Xenon Solar Simulator provides the source of actinic radiation to be used in this study. This source emits a spectrum which is nearly identical to that received on the earth's surface from natural sunlight, including ultraviolet, (290-360 nm). A radiometer measures the energy delivered at various wavelengths.

The unit of dosage in evaluating human response to exposure to ultraviolet light is called the minimum erythema dose (M.E.D.). This is defined as the lowest time related exposure of ultraviolet light which will

187

produce erythrema with a sharply defined border on a test site. The time required to produce an M.E.D. may be varied by altering the intensity of the ultraviolet beam or varying the distance from the test site to the beam aperture. It is desirable in this study to have the M.B.D. gange in the area of 50 to 60 seconds.

The ideal actinic blocking agent would possess the following characteristics:

a. The agent chould be nontoxic.

b. Frotection against a 3 M.E.D. exposure 8 hours after application.

c. The agent should not cause drying of the lips, but should offer protection against wind-burned and chapped lips.

- d. The agent should be cosmetically acceptable.
- e. The agent should not have an unpleasant taste.

Since all of the agents to be tested in this study are commercially available and cleared by the F.D.A., they are assumed to be nontoxic.

APPROACH:

The effectiveness of various actinic blocking agents will be determined in the following manner: Groups of 10 human volunteers will participate in each experiment. The first experiment will evaluate the range and consistency of the M.E.D.'s of the subjects, both on the lower lip and the ventral surface of the forearm.

The average M.E.D. will be adjusted to fall in the 50 to 60 second range by altering the intensity of the light source. When a reasonable intensity setting has been determined, then all settings on the Xenon Solar Simulator will remain constant for the entire experiment. This will be done by determining the M.E.D. to the nearest 5 seconds and repeating the determinations at 1 week, 2 weeks, 1 month, and 2 months. Careful attention to the condition of the lip at the time of exposure is important because dryness may have a significant effect on the M.E.D. The experiment will give background information on the convistency of the M.E.D. for each individual as well as the M.E.D. range between individuals. A correlation istween the M.E.D.'s, as determined on the ventral surface of the forearm and the lower lip, will also be made..

The second experiment will identify the agent which best protects the lip against ultraviolet light. Groups of 0 volunteers will have their individual M.E.D.'s determined. The agent to be tested will be applied to the lip and 5 hours later the site exposed to a 1, 1.5, and 2 M.E.D. dose. Agents, if any, which provide 2 M.E.D. protection after 5 hours will be tested at the 3 M.E.D. level and the time interval between application and testing prolonged until a protection profile for each agent is completed. In the event that no agent gives 1.5 M.E.D. protection after 5 hours, then the test will be repeated 3 hours after application.

RESULTS AND DISCUSSION:

Previous experiments for determining M.E.D.'s have been discarded because it was discovered that the intensity of the UV beam was not consistent for all parts of the field. This precludes using multiple sites with a single exposure. These experiments did provide familiarization with the machine and experience in applying radiation to mucosa and skin. As opposed to skin, lip mucosa when subjected to an exposure much over 1.5 to 2 M.E.D. tends to crack with healing by eschar taking place in 1-2 weeks. Some difficulty is encountered in seeing erythrema on lip mucosa, but this is overcome by extending the strip to be exposed over the vermilion border, thus marking the exposure site.

FUTURE PLANS:

To complete the project as outlined.

CLINICAL RESEARCH SUPPORT DIVISION

Constant Service

Program Element 6.11.02.A Defense Research Sciences, Army

Project Number 3A061102B71P Radiobiology

Task Area Number 09

Biochemistry

Task Area Number 01

A. 40,1 . . .

CLINICAL RESEARCH SUPPORT DIVISION

Clinical Research Support Division terminated its existence as a division of LAIR with the end of this fiscal year. During this year a wide range of clinical research projects were supported with monies, laboratory equipment, supplies and technical personnel. Primary technical support was afforded through the fully staffed and equipped biochemistry laboratory. Another major factor contributing to the success of the clinical research projects was the competent advice and guidance provided by this division as research review prior to initiation of projects.

The Pho/Gamma III scintillation Camera was the largest and most complex piece of equipment used in support of clinical and in-house research, and it will continue to be used to an even greater extent as more studies are initiated for its use. 190

ころう ちんかい いっ

,	ومناوعها التقاريك المتثل جرغال		الرباغ المتعادية والمتحدث والتر	_		-				191
RESEARCH	AND TECHHOLOG	Y WORK UNIT S	UMMARY	I AGEN	CV ACCESS	ON	S DATE OF SUI	HAAPT [®]	REPORT	ONTHOL STRUCT
A DATE PREV SUMPY	A STAD OF SUMARY			DA	DC 681	2	72 07	01	איז-סס	AE(AR1636
71 07 01	D. Change	U	U NORK SECURIT	P REGR	ading" IA	84 OIS	••• mita'n NL	CONTRACTOR	ACCESS	A WORK UNIT
ID. NO. CODES:*	PROGRAM ELEMENT	PROJECT	NUMBER	TASK /	AREA NUMI	IER		WORK UNIT	NUMBER	
& PRIMARY	61102A	3A061102	B71P	1	01			091		
. EXXXXXXX	61101A	3A061102	B71P	1-1	09			051	~~~~~	
C. CONTRIBUTING				†						
(U) Clinical 1	Management of P	,. atients Under	rgoing Radiat	ion Th	ierapy	(0	5)			
003500 - Cli	nical Medicine;	013900 - Ra	idioactivity							•
70 07		72 09	LETION DATE	DA	DING AGENC	*	1	C. In-hc	HCE WETH	100
	NA			10. RES	OURCES KST	MATE	A PROPESS	ONAL MAN YRS	L FUN	DE (In these ands)
& DATES/EFFECTIVE.	• • •	EXPIRATION:			PARCEDING		1		1	
N. NUMBER.				FISCAL	72		1	[1	50
C TYPE		4 AMOUNT:		YEAR	CURRENT		T		T	-
A KIND OF AVARD		f. CUM. AMT.			73	;		.025	1	0
	JRGANIERTROM	L		A PERI	FORMING OR	GANIZA	TION			T
AAME." Lettern Presidio Adoress:"	ian Army Institu) of San Francisc	te of Research o, CA 94129	h	HAME." ADORESI PRINCIP	Le Cli ¹⁰ Pro	ttern inical esidi	nan Army I Researci o of San I	/ Institute h Support Francisco,	of Res Divisio CA 94	search on 129
RESPONSIBLE INDIVIOU MAME: AKERS,	W.A., COL MC			NAME:	Bei	nson 5-56	i, J.D., CF 1-3600	TMSC		
TELEPHONE: 415-	<u>561-5181</u>			SOCIAL	SECURITY	ACCOU	INT NUMBER.			•
11. SENERAL USE				-		SATOR	•			
				HANC:						
				NA-IE:						DA
IL KEYNORDS (Frecede)	EACH with Security Viscolli	sation Code)						ميري معراق في معالية الأخلية. الكلية ا		
(U) radiation	i; (U) ionizing rad	diation; (U) ra	adiation treats	ment;	(U) rad	iatio	n lethalit	y		

13. TECHNICAL OBJECTIVE, " 24. APPROACH, 25. PROGRESS (Puminh Individual paragraphe identified by number. Presedo test al each sith Security Classification Cade 1

25. (U) 71 07 - 72 06 From two to fourteen days after x-ray exposure, mice exhibited greater concentrations of serum triglycerides than did sham-irradiated, pair-fed controls. Lipoprotein lipase and glyceride synthetase, enzymes which are associated with the assimilation of esterified fatty acids from the circulation, were more active in homogenates of adipose tissue from x-irradiated mice than from corresponding homogenates of sham-irradiated controls. The fatty acid esterifying capacities of liver homogenales were unaffected by exposure to sub-lethal doses of x-irradiation. Thus, the hypertriglyceridemia of x-irradiated mice is most likely due to a reduced uptake of triglycerides by extrahepatic tissues rather than an increased output by the liver.

The radioprotective action of SKF-525A is associated with an enhanced recovery of erythrocytes, and a histologically active bone marrow on the 12th to 15th days after x-irradiation. The concentration of lipid peroxides, as determined by uv absorption at 233 nm and by fluorescence, did not differ between x-irradiated and sham-irradiated mice. We conclude that SKF-525A most likely protects x-irradiated mice by stimulating the recovery of the hematopoietic system and not by inhibiting the formation of lipid peroxides.

and the second the Bar about the constant

DD FORM 1498 PREVIOUS

Clinical Management of Patients Undergoing Radiation Therapy

John D. Benson, CPT, MSC

PROBLEM:

The concentrations and pattern of serum triglycerides in animals that survive x-irradiation differ markedly from those in animals which eventually succumb. Consequently, serum triglycerides, or some fraction thereof, could be useful in the prognostic evaluation of radiation casualties or of patients undergoing treatment with ionizing radiation. An understanding of the mechanism responsible for the correlation between serum triglycerides and radiation lethality may suggest more effective measures for the prevention and treatment of radiation injury. こうちょうかい 「「「あるる」、「、」ない、」」、「ないない、いたちょう」、「、「ないない」、「というないな」、「なない、」」でいたいできまでない

- Bit to an an an an and

Will compare the control of the second of

If the peroxidative decomposition of structural lipids is one of the initial biochemical events leading to radiation-induced cell death, pharmacologic agents which modify the formation of lipid peroxides may significantly affect radiation lethality. Such agents may, therefore, be useful both for enhancing the clinical effectiveness of radiation therapy and for modifying the undesirable side effects of radiation therapy.

APPROACH:

のためであることがないためになったいであるというというからいで

and the second states of the s

Male, LAF₁ mice were exposed to sub-lethal doses of x-rays and sacrificed every three days for a 14-day post x-ray period. The following variables were measured in these and sham-irradiated mice: 1) serum triglycerides, 2) lipoprotein lipase and fatty acid esterifying activity of adipose tissue homogenates, and 3) fatty acid esterifying activity of liver homogenates. The enzymatic activities provided an estimate of the tissue's capacity to assimilate and esterify fatty acids.

To evaluate the role of lipid peroxidation in radiation lethality, female, LAF₁ mice were pretreated with drugs which either stimulate (phenobarbital) or inhibit (SKF-525A) chemically-induced lipid peroxidation. Thirty day mortalities were used to evaluate the radioprotective effect of these drugs. Tissue concentrations of lipid peroxides, blood cell concentrations, and histological changes of body tissues were monitored in both drug pretreated and saline treated mice.

RESULTS AND DISCUSSION:

Serun Triglycerides

From 2 to 14 days after x-ray exposure, serum triglyceride levels were greater in x-irradiated than in sham-irradiated mice.

Adipose Tissue Enzymes

Lipoprotein lipase and fatty acid esterifying activities of epididymal adipose tissue homogenates were generally lower than the corresponding activities from pair-fed, sham-irradiated controls. These results suggest that the hypertriglyceridemia of x-irradiated mice may be partially due to a reduced uptake of fatty acids into the adipose tissues.

Liver fatty acid esterification

The fatty acid esterifying capacities of liver homogenates from x-irradiated mice did not differ from those of sham-irradiated controls; thus, an increased hepatic synthesis of triglycerides was not responsible for the hypertriglyceridemia.

Drug Pretreatment

users a development of a contract of the second second second second second

Intraperitoneal injections of 50 mg/kg of SKF-525A given one hour prior to x-ray exposure, slightly, but consistently reduced the ID 50/30 of x-irradiation in female, LAF, mice (dose reduction factor = 1.1). A similar protective effect was noted when the drug was injected within one hour post irradiation; no radioprotection was observed, however, when the drug was injected one week before or one week after x-ray exposure. Thus, the protective effect of SKF-525A depended upon its presence in the tissues during or shortly after x-ray exposure.

SKF-525 inhibits the chemically induced formation of lipid peroxides in vivo; we sought to determine whether the radioprotective effect of this drug was being mediated by a similar mechanism. Lipid peroxides in whole homogenates of liver and spleen and in liver microsomes were estimated by the formation of conjugated dienes (uv absorption at 235 nm) and of fluorescent lipids. The content of lipid peroxides from spleen or liver was not affected by x-irradiation in the period from 1 to 12 days following exposure. In addition, the <u>in vitro</u> capacities of liver microsomes from x-irradiated mice to form peroxides was not significantly different from those of sham-irradiated mice.

Blood Cells

Hematocrits, reticulocyte and leukocyte concentrations of SKF-525A treated, x-irradiated (600 r) mice were significantly greater than those of saline-treated, x-irradiated mice on the 14th and 16th day after exposure in two separate studies.

A NUMBER OF A DESCRIPTION OF A DESCRIPTI

and the second second states and the second second states a subsecond of the second second states and the second second seconds and the second s

194

Pathology

Histological and gross examination of 8 tissues (brain, liver, heart, kidney, intestine, spleen, bone marrow, pancreas) from 1) SKF-525A treated sham-irradiated, 2) SKF-525A treated x-irradiated, 3) saline treated, sham-irradiated and 4) saline treated, x-irradiated revealed the following findings: 1) SKF-525A-treated mice exhibited inflamma-tory reactions in the peripancreatic tissues; 2) all irradiated mice regardless of drug treatment exhibited cellular degeneration in the germinal center of the spleen and depletion of the myeloid element in the bone marrow as early as two days post irradiation; 3) Myeloid regeneration in the bone marrow and return of function in the spleen appeared on the llth day after x-irradiation and was more pronounced in the SKF-525A treated group.

On the basis of these experiments we conclude that SKF-525A most likely protects x-irradiated mice by stimulating the recovery of the hematopoietic system and not by inhibiting the formation of lipid peroxides. าาการสมบัณฑาที่เป็นชีวิธีระหารสมบัตร์ที่สุดที่มีสารครั้งสมบัตร์ที่สุดที่มีสารครั้งสรรรรรรรรรรรรรรรรรรรรรรรรรร

FUTURE PLANS:

We intend to characterize the triglyceridemia of x-irradiated mice and to determine the serum concentrations of other lipid fractions. The in vivo incorporation of 14C fatty acids into tissue lipids will be determined and correlated with our in vitro results. The effect of SKF-525A on erythrocyte membrane stability will be ascertained and correlated with the radioprotective effects of this drug.

Art Petric Loss 1 All of Contains 1 Al	RESEARCH	AND TECHNOLOGY	WORK UNIT S	UMMARY	1 AGENI		CESSION®	2 OATE OF SU	I I	REPORT	CONTROL SYND R&E/AR)6.14
A. New U U NA NL Endows accurate values A series wards Box Codest * senies Box Codest* seni	DATE PREV SUMAY	4 KIND OF SUMMARY	SUMMARY SCTY	. BORK SECURITY	P ACOR	DING	* 0 01	18"4 INSTR'N	ISA SPECIFIC	OATA-	. LEVEL OF SU
0. CODE** endext* Endext* Product * Pr		A. New	U	U	N/	١		NL	T YES	0 #0	A WORK UM
Sector G102A 3A061102R71P 01 092 Construction Generatives Generatives Generatives Generatives Construction Generatives Generatives Generatives Generatives (0) 47: 15 and test for the formation of th	NO /CODES *	PROGRAM ELEMENT	PROJECT	NUMBER	TASK A	REA	NUMBER		WORK UN	T NUMBER	•
Contractions of Digitoxind-125 and its Metabolites with Cholestyramine and Tetraethylenepentamined Contractions of Digitoxind-125 and its Metabolites with Cholestyramine and Tetraethylenepentamined Contractions of Digitoxind-125 and its Metabolites with Cholestyramine and Tetraethylenepentamined Contractions of Digitoxind-125 and its Metabolites with Cholestyramine and Tetraethylenepentamined Contractions of Digitoxind-125 and its Metabolites with Cholestyramine and Tetraethylenepentamined Contractions of Digitoxind-125 and its Metabolites with Cholestyramine and Tetraethylenepentamined Contractions of Digitoxind-125 and its Metabolites Contractions of Digitoxind Metabolites Contractions of Digitoxin and Heal Contractions of Digitoxin and Heal <		01102A	<u>3A061</u>	<u>102R71P</u>		0	1	(92		
(b)	CONTRIBUTING				+		·				
with Cholestyramine and Tetraethylenepentamined control on Years With Cholestyramine and Tetraethylenepentamined Control on Years With Cholestyramine and Tetraethylenepentamined With Cholestyramine and the manner in which they may be removed from the bildet with digitoxin in the basels indicating and the manner in which they may be removed from the basels with Cholestyramine and tetraethylenepentamine and tetraethylenepentamined Yithowitania and the manner in which they may be removed from the basels with Cholestyramine and tetraethylenepentamined Yithowitania and the manner in which they may be removed from the basels with Cholestyramine and tetraethylenepentamined Yi	10+ """	Security Cleentlication Code	•		-						
Consider and the second and the second se	i-vitro Intera	actions of Digitox	in-I-125 and	its Metabolite	es with	Ch	olestyra	mine and	Tetraeth	ylenep	entamine(
0005000 *Chinka infection 71.09 73.01 DA C. In-house ************************************	DO2500 . C	CHNOLOGICAL ANEAS*		•							
71.09 73.01 DA C. In-house Contractive NA Exercise Contract Conternation Contract Contract Contract Conten	START DATE		14. ESTIMATED COM	PLETION DATE	TIS FUNC	HNG	AGENCY		14. PERFOR		M0.0
Control (Control (Contro) (Contro) (Contro) (Control (Contro) (Contro) (Contro) (Contro)	71 09		73 01		DA		1	1	C. In-h	ouse	
Answer: Image: Answer: Image: Transmer: Image: Tra	CONTRACT/GRANT	B! 4			H. RES	JURC	ES ESTINATI		IONAL MAN VI	IS D FUI	105 (In these and
Viet 4 MOUNTI FIGENIALIZATION S Viet 4 MOUNTI FIGENIALIZATION S Viet CUMMANY S S Viet CumMANY Institute of Research Presidio of San Francisco, CA 94129 New Comparison of San Francisco, CA 94129 Market Market Market Letterman Army Institute of Research Clinical Research Support Division news. New Comparison of San Francisco, CA 94129 Market Market Market Second San Francisco, CA 94129	ATES/EFFECTIVE.	NA	EXPERATION			PRE	CEDINE				
4 Autourt: Year (2017)3 .5 .5 Introduct Cool organization					PISCAL		72		1		5
Intervention I. COM. ANY Intervention I. Com. ANY Presidio of Son Francisco, CA 94129 Intervention Intervention <			& ANOUNT:		YEAR	COM	73		5		5
 Letterman Army Institute of Research Presidio of San Francisco, CA 94129 Mater Care and Presidio of San Francisco, CA 94129 Mater Care and Presidio of San Francisco, CA 94129 Mater Care and Presidio of San Francisco, CA 94129 Mater Atters, W.A., COL MC Mater Atters, M.J., SP4 Mater Atters, M.J., Materatter, M.J., SP4 Mater Atters, M.J., SP4	ESPONSIOLE DOD	CREANIZATION	T. CUM. AMT.		20. 22.	0.0	NG ORGAN	ATION			
Letterman Army institute of Research Presidio of San Francisco, CA 94129 Meta- Meta	E:⁴ • · · ·	. . .			-					Derr	<u>i</u>
 According to the intervent of the intervent	Letterm Presidio	an Army Institute of San Francisco	e of Research CA 94129	l		Ci	inical R	a Army (n esearch Si	situte of	vision	ren
 Portune information in the base in the information of colestipol and cholestyramine and tetrately interactions of digitoxin in the base in the information of digitoxin and its metabolites of digitoxin in the base in order to study the tools of the set mather in which they may be removed from the blood stream by resin adsorption intoxication and the manner in which they may be removed from the blood stream by resin adsorption intoxication and the manner in which they may be removed from the blood stream by resin adsorption intoxication and the manner in which they may be removed from the blood stream by resin adsorption intoxication and the manner in which they may be removed from the blood stream by resin adsorption intoxication and the manner in which they may be removed from the blood stream by resin adsorption. (U) 1 boratory studies evaluating 1) in vitro interactions of digitoxin and cholestyramine and tetratethy integentamine; 2) (U) 7 0 - 72 06 Preliminary in vitro examination of colestipol and cholestyramine as possible therape agents for digitalis toxicity has been completed. Experiments controlling pH isons of digitoxin significant by completions have delineated the optimum conditions. The infect of either resin, depending 'is dependent on a pH range of 5.8 to 8.1 with maximum phate it distiled water at pH 6.8. The effect of either resin, depending upon environmental conditions. The effect of either resin when administered on ally to 5 beagles following an induced intoxication was tested. The results indicate that eith	RESS:*		,		ADDRESS	. Pr	esidio o	f San Frai	ncisco, C	A 9412	9
 Provent: 415-561-5181 Pro					1						
 Akers, W.A., COL MC W.A., COL MC Waters, W.A., COL MC Water, Waters, W.A., COL MC Water, W.A., COL MC Water, W.Y., Waters, Wa					PRINCIP	AL 14	VESTIGATO	R (Fundah SEAN	II U.S. Atadee	ic įnelikulier	ŋ
 Alt - Solid - Sol	ALARS V				NAME:	G	ray, M.J	., 584			
Utrander, 413-301-5181 Deck secour account accou	NE ALCIO, V	561.5191			TELEP	HONI	^{1:} 415-56	1-3600			
(1) digitoxin: (U) adsorption; (U) cholestyramine; (U) teracthylenepentamine; (U) beagle 37. (U) 1) To verify the significant adsorption add/or binding phenomiena of the track with digitoxin. 200 digitoxin in order to more quickly and effectively reduce the levels in patients treated with digitoxin. 200 digitoxin and the manner in which they may be removed from the blood stream by resin adsorption. 200 intoxication and the manner in which they may be removed from the blood stream by resin adsorption. 200 intoxication and the manner in which they may be removed from the blood stream by resin adsorption. 200 intoxication and the manner in which they may be removed from the blood stream by resin adsorption. 4. (U) Laboratory studies evaluating 1) in vitro interactions of digitoxin and cholestyramine and tetraethyl nepentamine; 2) in vitro interactions of digitoxin and its metabolites with cholestyramine and tetraethyl nepentamine; 2) in vitro interactions of clostipol and cholestyramine and tetraethyl agents for digitalis toxicity has been completed. Experiments controlling pH, ionic strength, temperatu dilution, and metabolic competitors have delineated the optimum conditions of digitoxin "binding" by both resins in vitro. S. (U) 71 09 – 7.2 06 Preliminary in vitro examination of colestipol and cholestyramine and setraethyle distilled water at pH 6.8. The binding is independent of temperature, is inversely proportional to sample volume, and is effected by competitive binding from bile salts. Chromatographically pure digitoxin is reversibly assimilar into a complex with either resin chenching upon environmental conditions. The effect of either resin when administered orally to 5 beagles following an induced intoxication was tested. The results indicate that either resin can lower a toxic serum level of digitoxin significantly more effectively than a cereal placebo, and both resins are the proliciency of both statistically. The sam data suggests that the lowering of flaces is only accomplish	LEPHONE: 413	-301-3101	·	•	- SOCIAL	. 38C	URITY ACCO	UNT NUMBER-			
U) digitoxin: (U) adsorption; (U) cholestyramine; (U) tetracthylenepentamine; (U) beagle 37.(U) 1) To verify the significant adsorption antifor binding phenomient of digitoxim by steroth-binding response of digitoxin in the beagle in order to study the role of these metabolites play in digitox intoxication and the manner in which they may be removed from the blood stream by resin adsorption. 2. Photoratom studies entabolites of digitoxin in the beagle in order to study the role of these metabolites play in digitox intoxication and the manner in which they may be removed from the blood stream by resin adsorption. 4. (U) Laboratory studies evaluating 1) in vitro interactions of digitoxin and cholestyramine and tetraethyl nepentamine; 2) in vitro interactions of digitoxin and its metabolites with cholestyramine and tetraethyl nepentamine; 3. (U) 71 09 - 72 06 Preliminary in vitro examination of colestipol and cholestyramine and tetraethyl digitoxin, and metabolic competitors have delineated the optimum conditions of digitoxin "binding" by both resins in vitro. 5. (U) 71 09 - 72 06 Preliminary in vitro examination of colestipol and cholestyramine and tetraethyl digitoxin and increases with decreasing ionic strength due to buffer with maximum uptake in distilled water at pH 6.8. The binding is independent of temperature, is inversely proportional to sample volume, and is effected by competitive binding from bik salts. Chromatographically pure digitoxin is reversibly assimila into a complex with either resin, depending upon environmental conditions. The effect of either resin dependent of temperature, is inversely proportional to sample volume, and is effected by competitive binding from bik salts. Chromatographically pure digitoxin is reversibly assimilar into a complex with either resin, depending upon environmental conditions. The effect of either resin dependent of temperature, is inversely proportional to sample volume, and is effected by competitive binding from bik salts.					HAME:	1 16, 194		-2			
 U) digitoxin; (U) adsorption; (U) cholestyramine; (U) tetracthylenepentamine; (U) beagle U) digitoxin; (U) adsorption; (U) cholestyramine; (U) tetracthylenepentamine; (U) beagle U) digitoxin; (U) adsorption; (U) cholestyramine; (U) tetracthylenepentamine; (U) beagle U) to verify the significant adsorption antifor binding phenomenon of digitoxin by states of digitoxin. The beagle in order to study the role of these metabolites play in digitox intoxication and the manner in which they may be removed from the blood stream by resin adsorption. 4. (U) Laboratory studies evaluating 1) in vitro interactions of digitoxin and cholestyramine and tetraethyle nepentamine: 5. (U) 70 9 - 72 06 Preliminary in vitro examination of colestipol and cholestyramine as possible therape agents for digitalis toxicity has been completed. Experiments controlling pH, ionic strength, temperatu dilution, and metabolic competitors have delineated the optimum conditions of 5.8 to 8.1 with maximum pinding at 7.2 - 7.4 and increases with decreasing ionic strength due to buffer with maximum uptake ir distilled water at pH 6.8. The binding is independent of temperature, is inversely proportional to sample volume, and is effected by competitive binding from bile salts. Chromatographically pure digitoxin significantly more effectively than a cereal placebo, and both resins are the proficiency of both statistically. The sam data suggests that the lowering offects is only accomplished when the serum levels are elevated beyond acceptable maintenance range of 26.4 ± 7.9 ng/ml. A second experiment demonstrated a statistically insignificant lowering of the results indicate that either resins are the proficiency of both statistically. The sam data suggests that the lowering offects is only accomplished when the serum levels are elevated beyond acceptable maintenance range of 26.4 ± 7.9 ng/ml. A second experiment demonstrated a statistically insignificant base complex with the results. Chromat					NAME:						I
 U) digitoxin: (U) adsorption: (U) cholestyramine; (U) tetracthylenepentamine; (U) beage (U) To verify the significant adsorption anti/or binding phenomienation of an other set of the /li>	EVEORDS (Frecede	EACH ald Somethy Classifi	cation Code)		-		•				
 3. (U) 1) To verify the significant adsorption and/or binding phenomena of digitoxim by steront-binding results on order to more quickly and effectively reduce the levels in patients treated with digitoxin. 2 by duce metabolites of digitoxin in the beagle in order to study the role of these metabolites pluy in digito intoxication and the manner in which they may be removed from the blood stream by resin adsorption. 4. (U) Laboratory studies evaluating 1) in vitro inferactions of digitoxin and cholestyramine and tetraethyle nepentamine; 2) in vitro interactions of digitoxin and its metabolites with cholestyramine and tetraethyle nepentamine; 2) in vitro interactions of digitoxin and its metabolites with cholestyramine and tetraethyle nepentamine; 3. 5. (U) 71 09 - 72 06 Preliminary in vitro examination of colestipol and cholestyramine as possible therape agents for digitalis toxicity has been completed. Experiments controlling pH, ionic strength, temperatur dilution, and metabolic competitors have delineated the optimum conditions of digitoxin "binding" by both resins in vitro. Considering digitoxin only, the "binding" is dependent on a pH range of 5.8 to 8.1 with maximum binding at 7.2 - 7.4 and increases with decreasing ionic strength due to buffer with maximum uptake ir distilled water at pH 6.8. The binding is independent of temperature, is inversely proportional to sample volume, and is effected by competitive binding from bile salts. Chromatographically pure digitoxin is reversibly assimilar into a complex with cither resin, depending neon environmental conditions. The effectively than a cereal placebo, and both resins are the proficency of both statistically. The san data suggests that the lowering effects is only accomplished when the serum levels are elevated beyond incompation of the serum glycoside level when the resins were administered on day 5 of a 6-da maintenance range of 26.4 ± 7.9 ng/ml. A seccond experiment denonstrated a statistically insi	U) digitoxin	; (U) adsorption:	(U) cholest	yramine; (U)	tetrae	thy	lenepen	tamine; (l	J) beagle		
	 (U) 1) T in vitro duce me intoxica (U) Labo nepenta nepenta (U) 71 0 agents f dilution both res Co binding distilled mf fected t into a c Th was test more ef data suj accepta insignifi mainter Th 	overify the signif in order to more etabolites of digit ation and the man ratory studies eva- mine; 2) in vitro mine. 9 – 72 06 Prelim or digitalis toxici and metabolic constant in vitro or digitalis toxici at 7.2 – 7.4 and water at pH 6.8. The binding is inder by competitive bith at effect of either ied. The results in fectively than a constant lowering of hance program. The results of the in- ently stable comp id appearance of parts of the site and to stable comp	icant adsorption to a series a series and the series and the series are a series at the series and the series a	tion ant/or bi effectively receases in order they may be witro interact of digitoxin a examination ompleted. En- ave delineated binding" is d h decreasing is mperature, is ile salts. Chro ending upon e ending upon e ending upon e ending upon e crither resin ca b, and both re is only accor \pm 7.9 ng/ml ycoside level indicates tha resins. Chron in metabolites	inding luce the to stu- remov- tions of tions of perim d the o epende ionic st inverse omatog nviron wally t n lowe sinplishe. A sec when ti t a spe- natogra s attrib	plice le dy ed f ef d me esti ent ent ent ent ent ent ent ent ent ent	monitini evels in j the role from the igitoxin tabolite: ipol and s contro mum co on a pH ogth due proport bhically ntal con beagles toxic se toxic se when the d exper resins w s other t ic studie	for digito patients tr of these i e blood st and chold s with cho cholestyr illing pH, nditions of range of to buffer ional to s: pure digit ditions. following rum level iency of t e serum le iment den ere admin han digito s in vivo th hepatic	xill by sr cated win netabolit retarn by f styramin lestyram amine as ionic stree of digitox 5.8 to 8. with ma ample volo oxin is re an induc of digito oxin is re onth stati istered of poth state istered of poth state istered of oxin itself	the digit es play resin ad ine and t ine and t ingth, t in "bin 1 with ximum lume, a versibly ced inter xin sign stically levated d a stat n day S f is asso nples in a-hepat	inding resi oxin. 2)P in digitox. sorption. etraethylo tetraethylo tetraethylo tetraethylo tetraethylo tetraethylo maximum uptake in nd is ef- y assimilat oxication tificantly tistically of a 6-da ciated in idicate
	consiste the rapi metabo	lism.									

and a support of a support

** ** .

۰,

•

ì

~ * * * * *

:

•

a second of

112 5 17

and the second s

いたないないでいたの

Ĩ

いたかで、ためのためでは、おんないたかに、ためないいたいたいでは、「いたい」

Weiters Analytichterste

TOTAL DISCOUT

1

.

 A_{I}, C_{I}^{I}

In Vitro Interactions of Digitoxin and Its Metabolites with Cholestyramine and Colestipol

Michael J. Gray, SP4

PROBLEM:

The series of digitalis glycosides in common use today, including digitoxin and digoxin, possesses a high, positive inotropic activity but also a very low therapeutic ratio. Knowledge concerning normal digitalization, maintenance routines and computed physiological half-lives of digitalis glycosides has not effectively reduced the incidence of digitalis toxicity to a stastically acceptable level. The most promising new approach to this old problem involves the recent postulation that digitalis glycosides and their metabolites undergo enterohepatic circulation. A significant lowering of the incidence of toxicity could be anticipated with the discovery of an agent capable of interrupting the enterohepatic circulation and removal of the glycoside from circulation.

Long term studies of the steroid content of serum and duodenal aspirates in patients with hypercolesterolemia being treated with cholestyramine have revealed one possible glycoside-binding capabilities of the same agent. Such patients simultaneously received digitalis. The statistically significant lower levels of glycoside found in the serum of the drug group compared to placebo controls suggests that cholestyramine and a similar agent, colestipol, may lower toxic levels of digitalis glycosides undergoing enterohepatic circulation. たいないないである ないないてんないたんないないないないがく ちょうちょうしん たいいしょう たいしょう たいしょう たいないない いたいない ないない たいしょう ストック

LO COMPLETENDO -

APPROACH:

In Vitro

A simple mixing procedure with constant shaking was devised to determine the binding capacity of each resin for digitoxin. Four concentrations of digitoxin were prepared from weights of crystalline digitoxin: 25, 50, 75, and 100 ug/ml. Each solution contained 5 uc/ml digitoxin-³H. The solvent systems employed were 0.15M Tris-Tris HCl, pH 7.2, and deionized distilled water, pH 6.8, each containing 1.0% ethanol to effect solution. Four different weights of each resin were studied: 100, 200, 400, and 500 mg. The total volume of reaction solution ranged from 1 to 4 ml.

Sixteen numbered plastic tubes were divided equally into four groups representing 100, 200, 400 and 500 mg of resin. Each

weight of resin was prehydrated in an excess of solvent at 37 degrees C: over a 12 hour period, before the tubes were centrifuged at 1500 g's and the supernatant discarded. Into tubes 1-4, 5-8, 9 - 12 and 13 - 16 was pipeted respectively 0, 1, 2 and 3 ml of the same solvent used to hydrate. Into all sixteen tubes was pipeted 1 ml of one of the digitoxin solutions. The tubes were capped, shaken in a paint mixer for 30 min, centrifuged the supernatant decanted and filtered, added to scintillation cocktail, and cooled for two hours prior to counting. Each concentration of digitoxin prepared was run in duplicate with each solvent using one of two resins.

In Vivo

Six male beagles, ranging in weight from 14 to 25 pounds were studied based on successful metabolic analysis by the SMAL2 series. The dogs were fasted 24 hours prior to and during the experiment. Each animal, serving as a control for himself, underwent treatment following digitalization on three separate days, receiving either Cholestyramine, Colestipol, or a placebo of cereal. A 7 French urinary catheter was placed in the bladder on the morning of each experiment. Loading doses of 0.2 mg/10 pounds of body weight digitoxin sp. A. 5 uc/.1 mg were administered in the right cephalic vein. The specific treatment, as a slurry of 1.0 g resin/20 ml in distilled water, was administered initially by gastroscopy at 1.0 g/10 lb and 1.0/ 10 lb q 3 hours over six hours. Blood samples were drawn from either jugular vein at 1 minute, 0.5 hours, 1 hour, 3, 3.5, 6, 6.5 and 12 hours post-injection. Urine specimens were collected separately during the first six hours post-injection and feces obtained up to 24 hours post-injection. Total radioactivity determined in all samples was converted to ng glycoside/ml serum.

Determination of Radioactivity - All determinations of radioactivity were performed with a liquid scintillation counter (Nuclear Chicago Mark II analyzer). Serum samples (0.2 ml) were digested using 2.0 ml NCS tissue stabilizer and 200 ul 30% hydrogen peroxide to decolorize. Chomluminescence was halted by neutralizing with 100 ul glacial acetic acid and 10.0 ml scintillation cocktail was added. An equal volume of urine was decolorized with 100 ul 30% hydrogen peroxide and allowed to stand for 48 hours at room temperature before 10 ml of cocktail was added.

Total individual feces samples were homogenized with an equal weight of 10% alcohol and a 10 ml aliquote centrifuged an 2000 g's for 50 minutes. The supernatant and pulp washings were pooled and a 2.0 ml aliquote prepared for counting by decolorizing with 500 ul 30% hydrogen peroxide over a 48 hour period. Again 10 ml of cocktail was added and the samples allowed to equilibrate to chamber De server et de la de la de la construction de la

temperature before counting. Quenching in all cases was corrected for by both sample blanks and external standardization,

Digitoxin -3H and Labelled Metabolites - Serum specimens from all six dogs representing resin treatment and placebo were separately pooled. The same was done for urine and feces, however feces homogenates were lyophilized and reconstituted to a smaller volume before pooling. Serum, urine, and feces pools representing one minute, three hours, and six hours sampling time were then extracted, the chloroform and water phase separated by centrifugation and filtration, and each phase washed twice. Preoperative column chromatography was carried out as described by Beerman et al. (1971). The 20% ethanol-chloroform phase after column elution was then applied as a base-line streak to a 20 x 20 cm sheet of silica gel and developed with solvent system I (consisting of methyl isobutyl ketone - diisopropyl ether-methanol (80:20:10). Standards of digitoxin, digoxin, digoigenin, and digitoxose were run as parallel strips. Horizontal strips with Rf's similar to the standards were cut from the sample sheet and eluted. The extract forified with a standard of similar Rf was then applied as a spot to a second silica gel sheet and developed in a double phase, right angle system developing with solvent system I as the first phase and ethyl acetate-butanol (90:10) as system II. The carriers were visualized by spraying with a solution of acetic anhydride-sulfuric acid-methanol (5:5:50), and charring for one minute at 110° C. and visualizing under UV. Each spot was then cut from the sheet and, suspended in cocktail and counted.

The water phases of all samples were first deproteinized then lyophilized. The dried sample was then redissolved in 500 ul 25% methanol and the previously described systems of preparative and analytic TLC applied. To study the possible alteration of the digitoxin molecule during extraction 0.1 mg of digitoxin with sp. A of 50 uc/mg was incubated with either 10 ml distilled.water or freshly prepared canine serum for six hours and then analyzed as described.

RESULTS:

Digitoxin in vitro - Table 1 lists the results of one phase of the in vitro study, showing % bound for each resin weight in distilled water as a mean + S.D. for all four amounts of digitoxin. A greater degree of binding was obtained in the distilled water and increased with increased resin weight, but decreased with increased dilution. Subsequent washing of the resin with 10 ml volumes of the original solvent removed almost all of the drug (98.0%) by the sixth wash. Removal of digitoxin from colestipol by solvent extraction was accomplished with 40% less volume than that required to remove a similar amount from cholestyramine. 1KI 72-14

الله المالية ا

Reduction of glycoside level - The serum values expressed as ng/ml glycoside for each dog receiving a similar treatment were combined and plotted. Table 2 shows the results of the three treatments when applied to a single loading dose of digitoxin. A significant glycoside binding effect is exercised by both resins when the serum level is ≥ 50 ng/ml. The slopes of each treatment curve are dissimilar only during the first hour of treatment and thereafter are similar until treatment stops at 6.0 hours. Statistically, there is no difference between the capacities of either resin to lower glycoside level. There is, however, a pronounced difference between the placebo. The resins are capable of lowering the blood level to a statistically normal (26.4 hg/ml \pm 7.9) within six hours compared to the more than twelve hours with placebo. The resin values fall below 50 ng/ml within one hour.

The level in urine rises sharply to almost 300 ng/ml by 3.0 hours, levels off from 3.0 to 6.0 hours, and falls to less than 100 ng/ ml at the twelve hour mark in all three treatments. There is an increase in fecal glycoside concentration in resin therapy but data at present is incomplete. So the fall in serum glycoside levels witnessed in a six hour resin therapy program can probably be attributed to an increase in fecal excretion possibly attributed to the binding capacity of the resins, for there is no significant alteration of urine volume or glycoside content.

Detection of Metabolites - Recovery of tritiated digitoxin from the chloroform extracts of serum and water following the addition of the drug <u>in vitro</u> was: Water, 99.6%, unincubated serum, 98.0%, and incubated serum, 86% digitoxin, 14% metabolites. Although chromatographic analysis using a two solvent right angle system cannot be taken as firm proof of the identity of all of the radicactive compounds in the digitoxin "spot" with digitoxin, the failure so far to obtain any different results by using several solvent systems adds support to the contention that this spot did indeed contain only digitoxin. The extent and pattern of digitoxin metabolism was determined by the ratio in each experimental sample, expressed as percent, of the radicactivity in the digitoxin spot to the total activity on the chromatographic plate.

In each serum sample, at least 90% of the total radioactivity was recovered in the chloroform phase. Radioactivity in the water phase is largely associated with molecules of digoxin, digoxigenin and a similar metabolite dihydrodigoxigenin known to migrate with the front in both solvent systems used. In the chloroform phases most of the activity can be associated with digitoxin; however, even in the 1-5 minute samples there rapidly appears an abundance of metabolites. Table 3 shows the levels of digitoxin and metabolites

in chloroform extracts of three separate sample periods. It is apparent that as digitoxin undergoes absorption, metabolism, or excretion, an overall equilibrium between the present drug and its metabolites is constantly readjusting. That radioactivity not attributable to the major metabolites used as standards is largely distributed in lipid Rf's (cholesterol, triglycerides) or either at the origin or front. Several other metabolites of digitoxin, however, with more complicated alterations of molecular structure, are listed in the literature as having Rf's similar to these remaining areas of activity.

DISCUSSION:

The <u>in vitro</u> experiments suggest that the binding of digitoxin is not favored in the ionic medium present in the gastrointestinal tract. Whatever binding does occur more than likely involves weak ionic bonds, which if in a medium at low ionic strength could be considered a Zwitter ion effect. The <u>in vivo</u> experiments, indicate that despite predictions, both resins are capable of complexing some form of digitoxin and effectively removing it from enterhepatic circulation. It does not seem possible that the glycoside being bound is digitoxin itself. Both resins are ion-exchange in nature and, besides the probable saturation of the resin with steroids and bile salts, digitoxin is not an ionic entity. Either digitoxin is being combined in a complex which, as a more suitable unit, is being irreversibly bound, or it is a metabolite of digitoxin, presumably an ionic species, rather than the parent drug which is being bound. and the states of the states of the states of the states and the states and the states of the states o

The first case suggests a plausible incorporation of digitoxin and/or its metaboliets into a micelle. With subsequent binding of the micelle itself, of a transfer of the solubilized glycoside into the binding site with the micelle existing as a cofactor or intermediate. A similar mechanism involving micelle formation is postulated in the binding of cholesterol and other steroids in vivo. The second case, equally plausible, suggests that a polar metabolite of digitoxin is being bound. Results obtained from the TIC studies of serum samples indicate an abundance of polar metabolites being circulated.

A third possibility of trapping can be eliminated as a major contributor to the lowering effect. The trapping effect, being a purely nonchemical, physical phenomenon, depends so largely on momentary conditions in the lower tract that no consistent results could be expected from one animal on two different days, much less a group of five animals on three different days.

200

inter finnen Ordenanten er marten er die sonsteinigen ist in delt konsteinigen sind titte ander

The results of the in vivo study bear final analysis. According to the curves produced by graphing mean ng/ml + S. D. against time, the significant binding occurs in the first segment of the experiment, 0.0 to 1.0 hours. This makes sense since it is during this time that the largest amount of glycoside is being circulated. This is expressed in the graph by the dissimilarity of the slopes of each treatment in this period. If as the <u>in vitro</u> suggests a given weight of resin consistently binds a fixed percentage of the drug, then the net amount of glycoside removed from circulation during the period of the first hour would be several orders of magnitude greater than that removed during subsequent periods when the gross amount of glycoside in circulation is considerably less. During the later periods, although a similar percentage is being removed from circulation, the actual quantity of glycoside removed is not significant enough to effect a deviance from the normal.

Although it is not likely that a clinical situation will arise where intoxication is verified within one hour of drug administration, the <u>in vivo</u> experiment performed dose demonstrate that a reduction in the serum level can be achieved if the amount of drug in enterohepatic circulation is significantly high. Furthermore, a maintenance level of 50 ng/ml (considered the borderline of toxicity) indicates a level of tissue absorption quite different from what 50 ng/ml indicates in this experiment. It remains to be seen whether there are sufficient amounts of digitalis glycosides in enterohepatic circulation when 50 ng/ml is a maintenance serum level.

The observations of this study suggest a very convenient theory implying that the regimen rather than the dosage will be the critical factor in obtaining maximum lowering effect of the resin. Almost of equal importance is the fact that there is a specific amount of glycoside required in enterohepatic circulation critical in affecting significant reduction of the serum level. If this prerequisite is adhered to strictly in the lowering effect the treatment of toxicity will not jeopardize adequate maintenance.

COLESTI		POL	CHC	OLESTYRAMINE				
	Tota	% bound	·	Total % bound				
mg Resin			<u>mg Resin</u>	10.0.0				
100	26.5) + .80	100	42.U + .85				
400	42.0	7 + .03	400	04.3 4 .84 81 7 4 61				
500	62.4	$1 \pm .37$	500	$95.6 \pm .41$				
All value	s perta	in to maxi	mum % bound in	n 1 ml sample volume				
			TABLE 1					
t _i hrs.	PLA	CEBO	CHOLESTYRAMINE	COLESTIPOL				
1 min	196.0	+ 10.3	209.0 <u>+</u> 9.4	198.0 + 8.9				
0.5	78.7	+ 7.6	61.2 + 3.3	53.5 + 5.9				
30	0U./ A7 2	+ 1.8 T 8.2	44.0 T 4.1 31 2 F 3 1	39.3 ± 2.9 30 0 ± 4 0				
3.5	43.4	$\frac{1}{10.5}$	32.0 ± 4.6	27.7 ± 4.1				
6.0	35.4	+ 8.5	26.7 + 4.8	23.4 7 2.7				
6.5	31.7	- 6.3	25.1 ± 5.4	22.4 7 2.2				
12.0	26.9	∓ 6.7	21.0 ± 4.7	17.8 ± 2.8				
			TABLE 2					
 1		1-5 min.	3.0 hr.	6.0 hr.				
Digitoxi	i)	42.0%	55.0%	41.0%				
Digoxin		2.0	17.0	9.0				
Digitoxi	genin	34.0	4.0	6.0				
Digoxiger	nin	9.0	8.0	9.0				
UIGITOXO	Se fied	2.0	8.0	/.0				
unidenti:	ried	11.0	7.0	28.U				

2,577

15 - C - S - C - S - F

TABLE 3

4 . S. A

Street.

n de an and de actuelle a catalege de la destaigende de services de la complete de la complete de la complete d

CLINICAL RESEARCH SERVICE LETTERMAN GENERAL HOSPITAL

A.C. 00

and the fact that here the start and the sta

- server a construction of the server of the

CITY FOR STREET

Carebra Francis

Program Element 6.21.10.A Bio-Medical Investigations

Project Number 3A062110A826 Clinical Investigations

Task Area Number 00

203

11.20.00
RESEARCH AND TECHNOLOGY WORK UNIT SUMMARY			1. AGEN DA	OB 7	109°	72 07 1	8	REPONT CONTRUL SYMDOL DD-DR&E(AR)636			
71 08 10	H. Terminat	в. зиммаяч зсту ^а 2: U	A. WORK BECUNY	7. REAR	LOING	10 0.1	а'н <u>інбта'н</u> VL	CONTRACTOR	ACCESS	A WORK UNIT	
NO./CODES:*	PROGRAM ELEMENT	PROJECT	NUMBER	TASK	TASK AREA NUMBER			WORK UNIT	NUMBER	i	
PRIMARY	62110A	3A0621	3A062110A826		00		004				
CONTRIBUTING											
CONTRIBUTING	CONTRIBUTING										
Letterma	n Army Insti	'(U) Clinica tute of Res	al Investig search	gation	s - L	ette	rman C	eneral	Hosp	ital and	
003500 -	003500 - Clinical Medicine stant date 14 Estimated Completion Date		PLETION DATE	15 FUNDING AGENCY			IS. PENFOMIANCE NETHOD				
	!	l		1	1		1				
CONTRACT/GRANT		EXPIRATION: 4 AMOUNT:		10. RES!	IS RESOURCES ESTIMAT		E & PROFESSIONAL MAN YRS			L FUNDE (In these and a)	
DATES/EFFECTIVE:	,						1		+-		
				PISCAL	72					88	
TYPE:				YEAR	CURNENT						
KIND OF AWARD:		LCUM. AMT.	,		73					0	
RESPONSIBLE DOD O	PREANIZATION			20. PER		RGANIZ	ATION				
Lette	erm <mark>an Army</mark>	Inst. of Re	esearch								
Presidio of San Francisco, CA94129			ADDRES	ADDRESS:*							
				PRINCIP	PRINCIPAL INVESTIGATOR (Pumlah SAAN II U.S. Academic Inciduilan) NAME: ⁹						
Akors W.A. COL MC			TELE	TEL EPHONE							
(math 116, 115, 111, 000, 110, 000, 100, 000, 100, 000, 100, 000, 100, 000, 100, 000,			-	SOCIAL SECURITY ACCOUNT NUMBER:							
- GENERAL USE				ASSOCIATE INVESTIGATORS							
			-	WAME:							
				MAME1							
REYVORDS (Proved	BACH with Security Closeth	icalian Cado)	,						-		

25. 71 07 - 72 06 Thirty-eight clinical investigation studies being conducted at Letterman General Hospital at the end of FY 72 will continue but will now be funded by OMA funds. Project number 3A062110A826 has been deleted from this laboratory's project numbers as of 1 July 1972.

STUDY OF THE EFFECT OF AVAILABILITY OF A COMPUTER PROGRAM TO SUGGEST THE DIGOXIN DOSA JE AND ATTENDANT TOXICITY/EFFICACY

Carl C. Peck, Major, MC Lewis B. Sheiner, M. D. Carroll M. Martin, Major, MC Darrell T. Combs, Major, MC

PROBLEM

and the should be be an an an and an and

One problem always in digoxin therapy concerns the efficacy and toxicity of digoxin when administered to outpatients suffering from chronic congestive heart failure or atrial fibrillation. We assessed digoxin therapy in this group with two recently introduced innovations: 1) A computer program (DIGDOX-I), to enable the clinician to accurately administer proper dosages; and 2) serum digoxin levels determined by radioimmuno-assay.

Digoxin therapy relies upon generally effective 'recommended" dosages derived from previous studies of 'digitalizing" and 'maintenance" dosages.(1) These recommendations often result in an alarming toxicity rate - up to 20% in hospitalized patients (2) with a potential mortality up to 30%(3). 'Under-digitalization" may also be attendant(4). Serum digoxin levels can now be measured and Smith(5) has shown that serum digoxin levels correlate with toxicity better than do dosages.

Estimates of the influence of variations in renal and thyroid function as well as body size on digoxin pharmacokinetics have been developed(6,7) but the average clinician may find it difficult to relate the estimates to the state of digitalization in a given patient. Computer assistance has been developed (8) but no prospective study evaluating the utility of such a program has been reported.

This study tested the DIGDOS-I Program (DIP) to predict serum digoxin levels as well as the outcome of decisions 205

based on its application in terms of digoxin efficacy and toxicity. A prospective trial in which the physicians of randomly selected patients were offered DIGDOS-Assistance (DA) was conducted. The capabilities of DA were compared with a group of internists and cardiologists familiar with digoxin therapy.

APPROACH

The DIGDOS-I Program (DIP) was developed by Sheiner and has been described in detail elsewhere(9). Briefly, the pharmacokinetic model upon which it is based draws heavily from the data of Jellife (6). It utilizes six patient characteristics to derive estimates of body size, thyroid and renal function (sex, age, height, weight, designation of clinical thyroid status as hyper-, eu-, or hypothyroid, either BUN or serum creatinine). Entries for "desired" serum digoxin levels as well as all previous digoxin dosage information are required. From these data, the program is capable of generating the following:

- a. Predicted instantaneous serum digoxin level
- b. Predicted mean serum digoxin level (at steady state)
- c. Suggested digoxin dosage schedule designed to achieve the "desired" serum digoxin level

Patients drawn from the Letterman General Hospital Cardiology Clinic, were suffering from chronic congestive heart failure or supraventricular tachycardia, and all required digoxin for ammelioration of signs and symptoms of their disease. Burroughs Welcome Lanoxin from Lots No. 364-A, 376-A, was used.

Based on decisions made by their primary physicians (MD) regarding digoxin therapy, patients were assigned to 1 of 4 groups on cntry into the study:

Group I No previous digoxin therapy within 30 days. Deemed in need of initiating digoxin therapy. inder 1884 in the structure of the second structure of the number of the structure of the s

Group II On previous but 'inadequate'' digoxin therapy. Deemed in need of an increase in dose of digoxin.

- Group III On previous and "adequate" digoxin therapy. No change in dosage required.
- Group IV On previous digoxin therapy. Reduction of dosage advisable.

Each patient was randomly assigned to the Control or Experimental group. Because of the expected high number of Group III patients, this group was randomized separately from Groups I, II and IV. Control patients were managed thereafter exactly as the MD saw fit. Data on experimental patients was immediately submitted to DIP, following which the DIP generated predictions and dosage change suggestions were offered to the MD for his consideration. Experimental patients received DA suggested doses except when computer 'advice'' was not followed - DIGDOS-refused (DR). When this occurred, the MD continued to manage his patients as he saw fit, unassisted by DIP; and the data collected on these patients were analyzed separately.

Data collected on each patient at each visit are listed in Table 1. In addition, serum potassium, creatinine and digoxin levels were determined.

Each patient was followed for at least 2 weekly visits and most for 3 or more to achieve "steady state" measurement changes following alterations in digoxin dosages. Besides the clinical evidence of toxicity, an EKG was obtained on each patient visit; and the criteria of Beller et al(4) were used to determine electrocardiographic evidence of toxicity.

For comparing the MD and DIP level predictions, the measured serum digoxin level was extrapolated to a "mean measured serum digoxin level" according to known serum level-time relationships as modified by any decrease in renal function in the given patient. Besides the above, the MD was asked to record a "desired serum digoxin level" as well as

his 'predicted serum digoxin level. " Since physicians were accustomed to thinking in terms of digoxin dosage rather than serum level of digoxin, guidelines for setting 'desired" and "predicted" levels were offered as Tables 2 and 3 respectively.

RESULTS AND DISCUSSION OF RESULTS

208

Forty-two patients completed the study on whom 142 serum digoxin levels were determined. There were 12 Group I patients, 7 Group II, 18 Group III, and 5 Group IV. No significant differences between control and experimental groups can be identified as regards sex, age, height, weight, serum creatinine and initial CHF Index (Table 4).

The mean measured mean serum digoxin level was .92± .60ng/ml whereas the mean MD prediction was .96±.33ng/ml and for DIP it was 1.05±.36ng/ml. The mean prediction errors calculated for the entire group are -.04±.64ng/ml for the MD and -.14±.56ng/ml for DIP (p<.05). Both indicate a systematic 'over-prediction" by both the MD and DIP, which in the case of DIP is statistically significant.

Generation of dosage schemes: The coefficient of correlation between desired levels and levels attained are as follows: Control = .22, DA = .44, DR = .09. Only the DA was statistically significant (p<.05). The amounts of "miss" (i.e. mean non-achievement of desired levels), quantitated by subtracting the desired level from the mean measured level, are as follows: Control = $-.03\pm.64$ mg/ml, DA = $-.09\pm.54$ mg/ml, DR = $-.22\pm.44$ mg/ml. Only the DR value was significantly different from zero (p<.05). The root mean square achievement errors were not significantly different among the three groups: Control $= .64\pm.09$ mg/ml, DA = $.54\pm.09$ mg/ml, DR = $.49\pm.13$ mg/ml.

Outcome of therapeutic decisions - Toxicity and Efficacy: No clinical or EKG evidence of digoxin toxicity was encountered in this study.

Correlating the initial to final CHF-Index with corresponding

いいたいになるないないできょう

serum digoxin levels by individual patient revealed a mean decrease in the Index of .26±.48 (22±32%) accompanied by a mean decrease in serum digoxin level of .21±.71ng/ml (.56 (p<.05)). Similarly, the visit-to-visit variations in CHF-Index correlated significantly with serum digoxin levels as follows: mean increase in serum digoxin level = .08±.48ng/ml; mean decrease in CHF-Index per visit intervals = .10±32ng/ml (9±27%). [r.31 (p<.05)].

Analysis of the prediction data reveals that DIP predicted slightly but significantly (p <. 05) better than the primary physician, both by correlation coefficient and by absolute prediction error. However, one may ask, does an increase in predictive accuracy of .05ng/ml justify using the computer program? The answer must be no. The root mean square errors suggest that both the MD and DIP are capable only of predicting within .65ng/ml (68% confid. interval) or 1.2ng/ml (95% confid. interval). Since the probably efficacious level of serum digoxin is around lng/ml and the probably toxic level is around 2ng/ml, the .05ng/ml improvement by the program compared to the size of the 95% confidence interval is non-consequential. We conclude that DIP is slightly superior to the MD in predicting serum digoxin levels but the difference is not important.

In terms of attaining desired serum digoxin levels a statistically significant positive correlation coefficient resulted for the DIGDOS-Assisted cases, whereas Controls and DIGDOS-refused cases did not demonstrate this. The average amount of "miss" was significant only for the DR cases. Although DIP appears to generate suggestions of digoxin dosages schemes which come closer to attaining desired serum digoxin levels, the differences are unimportant in view of the wide range of error. This is further substantiated by the efficacy studies, which showed no demonstrable advantage in improvement in symptoms or signs of CHF from use of DA.

The Index is not a perfect measure of digoxin effect nor was attainment of desired levels by the Experimental Group markedly superior to that of Controls. Since no toxicity was encountered by the clinical and electrocardiographic methods employed in this study, no conclusions can be drawn regarding any difference in ability to avoid toxicity between DA and non-assisted cases. If the usual toxicity

rate approaches 20%, its lack in this study deserves explanation. Possibly with such careful follow-up, patients are less likely to err on the side of excess digoxin ingestion. Since only Burroughs-Wellcome Lanoxin was, used, perhaps the low variation in digoxin content in each tablet accounts for consistency in digoxin intake not attained in previous studies(10). Also the general level of serum digoxin attained in the patients of this study was below the toxic range since the mean of .92ng/ml for the group is lower than that for a group of non-toxic patients studied by Beller and Smith (4). The range of error in predictive capacity is uncomfortably large for both DIP and the MD, since the 95% confidence interval for predictions in the therapeutic range overlaps the toxic range.

PLANS

The study has confirmed a baseline level of performance for the computer program comparable to well-trained internists. Further development of a useful clinical method of measuring pharmacologic effect of digoxin therapy in ambulatory outpatients suffering from congestive heart failure is needed to answer the following questions:

1. What combination of weighted symptoms and signs of CHF best reflect variations in serum digoxin level?

- 2. Once this 'weighted' Index is devised, what is its magnitude of change per unit of change of serum digoxin level?
- 3. Is 'maintenance' digoxin therapy a justifiable therapeutic maneuver beyond initial improvement created by digitalization?

The DIGDOS-II Program is under development utilizing the feature of a "feed-back" system: measured serum digoxin levels will be utilized to modify the Program predictions for individuals in order to make all subsequent predictions more accurate.

REFERENCES

- 1. Batterman, R.C. et al: Comparative Study in the Use of the Purified Digitalis Glycocides, Digoxin, Digoxin and Lanatocide-C for the Management of Ambulatory Patients with Congestive Heart Failure. Am. Heart Journal 34:663, 1947.
- Rodensky, P. L., Wasserman, F.: Observations on Digitalis Intoxication, Arch. Intern. Med. 108:171, 1961.
- 3. Ogilvie, R.I., Ruedy, J.: Adverse Drug Reactions During Hospitalization, Canad M.A.J., 97:1450, 1967.
- 4. Beller, G.A. et al: Digitalis Intoxication, NEJM 284:989, 1971.
- 5. Smith, T.W., Butler, V.P., Haber, E.: Determination of Therapeutic and Toxic Serum Digoxin Concentraticns by Radioimmunoassay, NEJM 281:1212, 1969.
- 6. Jelliffe, R.W.: A Mathematical Analysis of Digitalis Kinetics in Patients with Normal and Reduced Renal Function, Math BioSci 1:305, 1967.
- Doherty, J.E., Perkins, W.D.: Digoxin Metabolism in Hypo- and Hyper-thyroidism, Ann Int Med 64:489, 1966.
- 8. Jelliffe, R.W., et al: A Computer Program for Digitalis Dosage Regimens, Math BioSci 9:179,1970.
- 9. Sheiner, L.: Manuscript submitted for publication in Computers and Biomedical Research
- Lindenbaum, J., et al: Variation in Biologic Availability of Digoxin.from Four Preparations, NEJM 185:1344, 1971.

No.

and the second

Alexandra and a second state of the second state of the second state of the second state of the second state of

1.2.1.1

Cimical Cal

23237

TABLE I

SEMI-QUANTITATIVE GRADING OF MEASUREMENT PARAMETERS

	GRADING					
	ABSENT=0	MILD= 1+	MODERATE= 2+	SEVERE= 3+		
Historical			•			
H1: Orthopnea	None	2 pillows	3 pillows	Must sit up		
H ₂ : PND	None	< 1/wk	>1,<7/wk	>7/wk		
H ₃ : Exer. tole: Stairs	Unlimited	SOB or stop @ 2 flights-	>½,>2 flights	<⅓ flight		
H ₄ : Blocks	Unlimited-	Unlimited except when carrying pkg. or at rapid pace	> 1 block,flat	< 1 block, flat		
Physical 0 ₁ : Wt X=Wt-usual usual V	Wt .03	X = 0.0306	X = .061	X =>.10		
0 ₂ : HR	< 100	> 100,<115	> 115, <130	> 130		
0 ₃ : S ₃	Absent	-	-	Present		
04: Est. CVP	0	0-1 cm above clav. at 90	> 2cm, < angle of jaw	To angle of jaw		
0 ₅ : Edema	0	1+	2+	3+		
Toxicity: Nausca Vomiting Visual changes	-	•••••••••••••••••••••••••••••••••••••••		Present Present Present		

ころいろう ちょうちょう いちょうちょう くう

ういろう しんちんち ちょうかい ちょうけいしんてい ちゅうち あままん

日本をかりたいという

and and all the second on a car a car and the second and a second and

CHF Index = $H_1 + H_2 + H_3 + H_4 + 0_1 + 0_2 + 0_3 + 0_4 + 0_5$

9

TABLE II

GUIDELINE FOR "DESIRED SERUM DIGOXIN LEVEL" (DDL)

DDL	Usual dose to achieve desired "amount" of effect in avg. patient with normal renal function	Corresponding mean digoxin blood level at steady state				
"very low"	.125 mg/d	.26 ng/ml				
"low"	.25 mg/d	.6 - 1.0 ng/ml				
"medium"	.375 mg/d	1.0 - 1.4 ng/ml				
"high"	.5 mg/d	1.4 - 1.8 ng/ml				

TABLE III

GUIDELINE FOR PREDICTION OF SERUM DIGOXIN LEVEL (PDL)

PDL	Usual dose to achieve observed "amount" of effect in ave, patient with normal renal function	Digoxin blood level		
absent		.2 ng/ml		
"very low"	.125 mg/d	.26 ng/ml		
"low"	.25 mg/đ	.6 - 1.0 ng/ml		
"medium"	.375 mg/d	1.0 - 1.4 ng/ml		
"high"	.5 mg/d	1.4-1.8 ng/ml		
"very high"	>.5 mg/d	>1.8 ng/ml		

and the set of the provide the state of the set of the set of the set

SENSORY CHARACTERISTICS OF AUTISTIC CHILDREN

Ernest Giraldi, Major, MC

PROBLEM

To identify and define communicative characteristics of autistic children by direct observation of facial expressions of these children when presented with sensory stimuli. To differentiate on a five-point aversion scale communicative characteristics of autistic children.

APPROACH

Design: Simple comparative design

T-1 = Autistic children T-2 = Normal controls

The design procedures are principally for gathering data which will afford opportunity to definitively examine communicative characteristics of treatment groups. They will be accomplished through filming 14,440 sensory situational responses for later analysis. Each stimulus will be highly specific and concentrated in order for us to better evaluate the responses. Each response will be recorded on film by four cameras operating at the same time from four different angles, focusing on the face.

RESULTS AND DISCUSSION OF RESULTS

Phase I and II have been completed.

Phase I - Orientation, preparation phase in which subjects were introduced to the test facility and procedures.

Phase II - The overall data collection which was conducted at the test facility. This consisted of filmed testing, 24 sets of tests in each of the five sensory modalities.

Phase III - To be completed at Brooke General Hospital after 21 September 1972.

Phase III - Data analysis whereby the investigator will retrieve filmed data and analyze according to a stimulus code.

FUTURE PLANS

Completion of Phase III over the next two years.

Completion of project paper within next two years.

Several articles will be written based on film analyses.

のなななないのないないののの

LECITHIN/SPHINGOMYELIN RATIO IN AMNIOTIC FLUID AND ITS CLINICAL APPLICATION

Donald L. Snyder, Colonel, MC

PROBLEM

Phospholipids, particularly lecithin, that appear in amniotic fluid originate principally from the fetal lung. Since lechithin is the major component of the surface active alveolar-lining layer, its biosynthesis appears to reflect the status of alveolar stability. Gluck et al have reported in 1971 that the changes during pregnancy in the amniotic fluid phospholipids reflect those in fetal lung. Therefore, it is proposed that the lecithin-sphingomyelin ratio may be used clinically to predict with a degree of accuracy maturity or immaturity of the fetal lung and thus which fetus is mature and will or will not develop Respiratory Distress Syndrome (RDS) if delivered at a specific time.

The aim of this study is to: 1) Establish a laboratory technique to measure lecithin and sphingomyelin in amniotic fluid and apply its measurement to clinical obstetrical management. 2) Correlate the L/S ratio in amniotic fluid as an indicator of intrauterine fetal pulmonary maturity. 3) Correlate the L/S ratio in amniotic fluid and the development of respiratory distress syndrome (RDS) in the newborn. 4) Correlate the L/S ratio in amniotic fluid with other currently employed procedures for predicting fetal maturity.

APPROACH

Lecithin/sphingomyelin ratios are measured by the technique described by Borer and Gluck. The technique is done as follows: The total lipids in previously centrifuged amniotic fluid are extracted with methanol and chloroform. The surface active phospholipids in the chloroform extract are isolated by adding ice cold acetone which causes them to precipitate. The surface-active phospholipids are separated by thin layer chromatography. Detection is by staining with 215

Bromothymol blue detector, heat and NaOH vapors. The ratio is obtained by dividing the product of the height times width of the lecithin by the sphingomyelin spots. If the L/S ratio is 1.5 or less the fetal lung is immature, if it is 1.5 to 1.8 the fetal lung is transitional in development and if it is 1.8 or above the fetal lung should be mature and thus should not develop RDS if delivered.

Collection of fluid: Five (5cc) of amniotic fluid, placed in a clean culture tube will be collected at the time of every abdominal amniocentesis. A sample will also be collected via the vagina in cases of established premature labor prior to indicated amniotomy. Each sample will be frozen until analysis is done.

Patients to collect fluid on: 1) All elective or indicated amniocenteses for other reasons. 2) All elective repeat Cesarean sections. 3) All primary Cesarean sections where technically feasible. 4) All patients in active labor with bulging membranes, when the membranes can be needled via the vagina. 5) All patients between 16-20 weeks gestation at the time saline amniocentesis for voluntary interruption of pregnancy.

RESULTS AND DISCUSSION

Data on over two hundred (200) sample determinations has revealed good correlation of the ratio of these two phospholipids and the length of the gestation of the intrauterine pregnancy from which the amniotic fluid was collected with other reported studies. In all cases when the L/S ratio was greater than 1.8 regardless of length of gestation, the baby did well in the nursery and did not develop respiratory distress syndrome indicating fetal lung maturity. During the period of study there were no infants delivered who developed RDS so there is no comparison of cases of RDS and the L/S ratio.

Data is presently being analyzed to correlate the L/S ratio results with the other available laboratory and clinical parameters in regards to reliability as a diagnostic test for prediction of fetal maturity.

FUTURE PLANS

Data appears to indicate the value of the test as a useful parameter as regards predicting fetal maturity, but more samples need to be collected especially in the critical range of 32-35 weeks gestation before definitive conclusions can be made.

A simplified Shake Test as a diagnostic test for the presence of surface active material in amniotic fluid has recently been described. A comparison study of the Shake Test versus the L/S ratio is presently being done.

Data is to be presented at the Armed Forces District Meeting of the American College of Obstetrics and Gynecology to be held at Seattle, Washington, October 1972. ź

IN VITRO STUDY OF THE PRAUSNITZ-KUSTNER REACTION

Joseph L. McGerity, Colonel, MC Edward Spitz, Major, MC

PROBLEM

The Prausnitz-Kustner reaction has for many years been a useful method for diagnostic study of atopic patients whose skin is not suitable for direct skin tests. This includes patients with atopic eczema or other skin disorders. This in-vivo technique was more recently used in the isolation of reagin (gE) and in the study of 'blocking antibody" produced by hyposensitization therapy. In the research milieu of today, use of human subjects in such studies is questionable and a reasonably accurate and available in-vitro test to replace the in-vivo technique is desirable. Several techniques utilizing monkey or human lung, human WBC's, rat mast cells, etc., have been developed. They have had the disadvantage of technical difficulty or limited availability of experimental material. In addition it would appear advantageous to be able to study in-vitro on an organ that is so frequently involved in-vivo allergic reactions i.e.. the human skin.

·)'r

It would be useful to be able to use surgical specimens of human skin for the in-vitro study of the biochemistry of anaphylaxis and the disease postulated to result from the interaction of skin sensitizing antibody and antigens. However, previous attempts to use such material have not been successful.

APPROACH

A bioassay system for histamine using the electronically amplified and recorded contraction of guinea pig ilieum has been established. Passive sensitization of human lung and release of histamine from the lung on challenge with appropriate antigen or anti-IgE has been accomplished. Us'ng these established techniques serums of atopic patients that are capable of sensitizing in-vitro human tissue has been and continues to be collected and used first in vitro sensitization of human lung and then applied in the study of in vitro sensitization of human skin.

RESULTS AND DISCUSSION

Human skin samples obtained incidental to routine surgical procedures has been successfully sensitized with atopic serum in vitro and such tissue has been found to release histamine on appropriate challenge in our prelininary studies.

FUTURE PLANS

1. The initially positive results are to be confirmed with repeated experiments including the use of further controls.

2. The ideal parameters of the time, temperature, and chemical medium for maximum sensitization and antigen release of histamine is to be found.

3. A comparison of the sensitivity of in vitro technique and in vivo techniques should be made.

4. The use of this technique to establish the release of SRS-A (slow reacting substance of anaphylaxis) from human skin in-vitro is contemplated.

5. Histologic study of the localization of the skin sensitizing antibody in-vivo and in-vitro is to be attempted using an adaption of the peroxidase-labelled antibody method of Nakane. In particular the presence or absence of localization of IgE to mast cells in the skin is to be studied before and after the in-vitro sensitization and challenge.

6. Application of this laboratory technique to the clinical problem is to be attempted.

a. We will attempt to develop an in-vitro method for the determination of 'blocking antibodies" using as clinical model patient's hyposensitized with grass pollen extract. ar and a structure of the the transmission of the structure of the structure of the states of the structure of the

220

State of the state

ALVER ALL STREET

b. This in-vitro technique will be used in a continuing study of the cross reactivity of Cedar and Cypress pollen with particular application to the cross reactivity of Sugi (Japanese Cedar), Mt. Cedar, and other members of the Cedar-Cypress family present in world wide distribution. Preliminary animal studies here indicate cross reactivity of precipitating antibodies of many of the Cedar-Cypress and suggest that these antigens have potential as significant allergens to personnel in many areas of the world.

.c. With establishment of the reliability of the technique measurement of both sensitizing and blocking antibodies in individuals infected with Trichophyton is proposed.

ANTIBIOTIC THERAPY OF ACUTE OTITIS MEDIA IN INFANTS AND YOUNG CHILDREN. INFECTIONS CAUSED BY HEMOPHILUS INFLUENZAE

James L. Stewart, Jr., Lieutenant Colonel, MC

PROBLEM

The management of otitis media is a major aspect of child health care. Although the common pathogens (pneumococci and <u>Hemophilus influenzac</u>) are well established and a variety of treatment regimens are available, no one regimen is agreed to be superior. Even though erythromycin is often used if the patient is allergic to penicillin, there is no good data as to its effectiveness in eradicating <u>Hemophilus influenzae</u> from the middle ear. The purpose of this study is to make a comparison of the effectiveness of ampicillin, erythromycin ethyl succinate and erythromycin ethyl succinate with triple sulfonamides in the therapy of acute bacterial otitis media with particular reference to <u>Hemophilus influenzae</u>.

APPROACH

This study has been designed by the Department of Clinical Development of Abbott Laboratories to be carried out in several medical centers.

Four hundred and fifty children over six months of age and less than 5 years of age, weighing between 10 and 60 pounds with clinically diagnosed otitis media as a primary diagnosis will be enrolled and randomly assigned to an initial antimicrobial therapy schedule. Bacteriological data will be obtained from culture of middle ear aspirate. Children with chronic otitis media, receipt of antibiotics during previous 2 weeks, or allergy⁴ to penicillins, erythromycin, or sulfonamides will be excluded. All medication is dispensed by a person other than the treating physician who is blinded as to which regimen is being given. All groups receive the same analgesics and decongestants. Scheduled follow-up visits will be made on days 3, 5, 14 and 31 for the physician to assess the disease course and adverse reactions to medications.

At each visit the parent brings all remaining antibiotics for measurement in order to verify amount of drug actually used. Clinical progress will be assessed on the basis of fever data, otoscopic appearances, and the presence or absence of malaise. Specimens of the middle ear aspirates are immediately inoculated in broth and sent to Dr. Sarah Sell, Vanderbilt University School of Medicine and Dr. Walton Grundy at Abbott Laboratories. No clinical improvement within 48 hours or the persistence of pain, fever, otoscopic appearance on days 5 and 14 will be considered a therapeutic failure.

RESULTS AND DISCUSSION

From the several hospitals contributing patients to the study, over 100 cases have been entered so far. Seven cases of proven bacterial otitis media have been entered from LGH. The study continues to be an important study to provide worthwhile medical information and enhance the training program by allowing the residents to participate in clinical research.

FUTURE PLANS

The study will continue under the guidance of Abbott Laboratories. All necessary equipment, drugs, bacteriological studies and statistical analysis are provided by Abbott Laboratories.

THE STUDY OF ADRIAMYCIN NSC-123127 FOR DISSEMINATED MALIGNANCY

Michael P. Corder, Major, MC Neil W. Culp, Lieutenant Colonel, MC James L. Stewart, Lieutenant Colonel, MC

PROBLEM

and Andrews and a state of the state of the second state of the se

There are several varieties of disseminated malignancy for which there is no efficacious therapy of proven value and the clinical situation often occurs in those tumors for which there is efficacious primary therapy of refractoriness to said therapy. For this reason, new chemotherapeutic agents are continually being screened in animal systems and then evaluated in man for both toxicity and clinical efficacy. Phase II clinical trials attempt to identify the antitumor spectrum of drugs which have been shown to be active in animal systems and for which the clinical spectrum of toxicity has been determined. Adriamycin (NSC-123127) is an antitumor antibiotic obtained from Streptomyces peucetius (variety caesius). It is closely related to Daunorubicin (NSC-82151) with Adriamycin having an improved therapeutic index over Daunomycin (1.21 vs 0.67). Adriamycin appears to act by inhibiting DNA synthesis and by intercalation between base pairs and to inhibit RNA synthesis by template disordering and steric obstruction.

In preliminary trials in man antitumor activity has been noted in ALL, AUL, CML, Wilm's tumor, Ewing's sarcoma, neuroblastoma, and some anaplastic sacromas. There have also been responses in transitional cell carcinomas of the bladder, reticulum cell sarcomas, lymphosarcoma, Hodgkin's disease, carcinoma of the breast, colon, testicle, chorio-epithelioma of the uterus, nasopharynx, soft tissue sarcomas and Ewing's sarcoma in adults.

The experience to date is limited with all of these tumor

types and many tumor classes have had less than five evaluable cases treated. It is the objective of this study to determine the antitumor efficacy in a variety of disseminated malignancies.

APPROACH

Adriamycin is given to patients for whom there is a microscopically proven diagnosis of cancer, and unavailability of or resistance to the rapy of proven value. The patients are given Adriamycin for three days IV consecutively and then a rest period until recovery of the counts and/or an additional 18 days has elapsed. Measureable tumor parameters are followed and a minimum of two courses is given prior to removal from study. The patients are evaluated weekly for toxicity and/or therapeutic response.

The patients who are previously untreated with myelosuppressive agents are given the drug 25 mg/m^2 per day for three days and previously treated patients with myelosuppressive therapies are given 20 mg/m^2 per day for three days. The drug dosage is modified for toxicity according to the protocol 71-2.

It is anticipated that results will be pooled with those of Major Nicholas DiBella, MC, at Fitzsimons General Hospital at the completion of the study.

RESULTS

To date, six patients have been treated and four are evaluable for response. The two unevaluable patients were both patients with mesiothelioma and one patient expired on day nine after initiation of therapy due to peritonitis, not related to therapy. The other patient had his therapy discontinued on day three due to an impression of cardiotoxicity which subsequently was demonstrated to be bacterial endocarditis.

One colon carcinoma metastatic to the liver was treated for two cycles and had progression in disease, one

carcinoma of the larynx with local recurrence was treated for two cycles and had progression in disease, one carcinoma of the nasopharynx with metastases to liver, bone, and epidural space had a greater than 50 percent reduction in tumor size by day 18 of the first course and the duration of the response was two months. The patient received four courses of Adriamycin. One patient with liposarcoma had no response after two courses of therapy.

THE REAL PROPERTY AND A DESCRIPTION OF THE REAL PROPERTY

FUTURE PLANS

Additional numbers of patients are required before any conclusions can be drawn. Patients will continue to be entered in the study. 225

2000 CV 200 T

A CARACTER STATE
TECHNIQUES OF VITREOUS SURGERY

Alexander R. Irvine, Major, MC Floyd L. Wergeland, Jr., Lieutenant Colonel, MC John P. Shock, Jr., Lieutenant Colonel, MC

PROBLEM

Massive vitreous hemorrhage is an all too common problem in the military. In young eyes, following ocular injury, vitreous hemorrhage often leads to strand formation and vitreous contraction, in turn producing inoperable retinal detachment. Recent methods of vitreous removal and replacement, as described by Dr. Machemer (1), offer a possible solution to the problem of vitreous opacification by hemorrhage. The present study was designed to determine the best method and time for such removal of vitreous hemorrhage.

APPROACH

Massive intraocular hemorrhage was simulated in rabbits by the intravitreal injection of 0.3 cc of vitreous blood. At varying times after injection, the opacified vitreous was removed and replaced with a physiologic salt solution using a Machemer type vitreous cutter. Control eyes included eyes with blood injection which were not operated upon and eyes which were operated upon without prior blood injection.

RESULTS AND DISCUSSION

The opacified vitreous could be successfully removed at any time from one day to one month following blood injection. The incidence of operative complications was approximately the same at all times after blood injection. After one month in rabbits, the hemorrhage tended to clear spontaneously with some strand formation but without the severe contraction and retinal detachment seen so often in young

humans.

í.

A few other probelms became apparent. Our present version of the Machemer instrument requires refining so as to insure a constant sharp cutting edge. When the edge becomes dulled from use, vitreous is pulled into the instrument and does not cut well, and hence excessive traction is put on the retina. A modification yielding a self-sharpening blade and a spring to hold it against the cutting edge is needed and planned. The second problem is that the relatively large lens and small vitreous cavity of the rabbit make it extremely difficult to work without touching the lens and producing a post-operative cataract. Evaluation of post-operative results must then be done on formalin fixed enucleated eyes rather than in vivo, since the cataract precludes viewing the retina in vivo.

The above problems, however, are relatively minor, and the technique has developed to the point where our first patient was operated upon in late March 1972. He has had a successful result, with return of useful vision in an eye that had only been able to perceive light for 18 months previously.

Two other projects have developed as offshoots of the original vitreous surgery. A method of coagulating abnormal vessels in the vitreous under direct microscopic control has been tested in rabbits and used successfully in one human eye which was being enucleated for other reasons. This procedure may have extremely important applications in diabetic retinopathy. Secondly, an inexpensive and simple technique has been developed for removing cataracts in animals or humans through a small incision by fragmenting the lens with ultrasound. This technique may have a very important effect on routine cataract extraction, by alleviating the problem of the large incision needed for traditional intracapsular lens extraction while avoiding the extreme expense and complexity of the ultrasound cataract instrument recently developed by Dr. Kelman (2).

FUTURE PLANS

Future work is planned along three lines. Our present vitreous suction cutter needs modification to insure a constantly sharper cutting surface. It is also possible that a fiber optic light source may be added to better illuminate the field deep in a hemorrhagic vitreous. Secondly, our method

of trans-vitreal diathermy coagulation needs further testing and refinement. A bipolar system may give a more localized tissue effect, an important advantage when one is treating abnormal vessels emanating from the optic nerve and must avoid damaging the latter. Finally, the ultrasound probe we are presently using for cataract work needs testing and refinement. Dr. Irvine will be leaving the Army to join the full time staff in the Ophthalmology Department of the University of California in San Francisco. Drs. Shock and Wergeland will carry on this research and Dr. Irvine plans to work in close cooperation with them and also continue this work at the University of California. ait sutide states of the statestic states of the second of the second of the statestic second of the second of t

くちちょうちょうないないのなかでいていいろう

REFERENCES

- 1. Machemer, R., et al. Amer. J. Ophthal. 73:1, 1972.
- 2. Kelman, C. D., Amer. J. Ophthal. 67:464, 1969.

EVALUATION OF THE RENIN ANGIOTENSIN I SYSTEM IN LABOR

Carl M. Hoffman, Major, MC Alex Karu, Ph. D. Jai Dev. B. S. M. S.

INTRODUCTION

The etiology of pre-eclampsia has long been sought. With recent advances in radioimmunoassays the possible role of the Renin-Angiotensin-Aldosterone system has been studied. Many problems are inherent in s dying this system but several recent studies have established differences between normal, hypertensive and pre-eclamptic pregnancies.

Most studies have involved isolated blood samples not taken during labor. In order to demonstrate a difference in these groups and to investigate a possible uterine contribution to the system a serial study of Renin activity during labor was undertaken.

PATIENTS AND METHODS

Fourteen patients were included in the study. All patients were followed from 8 - 14 weeks gestation through term and 6 weeks post partum. There were 4 normal controls, 5 preexisting hypertensives and 5 pre-eclamptics. The normal controls had normal blood pressure 'mean arterial pressure 90) throughout pregnancy and in labor no blood pressure change of mean arterial pressure greater than 10. The pre-existing hypertensives all had initial M.A.P. greater than 90 and pressures during labor of M.A.P. greater than 10 from pre-labor M.A.P., one of these patients also had super imposed severe pre-eclampsia. The pre-eclamptic group had M.A.P. less than 90 until 37-40 weeks when M.A.P. was greater than 90 with a change of M.A.P. greater than 10 over normal, 2+ proteinuria or greater and hyper-reflexia; all returned to normal post partum.

All patients were evaluated during labor when cervix was

dilated 4-6 cm. All patients had Corometric internal fetal monitoring and blood pressures recorded by the Arteriosonde (except one patient in each group), anesthesia consisting of Epidural block was in effect in one patient in each group without change in blood pressure.

A CANADA STATISTICS AND A CANADA

with the state of the state

The Arteriosonde uses a doppler principle to measure systole and diastole by flow changes in the brachial artery and used a ultrasound system to accomplish this. It has been shown to be as accurate as intra-arterial catheters in other studies.

The Corometric monitor is routinely used on high risk patients to detect fetal distress and was used in determining time of blood sample collections in addition to fetal monitoring.

Venous blood was drawn in 7 ml vaccutainers containing 1 ml of solution (pH 7.5) of 0.15 MEDIA, .9% NACE and 0.015 M BAL (2,3 dime: capto 1-propanol) as Renin preservative. The sample was immediately placed on ice and spun at 4° C 1500 R. P. M., plasma was separated and quick frozen for 1-2 weeks and run in groups of 10.

The samples were drawn with the patient in the lateral position from an antecubital vein with free flow of blood. Samples were collected prior to, upslope, peak, downslope, and post contraction.

METHOD OF ASSAY

Plasma Renin activity in all blood samples was measured by radioimmunoassay method. Labeled 125-1 Angiotensin-1 and antiserum (in guinea pigs) were produced at Biochemistry Lab at LAIR.

> Material and Methods: Radiolabeling of Angiotensin-1 with 125-1

Synthetic Angiotensin-1 (ASP-1 - llau 5) was used for

and the second
radiolabeling and to immunize guinea pigs. (Supplied by Cal-Biochem).

Reagents

0.1 IM Phosphate buffer with 0.85% NaCl of pH=7.5; INH+Cl; Kl - 0.01 mg/10 ml buffer Soln; Chloramine T -25 mg/10 ml; Angiotensin -1 + 1 mg/ml in 0.02 M Acetic Acid; 125-1 = 2.0 mc. (All reagents should be freshly prepared and kept on ice)

Procedure

Add 1.5 ml of Kl Soln. to a silanized small beaker + 10 Angiotensin - 1 + 2.0 mc 125-1 carefully. Adjust N_2 gently to blow over surface of reaction mixture. Put electrodes in touch of reaction mixture (platinum-mercury electrode was used). Note initial e. m. f. on scale. Slowly add Chloramine T (50 units or more as required) to start reaction. Note slow increase in e. m. f. Stop the reaction with $Na_2S_20_5$ when e. m. f. goes 60-70 mv higher than initial value. It will slowly come down to initial value. At this stage immediately add 0.5 ml of INHCL to stop the reaction. The whole reaction takes about 5-10 minutes.

Purification of Labeled Material

Dowex $1-X^4$ and $50W-X^4$ were used as ion exchanges. 125-1-Angiotensin-1 was eluted with 0.5NNH OH. Fractions were freeze dried and stored at $-40^{\circ}C$ (good enough for use for 30 days). It was diluted to give desired c.p.m. as needed from time to time. Silanized glassware was used to store this material.

Immunization of Guinea Pigs

Angiotensin-1 coupled with GPSA (guinea pig serum albumin 33% (NH5) 2SO4 fraction in presence of ECDI (2 Ethyl-(3 dimethylaminopropyl-) carbodiimide to make it immunizable.

Reaction Mixture

4.0 mg GPSA, 8.0 mg Angio-1 - dissolved in 0.25 ml of distilled H_20 ; 150 mg of ECDI dissolved in 0.25 ml of H_20 (ECDI Soln. was slowly added to Soln drop by drop

ちょうちょうかい ちょうちょう ちょうちょう ちょうちょうちょう ちょうちょう ちょうちょう ちょう

with gentle stirring at room temp. It was allowed to react 2-4 hours at room temp. (Generally formation of white. ppt. is indication of reaction completion). Reaction mixture was dialysed at 4°C against H₂0 overnight. It was mixed in 1:1 ratio with Freund's Adjuvant and Sonified).

Immunization Schedule

1st injection: was given in toe pads $(100\lambda - 150\lambda)$ under anesthesia (Diabetol was used as anesthetic). 2nd: After 8 days 2nd injection was given in neck and thighs (intramuscular). 3rd: Same as above after 8 days. After 15 days 3rd injection blood was taken by heart puncture. Serum was separated and quick frozen and stored in a small aliquots at -40° C (temp. was never allowed to rise more than 4° C). It was tested for specificity and diluted as required for assays. (1:100 dilution was generally used).

Assay Method: Reagents:

0.1M Phosphate buffer with 0.5 mg/ml. Lysozyme (pH=7.5); Angiotensin-1 1 mg/ml in above buffer (stock A); 10 λ of stock A + 0.99 ml buffer - (stock B); 10 λ of stock B + 0.99 ml of buffer - (stock C). (Stock C can be frozen and stored. Conc. = 10-4 mg/ml). いいたいでいたいないとうないですからい

Procedure: Standard Curve

Stock C can be diluted further as required to make Standard Angiotensin-1 Soln. (0.05 - 1.0 mg). Seven tubes (glass) were set up for Standard Angiotensin -1 Soln. as follows:

	d 1	d 2	d 3	d 4	d 5	d 6	d 7
Stock C 10A		20λ	40λ	60X	60λ 100λ 140λ		λ 200λ
Buffer (mi)	0. 99	0.98	0.96	0 .94	0. 90	0.86	0.80
(Conc. of Angio-1 in 50) aliquot in ngs)	0.05	0.10	0.20	0.30	0.50	0.70	1.0

 50λ aliquots were taken from the above tubes to the seven (plastic) tubes numbered in the same manner containing 0.5 ml of phosphate buffer w/Lysozyme. 5,000 - 10,000 c.p.m. of 125 1-Angiotensin-1 were added to each tube. Three more tubes were set up as controls and numbered as d0, d0c and d7c. d0 contains no cold Angio-1, d0c contains no cold Angio-1 and no antisera, and d7c contains only 1. 7 ml cold Angio-1 but no antisera. Each of them contains same amount of buffer and c.p.m. 50λ of antisera (1:100) was added to each tube at the end except d0c and d7c and shaken well. These were incubated at 4° C for 24 hours and free and bound counts were separated with Dextran coated charcoal (0.5 ml Dextran coated charcoal was added and centriguged). Supernatant was transferred carefully to other tubes numbered in the same manner and counted on solid crystal well type Y-counter). Standard curves should be done in duplicate or triplicate to get maximum accuracy for each assay.

Procedure

「ないないないないないないというないないないないないとう、とうないないないとうで、このないで、ケー

1. Mark two sets of plastic tubes for 0 minute and 5 minute incubation time at 4°C and 37°C (each tube should contain the same amount of phosphate buffer and c.p.m. of 1-125-Angio-1 as tubes for standard curve). 2. Mark two sets of glass tubes for samples for assay (one set for 4°C incubation and other for 37°C incubation). 3. Add to each glass tube: (a) 1.3 ml of glass distrilled water; (b) 0.1 ml of 0.2M Phosphate buffer with .3 ml EDTA (pH=6.0); (c) 0.1 ml of Renin-Substrate (0.5 mg/ml in above buffer, Renin-Substrate was extracted from hog blood in the laboratory and used in all assays.) Make one tube as control for Renin-Substrate. Ald 0.5 ml of water instead of plasma. 4. Add 0.5 ml plasma for assay to each tube (everything must be kept on ice). 5. Transfer 50λ alignots immediately to the plastic tubes containing buffer and c. p. m. of 1-125-Angio-1 marked at 0 minute (from both sets marked at 4° C and 37° C. 6. Put one set in water bath maintained at 37° and set timer at 5 minutes. 7. After 5 minutes exactly transfer another 50 aliquots from each set of tubes to plastic tubes marked for 5 minutes as quick as possible. 8. Add 50λ of antisera to each plastic tube and shake them well. Incubate them at 4°C for 24 hours. Separate free and bound counts by adding 0.5 ml Dextran coated charcoal and transferring supernatant to other tubes marked in the same manner. Count them on A counter.

たいあたいたかというたちない、ころいうので

หลาย เป็นไปไปไปไปไปไปเป็นที่มีที่มีการนะไปมีเห็นการและไปแรงและเห็นเห็นไปไปได้ไห้เห็นได้ได้ แก่หลาในการสาวให้ ก

CALCULATIONS '

 For the control tubes of the standard curves, total the
c.p.m. for the supernatant and the charcoal residue frac tion. Calculate the correction factor as: OC = F/B+F Where F = The C.P.M. of charcoal residue (free Anglo-1)

and B = The C.P.M. of Supernatant (Angio-1 bound to antibody)

2. For each level of standard and for each clinical assay, total B and F. Calculate the corrected (Tc) total as:

(B+F) Oc=Tc 3. Calculate the corrected bound fraction, Bc:Tc-F=Bc

4. Calculate F/Bc

5. Plot F/Bc vs. ng/ml Angio -1 for standard curve.

6. For the clinical assays, determine ng for each F/Bc from the standard curve.

7. Renin activity is calculated as Angiotensin -1 released per ml per minute. Renin activity = (ng $37^{\circ}C - ng 4^{\circ}C$) 20 = ng/ml/min.

Carlo Carlo Carlo Carlo Carlo Carlo Carlo Carlo

2.5 July 2.5 Marthales and the state of the street of the second of the second street of the second of

RESULTS

All three groups showed Renin activity during contractions. The activity tended to increase and peak after peak of the contraction. The most marked increase occurred in the pre-existing hypertensive group. The normal group showed an increase in M.A.F. with the contraction and an increase in Renin activity double the pre-contraction level. In the pre-eclamptic M.A.P. with an elevated pre-contraction level and increase during contraction, the Renin activity showed a marked rise. In the pre-existing hypertensive M.A.P. elevated, the increase during a contraction was marked and the Renin activity showed a marked increase during contractions. In comparing the three, the normal patients maintained Renin activity throughout contractions and between, while the other two groups had much lower activity between contractions and marked increase with contractions. M.A.P. in all groups increased with contractions to the same degree with the hypertensive groups

.234

reaching M.A.P. 100 and the normal group below 100 at peak contractions.

DISCUSSION

The Renin Angiotensin system has been studied in normal, hypertensive and pre-eclamptic patients in many studies, During pregnancy the plasma of normal patients shows a(1)Rise in Renin Activity and in (2) substrate of Angiogensin 1. Although the Renin increases and more vasoactive Angiotensin 11 is activated the blood pressure remains stable. The normal pregnancy produces a decreased (3) sensitivity to Angiotensin 11. Recent work (4 & 5) has shown a possible feedback control between Angiotensin 11 and Aldosterone as the Angiotensin 11 level increases the Aldosterone level increases. Aldosterone (6) levels are increased during pregnancy and reach a peak at 34-36 weeks(7). The Renin Substrate Angiotensinogen is increased by estrogen (8). Progesterone causes Na loss by acting as an Aldosterone antagonist. This increases both Aldosterone production and Renin release from the juxtaglomeruro cells. This yields increased (9) Angiotensin 11 levels and activates both Aldosterone release from the adrenal gland and Norepinephrine release from sympathetic nerves.

Patients with pre-sclampsia and/or pre-existing hypertension in pregnancy tend to have lower Renin levels during a pregnancy, although there is a great overlap between the groups (19 & 11). The highest Renin levels have been found in somen with molar pregnancy and Rh sensitized erythroblastotic fetus. The pre-eclamptic patient has been shown to be more sensitive to Antiotensin 11 infusion and require 1/2 as much Angiotensin 11 to give the same blood pressure response as normotensive pregnancies. Their response is similar to normal non-pregnant patients.

Angiotensinase activity has been shown to be increased in normal pregnancy (13) and decreased (14) in pre-eclamptic and hypertensive pregnancies reutrning to normal post partum. The (15) enzyme L-Aspartyl-B Naphthylamide Hydrolase inactivates Angiotensin 11. This enzyme has en and the second the hardened the server seconds of the treated of the server and the company of the second the second second to a second the second s

been shown to be increased by estrogens but not by progesterone.

The source of Renin has long been felt to be solely from the juxtaglomeruluo cells in the kidney and the previous studies have assumed this source as the only one. Recent work in both tissue culture, amniotic fluid and uterine muscle analysis suggest a possible fetoplacental source (16). Tissue culture of human myometrium, chorion, amnion, placenda decidua and chorion plate showed both chorion and myometrium to produce renin in utero. The myometrium. of humans does not produce Renin in vivo but the rabbit's myometrium (17) does have significant Renin activity. The Renin produced by the human myometrium did not appear until 12-14 days after culture and might reflect a normal inhibition of enzyme activator which was lost during culture. The chorion however showed production of significant Renin activity within 24 hours of culture. Other workers have confirmed a nigh Renin activity in chorion and fetal surface of the placenta (18 & 19).

The possibility of the Renin being the same as the 'hysterotonin" found by Doctors Hunter and Howard (20) in placenta of patients with pre-eclampsia is possible. Renin has been isolated in the amniotic fluid and showed markedly higher concentration than Renin in the venous blood of the women (21). The Renin activity was even found at 11 weeks gestation. Other vasoactive polypeptides possibly Angiotensin or an analogue have recently been studied in amniotic fluid (22).

The presence of a source of production and actual production of high concentrations of Renin in the utero placental complex raises speculation as t. its role in maternal-fetal hemostasis. The placenta has been shown to produce many hormones with fetal contributions which maintain homeostasis although their total function is not known. Among these are Human Chorionic Gonadotropin, Human Placental Lactinogen, Thyropotropin and now Renin.

It is possible that the Renin is used to help maintain the blood flow to the placenta by increased release during times of decreased blood flow in order to prevent fetal anoxia.

NUMERAL ADDRESS

han ber an the second of the second
The uterine blood flow is known to be decreased during labor (23). Studies of the rhesus monkey have shown reduction of uterine blood flow during contraction and the greater the contraction pressure the less the placental flow. Renal blood flow slightly increased as did other visceral organ blood flow.

In our experiments we showa 2-3 fold increase in Renin activity during contractions with return to normal prior to next contraction. The source of this Renin could be renal or uterine. Since renal blood flow does not decrease with contractions no stimulus for sudden release is operating. The uterus has a decreased blood flow and could be releasing the Renin in order to elevate blood pressure to increase its blood flow (8). Renin activates Angiotensinogen-1 rapidly which is converted to Angiotensin 11 by a converting enzyme. Blood pressure response to Angiotensin 11 occurs in 14-16 seconds with return to normal in 3 1/2 minutes. The possibility of Norerinephrine or Epinephrine contributing to the overall elevation during labor is possible since Angiotensin 11 causes release of Norephinephrine but takes 15-20 minutes to occur.

In the normal patient with decreased arteriolar responsiveness to Angiotensin 11, the blood pressure stays within "normal" levels although does increase in response to the increased Renin and the blood pressure can reach dangerous levels. Studies of Angiotensinase activity may explain the decreased reaction to Angiotensin 11 if Angiotensinase increases the Angiotensin 11 is destroyed more rapidly with lower levels. Angiotensinase increases in Angiotensin 11 could have much more vasoactivity. The vasospasm produced is marked at maternal arteriolar beds throughout the body and easily seen in the eye grounds. The vasospasm cause anoxic changes at these areas in the kidney glomerulous, liver, CNS and myoneural function (24). The renal lesion specific for pre-eclampsia is swelling of the endothelial cell cytoplasm in the glomerulous capillary wall causing narrowing of the lumina. The other findings such as thickening of basement membrane and fibrinoid deposits are not universal and are probably secondary to fibrin deposits in

ティー しょう とうちょうちちんしてき いちちろん

and the second structure of the second second second of the second second second second second second second se

response to the cell wall changes. The swelling of arteriolar walls is secondary to edema and reversible when biopsied post delivery. Lung changes showing decreased perfusion have (25) been found associated with mild intravascular coagulation in pre-eclampsia and eclampsia. The liver shows periportal damage mainly but extension to the center of the lobule occurs. Hemorrhage and fibrin deposit in the sinusoids is common. The brain shows edema and occasional hemorrhage but all specimens are at atopsy. The heart shows generalized arteriolar involvement and edema. The adrenals show petechial hemorrhage, thrombi and necrosis again post mortem.

THEORY

and the state of t

alarayo da darara da kuba na da wata da Parana ya Baraje na ana da da kata na da Barawa na da Parana na da Para

,23

The primary lesion is arteriolar wall damage secondary to spasm with mild to moderate disseminated intravascular coagulation through clotting activation at the site of cell wall damage. The initiating factor is increased Renin release in a patient with decreased Angiotensinase activity.

With the onset of labor the uterus releases increased amounts of Renin with each contraction causing marked blood pressure changes. In the normal patient with 'decreased arteriolar responsiveness'' secondary to increased Angiotensinase activity, the blood pressure stays within 'hormal'' levels although does increase in response to the increased Renin. The hypertensive and pre-eclamptic have marked arteriolar reaction to the sudden increased Renin and decreased Angiotensinase ability to inactivate Angiotensin 11 and the blood pressure can reach dangerous levels.

REFERENCES

- Brown, J.J., Davies, D.L., Doak, P.B., et al, Plasma-Renin in Normal Pregnancy, Lancet 2:900, 1963.
- Helmer, O. M., Judson, W. E., Influence of High Renin Substrate Levels on Renin-Angiotensin System In Pregnancy, Am. J. Obst & Gynec. 99:9, 1967.

- 3. Schwarz, R., Retzke, V., Cardiovascular Response to Infusions of Angiotensin 11 In Pregnant Woman, Obst & Gynec. 38: 714, 1971.
- 4. Sundsfjord, J.A., Aainaag, A., Plasma Angiotensin 11 and Aldosterone Excretion During the Menstrual Cycle, Acta Endocrinol. 64: 452, 1970.
- 5. Weir, R.J., Paintin, D.B., Robertson, J.I., Renin, Angiotensin and Aldosterone Relationships in Normal Pregnancy, Proc. Roy. Soc. Med. 63: 1101, 1970.
- Watanabe, M., Meeker, C.I., Gray, M.J., et al, Secretion Rate of Aldosterone In Normal Pregnancy, J. of Clin. Invest., 42: 1619, 1963.
- 7. Holmes, Griffith, Endocrinology 51: 421, 1952.

and the second second second second and the second
- Ehrlich, E.N., Laves, M., Lugibihl, K., et al, J. Lab. & Clin. Med. 59:588, 1962.
- 9. Zuspan, F.P., Talledo, O.E., Chesley, L.C., Angiotensin and Norepinephrine Infusions During Pregnancy, Alterations In Plasma Epinephrine and Norepinephrine, J. Clin. Endocrinol. 33: 929, 1971.
- Brown, J. J., Doak, P.B., Davies, D.L., Plasma-Renin Concentration In Hypertensive Disease of Pregnancy, J. Clin. Endocrinol. 33: 929, 1971.
- Brown, J. J., Davies, D. L., Plasma-Renin Concentration In The Hypertensive Diseases of Pregnancy, J. Obstet. Gynaec. Brit. Commonwealth, 73: 410,1966.
- Talledo, O.E., Rhodes, K., Livingston, E., Renin-Angiotensin System In Normal and Toxemic Pregnancies, Am. J. Obst. & Gynec. 97: 571, 1967.
- Talledo, O.E., Rhodes, K., Livingston, E., Renin-Angiotensin System In Normal and Toxemic Pregnancies, Am. J. Obst. & Gynec. 97: 571, 1967.
- Talledo, O.E., Renin-Angiotensin System in Normal and Toxemic Pregnancies, Inactivation of Angiotensin In Toxemic Pregnancy, Am. J. Obst. & Gynec. 101: 254, 1968.
- 15. Lubash, G.D., Bard, R.H., Klein, J.A., Serum "Angiotensinase Activity" and Female Steroidal Hormones, Amer. J. Med. Sci. 257: 155, 1969.
- Symonds, E.M., Stanley, M.A., Skinner, S.L., Production of Renin By In Vitro Cultures of Human Chorion and Uterine Muscle, Nature, 217: 1152, 1968.
- Ferris, T.F., Gorden, P., Mulrow, P.J., Rabbit Uterus As A Source of Renin, Am. J. Physiol. 212: 698, 1967.
- Gross, F., Schalaechtegin, G., Ziegler, M., A Renin-likė Substance In The Placenta and Uterus of The Rabbit, Lancet 1: 914, 1964.
- Skinner, S.L., Lumbers, E.R., Symonds, E.M., Renin Concentration In Human Fetal and Maternal Tissues, Amer. J. Obstet. & Gynec. 101: 529, 1968.

ころ、またいろうとうないないないないないないでものです。 ちょ

「お ちちつ しちょうしん しょういんちょう ちょう いいんいんち

- Hunter, C.A., Howard, W.F., Amer. J. Obstet. & Gynec. 79: 838, 1960.
- Brown, J. J., Davies, D. L., Doak, P. B., The Presence of Renin In Human Amniotic Fluid, Lancet 1: 64, 1964.
- 22. Carretero, O.A., Bujak, B., Hodari, A.A., et al, Identification of A Pressor Polypeptide In Human Amniotic Fluid, Am. J. Obstet. & Gynec. 111: 1075, 1971.
- Lees, M.H., Hill, J.D., Ochsner, A.J., et al, Maternal Placental and Myometrial Blood Flow Of The Rhesus Monkey During Uterine Contractions, Amer. J. Obstet. & Gynec. 110: 68, 1971.

24. Mahran, M., Fadel, H.E., Sabour, M.S., A Semi-Quantitative Analysis of The Renal Lesion of Pre-Eclampsia, Inter. J. of Gynec. & Obstet. 9: 50, 1971.

についたから

1

25. Starkie, C. M., Harding, L. K., Fletcher, D. J., et al, Intravascular Coagulation and Abnormal Lung Scans In Pre-Eclampsia and Eclampsia, Lancet 2: 889, 1971.

A WERE AND ALLEY ALLEY

Charles and the

241

ういたのないというないのである

DOCUMENTATION OF HAND FUNCTION: A Comparative Analysis of Direct Electrostatic Systems with Standard Clinical Procedures

PROBLEM

Evaluation of hand disability requires the use of objective, reliable and reproducible methods for measuring joint motion, muscle action, coordination, sensory loss, dimensional change and surface appearance. Serial goniometric measurements, voluntary muscle tests, and functional evaluations are the tools conventionally used by the therapist to describe a hand disability or deformity. The results of these tests appear as a numerical description and written summary which are frequently lengthy columns of figures and ambiguously worded narrative descriptions. They require much time to prepare as well as interpret.

It has been stated that photographic methods provide the most accurate means of recording deformity and disability. The elaborate equipment, cost of supplies, technical skill and time delay in developing the film have prevented use of this technique in general practice. Polaroid photography eliminates the time factor in film development, however, th s process is expensive, the prints produced are small and they are not easily reproduced.

Several years ago Regenos and Chyatte conducted a limited study with a Xerox copier to record deformity and the effects of treatment on the rheumatoid hand. The present study was initiated to evaluate this approach with other copying equipment and in other evaluation areas. It was hypothesized that this technique would be an improved method for evaluating, recording and documenting physical disability and/or deformity; the number of manhours spent in evaluating and documenting would be reduced; and the associated costs would be lowered.

APPROACH

All patients referred to the Physical Medicine Service, Occupational Therapy Section and Physical Therapy Section ないというのでもないというないのでのないできた。その

になるという。

at Letterman General Hospital for evaluation of a hand disability automatically became a part of the study. The final sample size was 109 patients. Data collected included name, age, sex, hand dominance, diagnosis and date of injury or onset of disease. Their diagnoses included peripheral nerve injuries, lacerations, rheumatoid disease, amputations, Dupuytren's contractures, hemiplegia, dermatomyositis, brachial plexitis and hemangioma. Some patients had multiple diagnoses. The following routine evaluation procedures were recorded by conventional methods: range of motion, voluntary muscle tests, sensory and functional tests. After all evaluations were completed patients were referred for documentation of hand function with the use of the office copier (Dennison Copymaster). The time required to perform the various evaluations was recorded by the individual therapists.

RESULTS AND DISCUSSION

л

Office copying equipment can be used as a practical method to accurately document hand function, appearance, sensory involvement and range of motion. Initial evaluation of the raw data indicates the photocopy technique requires onesixth the time standard evaluation procedures require. Looking at the photocopy provides an immediate picture of the problem and eliminates the necessity of interpreting columns of numbers or grades as well as the writing and reading of detailed narrative descriptions.

The photocopies provide immediate information to the referring physician when placed in the patient's chart and they also provide a serial record which can be used to evaluate treatment and the use of modalities, exercises, splinting, bracing and medication. They are invaluable documents for those persons who must determine disability ratings and/or insurance compensation. They can also be used for clinical education and research.

If range of motion measurements are necessary, they can be made directly on the photocopies with a ruler and protractor since the image of the hand on the photocopy is the exact size of the patient's hand. This permits the therapist ic make the measurements at a convenient time or they can be made by a well-trained assistant. The range of motion, muscle test strengths, sensory evaluation and grip strengths

シャック・ロ そうひとうないないちょう くろくちょう

can be recorded directly on the photocopy thus eliminating several extra reports from the patient's chart.

Ten professional individuals from the hospital staff (not involved with the project) were provided with the photocopies and standard evaluation forms of five subjects to make a comparative analysis of the two techniques. Evaluation of the raw data extracted from the questionnaires answered by these persons indicates a general preference for the photocopies. They also felt that there would be times when the standard evaluation procedures would be necessary, i.e. for surgical considerations and present army regulations governing disability ratings. Time required to evaluate and understand the patients problem was approximately onehalf that needed for the standard forms. The therapists involved in the study stated that they would prefer to use the photocopier instead of the standard procedures because of the time element, patient interest and permanency of the records.

Perhaps the most positive result of the study is the fact that the Physical Medicine Service has continued the contract for the photocopier for documenting hand function.

FUTURE PLANS

This study is now essentially complete, however statistical analysis of the raw data is still required for inclusion in the technical report presently being prepared.

u under stand die Bierkenstreken under der die die des under die einen die eine die voorgerieu beentuit aller u

PUBLICATIONS FY 72

- Akers, W.A. and Sulzberger, M.B.: The Friction Blister. Military Medicine, 137:1-7, 1972.
- Akers, W.A.: Tender Inguinal Lymph Nodes and Gonococcal Urethritis. Military Medicine, 137:107-108, 1972.
- Appell, L.H., Kovatch, R.M., Reddecliff, J.M., and Geroni, P.J.: Pathogenesis of Sendai Virus Infection in Mice. Am. J. Vet. Res. 32:2835-2841, 1971.
- Arthaud, L.E., Lewellen, G.R., and Akers, W.A.: The Dermal Toxicity of Isoamyl-2-Cyanoacrylate. J. Biomed. Mater. Res. 6:201-214, 1972.
- Benson, J.D., Schwarzhoff, R.H., and Dettor, C.M.: Blood cells and lipid per x des in tissues of mice treated with SKF-525A prior to x-irradiation. Rad. Res. (In Press)
- Cutcher, J.L., Woody, R.D., Richey, J.B., Heflich, R.H., and Corn, R.: A Method for Testing Inhibitory Effect of Dental Materials on Oral Bacteria. Internat. Assn. for Dental Research, March 1972, Abst. 856.
- Hall, W.C., Kovatch, R.M., Herman, P.H., and Fox, J.G.: Pathology of Measles in Rhesus Monkeys (<u>Macaca Mulatta</u>). Veterinary Pathology (In Press)
- Harris, D.R., Polk, B.F., and Willis, I.: Evaluating Sweat Gland Activity with Inoprint Techniques. J. Invest. Derm. 58:78-84, 1972.
- Harris, D.R. and Youkey, J.R.: Evaluating the Effects of Hemostatic Agents on the Healing of Supermicial Wounds. In: Epidermal Wound Healing, Ed. by Maibach and Rovee, 1972.
- Jones, J.C., Lilly, G.E., Hackett, P.B., and Osbon, D.B.: Mandibular Bone Grafts with Surface Decalcified Bone. J. Oral Surg. 30:269-276, 1972.

20141 FRUIL CANADA 444

<mark>lit</mark>ter tar anti dic 1920 dattantan diterandikaden kantan entan data kataban data daren an antaran antar an ana

- Jones, J.C., Osbon, D.B., Lilly, G.E., and Payne, T.F.: Alveolar Osteitis Associated with the Extraction of Mandibular Third Molars. Internat. Assn. for Dental Research, March, 1972, Abst. 359
- Lilly, G.E., Cutcher, J.L., and Jendresen, M.D.: Reaction of Oral Mucous Membranes to Selected Dental Materials. J. Biomed. Mat. Res. (In Press)
- Lilly, G. E., Cutcher, J. L., Jones, J. C., and Armstrong, J. H.: Reaction of Oral Tissues to Suture Materials, IV. Oral Surg., 33(1):152-157, 1972.
- Lilly, G.E., Heflich, R.H., Osbon, D.B., Hutchinson, R.A., and Nishimura, B.I.: Clinical and Bacteriologic Aspects of Polyglycolic Acid Sutures. Internat. Assn. for Dental Research, March 1972, Abst. 355.
- Payne, T.F.: An Analysis of the Clinical and Histopathological Parameters of the Odontogenic Keratocyst. Oral Surg., 33:538-546, 1972.
- Phillips, L., Steinberg, M., Maibach, H. and Akers, W.: A Comparison of Rabbit and Human Skin Response to Certain Irritants. Toxicology and Applied Pharmacology. 21:369-382, 1972.

~ おおお かっかいていないのかい

ちょうれないかいてい ちのちゃいろい

جويلية وسويده بدراني الأرواري بدروان المالية وموادية والإردار

- Richey, J.B., Cutcher, J.L., and Heflich, R.H.: Fluorescent Bacteria of the Human Tongue. Internat. Assn. for Denta Research, March 1972, Abst. 730.
- Salem, J., Lilly, G.E., Thompson, C.W., Burt, G., and Cutcher, J.L.: In Vivo Fabricatio of a Temporary Prosthesis for Maxillofacial Avulsion Wounds: A Clinical Trial in Vietnam. J. Trauma. (In Press)
- Sulzberger, M. B. and Harris, D.R.: Miliaria and Anhidrosis. III. Multiple small patches and the effects of different periods of occlusion. Arch Derm 105:845-850, 1972.
- Tempel, T.R., Marcil, J.F.A., and Seibert, J.S.: Clearance of Particulate and Soluble Oral Debris by Water Irrigation. Internat. Assn. for Dental Research, March, 1972, Abst. 694.

Distanting and the model of the state of the second states of the second states and the second states of the secon

- Akers, W.A. 'Urticaria.'' Presented at the American
 Academy of Dermatology, Chicago, Illinois,
 5 December 1971.
- Benson, John D. 'Blood cells and lipid perixides in tissues of mice treated with SKF-525A prior to x-irradiation."
 Presented at the Radiation Research Society Meeting, Portland, Oregon, 14-18 May 1972.
- Cutcher, J. L. "A Method for Testing Inhibitory Effect of Dental Materials on Oral Bacteria." Presented at the International Association for Dental Research Annual Meeting, Las Vegas, Nevada, March 1972.
- Harris, David R. "The Effects of Hemostatic Agents on the Healing of Superficial Wounds." Presented at the Epidermal Wound Healing Conference, Pebble Beach, California, 29 August 1971.
- Harris, David R. 'Problem Cases of Psoriasis and How They were Handled. " Presented at symposium, American Academy of Dermatology, Chicago, Illinois, 9 December 1971.
- Jones, Henry E. 'Reduced Rhus Sensitivity in Atopic Dermatitis.'' Presented at the American Academy of Dermatology, Chicago, Illinois, 7 December 1971.
- Jones, J.C. "Alveolar Osteitis Associated with Extraction of Mandibular Third Molars." Presented at the International Association for Dental Research Annual Meeting, Las Vegas, Nevada, March 1972.
- Jones, & C. "Tissue Reaction to Sutures." Presented at See Dental Society, Salt Lake City, Utah, May 1972.
- Lilly, Carlow Clinical and Bacteriologic Aspects of Polyglyc Rescard Sutures. "Presented at the International Association for Dental Research Annual Meeting, Las Vegas, Nevada, March 1972.

Lilly, G.E. 'Military Dental Research." Presented at the San Antônio District Dental Society, San Antonio, Texas, November 1971.

Lilly, G.E. "Mandibular Bone Grafts with Surface Decalcified Bone." Presented at the Army Science Conference, West Point, N.Y., May 1972.

Richey, J.B. 'Fluorescent Bacteria of the Human Tongue." Presented at the International Association for Dental Research Annual Meeting, Las Vegas, Nevada, March 1972.

Tempel, T.R. 'Clearance of Particulate and Soluble Oral Debris by Water Irrigation." Presented at the International Association for Dental Research Annual Meeting, Las Vegas, Nevada, March 1972.

Willis, Isaac. 'Effects of Prolonged Water Exposure on Human Skin."; 'Phototherapy: Light Sources.";
'Light Testing in Man for Photoallergy and Phototoxicity." Presented at the American Academy of Dermatology, Chicago, Illinois, 4 - 7 December 1971.

 Willis, Isanc. 'Effects of Long Wave Ultraviolet Light on Skin: Photoprotective or Photoaugmentative."
 Presented at the American Federation of Clinical Research Meeting, Carmel, California, 5 February 1972.

OCONUS

Jones, Henry E. 'Experimental Fungal Infection in Man." University of Glasgow, Scotland, May 1972.

"Incidence of Skin Disease in Military Dermatology Clinics. " University of Liverpool, England, May 1972.

"Cell Mediated Immunity in Atopic Dermatitis." University of Sheffield, England, May 1972.

'Epidemiology of Trichophytin Hypersensitivity in Man. " University of Birmingham, England, May 1972.

"The Pathomechanism of Fungus Infections in Man."

Presented at the Internation Congress of Dermatology Meeting, Padova, Italy, May 1972.

AFARATA